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SUMMARY 
Background Despite several decades of research, the relevance of body fat and body fat 
distribution to the risk of cardiovascular disease remains unclear. This thesis aims to investigate 
associations of body-mass index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) 
with risk of first-onset cardiovascular disease under a range of different circumstances.  
Methods This thesis used individual records from the Emerging Risk Factors Collaboration to 
calculate risk ratios, and measures of discrimination and reclassification. 118 prospective studies, 
involving 1,064,541 participants without known history of cardiovascular disease, had information 
on BMI at baseline examination. 58 of these studies, involving 221,934 participants, had additional 
information on waist and hip circumference at baseline examination. Serial measurements made in 
42,300 participants from 12 studies with concomitant information on these adiposity measures 
enabled quantification of within-person variability in BMI, WC and WHR.  
Results Cross-sectional analyses demonstrated that although the correlations of adiposity 
measures differed with one another, BMI, WC and WHR were similarly and importantly associated 
with mediating cardiovascular risk factors, such as blood pressure, fasting glucose and lipids. 
Within-person variability was lower in BMI (regression dilution ratio: 0.96) than in WC (0.88) and 
WHR (0.66). The variability of adiposity measures was not materially influenced by several 
characteristics, although the variability of WHR varied somewhat by sex, diabetes status and 
baseline WHR values. 1,064,541 individuals with information on BMI recorded 161,903 deaths or 
non-fatal cardiovascular outcomes during 15.0 million person-years of follow-up. In analyses 
adjusted for age, sex and smoking status, BMI had positive and nearly loge-linear associations with 
coronary heart disease and ischaemic stroke (except at BMI values below 20 kg/m2), which were 
largely explained by the intermediate risk factors noted above. The association between BMI and 
non-vascular mortality was curvilinear. Data on 221,934 individuals with complete information on 
weight, height, and waist and hip circumference (14,297 incident cardiovascular outcomes; 1.87 
million person-years of follow-up) demonstrated that BMI, WC and WHR were substantially and 
similarly related to risk of coronary heart disease and ischaemic stroke. For cardiovascular risk 
prediction, additional information on BMI, WC or WHR to a prediction model containing 
conventional risk factors did not importantly improve risk discrimination, nor classification of 
participants to risk categories of predicted 10-year risk.  
Conclusions BMI, WC and WHR are similarly associated with risk of cardiovascular disease, with 
much of the risk explained by intermediate risk factors. These clinical measures of adiposity do not 
importantly improve cardiovascular risk prediction when additional information is available on blood 
pressures, history of diabetes and lipids. 
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PREFACE 
 
The aim of this thesis was to investigate in detail the association of clinical measures of 
adiposity, such as body-mass index, waist circumference and waist-to-hip ratio, with risk of 
cardiovascular disease. During my doctoral studies, I have also conducted research on adult 
stature and risk of cause-specific mortality and vascular morbidity, which is presented in the 
appendix.  
 
This dissertation is the result of my own work and includes nothing which is the outcome of 
work done in collaboration except where specifically indicated in the text. 
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CHAPTER 1: Introduction  
 
Summary 
Although the mortality rate of cardiovascular disease has decreased in many European 
countries and in North America during the past 50 years, cardiovascular disease is still the 
leading cause of death worldwide, responsible for over 17 million annual deaths. At the same 
time, there has been a dramatic increase in the prevalence of obesity, resulting in more than 1 
billion overweight adults and 300 million obese worldwide. Excess body fat has been 
associated with metabolic perturbations and an increased risk of cardiovascular disease and 
other chronic diseases in numerous epidemiological studies. Although adiposity has been 
recognised as a major cardiovascular risk factor, the relative importance of overall adiposity 
versus body fat distribution is still unclear. Body-mass index (BMI) is an indirect measure of 
overall adiposity, while waist circumference (WC) and waist-to-hip ratio (WHR) are surrogates 
of abdominal adiposity. This thesis aims to characterise more reliably than has previously been 
possible the associations of BMI, WC and WHR with cardiovascular disease under a range of 
different circumstances through re-analysis of individual participant data from prospective 
observational studies. This chapter describes the biology of adiposity, reviews the current 
evidence on the relationship between clinical measures of adiposity and cardiovascular 
disease, and outlines the aims of the thesis. 
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Background 
Despite the reduction in the cardiovascular mortality rate in many European countries and in 
North America in recent decades, cardiovascular disease is still the leading cause of death 
worldwide, including the UK.1-3 According to World Health Organization estimates from 2004, 
about one third of all global deaths can be attributed to cardiovascular disease.4 It is estimated 
that worldwide 7.2 million people die annually from coronary heart disease and 5.7 million 
people from stroke.5 In the USA in 2007, one in every 2.9 deaths resulted directly from 
cardiovascular disease and one in every 6 deaths from coronary heart disease.6 In the UK, 
cardiovascular disease accounted for almost 200,000 deaths in 2008. About half of these 
cardiovascular deaths were from coronary heart disease and more than a quarter were from 
stroke.3 In the UK in 2008, the yearly overall costs of cardiovascular disease alone are 
estimated to be nearly £31 billion, including the direct costs of health care, indirect losses to 
productivity and other informal care costs.3 Equivalent figures for the EU and the USA are 
around €169 billion and $287 billion, respectively.6,7  
 
The objectives of this chapter are to describe the biology of adiposity, review the current 
evidence on the relationship between clinical measures of adiposity and cardiovascular 
disease, and outline the aims of the thesis. 
 
Cardiovascular disease 
The term cardiovascular disease embraces all disorders that affect the cardiovascular system, 
such as coronary heart disease, cerebrovascular disease/stroke, heart failure and other 
vascular diseases.8 Most types of cardiovascular disease involve chronic pathologic processes 
that lead to acute outcomes, such as myocardial infarction or sudden cardiac death. Coronary 
heart disease, also called ischaemic heart disease or coronary artery disease, is the most 
common form of cardiovascular disease, and refers to a group of related syndromes resulting 
from myocardial ischemia – an imbalance between the capacity of the coronary vessels to 
supply sufficient blood flow and the myocardial oxygen demand.8-10 The basic clinical 
manifestations of coronary heart disease are stable angina, acute coronary syndrome 
(including myocardial infarction and unstable angina), heart failure, arrhythmia and sudden 
cardiac death.8-10 Stroke refers to an interruption of the blood supply to any part of the brain. 
Ischaemic stroke (the most common type) results from an obstruction in the blood vessels, 
while haemorrhagic stroke occurs when a weakened blood vessel ruptures and bleeds into the 
surrounding tissue.11 Because of the complex anatomy of the brain and its vasculature, the 
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clinical manifestations of stroke are highly variable, but commonly include inability to move one 
or more limbs on one side of the body, or to understand or formulate speech.12 
 
Both coronary heart disease and ischaemic stroke are almost always caused by atherosclerotic 
narrowing of arteries due to progressive accumulation of lipids and fibrous elements in lesions 
within the arterial wall (Figure 1.1).10,13,14 Following endothelial damage or dysfunction, which 
may be stimulated by factors such as smoking and type II diabetes, low-density lipoprotein 
(LDL) cholesterol particles enter the arterial wall where they are oxidised by macrophages and 
smooth muscle cells. Additional mono-nuclear cells such as monocytes are attracted to the site 
of damage, where they engulf LDL cholesterol and become foam cells.10,13,14 Accumulation of 
foam cells and proliferation of smooth muscle cells results in growth of the plaque. Apoptosis, 
matrix degradation and release of inflammatory mediators generate a vulnerable plaque with a 
thin fibrous cap and a lipid-rich core. If the cap ruptures, contact between core molecules and 
coagulation factors in the blood results in formation of a thrombus that can cause acute 
occlusion of the vessel.13-16 Either progressive or acute occlusion of the artery may lead to 
impeded blood flow, ischaemia, and infarction of the cardiac or cerebral tissue.10,13,14 
 
Risk factors for cardiovascular disease 
Over the last 50 years, more than 300 risk factors have been correlated to the occurrence of 
coronary heart disease and stroke, although most of them are of uncertain causal relevance.1 
In addition to the known non-modifiable risk factors, such as age and family history of 
cardiovascular disease, epidemiological and other studies have indentified a range of 
modifiable cardiovascular risk factors, including smoking, diabetes, and elevated blood 
pressure and cholesterol levels.17-20 Because of these insights, improved strategies for primary 
and secondary prevention, as well as prognosis and treatment regimes have been developed 
that have contributed to a reduction in cardiovascular morbidity and mortality in many 
countries.21-25 However, these established risk factors do not entirely explain coronary heart 
disease incidence26 and existing interventions do not entirely eliminate cardiovascular 
risk.24,27,28 
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Adiposity 
Obesity or adiposity is generally defined as a condition of abnormal or excessive fat 
accumulation, which results in an impairment of physical or psychological health.29,30 The 
World Health Organization criteria define overweight as a body-mass index (BMI) of at least 25 
kg/m2 and obesity as a BMI of at least 30 kg/m2 (Table 1.1).31 Over the past few decades, 
there has been a dramatic increase in the prevalence of obesity, resulting in more than 1 billion 
overweight adults and 300 million obese worldwide (Figure 1.2).1,32,33 In the United States, the 
prevalence of obesity more than doubled between 1960 and 2004, rising from 15.0% to 31.1% 
in adult men and from 15.1% to 33.2% in adult women.34,35 In 2007-2008, the prevalence of 
obesity was 32.2% among men and 35.5% among women.36 In the majority of European 
countries, the proportion of obese individuals increased by about 10% to 40% in the last ten 
years.31 Estimates of the prevalence of obesity vary considerably, ranging from 4.0% to 28.3% 
in men and from 6.2% to 36.5% in women.37 The highest prevalences were observed in 
regions of Italy and Spain in both sexes, as well as in Portugal, Poland, the Czech Republic, 
Romania, and Albania in Women. The lowest prevalences were observed in regions of France 
and Austria. Overall, Western and Northern Europe showed a lower prevalence of obesity 
compared to Eastern Europe and Mediterranean countries (Figure 1.3).37 England has 
observed a particularly dramatic increase in prevalence. The proportion of obese adults 
increased from 13.2% in 1993 to 23.7% in 2006 for men and from 16.4% in 1993 to 24.2% in 
2006 for women.38 In the UK, the yearly direct cost of overweight and obesity is estimated to 
be around £3.2 billion, representing around 5% of the costs of the National Health Service.39 
Equivalent figures for the USA are $61 billion.40 
 
Excess body fat has been linked with cardiovascular disease and other chronic diseases in 
various epidemiological studies.41 Obesity is a heterogeneous disorder that is closely 
associated with metabolic perturbations. It impacts unfavourably on the prevalence of 
cardiovascular risk factors, such as impaired glucose tolerance, type II diabetes, hypertension, 
and dyslipidemia – all important contributors to the processes underlying the development of 
atherosclerosis.42,43 Adipose tissue in the abdominal region, particularly in the visceral area, 
has been suggested to be an important risk factor for a range of metabolic abnormalities, which 
impact cardiovascular morbidity and mortality.44-47 In light of the epidemiological evidence, the 
American Heart Association and the American Diabetes Association have called for action and 
have reclassified obesity as a major modifiable risk factor.48-50 
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Biological evidence linking adiposity with cardiovascular disease 
Current understanding of the biology of adipose tissue suggests that this is not merely a 
repository for excess body fat but, instead, a dynamic organ involved in various metabolic 
processes capable of affecting several organs and physiological systems in the body. There is 
increasing evidence to suggest that the adverse effects of excess body fat are mediated 
through the interplay of several factors (Figure 1.4) including: increases in the fat mass per se, 
its pattern of distribution and the physiological consequences thereof; alterations in lipid 
metabolism; insulin resistance; inflammation; activation of the coagulation cascade; endocrine 
and paracrine effects of adipose tissue; increased oxidative stress; and the co-occurrence of 
other cardiovascular risk factors with obesity.51,52 
 
An increased whole body fat mass, in particular abdominal fat, has been linked to increased fat 
content of the liver and the deposition of fat in ectopic areas such as the heart, blood vessels 
and the kidneys, resulting in impaired function of these organs due either to mechanical effects 
or to the intracellular deposition of lipids and consequent cellular damage (lipotoxicity).51,52 This 
is particularly important in peripheral vessels where periadventitial fat deposition has been 
shown to increase arterial stiffness – a phenomenon compounded by the release of growth 
factors from adipose cells which leads to vascular smooth muscle cell growth.51 Adiposity also 
results in increased cardiac output, increased peripheral vascular resistance, increased effort 
of breathing and reduced functional reserve volume of the lung with important cardio-
respiratory consequences.52 In Pickwickian syndrome (seen in severe obesity) there is, 
additionally, a restrictive type of lung defect with hypoventilation.  
 
However, perhaps even more important than the mechanical consequences of obesity are the 
physiological and metabolic perturbations it causes. Obesity, in particular visceral adiposity, 
leads to several qualitative and quantitative changes in lipid metabolism, a phenomenon 
compounded by the close proximity of abdominal fat to the liver. The increased lipolytic state of 
obesity is responsible for the delivery of large amounts of non-esterified fatty acids (NEFAs) to 
the liver where they are converted to triglyceride-rich very low density lipoprotein (VLDL) 
particles and, by the action of cholesteryl ester transfer protein (CETP), to triglyceride-rich LDL 
cholesterol particles. CETP activity is upregulated in obesity, as is hepatic lipase activity. By 
contrast, lipoprotein lipase (LPL) enzyme activity is reduced. The net result of these changes is 
the characteristic dyslipidemia of obesity: increased VLDL, triacylglycerols, triglyceride and 
small dense LDL particles and decreased high density lipoprotein (HDL) concentrations.51 
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Small dense LDL particles are highly atherogenic due to their ability to penetrate endothelial 
fenestrations and reach the subendothelial spaces where they are taken up by the 
macrophage scavenger receptor (rather than LDL receptor) setting off a series of events that 
lead to the development of atherosclerotic plaques.43,51 Furthermore, an increased production 
of reactive oxygen species (ROS) in obesity leads to the oxidation of LDL particles (ox-LDL) 
that are in turn taken up by macrophages of the arterial wall, also contributing to atheroma 
formation.51 In addition to these direct proatherogenic effects of obesity, there are several 
indirect effects of the dyslipidemic state. For instance, increased NEFA levels impair 
endothelium-dependent vasodilation (as a consequence of reduced endothelial nitric oxide 
production), increase myocardial stress (through increased oxygen demand of cardiomyocytes 
and an impairment in their contractile function), and contribute to the insulin-resistant state of 
adiposity.51 On the other hand, reduced HDL-cholesterol levels along with reduced HDL 
particle size have been shown in vitro to be less efficient in reducing oxidative stress.43 Thus, 
both direct and indirect effects of lipid dysregulation may be responsible for the atherosclerosis 
and vascular complications of obesity. 
 
One of the principal consequences of excess body fat (especially abdominal fat) is the 
development of insulin resistance and related metabolic effects. Insulin resistance in the liver 
and peripheral tissues results in glucose intolerance, excess production of NEFAs, increased 
production of small dense LDL and reduced clearance of apolipoprotein-B and triacylglycerol-
rich lipoproteins, as well as delayed clearance of VLDL.51 As described earlier, small dense 
LDL particles are highly atherogenic and, together with other abnormalities characteristic of 
insulin resistance syndromes, contribute to the excess burden of atherosclerosis in obesity. 
Besides, insulin resistance has also been shown to cause direct injury to cardiomyocytes 
leading to reduced glucose uptake and impaired contractile function thereof.51 Additionally, 
insulin resistance is also associated with the release of several adipocytokines, which have 
important biological effects (see below). 
 
In addition to fat cells (adipocytes), which constitute the major cell type, adipose tissue is also 
composed of macrophages, fibroblasts and other cells which appear in increased proportions 
in obesity. These cells produce cytokines, inflammatory mediators and procoagulant 
substances which are closely linked to the atherosclerotic process. Some of these molecules 
(like TNF-α, IL-1β and IL-6) stimulate the liver to generate additional bioactive substances 
including: (a) inflammatory markers (e.g. IL-8, IL-10, IL-15, complement factors B, D, C3, and 
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C-reactive protein [CRP]); (b) procoagulant substances (e.g. PAI-1, P-selectin, VCAM-1, ICAM-
1, fibrinogen, tissue factor, von Willebrand factor and factor VII); (c) adipocytokines; and (d) 
vasoactive substances (e.g. angiotensinogen).43,51,53 Increased circulating levels of some of 
these markers (such as TNF-α and IL-6) are associated with insulin resistance, increased CRP 
production and stimulation of the hypothalamic-pituitary-adrenal axis and, in combination with 
increased clotting factor levels and fibrinogen levels as well as decreased fibrinolysis, result in 
vascular injury and atherothrombosis.53 
 
As stated previously, adipose tissue exerts endocrine and paracrine functions through the 
production of several adipocytokines. In obese individuals, increased levels of leptin, a 
molecule which influences food intake and energy expenditure, have been implicated in insulin 
resistance, atherogenesis, increased platelet aggregation and vascular thrombosis.51 Raised 
leptin levels also activate the central sympathoregulatory pathways resulting in hypertension 
and vascular damage.43,53 Leptin may also play a role in vascular calcification – a marker of 
coronary atherosclerosis.51 Whilst adiposity leads to increased leptin levels, it produces an 
opposite effect on adiponectin concentrations. Adiponectin has been associated with several 
beneficial effects such as improvements in insulin sensitivity of the liver and peripheral 
organs,51,53 anti-inflammatory effects, inhibition of the expression of intercellular adhesion 
molecules such as ICAM-1, VCAM-1 and E-selectin, and inhibition of foam cell formation within 
the atheroma as a result of inhibition of MMP enzyme activity.51 Thus, reduced levels of 
adiponectin in obesity result in an increased propensity for atherothrombosis. Other biologically 
important mediators secreted in increased amounts in obesity include visfatin, 
angiotensinogen, ACE, angiotensin II and VEGF.43,51,53 Visfatin is correlated with visceral fat 
depots and is believed to exert insulin-mimetic functions and promote adipogenesis.51 
Angiotensinogen, ACE and angiotensin II exert a vasoconstrictive influence on the vascular 
smooth muscle whilst VEGF promotes vascular smooth muscle cell proliferation and growth, 
resulting in vasculopathy and hypertension.43,51,53 
 
An important consequence of the aforementioned phenomena related to adiposity is the 
development of other co-morbid conditions like type II diabetes and hypertension among 
overweight and obese individuals. Insulin resistance, activation of the renin-angiotensin system 
and sympathetic nervous system, decreased endothelium-dependent vasoreactivity and further 
augmentation of arterial thickness by VEGF are amongst the factors incriminated in the 
development of these additional cardiovascular risk factors in obesity. 
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Measurement of adiposity 
Various methods exist for accurate measurement of the amount and distribution of body fat. 
Traditional methods, such as underwater weighing (densitometry) and isotope dilution 
(hydrometry), calculate body composition based on a two-compartment model that divides 
body weight into fat mass and fat-free mass.54 Multi-compartment models that directly measure 
bone mineral, fat, protein and other components provide more accurate measurement of body 
composition.54 For instance, the Dual-Energy X-Ray Absorptiometry (DXA) is a frequently used 
technique to estimate body composition in clinical studies.55 It provides accurate 
measurements of the three components (fat mass, fat-free mass and bone mineral density) for 
the whole body, as well as for specific body regions. Imaging methods are considered the most 
accurate technique for measuring body composition and ascertaining fat distribution at the 
tissue-organ level.56 Computer tomography and magnetic resonance imaging produce high-
resolution images of selected tissue and organs to accurately quantify percentage body fat, 
and visceral and subcutaneous fat.57 Although these techniques are highly reproducible and 
accurate, they are very expensive and time consuming and therefore may not currently suitable 
for clinical settings and most large-scale epidemiological studies (although UK Biobank, a 
prospective study of 500,000 people, may be an exception). For this reason, most studies 
measure weight, height and other anthropometric variables to assess amount and distribution 
of body fat. The following two sections discuss the properties of BMI, waist circumference (WC) 
and waist-to-hip ratio (WHR).  
 
Body-mass index 
BMI, defined as the ratio of weight in kilograms to the square of height in metres, represents a 
simple, but crude index that is widely used to indirectly estimate overall or general adiposity 
(without taking into account fat distribution). Overall adiposity has been generally expressed as 
a percentage of body fat (100×fat mass/total mass).58 The validity of BMI has been 
demonstrated by various studies, as BMI correlates with percentage body fat that was 
assessed by superior techniques.59-61 BMI values are considered age and sex independent.31 
BMI is recommended as the most useful epidemiological measure of obesity by the World 
Health Organization.31 Their guidelines define BMI between 18.5 and 24.9 kg/m2 as normal, 25 
kg/m2 or higher as overweight and 30 kg/m2 or higher as obese (Table 1.1).31 
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Although BMI correlates well with body fat and predicts cardiovascular outcomes, the measure 
itself has some major limitations. BMI cannot distinguish between fat mass and lean (fat-free) 
mass, leading to potentially substantial differences in percentages of fat mass between 
individuals with similar BMI.31,57 BMI values do not correspond to the same degree of fatness 
across the different populations because of ethnic variation in body composition. For instance, 
the percentage of body fat tends to be higher in whites than in blacks for a given BMI. Studies 
have shown that, although black individuals generally have higher BMI values compared with 
white individuals, the percentage of body fat as assessed by DXA is similar in blacks and 
whites.59,62 By contrast, the percentage of body fat is generally higher in Asian than in 
Caucasian populations for a given BMI.63 Asians have been shown to be at increased risk of 
type II diabetes and cardiovascular disease at BMI values lower than the existing World Health 
Organization cut-off point for overweight (ie, ≥25 kg/m2).64 However, because there were no 
clear cut-points for overweight and obesity in all Asian populations, the World Health 
Organization expert consultation decided not to lower the BMI cut-points for Asians.64 
Moreover, for a given BMI, body fat varies considerably between men and women.59,65,66 
Because men develop more lean body mass, especially bone mass and skeletal muscle, the 
percentage of body fat is generally higher in women than in men for the same BMI.57,67 Also, 
BMI estimates lose reliability in persons of extreme heights and with very muscular builds.29 
Among older individuals, body fat estimated by BMI can be considerably erroneous due to 
some increase in fat mass and substantial loss of lean body mass during the aging 
process.58,59,68,69 Thus, the interpretation of BMI as a measure of body fatness among an 
elderly population may be even more complex.  
 
Waist circumference and waist-to-hip ratio 
Location of body fat or body fat distribution has been recognised to be associated with several 
obesity-related diseases.70 There is growing evidence that android obesity (ie, excess fat mass 
in the upper part of the body, such as the abdomen) is more strongly linked with metabolic 
abnormalities, which could subsequently lead to cardiovascular disease, than gynecoid obesity 
(ie, fat accumulation in the lower part of the body, such as the hips and thighs).57,71,72 
Particularly, visceral adipose tissue in the abdominal region is believed to be more 
metabolically active than other fat depots, such as abdominal subcutaneous fat.73  
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Waist circumference (WC) and waist-to-hip ratio (WHR; defined as the ratio of circumference in 
waist to hip), are indirect measures of fat mass in the abdominal or central body region. 
Although these measures take into account body fat distribution and have been validated, they 
have been criticised for failing to distinguish between abdominal visceral fat and abdominal 
subcutaneous fat.47,57,73-75 WC is commonly measured at the midpoint between the lowest rib 
margin and the iliac crest, at the level of the umbilicus, or at the narrowest WC.76 Hip 
circumference is typically measured at the maximal circumference over the buttocks.57 While 
the interpretation of WC is straightforward (ie, WC is simply a proxy of abdominal fat), the 
interpretation of WHR is a bit more complex. Higher values of WHR can be due to both 
increased abdominal fat mass (ie, reflected in higher WC) and/or reduced gluteofemoral 
muscle or fat mass (ie, reflected in lower hip circumference).57,73 Because the risk associated 
with particular values of WC or WHR differs across ethnic populations and sex, no cut-points 
are available globally.31 
 
Epidemiological evidence linking adiposity with cardiovascular disease 
Overall adiposity and cardiovascular risk 
Several key publications in recent years have reported on the association between overall 
adiposity, as measured by BMI, and risk of cardiovascular disease. These large-scale 
observational studies have varied considerably with regard to their study design and participant 
characteristics, and used different methodologies to collate data. The INTERHEART study, the 
largest multinational case-control study of acute myocardial infarction to date which involved 
data on approximately 12,000 cases and 15,000 controls from 52 countries, reported modest 
and graded associations between BMI and myocardial infarction.46 These relations, however, 
disappeared after adjusting for potential confounders (such as smoking, physical activity, 
alcohol consumption, diet and psychosocial factors) and potential mediating risk factors (such 
as apolipoprotein-AI and -B, hypertension and diabetes). Since results based on case-control 
studies, however robust they may be, have inherent limitations such as biases due to selection 
bias and reverse causality, findings from prospective study designs are generally considered 
more informative. Data from the prospective Physicians’ Health Study (PHS),77 involving 
16,332 men and 1,505 cardiovascular events, and the Women’s Health Study (WHS),77 
involving 32,700 women and 414 cardiovascular events, showed that higher BMI levels are 
generally associated with an increased risk of cardiovascular disease, even after controlling for 
several potential confounders, such as age, smoking, physical activity, ethnicity, alcohol 
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consumption and family history.A A systematic review of prospective cohort studies reporting 
on the association between BMI and coronary heart disease risk has shown both positive and 
J-shaped associations (ie, the risk being greatest at the extremes of BMI with a graded, non-
linear increase in risk above the optimum) between BMI and risk of coronary heart disease.78 
Among the larger studies included in this review, the average increase in coronary heart 
disease risk for each 2 kg/m2 higher BMI was 14%. 
 
Although systematic reviews and literature-based meta-analyses offer useful summary data on 
various exposure-disease associations, they have some limitations (Chapter 1 on page 14). 
Individual participant data meta-analyses overcome these deficiencies by pooling subject-level 
data from various studies and by applying uniform methods for their analyses. For example, 
the Asia Pacific Cohort Studies Collaboration (APCSC) pooled data from 33 cohort studies 
from the Asia-Pacific region with information on 310,000 participants and 3,332 stroke and 
2,073 coronary events.79 Age, sex and smoking adjusted findings of the APCSC have shown a 
continuous, positive and significant association between baseline BMI and risk of ischaemic 
stroke, haemorrhagic stroke and coronary heart disease, with each 2 kg/m2 lower level of BMI 
associated with a 12% (95% confidence interval [CI] 9% to 5%) lower risk of ischaemic stroke, 
8% (95% CI 4% to 12%) lower risk in haemorrhagic stroke and 11% (95% CI 9% to 13%) lower 
risk of coronary heart disease. More recently, the Asia Cohort Consortium BMI Project, a 
collaboration with more than 1.1 million participants from 19 cohorts in Asia, showed that 
underweight in Asians was associated with a substantially increased risk of death, including 
death from cardiovascular disease.80 The Prospective Studies Collaboration (PSC) 
investigated the association between BMI and cause-specific mortality, by pooling primary data 
from 57 prospective studies with 900,000 participants from Western populations.41 After 
controlling for age, sex and smoking status, BMI and death from coronary heart disease were 
positively and strongly associated throughout the BMI range from 20 to 40 kg/m2. In the BMI 
range 25 to 50 kg/m2, each 5 kg/m2 higher baseline BMI level was associated with about 40% 
higher risk of death from coronary heart disease, while in the lower BMI range (15 to 25 kg/m2) 
each 5 kg/m2 higher baseline BMI level was associated with about 22% higher risk of death 
                                                 
A
 PHS and WHS are sex-specific prospective cohort studies. Compared to the reference category (22.5 to 24.9 
kg/m2), the adjusted relative risk for cardiovascular disease for men in PHS was 0.83 (95% CI 0.55-1.24) in the 
lowest BMI category (BMI<20 kg/m2) and 2.12 (95% CI 1.36-3.30) in the highest BMI category (BMI ≥35 
kg/m2).77 Corresponding relative risk ratios in the WHS were 0.89 (95% CI 0.54-1.02) in the lowest BMI 
category and 2.11 (95% CI 1.46-3.05) the highest BMI category.77 
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from coronary heart disease. In this study, the optimal BMI range as regards stroke mortality 
was between 22.5 and 25 kg/m2. As for coronary heart disease, each 5 kg/m2 higher BMI level 
in the higher BMI range (25 to 50 kg/m2) was associated with about 40% increase in stroke 
mortality. Despite a positive relationship between BMI and systolic blood pressure across all 
values, there was no evidence of a positive association between BMI and stroke in the lower 
BMI range (15 to 25 kg/m2). The flattening of the association with stroke mortality at lower BMI 
values was not removed after excluding participants who had ever smoked. A large meta-
analysis with individual records from 388,622 individuals from 26 Western cohort studies with 
18,000 coronary events, demonstrated that the adverse affects of adiposity are partially 
mediated by blood pressure and cholesterol levels.81 The relative risk for coronary heart 
disease per 5 kg/m2 higher baseline BMI reduced from 1.29 (95% CI 1.22-1.35), after 
adjustment for age, sex, smoking status and physical activity, to 1.16 (95% CI 1.11-1.21) after 
further adjustment for baseline values of systolic blood pressure and total cholesterol. Because 
it lacked information on diabetes, other lipids and inflammatory markers, however, this study 
could not investigate whether the effect of BMI on coronary heart disease is independent from 
such intermediate risk factors. 
 
Overall versus abdominal obesity 
Although recent studies have shown that abdominal adiposity, as measured by WC or WHR, 
may be even more important in determining cardiovascular risk rather than overall obesity, 
these findings, however, have been inconsistent. Table 1.2 summarises the key features of 
prospective studies that reported on the association between overall adiposity (as assessed by 
BMI) and abdominal adiposity (as assessed by WC or WHR) with cardiovascular disease. 19 
prospective cohort studies77,82-99 and one meta-analysis,100 involving individual participant data 
from essentially general populations (ie, participants not selected on the basis of having 
cardiovascular or other chronic disease at baseline examination), reported adjusted 
associations between different measures of adiposity and cardiovascular risk. Overall, these 
findings show that central or abdominal adiposity is an important indicator of cardiovascular 
risk. For instance, the European Prospective Investigation into Cancer in Norfolk (EPIC-
Norfolk), involving more than 2,300 incident coronary heart disease cases in almost 23,000 
participants, reported adjusted relative risk estimates of 1.83 (95% CI 1.37-1.93) in men and 
2.20 (95%CI 1.67-2.90) in women, when comparing people in the upper versus lower quintiles 
of baseline WHR.83 When similar comparisons were made for BMI, the corresponding relative 
risks were 1.63 (95% CI 1.38-1.91) for men and 1.73 (95% CI 1.37-2.20) for women. By 
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contrast, the PHS reported somewhat stronger associations with BMI than with WHR.77 
Compared to the reference category (22.5 to 24.9 kg/m2), the relative risk for cardiovascular 
disease after adjusting for several confounders was 2.25 (95% CI 1.36-3.30) in the highest BMI 
category. Corresponding estimates for WHR were 1.64 (95% CI 1.07-2.52), when compared to 
the reference category (0.89 to <0.94). Similar findings were observed in the WHS.77 The 10-
country EPIC prospective study, a European prospective study involving 350,000 participants 
and 15,000 deaths (of which the aforementioned EPIC-Norfolk study was a part) showed that 
both general and abdominal adiposity are associated with the risk of death, including 
cardiovascular disease.89 
 
By comparison, WHR in the INTERHEART study showed a strong continuous positive 
association with acute myocardial infarction.46 The odds ratios with increasing WHR quintile 
were greater than the odds ratios associated with increasing BMI quintiles. Because the 
associations with WHR and WC remained significant even after adjustment for various 
cardiovascular risk factors (while BMI became non-significant), the authors suggested that 
abdominal adiposity, as assessed by WHR or WC, may act through biological mechanisms that 
differ from known risk factors. However, powerful examination of the associations of BMI, WC 
and WHR with such possible intermediate risk factors is currently lacking, making it difficult to 
understand the biological pathways underlying these associations. After adjustment for age, 
sex and geographical region, odds ratios per one standard deviation higher baseline WHR and 
WC were 1.37 (95% CI 1.34-1.41) and 1.19 (95% CI 1.16-1.22), respectively. The 
corresponding odds ratio for one standard deviation higher baseline BMI was 1.10 (95% CI 
1.07-1.13).  
 
In summary, there is no conclusive evidence on whether clinical measures of abdominal 
adiposity are more strongly associated with cardiovascular outcomes than is BMI, a measure 
of overall adiposity. These uncertainties may explain why national and international guideline 
statements have provided differing recommendations about the value of assessment of clinical 
measures of adiposity for prediction of cardiovascular disease in primary prevention.101 
Recommendations range from omission of adiposity measures to their inclusion as additional 
screening tests to their formal inclusion as risk factors in prediction models. For example, 
whereas the World Health Organization31 and the US National Heart, Lung and Blood 
Institute102 recommend BMI measurement as well as assessment of WC in people with a BMI 
between 25.0 and 34.9 kg/m2, several commonly-used cardiovascular risk scores omit 
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adiposity measures (eg, Framingham, SCORE, PROCAM, Reynolds), but others include BMI 
(eg, QRISK).103 
 
Individual participant data meta-analysis 
Meta-analysis is a statistical tool that combines results from similar studies in order to provide a 
pooled estimate. This technique can reduce bias, enhance precision, reduce exaggeration, 
assess consistency of results and help prioritise research.104 Literature-based meta-analysis 
does this by pooling aggregated data from published studies of similar methodology and 
quality. However, this method has several potential important shortcomings. It cannot provide 
(i) precise analyses of risk marker-disease associations under a range of different 
circumstances (including assessment of any interactions); (ii) reliable characterisation of the 
shape of exposure-risk relationship; (iii) consistent approaches to adjustment for confounding 
factors; or (iv) detailed investigation of heterogeneity by both study and individual-level 
characteristics. These limitations can be overcome by performing an individual participant data 
meta-analysis, in which individual data from relevant studies are combined and re-analysed in 
order to obtain a reliable estimate of the associations between exposure and disease outcome. 
This method has several advantages, including the following: ability to adjust in a consistent 
manner for common potential confounders across the separate studies, ability to explore 
heterogeneity by both individual and study-level characteristics, ability to investigate 
hypotheses not addressed in the original publication, ability to include non-published 
information, ability to extend and update follow-up information, and ability to check and 
harmonise data from different sources and, thus, to use common outcome and exposure 
definitions.105-107 Individual participant meta-analyses are, therefore, considered the gold 
standard of systematic review.  
 
Thesis outline 
The aims of this thesis are: (i) to assess precisely any lifestyle and biological correlates of BMI, 
WC and WHR; (ii) to determine the long-term within-person variability in BMI, WC and WHR; 
(iii) to characterise in detail the association of BMI with risk of first-ever vascular disease and 
cause-specific mortality (including investigation of the shape of any dose-response 
relationships; assessment of the role of confounders and biological mediators; exploration of 
potential sources of diversity); (iv) to characterise (and compare) in detail the associations of 
BMI, WC and WHR with risk of coronary heart disease and ischaemic stroke in participants 
 15
with concomitant information on weight, height, and waist and hip circumference, and (v) to 
investigate the ability of BMI, WC and WHR to predict cardiovascular disease. 
 
Chapter 2 describes the methods used to establish the Emerging Risk Factors Collaboration 
(ERFC), an individual participant meta-analysis with data from up to 121 prospective 
epidemiological studies of cardiovascular disease. It also describes the design of the analysis 
in the ERFC focused on the 118 studies with information on BMI only (Chapter 5 is based on 
data from this subset) and the 58 studies with concomitant information on BMI, WC and WHR 
(Chapters 3, 4, 6 and 7 are based on data from this subset). Chapter 3 reports the cross-
sectional correlates of BMI, WC and WHR with several conventional cardiovascular risk factors 
and other characteristics recorded in the ERFC. Chapter 4 reports on the long-term within-
person variability of BMI, WC and WHR using data on serial measurements available in the 
ERFC. Chapter 5 reports on shape, magnitude, specificity and mediation of associations of 
BMI with future risk of coronary heart disease, stroke and cause-specific mortality in the ERFC. 
Chapter 6 reports on shape, magnitude, specificity and mediation of associations of BMI, WC 
and WHR with risk of coronary heart disease and ischaemic stroke. Chapter 7 reports on the 
incremental predictive ability of BMI, WC and WHR for cardiovascular risk prediction. Chapter 
8 summarises the findings of the thesis, discusses strengths and limitations, and makes 
suggestions for future work. Appendix 1 lists the publications I have authored during my 
doctoral studies. Appendix 2 describes the rationale for using for some of the statistical 
analyses conducted. Appendix 3 reports findings from a research project on adult height and 
risk of vascular disease and death, undertaken during my doctoral studies. Appendix 4 lists 
the acronyms of the studies contributing to the ERFC.  
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Table 1.1 Classification of adult underweight, overweight and obesity according to body-mass 
index (BMI) 
 
Classification BMI (kg/m2)
Underweight <18.5
Severe thinness <16.00
Moderate thinness 16.00-16.99
Mild thinness 17.00-18.49
Normal range 18.50-24.99
Overweight ≥25.00
Pre-obese 25.00-29.99
Obese ≥30.00
Obese class I 30.00-34.99
Obese class II 35.00-39.99
Obese class III ≥40.00
 
 
Source: World Health Organization Consultation of Obesity. Obesity: Preventing and Managing the Global Epidemic. 
Division of Non-communicable Disease. 2000. Geneva, World Health Organization.  
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Table 1.2 Prospective studies reporting cardiovascular risks with BMI, WC and WHR in approximately general populations  
 
Thailand Aekplakorn et al., 2007 (80) Thailand CHD death, nonfatal MI 2 536 66 17 ↑ ↑ → Similar associations for WC and BMI
APCSC Asia Pacific Cohort 
Studies Collaboration, 2006 (98)
Asia & Australia CHD death, nonfatal MI 45 988 601 6 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
EPIC-Norfolk Canoy et al., 2007 (81) UK CHD death, nonfatal MI 22591 2600 9.1 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
ARIC Folsom et al., 1998 (82) US CHD death, nonfatal MI 14 040 398 6.2 ↑ NA ↑↑ Associations with WHR were particularly 
stronger in women
PHS Gelber et al., 2008 (75) US CVD death, nonfatal MI, 
nonfatal ischaemic stroke
16 332 1505 14.2 ↑↑ ↑↑ ↑ Similar associations for WC and BMI
WHS Gelber et al., 2008 (75) US CVD death, nonfatal MI, 
nonfatal ischaemic stroke
32 700 414 5.5 ↑↑ ↑↑ ↑ Similar associations for WC and BMI
PRIME Gruson et al., 2009 (83) France/Northern
Ireland
CHD death, nonfatal MI 10 602 659 10 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
KIHD Lakka et al., 2002 (84) Finland CHD death, nonfatal MI 1 346 123 10.6 ↑ ↑ ↑ Similar associations for all three 
adiposity measures
BWHHS Lawlor et al., 2006 (85) UK CHD death, nonfatal MI 3589 194 4.4 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
EPIC Pischon et al., 2008 (87) Europe CVD 359 387 3443 9.7 ↑ ↑ ↑ All three measures were associated with 
CVD, although no direct comparison was 
done
GOTO13 Larsson et al., 1984 (88) Sweden CHD death, nonfatal MI 792 91 13 → NA ↑
GOTOW Lapidus et al., 1984 (86) Europe CHD death, nonfatal MI 1462 73 12 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
MDC Li et al., 2006 (89) Sweden CHD deaths, nonfatal MI 
and ischaemic stroke
27007 1100 7 (↑)↑↑* NA (↑↑)↑* Analyses were stratified by sex
IWHS Prineas et al., 1993 (90) US CHD death 32 898 115 4 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
NHS Rexrode et al., 1998  (91) US CHD death, nonfatal MI 44 702 320 8 NA ↑ ↑ Similar associations for WC and WHR
HPFS Rimm et al., 1995 (92) US CHD death, nonfatal MI, CAS 29 122 420 3 ↑↑ NA ↑
Finland Silventoinen at al., 2003 (93) Finland CHD death, nonfatal MI 11 510 386  - → → →
HBS Terry et al., 1992 (94) US CHD death 84 910 1347 23 ↑ NA ↑ Similar associations for BMI and WHR
ARFPS Welborn et al. 2003 (95) Australia CVD death 9 206 81 11 → ↑↑ ↑↑ Similar associations for WC and WHR
WLH Yang et al., 2008 (96) Sweden CHD death, nonfatal MI 48 052 256 12 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
SWHS Zhang et al., 2004 (97) China CHD death, nonfatal MI 67 334 70 2.5 ↑ ↑↑ ↑↑ Similar associations for WC and WHR
CommentsEndpoint No ofparticipants WHRBMI
Direction of associations
WC
No of
events
Follow-up
(years)Study 
Author, Year of publication
(Reference) Location
 
 
Key: ↑, study reported positive association; ↑↑, study reported stronger positive association compared to that of other adiposity measure(s); →, study reported no significant 
association; APCSC, Asia Pacific Cohort Studies Collaboration; ARFPS, Australian Risk Factor Prevalence Study; ARIC, Atherosclerosis Risk in Communities Study; BMI, body-
mass index; BWHHS, British Women’s Heart and Health Study; CAS, coronary artery surgery; CHD, coronary heart disease; EPIC, European Prospective Investigation Into Cancer 
and Nutrition; GOTO43, Gothenburg Study 1943; GOTOW, Population Study of Women in Gothenburg; HBS, Harvard Build Study; HPFS, Health Professionals Follow-up Study; 
IWHS, Iowa Women's Health Study; KIHD, Kuopio Ischaemic Heart Disease Risk Factor Study; MDC, Malmo Diet and Cancer; MI, myocardial infarction; NHS, Nurses’ Health 
Study; PHS, Physicians' Health Study; PRIME, Prospective Epidemiological Study of Myocardial Infarction; SWHS, Shanghai Women's Health Study; WHR, waist-to-hip ratio; 
WLH, Women's Lifestyle and Health Cohort Study; WHS, Women’s Health Study; NA, not available. 
*Associations of WHR are stronger in women, while association of BMI stronger in men. 
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Figure 1.1 Plaque formation during atherosclerosis  
 
 
 
Source: Watkins H et al. Nat Rev Genet. 2006;7(3):163-173 
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Figure 1.2 Age-standardised mean BMI values in men (panel A) and in women (panel B) 
worldwide in 2008 
 
(A) Men 
 
 
 
(B) Women 
 
 
 
 
Source: Finucane et al. Lancet 2011;377:557-567 
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Figure 1.3 Regional variation in prevalence of obesity (BMI ≥30 kg/m2) in men (panel A) and 
women (panel B) in Europe 
 
 
Source: Berghöfer et al. BMC Public Health. 2008;8:200 
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Figure 1.4 Interplay between visceral adipose tissue and other pathways in the pathogenesis 
of atherosclerotic vascular disease  
 
 
Source: Van Gaal et al. Nature. 2006;444:875 
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CHAPTER 2: The Emerging Risk Factors Collaboration 
 
Summary 
The Emerging Risk Factors Collaboration (ERFC) is an individual participant data meta-
analysis of 121 prospective studies with information on lipid, inflammatory and/or metabolic 
markers, other established risk factors and characteristics, as well as major cardiovascular 
morbidity and/or cause-specific mortality. This chapter describes the methods used to establish 
the ERFC, and the data available for analyses on clinical measures of adiposity. 118 studies, 
involving more than 1 million participants with no known history of cardiovascular disease, had 
information on body-mass index, age and sex at baseline examination. 58 of these studies, 
involving more than 220,000 participants, had additional information on waist and hip 
circumference at baseline examination. Analysis of individual data from these studies in a 
meta-analysis should help to characterise more reliably and precisely than previously possible 
the association of adiposity measures with vascular and non-vascular outcomes under a range 
of different circumstances. 
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Background 
Many prospective observational studies have reported on the associations between clinical 
measures of adiposity and subsequent risk of coronary heart disease and/or other 
cardiovascular outcomes.1-24 However, individual studies have generally not been large 
enough to reliably characterise important features of these associations, including (i) reliably 
characterising the shape of any dose-response relationship; (ii) precisely estimating the 
magnitude of risk marker-disease association; or (iii) quantifying any potential variation of the 
association by levels of various relevant characteristics, such as by age groups or sex. 
Literature-based meta-analyses are primarily based on published data and, as described in 
Chapter 1 on page 14, have some important limitations.  
 
Re-analysis of individual data from a comprehensive set of relevant prospective studies can 
help to overcome the limitations of individual studies and literature-base meta-analyses. The 
Emerging Risk Factors Collaboration (ERFC) was set up to facilitate detailed evaluation of the 
association of emerging and established risk factors with cardiovascular disease. By October 
2010, it involved individual participant data on over 1.3 million participants from 121 cohorts in 
predominantly Western populations (Figure 2.1).3,5,8,14,25-112 The ERFC builds on and 
complements two existing collaborative meta-analyses of individual data from prospective 
studies of cardiovascular disease. The Prospective Studies Collaboration (PSC) consists of 
approximately 1 million participants from 61 cohort studies.113 It is also based on studies from 
predominantly Western populations and thus, involves a number of the same cohorts as in the 
ERFC. But, whereas the ERFC collected data on lipid, inflammatory and metabolic markers 
and recorded both major cardiovascular morbidity and cause-specific mortality, the PSC 
focused principally on blood pressure,114 total cholesterol115 and body-mass index (BMI)116 
(without any information on abdominal adiposity, ie, waist and hip circumference) in relation to 
cause-specific mortality. The Asia Pacific Cohort Studies Collaboration (APCSC), involving 44 
cohorts with 600,000 participants from mostly East Asian populations, recorded data on lipids 
and other markers in relation to cardiovascular morbidity and mortality.117 However, as the 
APCSC involves mostly East-Asian participants who tend to have much lower incidence of 
coronary heart disease than Western participants, it has so far recorded only a small fraction of 
the incident coronary outcomes available in either the ERFC or the PSC. As the ERFC, the 
APCSC collected information on both overall and abdominal adiposity.21 Because body 
composition differs between Western and East-Asian populations, however, findings from the 
APCSC may not be generalisable to Western individuals.118 The overlap between these three 
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collaborations is small. Whereas approximately 20% of the data in the ERFC overlap with the 
PSC, there is virtually none between the ERFC and the APCSC.  
 
This chapter presents the objectives of the ERFC, the methods of study identification, data 
collection and study management, a brief overview of the statistical methods, and a summary 
of the available data on adiposity measures. The majority of the information presented has 
previously been published as a protocol for the ERFC.119 
 
Objectives of the Emerging Risk Factors Collaboration 
The primary objectives of the collaboration were: (i) to assess, in people without known 
cardiovascular disease at baseline examination, the age and sex-specific associations of major 
lipids (ie, high-density lipoprotein [HDL] and low-density lipoprotein [LDL] cholesterol, and 
triglyceride), inflammatory markers (eg, C-reactive protein [CRP]) and other risk cardiovascular 
risk factors (eg, adiposity measures or diabetes) in relation to first-ever confirmed non-fatal 
myocardial infarction or coronary death, before and after taking into account within-person 
variability; (ii) to determine to what extent any associations with coronary heart disease are 
independent of possible confounding factors; (iii) to assess any joint effects (ie, effect 
modification) with established and emerging risk factors; (iv) to determine any incremental 
predictive value of these markers for cardiovascular disease, either separately or in 
combination, beyond that provided by established risk factors; and (v) to enable detailed 
exploration of potential sources of heterogeneity for each marker, involving both study-level 
characteristics (such as geographical region or study design) and individual-level 
characteristics (such as age, sex and levels of several established risk factors). Secondary 
objectives included: (i) investigating associations of these markers in relation to other vascular 
and non-vascular conditions; (ii) examining the cross-sectional correlates of these markers; 
and (iii) quantifying long-term within-person variability for each marker over time. 
 
Identification of relevant studies and collection of data 
Selection criteria and identification of studies 
The initial focus of the collaboration was on circulating lipid markers (such as triglyceride, LDL 
and HDL cholesterol, lipoprotein(a) [Lp(a)] and apolipoprotein-AI and -B) and circulating 
markers of inflammation (such as CRP, albumin and leukocyte count). In 2009, the ERFC 
agreed to extend the collaboration to analyses to adiposity and other metabolic markers in 
relation to vascular disease and cause-specific morality.. Studies with information on relevant 
 31
markers were identified either in previously published meta-analyses, with additional studies 
indentified through updated computer-assisted literature searches of databases, scanning of 
reference lists, hand-searching of relevant journals and correspondence with authors of 
relevant studies. Prospective studies (reported variously as observational cohort studies, trials 
or analyses of nested case-control studies or case-cohort subsets) were eligible to participate 
in the ERFC if the following criteria were met: (i) data were available from baseline for at least 
one of the relevant markers; (ii) at least one year of follow-up; (iii) participants were selected 
from population-based samples (ie, were not selected on the basis of having previous 
cardiovascular diseases); and (iv) information on cause-specific mortality and/or major 
cardiovascular morbidity was collected during follow-up. Studies were prioritised for inclusion if 
they were known to have recorded at least 20,000 person-years at risk. Studies with data on 
adiposity measures were prioritised for inclusion if information on anthropometric indicators 
was measured by a trained person rather than self-reported. All, except two of the contacted 
studies agreed to provide data on adiposity measures to the ERFC.  
 
Baseline covariates and characteristics recorded 
Data were sought from investigators for each individual on lipids, inflammatory and metabolic 
markers and other characteristics recorded at the baseline survey and at any subsequent 
surveys during follow-up to enable study-specific correction for regression dilution.120,121 Table 
2.1 lists the core variables that were sought (where available) from the initial baseline 
examination. Information on categorical variables, such as alcohol consumption status, 
physical activity and smoking status, has been systematically re-coded to maximise 
comparability amongst studies. Similarly, data from all subsequent resurvey examination were 
sought. Collection of data on sex, age at baseline and at the disease event (or at last follow-up) 
enabled age and sex-specific analyses. Data have been collected on features of study design 
(eg, population sampling framework, geographical location: Tables 2.2-2.3), blood storage and 
handling conditions, and measurement methods (eg, methods to assess waist and hip 
circumference: Table 2.4) used to help to characterise baseline evidence of coronary disease.  
 
Outcome studied 
For each individual, data have been sought on any of the following outcomes and their dates of 
occurrence: non-fatal coronary heart disease; non-fatal stroke; cause-specific mortality (or at 
least occurrence of fatal coronary heart disease and fatal stroke) and other cardiovascular 
outcomes. Precise details of the diagnostic criteria used for the definition of cases were sought 
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from each study (as were data on the completeness of follow-up in the prospective studies). 
Analyses were based on events classified according to codings from the International 
Classification of Diseases to at least three digits (outcome definitions are provided in Table 
2.5) or, when unavailable, on study-specific classification systems. Attribution of death refers to 
the primary cause provided (or in its absence, the underlying cause provided) on death 
certificates. Non-fatal events that occurred on the same day were ranked as described in Table 
2.6, and only the highest ranked event contributed to the primary analysis.  
 
Data transfer and checking 
Data were transferred from the individual studies to the coordinating centre using machine-
readable formats convenient to the collaborator(s). Data were accepted in whatever format 
they were originally coded and stored by the study investigators. The data obtained from each 
participating study have been checked for internal consistency by the coordinating centre and 
any queries referred back, in confidence, to the study collaborator(s). Data were converted to a 
standard format for incorporation into a central database to be used for combined analyses. 
The content of the data were unchanged by this process, and computer-generated detailed 
summary tabulations based on the converted data were returned to each collaborator for 
review and confirmation. Figure 2.2 describes the steps involved in data sharing, checking and 
ratification.  
 
Study management 
Confidentiality of data provided 
The data provided from each study remain entirely the property of the principal investors of that 
study, and were held in strict confidence by the coordinating centre. Anonymous data on 
individual participants in each of the studies were stored securely on the computer database at 
the coordinating centre. The database at the coordinating centre is protected by two firewalls 
and a password-entry system accessible only to designated staff working under the 
supervision of the study coordinator. Only the coordinating centre has direct access to the 
combined dataset, and investigators retain the right to withdraw their data from some or all of 
the meta-analyses. 
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Ethical approval 
The ERFC was approved by the Cambridge Ethics Review Committee (Cambridgeshire, UK). 
In addition, each of the studies included has previously received local institutional review board 
approval and consent from participants.  
 
Statistical methods 
Details of the statistical analyses have been published.122 Briefly, the principal analyses 
adopted by the ERFC involved a two-stage approach with estimates of association calculated 
separately within each study before pooling across studies by random effects meta-analysis. 
Most of these study-specific estimates were based on Cox proportional-hazards regression 
models, stratified, where appropriate, by sex and trial arm. Detailed descriptions of relevant 
statistical methods are provided in Chapter 3 (cross-sectional correlates), Chapter 4 (within-
person variability), Chapters 5-6 (associations with disease risk) and Chapter 7 (risk 
prediction).  
 
Summary of data available 
Summary of data available on body-mass index  
By October 2010, 121 prospective studies of cardiovascular disease, involving 1.3 million 
participants, had shared individual records. 118 of these studies, involving 1,064,541 
participants, had information at baseline on weight and height (hence BMI), after exclusion of 
participants with known history of cardiovascular disease (ie, myocardial infarction, angina, 
stroke or other cardiovascular events) at initial ("baseline") examination (Figure 2.3). Three 
studies participating in the ERFC were not included in the BMI analysis because they did not 
have information on BMI at baseline survey,123 had no follow-up time,124 or a prior history of 
disease.31 Overall, the mean (SD) age at baseline was 55 (9) years. 560,793 (53%) 
participants were male, 686,407 (64%) were from studies based in Europe, 321,840 (30%) 
from North America, 32,630 (3%) from Japan, 17,322 (2%) from Australia and 6,342 (1%) from 
the Caribbean (Table 2.2). Median year of baseline survey was 1986 (IQR 1977-1992). After 
excluding implausible BMI values (ie, the 18 participants with BMI above 100 kg/m2), the 
overall distribution of BMI was approximately normal with mean (SD) of 26 kg/m2 (4.1). Most 
studies sampled participants from population registers (eg, general practitioner lists, electoral 
roll lists) or in workplaces (Table 2.2). For 856,633 (80%) of the participants, height and weight 
were measured using standardised protocols; for the remainder, height and weight were self-
reported (Table 2.2). Concomitant information was available on BMI, age, sex, smoking status 
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(current versus not current), systolic blood pressure (SBP), history of diabetes (yes versus no), 
and total cholesterol in 572,114 participants from 101 studies. 306,371 participants from 76 
studies had additional information on HDL cholesterol and triglyceride. Repeat measurements 
were available on a total of 354,564 participants from 66 studies. 79 of the 118 contributing 
studies involved medical records, autopsy findings and other supplementary sources. 77 
studies used definitions of myocardial infarction based on World Health Organization criteria. 
58 studies reported diagnosis of strokes on the basis of brain imaging, and attributed stroke 
subtype.  
 
Available data on body-mass index, waist circumference and waist-to-hip ratio 
Fifty-eight3,5,8,14,28,29,32,33,35,36,38-42,45,50,51,53-55,57,59,61-63,66,69-73,78,80,81,85,90,93-95,97,98,100,101,105,107,108,108 
of the 118 studies, involving 221,934 participants without known history of cardiovascular 
disease at initial baseline examination, also had data on waist and hip circumference at 
baseline (Figure 2.3). The dataset was restricted to participants with concomitant information 
on weight, height and waist and hip circumference to allow direct comparisons between BMI, 
waist circumference (WC) and waist-to-hip ratio (WHR). 155,938 (70%) of these participants 
also had data on smoking status, SBP, history of diabetes, and total and HDL cholesterol. 
Resurvey data were available on 42,300 participants from 12 studies with concomitant 
information on weight and height, and waist and hip circumference at baseline examination and 
at resurvey. 43 of the 58 contributing studies involved medical records, autopsy findings and 
other supplementary sources to help classify deaths. 50 studies used definitions of myocardial 
infarction based on World Health Organization criteria. 43 studies reported diagnosis of strokes 
on the basis of brain imaging, and attributed stroke subtype. Four studies14,45,62,108 provided 
self-reported height and weight and three studies14,62,108 reported self-reported waist and hip 
circumference (Table 2.4). Weight and height was generally measured with participants 
dressed in light clothes and no shoes (Table 2.4). A majority of studies measured waist 
circumference either at the midway between lower rib margin and the iliac crest or at the 
umbilical level. Hip circumference was generally measured at the maximum circumference 
over the buttocks (Table 2.4). Mean (SD) age of participants at baseline was 58 (9) years, 
97,745 (44%) were men, 129,326 (58%) were in Europe, 73,707 (33%) were in North America, 
9,204 (4%) were in Australia and 9,697 were in Japan (Table 2.3). Median year of baseline 
survey was 1994 (IQR 1991-1998). After excluding participants with implausible adiposity 
values (ie, the 12 participants with BMI values above 100 kg/m2, WC values above 250 cm or 
WHR values above 2.5), adiposity measures in the 58 studies were approximately normally 
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distributed (mean [SD]: 27 kg/m2 [4.56] for BMI, 91 cm [12.6] for WC and 0.90 [0.083] for 
WHR), with higher WC and WHR values in men than in women (Figure 2.4). The distributions 
of adiposity measures were broadly similar across studies (Figure 2.5).  
 
Conclusion 
The ERFC is a collaboration of prospective studies that have recorded information on adiposity 
measures and other cardiovascular risk markers, as well as on cardiovascular morbidity and/or 
cause-specific mortality. Over 1 million people in 118 studies without known cardiovascular 
disease at baseline had complete information on baseline BMI, age and sex. 58 of the 118 
studies, involving more than 220,000 participants, had additional information on baseline waist 
and hip circumference. Analysis of individual data from these studies in a meta-analysis should 
help to characterise more reliably and precisely than previously possible the association of 
adiposity measures with vascular and non-vascular outcomes under a range of different 
circumstances.  
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Table 2.1 List of core variables sought in the Emerging Risk Factors Collaboration 
From baseline examination 
• Date of baseline survey 
• A unique (but anonymous) identifier 
• Date of birth (or age at baseline) and sex 
• A unique identifier for case-control matched sets for studies in which controls are ‘individually 
matched’ to cases 
 
Baseline survey (biochemistry, clinical measurements etc. made at the initial examination) 
• Ethnicity 
• Smoking and alcohol use (current / ex / never; amount / duration etc.) 
• Use of cardiovascular medications (current and past use, in as much detail as possible, 
including anti-hypertensive drugs, ‘statins’, fibrates) and other medications (e.g. hypoglycemic 
agents, hormone replacement therapy) – also, treatment allocation made in randomized 
controlled trials  
• Use of postmenopausal hormone therapy or oral contraceptives 
• Prior history of coronary heart disease (in particular myocardial infarction and angina), stroke, 
transient ischemic attack (TIA), peripheral vascular disease (PVD) and diabetes 
• Systolic and diastolic blood pressure 
• Weight, height, waist and hip circumference 
• Physical activity and socio-economic status 
• Total, high- and low-density lipoprotein cholesterol (including particle size and numbers, 
where available); triglycerides; lipoprotein (a); apolipoprotein-AI and -B (including information 
about fasting status at time blood samples were taken); lipoprotein-associated phospholipase 
A2 mass and activity levels 
• Inflammatory markers (including C-reactive protein, fibrinogen, albumin, interleukin-6 and the  
leucocyte count) 
• Creatinine, uric acid 
• Haemostatic factors (including von-Willebrand factor, fibrin D-dimer) 
• Metabolic factors (including fasting glucose, post load glucose, glycosylated hemoglobin and 
insulin) 
 
From re-survey examinations 
• The unique (but anonymous) identifier used for baseline visit 
• Date of the visit (or, if not available, age at visit) 
• Data on baseline items that were collected at repeat surveys (particularly established risk 
factors and other biochemical markers)  
 
Non-fatal events during follow-up 
• Myocardial infarction and date of MI 
• Stroke (including subtype if available: e.g. ischaemic / haemorrhagic) and date of stroke 
• Other subsidiary cardiovascular outcomes: e.g. angina, PVD, coronary artery bypass grafting 
(CABG), percutaneous transluminal coronary angioplasty (PCTA), congestive heart failure 
• Dates of censoring for end of follow-up for non-fatal events 
 
Fatal events during follow-up 
• Date last known to be alive (if not recorded as dead) 
• Date of death (or, if not available, age at death) 
• Underlying cause of death (preferably coded according to some specified version of the 
three-digit International Classification of Diseases (ICD); but if a three-digit ICD code is not 
available then whatever code the study already uses) 
• Date of censoring for end of follow-up for fatal cases 
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Table 2.2 Some baseline characteristics of 118 prospective studies providing information on 
BMI to the ERFC 
 
Study 
abbreviation
Country Year(s) of 
baseline survey
Population source Sampling Measurement of 
height and 
weight
Total 
subjects
BMI (kg/m2) 
mean (sd)
Age at 
survey
(yrs) 
mean (sd)
Male (%)
AMORIS Sweden 1987-1991 Screening Complete Assessed 58082 25 (4) 46 (10) 33334 (57)
ARIC USA 1987-189 Households Random Assessed 14600 28 (5) 54 (6) 6302 (43)
ATENAb Italy 1994-1996 General population Random Assessed 4741 27 (4) 50 (7) 0 (0)
ATS_SARc Italy 1983-1984 Combination or other Complete & random Assessed 4263 27 (5) 46 (8) 2065 (48)
ATTICA Greek 2001 General population Random Assessed 1577 27 (4) 51 (11) 808 (51)
AUSDIAB Australia 1999-2000 NR NR Assessed 9260 27 (5) 53 (13) 4110 (44)
BHS Australia 1969-1978 Electoral rolls Complete Assessed 5992 25 (4) 45 (16) 2829 (47)
BRHS UK 1978-1979 GP/Health service lists Random Assessed 6809 25 (3) 50 (6) 6809 (100)
BRUN Italy 1990 General population Random Assessed 817 25 (4) 58 (11) 398 (49)
BUPA UK 1976-1980 GP/Health service lists Complete Assessed 20885 25 (3) 47 (8) 20885 (100)
BWHHS UK 1999-2000 General population Random Assessed 2796 27 (5) 68 (5) 0 (0)
CAPS UK 1980-1982 Electoral rolls Random Assessed 2133 26 (4) 52 (5) 2133 (100)
CASTEL Italy 1983-1985 Screening Complete Assessed 2499 26 (4) 73 (5) 951 (38)
CHARL USA 1960-1961 Households Random Assessed 2031 25 (5) 50 (11) 952 (47)
CHS1a USA 1989-1990 GP/Health service lists Random Assessed 3883 26 (5) 72 (5) 1491 (38)
CHS2a USA 1993 GP/Health service lists Random Assessed 482 29 (5) 72 (5) 181 (38)
COPEN Denmark 1992-1993 General population Random Assessed 8186 26 (4) 58 (15) 3508 (43)
DISCOc Italy 1984-1987 Combination or other Complete & random Assessed 1923 28 (5) 50 (11) 843 (44)
DRECE Spain 1991 General population Random Assessed 2819 26 (5) 41 (11) 1357 (48)
DUBBO Australia 1988-1989 Electoral rolls Complete Assessed 2070 26 (4) 68 (7) 866 (42)
EAS Scotland 1987-1988 GP/Health service lists Random Assessed 1036 25 (4) 64 (6) 515 (50)
EMOFRIb Italy 1995-1996 General population Complete Assessed 360 26 (4) 55 (6) 176 (49)
EPESEBOS USA 1988-1989 General population Complete Self-reported 757 27 (5) 77 (4) 263 (35)
EPESEIOW USA 1988 General population Random Assessed 1225 27 (5) 78 (5) 368 (30)
EPESENCA USA 1992-1993 General population Random Self-reported 1017 27 (5) 77 (5) 337 (33)
EPESENHA USA 1988 General population Complete Self-reported 593 26 (4) 78 (5) 228 (38)
ESTHER Germany 2001 GP list Complete Assessed 8160 28 (4) 62 (7) 3447 (42)
FINE_FIN Finland 1989 Combination or other Complete Assessed 275 26 (4) 77 (5) 275 (100)
FINE_IT Italy 1985 General population Random Assessed 461 26 (4) 72 (4) 461 (100)
FINRISK92 Finland 1992 General population Random Assessed 5279 26 (4) 46 (10) 2448 (46)
FINRISK97 Finland 1997 General population Complete & random Assessed 6395 27 (4) 51 (11) 3170 (50)
FRAMOFF USA 1992-1993 General population Complete Assessed 3399 27 (5) 54 (10) 1547 (46)
GOH Israel 1970-1971 General population Random Assessed 5558 25 (4) 43 (8) 2693 (48)
GOTO13 Sweden 1967 General population Complete Assessed 765 25 (3) 54 (2) 765 (100)
GOTO33 Sweden 1984 General population Complete Assessed 733 26 (3) 51 (0) 733 (100)
GOTO43 Sweden 1993 General population Complete Assessed 773 26 (3) 50 (0) 773 (100)
GOTOW Sweden 1969 General population Random Assessed 1425 24 (4) 47 (6) 0 (0)
GREPCOc Italy 1980 Combination or other Complete & random Assessed 794 25 (4) 44 (8) 0 (0)
GRIPS Germany 1982 Occupational Complete Assessed 5785 26 (3) 48 (5) 5785 (100)
GUBBIOc Italy 1983-1985 Combination or other Complete & random Assessed 3408 27 (4) 55 (13) 1515 (44)
HBS Finland 1986 Occupational NR Assessed 1300 26 (3) 60 (4) 1300 (100)
HELSINAG Finland 1989 General population Random Assessed 424 25 (4) 79 (4) 108 (25)
HISAYAMA Japan 1988 General population Complete Assessed 2575 23 (3) 59 (12) 1087 (42)
HONOL USA 1991-1992 GP/Health service lists Complete Assessed 2523 23 (3) 78 (4) 2523 (100)
HOORN Netherlands 1990-1991 General population Random Assessed 2230 27 (4) 61 (7) 982 (44)
HPFS USA 1986 Occupational Complete Self-reported 47788 26 (3) 54 (10) 47788 (100)
IKNS Japan 1990-1992 Screening Complete Assessed 8047 23 (3) 58 (10) 3302 (41)
ISRAEL Israel 1963 Occupational Complete Assessed 7702 25 (3) 49 (7) 7702 (100)
KARELIA Finland 1972 General population Random Assessed 10784 26 (4) 41 (10) 5199 (48)
LASA Netherlands 1992-1993 General population Random Assessed 1856 27 (4) 69 (9) 839 (45)
MALMO Sweden 1978-1983 Screening Random Assessed 32483 25 (4) 46 (7) 21913 (67)
MATISS83b Italy 1983-1984 General population Random Assessed 2562 28 (4) 51 (10) 1202 (47)
MATISS87b Italy 1986-1987 General population Random Assessed 2116 29 (5) 52 (10) 937 (44)
MATISS93b Italy 1993-1995 General population Random Assessed 1215 28 (5) 49 (9) 588 (48)
MCVDRFP Netherlands 1988-1990 General population Random Assessed 23169 25 (4) 42 (10) 10727 (46)
MESA USA 2001 General population Random Assessed 6768 28 (5) 62 (10) 3190 (47)
MICOLc Italy 1985-1986 Combination or other Complete & random Assessed 19394 26 (4) 51 (10) 10859 (56)
MOGERAUG1 Germany 1984-1985 General population Random Assessed 871 28 (3) 54 (6) 871 (100)
MOGERAUG2 Germany 1989-1990 General population Random Assessed 3963 27 (4) 53 (12) 1949 (49)
MOGERAUG3 Germany 1997-1995 General population Random Assessed 3373 28 (4) 55 (10) 1664 (49)
MONFRI86b Italy 1986 General population Random Assessed 1408 27 (4) 49 (9) 691 (49)
MONFRI89b Italy 1989 General population Random Assessed 1344 26 (4) 49 (8) 666 (50)
MONFRI94b Italy 1994 General population Random Assessed 1294 26 (4) 49 (8) 630 (49)
MONICAc Italy 1983-1986 Combination or other NR Assessed 3661 27 (4) 49 (9) 1830 (50)
MORGEN Netherlands 1994-1996 General population Random Assessed 17736 26 (4) 46 (9) 8060 (45)
MOSWEGOT Sweden 1986-1994 General population Random Assessed 4158 25 (4) 47 (11) 1974 (47)
Cohort studies
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Table 2.2 cont’d Some baseline characteristics of 118 prospective studies providing information 
on BMI to the ERFC 
 
Study 
abbreviation
Country Year(s) of 
baseline survey
Population source Sampling Measurement of 
height and 
weight
Total 
subjects
BMI (kg/m2) 
mean (sd)
Age at 
survey
(yrs) 
mean (sd)
Male (%)
MRCOLD UK 1996-1997 GP/Health service lists Complete Assessed 10145 26 (4) 80 (4) 3825 (38)
NCS1 Norway 1976-1977 General population Complete Assessed 24199 25 (4) 42 (4) 11914 (49)
NCS2 Norway 1975 General population Complete Assessed 13056 25 (3) 42 (4) 6654 (51)
NCS3 Norway 1974 General population Complete Assessed 10029 25 (4) 42 (4) 5203 (52)
NFRc Italy 1980 Combination or other Complete & random Assessed 3088 26 (3) 55 (5) 3088 (100)
NHANESI USA 1972-1973 General population Cluster Assessed 9356 26 (5) 50 (16) 3646 (39)
NHANESIII USA 1990 General population Cluster Assessed 12436 27 (5) 54 (16) 5754 (46)
NHS USA 1976 Occupational Complete Self-reported 118622 24 (4) 43 (7) 0 (0)
NPHSI UK 1974-1977 Occupational Complete Assessed 1389 25 (3) 52 (7) 1389 (100)
NPHSII UK 1990-1991 GP/Health service lists Complete Assessed 2964 26 (4) 57 (3) 2964 (100)
NSHS Canada 1995 GP/Health service lists Random Assessed 1612 27 (6) 54 (15) 768 (48)
OB43c Italy 1984 Combination or other Complete & random Assessed 3611 27 (4) 47 (8) 1735 (48)
OSAKA Japan 1991-1994 Combination or other NR Assessed 12398 23 (3) 52 (10) 8430 (68)
OSLO Norway 1972-1973 General population Complete & random Assessed 17253 25 (3) 44 (6) 17253 (100)
OYABE Japan 1988 Screening Complete Assessed 5087 23 (3) 57 (11) 1567 (31)
PARIS1 France 1968-1971 Occupational Complete Assessed 7072 26 (3) 47 (2) 7072 (100)
PREVEND Netherlands 1997-1998 NR NR Assessed 7387 26 (4) 50 (12) 3589 (49)
PRHHP Caribbean 1966-1968 General population Complete Assessed 6342 25 (4) 54 (6) 6342 (100)
PRIME France / NI 1992-1993 General population Quota Assessed 9581 27 (3) 55 (3) 9581 (100)
PROCAM Germany 1981-1986 Occupational Complete Assessed 20163 26 (4) 44 (10) 14603 (72)
QUEBEC Canada 1985 General population Random Assessed 967 26 (4) 56 (7) 967 (100)
RANCHO USA 1984-1985 Households Complete Assessed 1785 25 (4) 68 (11) 739 (41)
REYK Iceland 1970-1980 General population Complete Assessed 16771 25 (4) 52 (9) 8037 (48)
RF2c Italy 1978 Combination or other Complete & random Assessed 5431 26 (4) 44 (9) 2549 (47)
ROTT Netherlands 1991-1993 General population Complete Assessed 4750 26 (4) 68 (8) 1801 (38)
SHHEC UK 1986-1989 GP/Health service lists Random Assessed 13529 26 (4) 49 (8) 6585 (49)
SHS USA 1990-1991 General population Complete Assessed 4145 31 (6) 56 (8) 1620 (39)
SPEED UK 1979-1981 GP/Health service lists Complete Assessed 2123 26 (3) 55 (4) 2123 (100)
TARFS Turkey 1990-1998 Households Random Assessed 3383 27 (5) 46 (13) 1680 (50)
TOYAMA Japan 1996 Occupational NR Assessed 4523 23 (3) 46 (7) 2907 (64)
TROMSØ Norway 1986-1994 Households Complete Assessed 22037 24 (4) 43 (14) 10414 (47)
ULSAM Sweden 1971-1972 General population Complete Assessed 2284 25 (3) 50 (1) 2284 (100)
USPHS2 USA 1996-1999 General population Complete Self-reported 10716 25 (3) 64 (8) 10716 (100)
VHMPP Austria 1986-1992 Screening Complete Assessed 120611 25 (4) 48 (14) 55100 (46)
VITA Italy 1994-1996 General population Random Assessed 8983 25 (4) 51 (8) 4027 (45)
WHITEI UK 1997 Occupational Complete Assessed 4007 25 (3) 76 (5) 4007 (100)
WHITEII UK 1986-1987 Occupational Complete Assessed 10200 25 (4) 45 (6) 6805 (67)
ZARAGOZA Spain 1994 GP/Health service lists Complete Assessed 2838 29 (5) 59 (12) 1175 (41)
ZUTE Netherlands 1990 General population Random Assessed 391 26 (3) 76 (4) 391 (100)
Clinical trials
AFTCAPS USA 1991-1993 Screening Complete Assessed 6605 27 (3) 58 (7) 5608 (85)
ALLHAT
USA/Canada/
Puerto Rico/US 
Virgin Islands
1994 Individuals with
 hypertension NR Assessed 28063 30 (6) 66 (8) 13758 (49)
LEADER UK 1994-1998 GP/Health service lists Complete Assessed 927 26 (4) 68 (9) 927 (100)
MRFIT USA 1974-1976 Screening Complete Assessed 12840 28 (3) 47 (6) 12840 (100)
PROSPER  Scotland/Ireland/Netherland 1998-1999 Screening Complete Assessed 3252 27 (4) 75 (3) 1350 (42)
TPT UK 1989-1991 GP/Health service lists Complete Assessed 22715 27 (4) 56 (7) 22715 (100)
WHS USA 1994-1995 Occupational Complete Assessed 27479 26 (5) 55 (7) 0 (0)
WOSCOPS UK 1989-1991 Screening Complete Assessed 6191 26 (3) 55 (6) 6191 (100)
Nested case-control studies
EPICNOR UK 1993-1998 GP/Health service lists Complete Assessed 1424 27 (4) 66 (8) 966 (68)
FIA Sweden 1985-1999 General population Random Assessed 2636 26 (4) 54 (7) 2128 (81)
GLOSTRUP Denmark 1976-1984 General population Random Assessed 207 26 (4) 51 (9) 168 (81)
USPHS USA 1982 Occupational Complete Self-reported 936 25 (3) 60 (9) 936 (100)
WHIHABPS USA 1994 General population Complete Assessed 1212 27 (6) 68 (6) 0 (0)
TOTAL 1064541 26 (4.1) 55 (9.4) 560793 (53)
 
aCHS included an original cohort (here termed CHS1) and a supplemental African-American cohort (here termed CHS2), 
which were analysed separately; bProgetto CUORE was analysed as 8 different studies (ie, ATENA, EMOFRI, MATISS83, 
MATISS87, MATISS93, MONFRI86, MONFRI89 and MONFRI94); cRIFLE Study was analysed as 9 different studies (ie, 
ATS_SAR, DISCO, GREPCO, GUBBIO, MICOL, MONICA, NFR, OB43 and RF2); Study acronyms are provided in Appendix 
4. Abbreviations: Assessed = weight and height were assessed by a trained person; Self-reported = weight and height were 
measured by the subject itself; NR = information not reported. Summaries were based on participants without history of 
cardiovascular disease. 
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Table 2.3 Some baseline characteristics of the 58 prospective studies providing concomitant 
information on BMI, WC and WHR to the ERFC 
 
Study 
abbreviation Country
Year(s) of 
baseline survey Population source Sampling
No of
subjects
BMI (kg/m2)
mean (sd)
WC
 (cm)
mean (sd)
WHR
mean (sd)
Age (yrs)
mean (sd)
Male
(%)
Cohort studies
ARIC USA 1987-1989 Households Random 14383 28 (5) 97 (14) 0.92 (0.08) 54 (6) 6213 (43)
ATENAb Italy 1993-1996 Electoral rolls Random 4741 27 (4) 85 (10) 0.82 (0.07) 50 (7) 0 (0)
ATTICA Greece 2001 General population Random 1503 27 (4) 93 (14) 0.88 (0.11) 51 (11) 769 (51)
AUSDIAB Australia 1999-2000 NR NR 9204 27 (5) 91 (14) 0.87 (0.09) 53 (13) 4079 (44)
BRHS UK 1998-2000 GP/Health service lists Random 3466 27 (4) 97 (10) 0.95 (0.06) 68 (5) 3466 (100)
BRUN Italy 1990 General population Random 817 25 (4) 87 (11) 0.89 (0.07) 58 (11) 398 (49)
BWHHS UK 1999-2001 General population Random 2779 27 (5) 85 (12) 0.81 (0.07) 68 (5) 0 (0)
CAPS UK 1990-1993 Electoral rolls Random 1062 27 (4) 93 (10) 0.93 (0.06) 62 (4) 1062 (100)
CHARL USA 1987-1989 Households Random 428 27 (5) 95 (13) 0.94 (0.08) 71 (7) 179 (42)
CHS1a USA 1989-1990 GP/Health service lists Random 3881 26 (5) 93 (13) 0.92 (0.09) 72 (5) 1489 (38)
CHS2a USA 1992-1993 GP/Health service lists Random 480 29 (5) 99 (15) 0.94 (0.07) 72 (5) 181 (38)
COPEN Denmark 1992-1994 General population Random 8166 26 (4) 87 (13) 0.87 (0.10) 58 (15) 3502 (43)
DRECE Spain 2006 General population Random 497 28 (4) 95 (13) 0.92 (0.11) 57 (11) 222 (45)
EMOFRIc Italy 1995-1996 General population Random 360 26 (4) 91 (11) 0.90 (0.07) 55 (6) 176 (49)
EPESENCA USA 1992-1993 General population Random 1001 27 (5) 93 (13) 0.88 (0.08) 77 (5) 333 (33)
FINRISK92 Finland 1992 General population Random 5276 26 (4) 88 (13) 0.86 (0.10) 46 (10) 2446 (46)
FINRISK97 Finland 1997 General population Random 6382 27 (4) 90 (13) 0.87 (0.09) 52 (11) 3167 (50)
FRAMOFF USA 1998-2000 General population Complete 2685 28 (5) 99 (14) 0.94 (0.08) 60 (9) 1183 (44)
GOH Israel 1999-2005 General population Random 634 28 (5) 99 (11) 1.03 (0.12) 70 (7) 305 (48)
GOTO13 Sweden 1967 General population Complete 756 25 (3) 87 (9) 0.93 (0.05) 54 (0) 756 (100)
GOTO33 Sweden 1983-1984 General population Complete 729 26 (3) 95 (9) 0.93 (0.06) 51 (0) 729 (100)
GOTO43 Sweden 1993-1994 General population Complete 762 26 (3) 95 (9) 0.99 (0.06) 50 (0) 762 (100)
GOTOW Sweden 1968-1969 General population Random 1401 24 (4) 74 (9) 0.74 (0.05) 47 (7) 0 (0)
HBS Finland 1986 Occupational NR 1268 26 (3) 97 (9) 0.97 (0.06) 60 (4) 1268 (100)
HISAYAMA Japan 1988 General population Complete 2515 23 (3) 81 (9) 0.91 (0.07) 59 (11) 1068 (42)
HOORN Netherlands 1990-1991 General population Random 2226 27 (4) 91 (11) 0.89 (0.09) 61 (7) 979 (44)
IKNS Japan 1990-1993 Screening Complete 1942 24 (3) 83 (9) 0.90 (0.07) 59 (10) 830 (43)
LASA Netherlands 1992-1993 General population Random 1806 27 (4) 97 (11) 0.94 (0.08) 69 (8) 827 (46)
MATISS83b Italy 1993-1996 Electoral rolls Random 1317 29 (4) 94 (10) 0.91 (0.09) 61 (9) 614 (47)
MATISS87b Italy 1993-1996 Electoral rolls Random 1077 29 (4) 94 (11) 0.91 (0.09) 58 (9) 510 (47)
MATISS93b Italy 1993-1995 Electoral rolls Random 1206 28 (5) 91 (11) 0.91 (0.08) 49 (9) 579 (48)
MESA USA 2001 General population Random 6768 28 (5) 98 (14) 0.93 (0.08) 62 (10) 3190 (47)
MOGERAUG2 Germany 1989-1990 General population Random 3934 27 (4) 90 (12) 0.87 (0.08) 53 (12) 1935 (49)
MOGERAUG3 Germany 1994-1995 General population Random 3368 28 (4) 92 (12) 0.88 (0.09) 55 (10) 1663 (49)
MONFRI89b Italy 1989 Electoral rolls Random 1330 26 (4) 88 (12) 0.87 (0.09) 49 (8) 658 (49)
MONFRI94b Italy 1994 Electoral rolls Random 1291 26 (4) 90 (12) 0.88 (0.09) 49 (8) 627 (49)
MORGEN Netherlands 1993-1997 General population Random 17707 26 (4) 88 (12) 0.86 (0.09) 46 (9) 8046 (45)
MOSWEGOT Sweden 1985-1995 General population Random 4132 25 (4) 85 (12) 0.86 (0.09) 47 (11) 1966 (48)
MRCOLD UK 1995-1998 GP/Health service lists Complete 9933 26 (4) 90 (12) 0.88 (0.08) 80 (4) 3747 (38)
NHANESIII USA 1988-1993 General population Cluster 10450 27 (6) 95 (14) 0.93 (0.09) 53 (16) 4859 (46)
NSHS Canada 1995 GP/Health service lists Random 1608 27 (6) 90 (15) 0.87 (0.10) 54 (15) 765 (48)
OSAKA Japan 1992-1997 Combination or other NR 717 23 (3) 84 (8) 0.90 (0.05) 49 (7) 602 (84)
PREVEND Netherlands 1997-1998 NR NR 7368 26 (4) 89 (13) 0.88 (0.09) 50 (12) 3583 (49)
PRIME France/N. Ireland 1991-1993 General population Quota 9563 27 (3) 95 (10) 0.96 (0.06) 55 (3) 9563 (100)
RANCHO USA 1984-1986 Households Complete 1784 25 (4) 85 (12) 0.84 (0.09) 68 (11) 739 (41)
ROTT Netherlands 1990-1993 General population Complete 4607 26 (4) 90 (11) 0.90 (0.09) 68 (8) 1752 (38)
SHHEC UK 1989-1995 GP/Health service lists Random 3489 26 (5) 86 (13) 0.85 (0.10) 49 (11) 1625 (47)
SHS USA 1989-1991 General population Complete 4135 31 (6) 105 (15) 0.95 (0.06) 56 (8) 1615 (39)
TARFS Turkey 1998 Households Random 2559 28 (5) 93 (12) 0.89 (0.09) 49 (12) 1270 (50)
TOYAMA Japan 1996 Occupational NR 4523 23 (3) 78 (9) 0.85 (0.07) 46 (7) 2907 (64)
TROMSØ Norway 1994-1995 Households Complete 1573 26 (4) 91 (11) 0.87 (0.08) 60 (10) 811 (52)
ULSAM Sweden 1991-1994 General population Complete 962 26 (3) 94 (9) 0.94 (0.05) 71 (1) 962 (100)
WHITEII UK 1991-1993 Occupational Complete 7862 25 (4) 85 (11) 0.87 (0.09) 49 (6) 5414 (69)
WHS USA 1999-2001 Occupational Complete 24138 27 (5) 89 (14) 0.83 (0.08) 60 (7) 0 (0)
Nested case-control studies
EPICNOR UK 1993-1997 GP/Health service lists Complete 1417 27 (4) 93 (11) 0.90 (0.08) 66 (8) 960 (68)
HPFS USA 1996 Occupational Complete 394 26 (4) 99 (10) 0.96 (0.06) 66 (8) 394 (100)
NHS USA 1986 Occupational Complete 372 25 (4) 81 (11) 0.79 (0.07) 58 (6) 0 (0)
WHIHABPS USA 1994 General population Complete 1200 27 (6) 86 (13) 0.82 (0.09) 68 (6) 0 (0)
TOTAL 221934 27 (4.56) 91 (12.6) 0.90 (0.08) 58 (9) 97745 (44)
 
aCHS included an original cohort (here termed CHS1) and a supplemental African-American cohort (here termed CHS2), 
which were analysed separately. bProgetto CUORE was analysed as 7 different studies (ie, ATENA, EMOFRI, MATISS83, 
MATISS87, MATISS93, MONFRI89 and MONFRI94). Study acronyms are provided in Appendix 4. Abbreviation: NR = 
information not reported. Summaries were based on participants without history of cardiovascular disease. 
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Table 2.4 Description of methods used to assess adiposity measures in the 58 studies providing concomitant information on BMI, WC and WHR  
 
Study abbreviation Measurement of height & weight
Measurement of 
waist & hip Assessment of height & weight Assessment of waist circumference Assessment of hip circumference
ARIC Assessed Assessed participant wearing a scrub suit and no shoes umbilical level around the maximum buttocks
ATENA Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
ATTICA Assessed Assessed light undergarments and no shoes midway between lower rib margin and the iliac crest around the maximum buttocks
AUSDIAB Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
BRHS Assessed Assessed light undergarments and no shoes midway between lower rib margin and the iliac crest largest circumference below the waist
BRUN Assessed Assessed measured after an overnight fast, subjects wearing only undergarments. umbilical level at greater trochanters
BWHHS Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest largest circumference below the waist
CAPS Assessed Assessed NA narrowest point between the costal line and the iliac crest at greater trochanters
CHARL Assessed Assessed light clothing and no shoes umbilical level at greater trochanters
CHS1 Assessed Assessed NA umbilical level maximum hip circumference
CHS2 Assessed Assessed NA umbilical level maximum hip circumference
COPEN Assessed Assessed light clothing or underwear and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
DRECE Assessed Assessed NA NA NA
EMOFRIc Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
EPESENCA Self-reported Assessed NA umbilical level NA
EPICNOR Assessed Assessed no shoes smallest circumference between the ribs and iliac crest maximum circumference between the iliac crest and the crotch
FINRISK92 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
FINRISK97 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
FRAMOFF Assessed Assessed light clothing and no shoes umbilical level NA
GOH Assessed Assessed light clothing and no shoes one finger width above superior iliac crest At groin level
GOTO13 Assessed Assessed wearing underpants umbilical level at the level of the anterior iliac crest 
GOTO33 Assessed Assessed after an overnight fast, indoor clothing, and 0.8 kg deducted from the recorded weight umbilical level at the level of the anterior iliac crest 
GOTO43 Assessed Assessed after an overnight fast, indoor clothing, and 0.8 kg deducted from the recorded weight umbilical level at the level of the anterior iliac crest 
GOTOW Assessed Assessed no shoes midway between lower rib margin and the iliac crest widest point between hip and buttock
HBS Assessed Assessed without shoes and shirt umbilical level at the level of the anterior iliac crest 
HISAYAMA Assessed Assessed light clothing and no shoes umbilical level Around the buttocks, 4cm below the anterior superior iliac spine
HOORN Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest widest level over the greater trochanters
HPFS Self-reported Self-reported NA umbilical level largest circumference between the waist and thighs
IKNS Assessed Assessed light clothing and no shoes umbilical level maximum circumference over the buttocks
LASA Assessed Assessed light clothing midway between lower rib margin and the iliac crest widest level over the greater trochanters
MATISS83 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MATISS87 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MATISS93 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MESA Assessed Assessed light clothing and no shoes umbilical level NA
MOGERAUG2 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MOGERAUG3 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MONFRI89 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MONFRI94 Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MORGEN Assessed Assessed indoor clothing and no shoes midway between lower rib margin and the iliac crest at the level of the greater trochanters
MOSWEGOT Assessed Assessed light clothing and no shoes after at least 4 h of fasting midway between lower rib margin and the iliac crest maximum circumference over the buttocks
MRCOLD Assessed Assessed light undergarments and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks and below the iliac crest
NHANESIII Assessed Assessed paper shirt and pants and foam slippers at level with the iliac crest at the end of a normal expiration maximum circumference over the buttocks
NHS Self-reported Self-reported NA umbilical level largest circumference around hips (including buttocks)
NSHS Assessed Assessed light clothing and no shoes at the point of noticeable waist narrowing at the level of the symphysis pubis and the greatest gluteal protuberance
OSAKA Assessed Assessed light clothing and no shoes umbilical level maximum circumference over the buttocks
PREVEND Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
PRIME Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest above the buttocks
RANCHO Assessed Assessed indoor clothing and no shoes at the bending point (the natural indentation when bending sideways) largest girth below the waist
ROTT Assessed Assessed no shoes and heavy outer garments midway between lower rib margin and the iliac crest maximum circumference over the buttocks
SHHEC Assessed Assessed NA NA NA
SHS Assessed Assessed light clothing and no shoes umbilical level at the maximum protrusion of  gluteal muscles
TARFS Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest at the level of the greater trochanters
TOYAMA Assessed Assessed light clothing and no shoes midway between lower rib margin and the iliac crest maximum circumference over the buttocks
TROMSØ Assessed Assessed light clothing and no shoes umbilical level at the widest point at the hips
ULSAM Assessed Assessed NA midway between lower rib margin and the iliac crest measured over the widest part
WHIHABPS Assessed Assessed light clothing and no shoes at the natural waist or narrowest part of the torso maximum circumference over the buttocks
WHITEII Assessed Assessed NA midway between lower rib margin and the iliac crest at the level of the greater trochanters
WHS Self-reported Self-reported NA umbilical level maximum circumference between the umbilicus and the thigh
 
 
Study acronyms are provided in Appendix 4. Abbreviations: Assessed = anthropometric marker was assessed by a trained person; Self-reported = anthropometric marker was measured by the 
subject itself; NA = information not available. 
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Table 2.5 Definition of endpoints in the ERFC 
 
Endpoint ICD-10 codes
All cardiovascular* G45, I01, I03-I82, I87, I95-I99, F01, Q20-2Q28, R96
Coronary heart disease (CHD)* I20-I25
Myocardial infarction I21, I22
All cerebrovascular* F01, I60-I69
Ischaemic stroke* I63
Haemorrhagic stroke* I61
Subarachnoid stroke* I60
Unclassified stroke†* I64
Other vascular deaths Remainder of cardiovascular disease (fatal)
Cardiac dysrhythmia I47-I49
Hypertensive disease I10-I15
Pulmonary embolism I26
Ill-defined descriptions and complications of the 
dearth disease
I51
Sudden death R96
Aortic aneurysm I71
Heart failure I50
Peripheral vascular disease I73-I74, I77-I78
Other Remainder of vascular
All cancer C00-C97, D00-D48
Oral C00-C14
Colorectum C18-C21
Oesophagus C15
Stomach C16
Liver C22
Pancreas C25
Lung C34
Prostate C61
Ovary C56
Bladder C67
Haematological C81-C96
Endocrine & nervous C69-C75
Melanoma C43
Connective tissue C40-C42, C45-C49
Breast (female) C50
Other/unspecified Remainder of cancer/ unspecified to ERFC
All non-cancer, non-vascular A00-A99, B00-B99, D50-D99,E00-E99, F00, F02-F99, G00-G44, G46-G99, H00-H99, I00, 
I02, I83-I86, I88-I89, J00-J99, K00-K99, L00-L99, M00-M99, N00-N99, O00-O99, P00-P99, 
Q00-Q18, Q30-Q99, S00-S99, T00-T99, U04, V00-V99, W00-W99, X00-X99, Y00-Y99, Z00-
Z99
All external cause S00-S99, T00-T98, U04, V01-V99, W00-W99, X00-X99, Y00-Y98, Z00-Z99
Falls W00-W19
Intentional self-harm X60-X84
Infections A00-A99, B00-B14, B20-B99
Diabetes mellitus E10-E14
Mental disorders F04-F99
Alzheimer's disease and related conditions F00, F02, F03, G30-G32
Liver disease B15-B19, K70-K77
Respiratory system disease J00-J99
Pneumonia J12-J18
COPD and related conditions J40-J47
Digestive system disease (except liver) K00-K69, K78-K93
Renal disease N00-N19
Other/unspecified Remainder of non-cancer, non-vascular/ unspecified to ERFC
Deaths of unknown cause or ill-defined cause R00-R96, R97-R99 and non-vascular deaths defined according to study-specific read-codes 
for mortality, and not standard ICD codes.
All-cause mortality A00-Y89
 
Attribution of deaths refers to the primary cause (or, in its absence the underlying cause) provided by individual studies. 
Corresponding ICD-6, 7, 8 or 9 codes were used for studies that recorded outcomes using earlier ICD versions. *includes 
both fatal and non-fatal events; †Unclassified stroke was defined by the ICD codes stated, or as strokes nor specified as 
ischaemic or haemorrhagic by study-specific codes. 
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Table 2.6 Order of priority for any non-fatal events that occurred on the same day 
 
Rank Type Sub-type 
   
1 MI Definite 
2 MI Acute 
3 MI ST elevated 
4 MI non-ST elevated 
5 MI General 
6 Coronary CHD (general) 
7 Stroke Ischaemic 
8 Stroke Haemorrhagic 
9 Stroke definite general 
10 Stroke General 
11 MI non-transmural 
12 Stroke sub-arachnoid 
13 MI during surgery 
14 MI Silent 
15 MI Probable 
16 Stroke probable general 
17 MI Possible 
18 Stroke possible general 
19 TIA General 
20 Angina Unstable 
21 MI Suspect 
22 Angina definite general 
23 Angina General 
24 Stroke suspect general 
25 Surgery CABG 
26 Surgery angioplasty (PTCA) 
27 Surgery revascularisation 
28 Surgery cardiovascular 
29 Angina Stable 
30 MI Old 
31 Angina Possible 
32 Coronary coronary insufficiency (definite) 
33 Coronary coronary insufficiency (possible) 
34 Coronary cardiac arrest 
35 Coronary heart failure 
36 Coronary Arrhythmia 
37 PVD General 
38 PVD definite general 
39 PVD probable general 
40 PVD possible general 
41 PVD suspect general 
42 Surgery Amputation 
43 Surgery vascular surgery 
44 Coronary other heart disease 
45 Coronary General 
46 Other thromb/embolism 
47 Other ulcer/gangrene 
48 Other other CV 
49 Other other non-CV 
50 Diabetes General 
51 Cancer General 
52 Surgery General 
53 Other General 
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Figure 2.1 Map of countries participating in the ERFC 
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Figure 2.2 Sequence of data sharing, cleaning and ratification in the ERFC 
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Figure 2.3 Flow diagram of available data on adiposity measures in the ERFC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 prospective studies included in 
the Emerging Risk Factors 
Collaboration by October 2010
3 studies did not have information 
on BMI at baseline examination, 
had no follow-up time or prior 
history of disease
118 studies (involving 1,064,541 
participants) provided data on BMI
60 studies did not have 
concomitant information at 
baseline examination on height, 
weight and waist and hip 
circumference
58 studies (involving 221,934 
participants) provided data on height, 
weight, and waist and hip 
circumference at baseline 
examination.
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Figure 2.4 Sex-specific distributions of baseline BMI, WC and WHR across the 58 studies 
providing concomitant information on BMI, WC and WHR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean (SD) in men and women, respectively, were 26.4 kg/m2 (3.8) and 26.6 kg/m2 (5.0) for BMI, 94.9cm (10.5) and 86.6 cm 
(12.9) for WC, and 0.95 (0.064) and 0.84 (0.075) for WHR.  
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Figure 2.5 Study-specific box plots of baseline BMI, WC and WHR in the 58 studies providing 
concomitant information on BMI, WC and WHR 
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CHAPTER 3: Cross-sectional correlates of adiposity measures 
 
Summary 
The adverse effects of excess body fat on cardiovascular disease are believed to be mediated 
through the complex interplay of several well-established and putative risk factors, such as 
increased blood pressure levels, alterations in lipid metabolism, insulin resistance and 
potentially inflammation. This chapter reports on the cross-sectional associations of body-mass 
index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) with several biochemical, 
lifestyle and other characteristics in 221,934 participants without known cardiovascular disease 
at baseline examination in the Emerging Risk Factors Collaboration. The data demonstrate that 
there were approximately linear and strong associations between BMI and WC, and WHR and 
WC, and only moderately strong correlations between BMI and WHR. These adiposity 
measures had broadly similar and approximately linear associations with cardiovascular risk 
factors, such as blood pressure, fasting glucose and inflammatory markers, and slightly 
curvilinear associations with lipid markers. In both males and females, BMI, WC and WHR 
were most strongly associated with blood pressure, high-density lipoprotein cholesterol, 
triglyceride, C-reactive protein and interleukin-6. Overall, adiposity measures were higher in 
individuals of non-European descent, in physically inactive people, in people with diabetes and 
people with low levels of education. Whereas mean BMI and WC values were somewhat lower 
in current smokers and current alcohol drinkers, mean WC and WHR values were higher in 
males than in females. These findings demonstrate that although the correlations between the 
three clinical measures of adiposity differ, BMI, WC and WHR are similarly and importantly 
associated with blood pressure, fasting glucose, lipids and inflammatory markers. This result 
supports the importance of intermediate risk factors on the pathway between excess body fat 
and cardiovascular disease. Furthermore, the findings suggest possible scope for confounding 
by lifestyle factors in observational studies of associations of adiposity measures with disease 
risk.  
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Background 
As discussed in Chapter 1 on pages 5-7, the adverse effects of excess body fat on 
cardiovascular disease are believed to be mediated through the complex interplay of several 
well-established and putative risk factors, such as increased blood pressure levels, alterations 
in lipid metabolism, insulin resistance and inflammation. In obesity, adipose tissue, particularly 
visceral fat in the abdominal region, is thought to promote lipolysis and resistance to insulin, 
which leads to increased levels of non-esterified fatty acids that are toxic to the liver, causing 
decreased insulin clearance, increased glucose production and dyslipidemia.1,2 Moreover, 
adipose tissue releases inflammatory cytokines (eg, interleukin 6 [IL-6] and tumour necrosis 
factor-α [TNF-α]), which stimulate the liver to generate additional bioactive markers that are 
associated with insulin resistance and increased C-reactive protein (CRP).1,3,4 The production 
of leptin by adipose tissue has also been implicated in insulin resistance and hypertension due 
to the activation of the central sympathoregulatory pathways.1 Because of these relationships, 
body-mass index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) are likely to be 
strongly correlated with blood pressure, fasting glucose, lipids and inflammatory markers.5,6 
 
Several epidemiological studies have reported on the cross-sectional association of adiposity 
measures with lipids, inflammatory markers and other characteristics.7-12 These studies have, 
however, generally been underpowered to quantify reliably the magnitude, or to characterise 
the shape of any association. Furthermore, because they have often lacked concomitant 
measurement of height, weight, waist and hip circumference, it has been difficult to compare 
directly the cross-sectional associations with BMI, WC and WHR.  
 
This chapter reports on the cross-sectional associations of BMI, WC and WHR with 
biochemical, lifestyle and other factors in 221,934 participants without known cardiovascular 
disease at baseline examination from 58 prospective studies in the Emerging Risk Factors 
Collaboration (ERFC). Reliable characterisation of these relationships with various factors will 
help to (i) determine the extent to which adiposity measures provide related information; (ii) 
better understand the biological pathways of the underlying association between adiposity and 
cardiovascular disease, and (iii) identify potential sources of confounding in epidemiological 
studies of associations of adiposity measures with disease risk.  
 58
Methods 
Study design 
Details of study selection, data collection and harmonisation in the ERFC have been described 
in Chapter 2. Briefly, the current analysis involved individual records from 58 prospective 
studies with complete information on age, sex, weight, height, and waist and hip 
circumference.  
 
Statistical analysis 
Descriptive statistics were calculated for a range of covariates measured at baseline 
examination of the 58 contributing studies. Continuous variables were summarised by pooling 
within-study means by random effects meta-analysis and categorical variables were 
summarised as raw counts and proportions.  
 
The statistical methods used for the analysis of cross-sectional correlates of adiposity 
measures generally followed those used by the Fibrinogen Studies Collaboration.13 
Associations with blood pressure, lipids, inflammatory markers and other characteristics were 
calculated in relation to BMI, WC and WHR. For continuous variables, correlation coefficients 
were pooled across studies by random effects meta-analysis of study-specific Fisher’s Z-
transformed partial correlation coefficients (adjusted for age and sex).13 So, for each study 
Ss K1= , Fisher’s Z-transformed correlation coefficient Zs and its standard error sσ  are given 
by 
 
 
 
 
where rs is the study-specific correlation coefficient and sn  the number of participants in study 
s. The Fisher’s Z-transformed correlation coefficients Zs were subsequently combined over 
studies using random effects meta-analysis (ie, allowing for heterogeneity between studies)14 – 
see model (5.2) from Chapter 5 on page 112 for more details. The pooled Z-transformed 
correlation coefficient cZ  was then back transformed, using following equation 
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where rc is the combined correlation coefficient of rs. Positively skewed variables (eg, 
triglyceride, lipoprotein(a) [Lp(a)], CRP) were loge-transformed to approximate the normal 
distribution.  
 
The magnitude of association between adiposity measures and risk factors was estimated by 
regressing each risk factor on the relevant adiposity measure using linear mixed models 
adjusted for age, sex and study, allowing for between-study heterogeneity at the study level. 
The regression model for studies Ss K1= , and individuals sni K1= , with risk factor siY , 
exposure of interest siE  and other covariates siX can be written as  
 
 
 
where ),0(~ 2us Nu σ , ),0(~ 2esi N σε  and β  is the parameter of interest, being the change in 
risk factor per unit increase in exposure, adjusted for covariates siX . Between-study 
heterogeneity in the estimated association β  is represented by 2uσ . In order to directly 
compare associations between adiposity measures, standardised regression coefficients were 
calculated by multiplying the regression coefficient from the mixed model by the standard 
deviation of the relevant adiposity measure. For associations with categorical variables, values 
of adiposity measures were Z-transformed (ie, standardised) to a mean 0 and a standard 
deviation of 1 to allow meaningful comparisons across adiposity measures. Associations were 
calculated by linear mixed models as described in (3.3), except that corresponding adiposity 
measures were regressed on categorical variables (in contrast to the previous model, where 
continuous risk factors were the dependent variables). Subsidiary analyses were further 
adjusted for smoking status, alcohol consumption, physical activity and education. 
 
Shapes of the cross-sectional associations of adiposity measures with several continuous risk 
factors were assessed using a linear mixed model that included random effects at the study 
level.13 Risk factors were standardised to allow meaningful graphical presentation. To allow 
assessment of the shape of association without imposing a priori any particular relationship, 
relevant adiposity measure was divided into tenths based on the overall distribution in males 
and females combined and fitted in the regression models as dummy variables. Model (3.3) 
was extended to include the fixed effects: study, age, age2, sex, age× sex, age2× sex, 
adiposity-tenth, adiposity-tenth × age and adiposity-tenth× sex (where ×  denotes an 
(3.3),)( sisisisssi XEuY ελβα ++++=
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interaction), and to allow the coefficient adiposity-tenth (entered as a continuous variable) to 
vary randomly across studies. Coefficients that were allowed to vary randomly across studies 
in subsidiary analyses were: age, age2 and adiposity-tenth (entered as a continuous variable). 
From each fitted mixed model, overall adjusted means and 95% confidence intervals (CIs) of 
the continuous risk factor by sex within tenths of relevant adiposity measure were obtained with 
age fixed at 50 years (age was adjusted to 65 years in supplementary analyses). These 
adjusted means (95% CI) were plotted against the mean value of the relevant adiposity 
measure within each tenth to assess the shape of association. An inverse-variance weighted 
polynomial was superimposed across adjusted means to better investigate the shape of the 
association.  
 
All analyses were performed using Stata release 11 (StataCorp LP, College Station, Texas 
USA). 
 
Results 
Table 3.1 provides descriptive summaries of baseline characteristics of the participants 
included in the current analysis. Complete information on age, sex, weight, height, and waist 
and hip circumference were available on 221,934 participants in 58 studies without known 
history of cardiovascular disease at baseline examination. 155,938 of these participants also 
had data on smoking status, systolic blood pressure (SBP), history of diabetes, and total and 
high-density lipoprotein (HDL) cholesterol. Mean (SD) age of participants at baseline was 58 
years (9), 124,189 (56%) were women. 
 
Associations between adiposity measures  
Figure 3.1 (panel A) shows that BMI, WC and WHR had broadly similar distributions across 
studies. For BMI, the studies with the lowest and highest BMI values had means of 22.9 kg/m2 
and 30.9 kg/m2, respectively. For WC, the studies with the lowest and highest WC values had 
means of 74 cm (study consisting of females only) and 105 cm (study consisting of males 
only), respectively. For WHR, the studies with the lowest and highest WHR values had means 
of 0.74 (study consisting of females only) and 1.03, respectively. Figure 3.1 (panel B) shows 
mean values of adiposity measure by sex in 5-year age bands. Overall, mean values of 
adiposity measures generally increased with age until about 55-75 years, then flattened or 
declined at older ages. Adiposity measures were continuously and approximately linearly 
associated with one another across the range of values in both sexes (Figure 3.2). Correlation 
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coefficients adjusted for age and sex were 0.85 (95% CI 0.84-0.86) between BMI and WC, 
0.43 (95% CI 0.40-0.45) between BMI and WHR and 0.70 (95% CI 0.68-0.72) between WC 
and WHR. In studies comprising both males and females, these correlates were broadly similar 
in men and women, except for the correlation between BMI and WHR which was somewhat 
lower in women than in men (Table 3.2). Overall, BMI values were 4.06 kg/m2 and 2.21 kg/m2 
higher per one standard deviation greater WC and WHR, respectively; WC values were 10.05 
cm and 9.50 cm higher per one standard deviation greater BMI and WHR, respectively; and 
WHR values were 0.03 and 0.05 higher per one standard deviation greater BMI or WC, 
respectively (Table 3.3). 
 
Associations of adiposity measures with categorical variables 
Overall, mean WC and WHR values were significantly lower in women than men (mean 
differences: 7.95 cm for WC and 0.10 for WHR), whereas mean BMI values were similar in 
both sexes (Table 3.4). Mean WC and WHR values were significantly lower in non-white men 
compared to white men, while non-white women had significantly higher mean values for all 
adiposity measures compared to white women (Table 3.5). Overall BMI and WC values were 
significantly lower in current smokers than in ex- or never smokers (overall mean differences: 
0.95 kg/m2 for BMI and 1.49 cm for WC) (Table 3.4). By contrast, overall WHR values were 
slightly higher in current smokers than in other people (although such differences were not 
statistically significant in analyses done in men and women separately; Table 3.5). 
Furthermore, current alcohol drinkers had lower BMI and WC values than ex- or never alcohol 
drinkers (overall mean differences: 0.59 kg/m2 for BMI and 1.01 cm for WC), while no 
significant differences were observed for WHR (Table 3.4). Moreover, in both sexes, mean 
values of adiposity measures were significantly higher in people with a history of diabetes 
compared to those without (overall mean differences: 1.96 kg/m2 for BMI; 5.81 cm for WC; and 
0.03 for WHR), in physically inactive compared to physically active individuals (overall mean 
differences: 0.69 kg/m2 for BMI; 2.31 cm for WC; and 0.01 for WHR), and in people with no, or 
primary schooling only, compared to those with a tertiary education (overall mean differences: 
1.31 kg/m2 for BMI; 3.04 cm for WC; and 0.02 for WHR) (Tables 3.4-3.5). Qualitatively similar 
results to those above were observed in analyses with further adjustment for smoking status, 
alcohol consumption, physical activity and education (Table 3.6).  
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Associations of adiposity measures with blood pressure and fasting glucose 
Figure 3.3 plots mean blood pressure and fasting glucose values by sex against mean values 
in tenths of adiposity measures, suggesting positive and approximately linear associations 
across the full range of values observed. Age and sex adjusted correlates of blood pressure 
were slightly weaker with WHR (r = 0.15 for both SBP and diastolic blood pressure [DBP]) than 
with BMI (r = 0.22 for SBP; r = 0.25 for DBP) or WC (r = 0.21 for SBP; r = 0.23 for DBP). Age 
and sex adjusted differences in SBP and DBP, respectively, per one standard deviation higher 
adiposity measure were 4.4 mmHg and 3.0 mmHg with BMI, 4.4 mmHg and 2.9 mmHg with 
WC and 3.4 mmHg and 2.1 mmHg with WHR (Table 3.3). Associations with fasting glucose 
were broadly similar across adiposity measures, but slightly weaker than those with blood 
pressure (Figure 3.3). Associations were broadly similar in males and females (Table 3.2). 
 
Associations of adiposity measures with lipid markers 
Adiposity measures had curvilinear and positive associations with total cholesterol, non-HDL 
cholesterol, triglyceride and apolipoprotein-B; negative associations with HDL cholesterol and 
apolipoprotein-AI; and no association with Lp(a) (Figures 3.4-3.5). Correlations of adiposity 
measures with these markers were the strongest for triglyceride (r = 0.28 for BMI; r = 0.31 for 
WC; r = 0.28 for WHR) and HDL cholesterol (r = -0.26 for BMI; r = -0.28 for WC; r = -0.21 for 
WHR). There were somewhat less strong correlations with non-HDL cholesterol (r = 0.16 for 
BMI; r = 0.17 for WC; r = 0.16 for WHR); apolipoprotein-AI (r = -0.17 for BMI; r = -0.17 for WC; 
r = -0.13 for WHR); and apolipoprotein-B (r = 0.14 for BMI; r = 0.15 for WC; r = 0.14 for WHR); 
and weaker correlations with total cholesterol (r = 0.07 for BMI; r = 0.07 for WC; r = 0.09 for 
WHR). Differences in non-HDL and HDL cholesterol and the geometric mean of triglyceride, 
respectively, per one standard deviation higher adiposity measure were: 0.19 mmol/l, -0.11 
mmol/l, 1.17 mmol/l with BMI; 0.21 mmol/l, -0.12 mmol/l, 1.19 mmol/l with WC; and 0.22 
mmol/l, -0.10 mmol/l, 0.19 mmol/l with WHR (Table 3.3). Associations were broadly similar 
across adiposity measures and sex (Tables 3.2-3.3). 
 
Associations of adiposity measures with inflammatory markers 
Adiposity measures demonstrated continuous and approximately linear associations with CRP, 
fibrinogen, leukocyte count and IL-6, and no association with albumin (Figure 3.6). Among 
these associations assessed, CRP (r = 0.29 for BMI; r = 0.30 for WC; r = 0.22 for WHR) and 
IL-6 (r = 0.24 for BMI; r = 0.25 for WC; r = 0.18 for WHR) were the strongest correlates. 
Associations were modest with fibrinogen (r = 0.15 for BMI; r = 0.16 for WC; r = 0.12 for WHR), 
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and weak with leukocyte count (r = 0.09 for BMI; r = 0.11 for WC; r = 0. 12 for WHR). 
Associations were broadly similar across adiposity measures (Table 3.3), but somewhat 
stronger in women than in men (Table 3.2). 
 
In analyses restricted to participants with complete information on relevant covariates, age and 
sex adjusted correlation coefficients between adiposity measures and continuous variables 
were similar to those that were further adjusted for smoking status, alcohol consumption, 
physical activity and education (data not shown). 
 
Discussion 
This meta-analysis of individual data on 221,934 participants from 58 prospective studies 
without known cardiovascular disease at baseline examination quantified the cross-sectional 
correlates of BMI, WC and WHR with several established and emerging cardiovascular 
disease risk factors, in more detail and with greater precision than has previously been 
possible. Overall, there were approximately linear and strong associations between BMI and 
WC, and WHR and WC, and only moderately strong correlations between BMI and WHR. All 
three measures of adiposity showed continuous and approximately linear associations with 
blood pressure, fasting glucose and inflammatory markers, and slightly curvilinear associations 
with lipid markers. Despite suggestions that visceral fat is more metabolically active than other 
fat depots,15 correlations with these intermediate risk factors on the pathway between excess 
body fat and cardiovascular disease were broadly similar for BMI, WC and WHR. In both males 
and females, BMI, WC and WHR were most strongly associated with blood pressure, HDL 
cholesterol, triglyceride, CRP and IL-6. Overall, adiposity measures were significantly higher in 
individuals of non-European descent, in physically inactive people, in people with a history of 
diabetes and in people with low levels of education. Whereas mean BMI and WC values were 
somewhat lower in current smokers and current alcohol drinkers, mean WC and WHR values 
were higher in males than in females.  
 
Adiposity measures 
The current analysis showed strong positive and approximately linear correlations between 
BMI and WC, and WHR and WC for both men and women, while there were only moderately 
strong correlations between BMI and WHR for both sexes. Consistent with the European 
Prospective Investigation into Cancer16 (EPIC), a large prospective cohort study with more 
than 350,000 participants from 9 countries, the association between BMI and WHR was 
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somewhat stronger in men than in women. The current data suggest that BMI, WC and WHR 
may provide related but somewhat distinct information on adiposity. BMI correlates strongly 
with total fat mass, while WHR correlates well with abdominal fat mass.17,18 Therefore, the 
strong correlation of WC with both BMI and WHR suggests that WC may capture information 
on body fat distribution, as well as on total body fatness. 
 
Age, sex and ethnicity 
In keeping with previous studies,19-21 the present data demonstrate that mean values of 
adiposity measures generally increased with the age of participants until about 55-75 years, 
then flattened or declined in participants at older ages. The observed reduction of BMI values 
may be explained by a relatively greater loss of lean body mass than gain in fat mass at older 
ages.22,23 As expected, mean BMI values were similar in males and females, while there were 
large sex differences in WC and WHR, with higher values in men than in women. The similarity 
in BMI values in both sexes is in contrast to the findings of a large cross-sectional study 
involving 150,000 men and women living in Mexico City, which observed much higher BMI 
values in women than in men.24 The majority of participants in the ERFC are of European 
ancestry, hence relatively little information was available on other ethnicities. The current 
analysis combined all participants of non-European ancestry into one single category that 
consisted predominantly of black (37%) and East-Asian (36%) participants. Because body 
composition varies between different ethnicities, the interpretation of the observed differences 
is difficult. East-Asians are known to have generally lower values in adiposity measures 
compared to people of European ancestry.25-27 By contrast, several studies have reported 
higher adiposity measure values in black women than in white women, while adiposity 
measure values were generally lower in black men compared to white men.25,26,28-32 Such sex 
differences in the black population might explain the opposing associations observed for non-
white men and non-white women in the current analysis.  
 
Smoking, alcohol consumption, physical activity and socioeconomic status 
The present data demonstrate that overall BMI and WC values were lower in current smokers 
than in ex- and never smokers. By contrast, overall WHR values were slightly lower in ex- and 
never smokers than in current smokers, even after adjustment for alcohol consumption, 
physical activity and education. The current data are supported by the findings of several 
studies.21,33-44 The biological mechanisms of such differences in adiposity measures are 
unclear. It has been suggested that increased androgenicity may mediate the effect of smoking 
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on the distribution of body fat, leading to a relatively greater deposition of adipose tissue in the 
abdominal region compared to the gluteofemoral area.38,43 Consistent with findings from the 
Prospective Studies Collaboration (PSC),19 overall BMI values were lower in alcohol drinkers 
than in alcohol abstainers. Whereas overall WC values were also lower in current alcohol 
drinkers, no significant differences were observed in overall WHR values between current 
drinkers and ex- or never drinkers. Given that alcohol is high in calories, these findings may be 
surprising, as values of adiposity measures would be expected to be higher in alcohol drinkers. 
Further investigation of possible mechanisms is needed. Values of adiposity measures were 
lower in physically active people than in less active participants. Previous studies have 
suggested that increased physical activity is related to reductions in abdominal adiposity, 
however not necessarily in BMI.45-48 The mechanism by which physical activity reduces 
obesity, in particular abdominal adiposity, is not fully understood but it is believed to be related 
to a relative increase in lipolysis in subcutaneous abdominal adipose tissue.47 BMI, WC and 
WHR values tended to be higher in persons with low socioeconomic status (as indicated by the 
level of education reached). Consistent with previous findings,49-51 the inverse association 
between socioeconomic status and adiposity measures was stronger in women than in men in 
the current analysis. Possible explanations for the sex differences are still unknown. Education 
is an indicator of acquisition of beliefs and knowledge.52 It has been suggested that people with 
higher education are more likely to integrate healthy behaviours into their everyday lives than 
people with less education.53 This may provide an explanation as to why people with higher 
socioeconomic status have lower adiposity measure values.  
 
Blood pressure, fasting glucose and diabetes  
BMI, WC and WHR were linearly and positively correlated with blood pressure levels, although 
the correlation of WHR was somewhat weaker. The positive relationship between adiposity and 
blood pressure is well established, however the underlying biological mechanisms are poorly 
understood.54,55 It has been suggested that in overweight and obese persons the complex 
interaction of several metabolic and neurohormonal pathways, such as the rennin-angiotensin-
aldosterone and sympathetic nervous systems, leads to increased peripheral vascular 
resistance.55-58 Contrary to previous suggestions that measures of abdominal adiposity are 
more strongly related to diabetes,59 BMI, WC and WHR were similarly and positively correlated 
with fasting glucose, and were all significantly higher in people with a history of diabetes. 
Obesity is associated with insulin resistance which, in combination with impaired pancreatic β-
cell function, leads to hyperglycaemia and type II diabetes.60 
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Lipid markers 
BMI, WC and WHR were similarly associated with lipid markers, with particularly strong 
correlates for non-HDL cholesterol and triglyceride. It has been postulated that obesity, in 
particular visceral adiposity, promotes the release of non-esterified fatty acids which are 
converted by enzymes in the liver into triglyceride-rich very low density lipoprotein (VLDL) 
particles and, by the action of cholesterol ester transfer protein (CETP), into triglyceride-rich 
low density lipoprotein (LDL) cholesterol particles (VLDL plus LDL comprise non-HDL 
cholesterol).1,61 This also explains the observed correlation with apolipoprotein-B, as this 
apolipoprotein is specifically incorporated into non-HDL cholesterol particles. The up-regulation 
of CETP leads simultaneously to a decrease in HDL particles and hence apolipoprotein-AI, 
which may explain the inverse correlation with adiposity measures.1,61 
 
Inflammatory markers 
Adiposity measures were positively correlated with inflammatory markers, such as CRP, IL-6, 
fibrinogen and white cell count. These findings are consistent with the suggestion that obesity 
induces low-grade inflammation. As described in Chapter 1 on pages 5-7, adipose tissue, 
composed of adipocytes, macrophages and other cells, releases several cytokines and 
inflammatory markers, such as TNF-α, IL-6 and IL-1β, which stimulate the liver to produce 
CRP and other inflammatory markers.1,3,4 However, the relevance of inflammation for the 
pathogenesis of cardiovascular disease is still unclear, as discussed in detail in Chapter 5 on 
page 121.  
 
Strength and limitations 
The general strengths and limitations of the ERFC are described in more detail in Chapter 8. 
Briefly, the present analysis provides the most precise, reliable and comprehensive 
assessment of the cross-sectional correlates of BMI, WC and WHR in up to 221,934 adults 
from 58 prospective studies with concomitant information on weight, height, and waist and hip 
circumference. In contrast to some previous investigations, the present meta-analysis should 
have minimised any impact of pre-existing cardiovascular diseases, because it involved only 
participants without known cardiovascular disease. Subsidiary findings excluding participants 
with death or a cardiovascular event during the first five years of follow-up were very similar to 
the overall findings, further limiting the scope of any "reverse association" biases due to 
subclinical or unreported disease. Because the present analyses were restricted to data 
available to the ERFC, it was not possible to investigate the association with dietary factors 
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(eg, calorie intake), cytokines (eg, TNF-α and other interleukins), or hormone concentrations 
(eg, leptin or adiponectin). The impact of any measurement error in adiposity measures or 
correlates on the associations was not assessed. Because within-person variability of WHR is 
larger than that of WC and BMI (Chapter 4), the observed associations with WHR may be 
somewhat underestimated. But as all analyses of error-prone traits were restricted to 
measurements taken at the same time as adiposity measures, the impact of any temporal 
trend (such as within-person variability through time) should have been minimised.  
 
Conclusion 
Although the correlations between clinical measures of adiposity differed, BMI, WC and WHR 
were similarly and importantly associated with blood pressure, fasting glucose and lipids. This 
finding highlights the importance of these intermediate risk factors on the pathway between 
excess body fat and cardiovascular disease. Furthermore, adiposity measures were correlated 
with age, smoking status and other lifestyle characteristics (such as alcohol consumption, 
physical activity and socioeconomic status), suggesting possible scope for confounding in 
observational studies of associations of adiposity measures with disease risk.  
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Table 3.1 Summary of data available on BMI, WC, WHR and other covariates 
 
No of 
studies
No of 
participants
Mean (SD)
 or % 
Adiposity measures
BMI (kg/m2) 58 221934 27 (4.56)
WC (cm) 58 221934 91 (12.6)
WHR 58 221934 0.90 (0.083)
Age at survey (yrs) 58 221934 58 (9)
BP and fasting glucose
Systolic BP (mmHg) 53 191170 135 (20)
Diastolic BP (mmHg) 53 191112 80 (11)
Fasting glucose (mmol/l) 34 85330 5.6 (1.8)
Lipid markers
Total cholesterol (mmol/l) 53 179735 5.80 (1.10)
Non-HDL cholesterol (mmol/l) 50 174024 4.40 (1.12)
HDL cholesterol (mmol/l) 50 174095 1.40 (0.40)
Loge triglyceride (mmol/l) 47 146974 0.31 (0.53)
Apo AI (g/l) 17 63156 1.53 (0.30)
Apo B (g/l) 16 62347 1.13 (0.30)
Loge Lp(a) (mg/dl) 15 55520 2.45 (1.17)
Inflammatory markers
Fibrinogen (µmol/l) 28 97608 8.7 (2.1)
Loge CRP (mg/l) 30 67483 0.66 (1.08)
Albumin (g/l) 19 64230 43 (3)
Loge leukocyte count (x109 per l) 18 61522 1.82 (0.28)
Loge Interleukin 6 (ng/l) 8 24290 0.57 (0.64)
Categorical variables
Sex 58 221934
    Female 124189 56%
    Male 97745 44%
Ethnicity 44 145882
    Non-white 28956 20%
    White 116926 80%
Smoking status 58 219092
    Current 52261 24%
    Not current 166831 76%
Alcohol status 47 195186
    Current 110199 56%
    Not current 84987 44%
Physical activity 26 81707
    Active 26659 33%
    Not active 55048 67%
History of diabetes 56 203849
    Yes 13899 7%
    No 189950 93%
Level of education reached 33 125162
    Tertiary 34013 27%
    Secondary 64186 51%
    No schooling/Primary 26963 22%
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Table 3.2 Correlations (95% CI) of BMI, WC and WHR with several continuous variables, stratified by sex 
 
Males Females Males Females Males Females
Adiposity measures
BMI (kg/m2)  -  - 0.86 (0.85, 0.87) 0.84 (0.82, 0.85) 0.52 (0.49, 0.54) 0.37 (0.34, 0.41)
Waist circumference (cm) 0.86 (0.85, 0.87) 0.84 (0.82, 0.85)  -  - 0.73 (0.71, 0.76) 0.71 (0.69, 0.74)
Waist/hip ratio 0.52 (0.49, 0.54) 0.37 (0.34, 0.41) 0.73 (0.71, 0.76) 0.71 (0.69, 0.74)  -  -
Age at survey (yrs) -0.01 (-0.05, 0.03) 0.10 (0.06, 0.15) 0.10 (0.05, 0.14) 0.19 (0.16, 0.23) 0.16 (0.12, 0.21) 0.23 (0.20, 0.25)
BP and fasting glucose
Systolic BP (mmHg) 0.19 (0.17, 0.22) 0.25 (0.22, 0.28) 0.21 (0.19, 0.24) 0.27 (0.24, 0.30) 0.20 (0.17, 0.23) 0.22 (0.19, 0.24)
Diastolic BP (mmHg) 0.26 (0.23, 0.28) 0.26 (0.24, 0.29) 0.24 (0.21, 0.27) 0.25 (0.22, 0.27) 0.18 (0.14, 0.21) 0.15 (0.12, 0.18)
Fasting glucose (mmol/l) 0.16 (0.14, 0.17) 0.22 (0.19, 0.24) 0.18 (0.16, 0.19) 0.24 (0.22, 0.26) 0.16 (0.14, 0.18) 0.20 (0.17, 0.23)
Lipid markers
Total cholesterol (mmol/l) 0.11 (0.08, 0.13) 0.09 (0.06, 0.12) 0.10 (0.08, 0.13) 0.11 (0.08, 0.15) 0.11 (0.08, 0.14) 0.14 (0.11, 0.16)
Non-HDL cholesterol (mmol/l) 0.19 (0.17, 0.21) 0.18 (0.15, 0.21) 0.19 (0.16, 0.21) 0.21 (0.18, 0.24) 0.17 (0.14, 0.20) 0.21 (0.18, 0.24)
HDL cholesterol (mmol/l) -0.27 (-0.28, -0.25) -0.26 (-0.28, -0.25) -0.26 (-0.27, -0.24) -0.28 (-0.30, -0.26) -0.19 (-0.21, -0.17) -0.22 (-0.25, -0.20)
Loge triglycerides (mmol/l) 0.30 (0.28, 0.32) 0.28 (0.25, 0.32) 0.31 (0.29, 0.33) 0.34 (0.31, 0.37) 0.28 (0.25, 0.30) 0.32 (0.28, 0.35)
Apo AI (g/l) -0.17 (-0.19, -0.15) -0.16 (-0.19, -0.14) -0.16 (-0.19, -0.13) -0.17 (-0.20, -0.14) -0.12 (-0.15, -0.08) -0.13 (-0.16, -0.09)
Apo B (g/l) 0.16 (0.12, 0.20) 0.14 (0.08, 0.21) 0.17 (0.13, 0.22) 0.18 (0.11, 0.24) 0.16 (0.11, 0.21) 0.19 (0.14, 0.25)
Loge Lp(a) (mg/dl) -0.03 (-0.06, -0.01) 0.03 (-0.02, 0.08) -0.05 (-0.08, -0.02) 0.02 (-0.03, 0.06) -0.06 (-0.10, -0.01) 0.00 (-0.03, 0.04)
Inflammatory markers
Loge CRP (mg/l) 0.21 (0.17, 0.26) 0.37 (0.33, 0.41) 0.26 (0.22, 0.30) 0.37 (0.33, 0.41) 0.25 (0.21, 0.29) 0.24 (0.21, 0.27)
Fibrinogen (µmol/l) 0.09 (0.06, 0.12) 0.25 (0.22, 0.28) 0.14 (0.10, 0.17) 0.26 (0.23, 0.29) 0.16 (0.13, 0.19) 0.18 (0.15, 0.21)
Albumin (g/l) 0.03 (-0.01, 0.07) -0.09 (-0.14, -0.03) -0.01 (-0.05, 0.03) -0.09 (-0.14, -0.04) -0.03 (-0.07, 0.01) -0.03 (-0.06, -0.01)
Loge leukocyte count (x109 per l) 0.06 (0.04, 0.07) 0.09 (0.07, 0.12) 0.10 (0.08, 0.12) 0.10 (0.08, 0.13) 0.13 (0.10, 0.16) 0.10 (0.07, 0.13)
Loge Interleukin 6 (ng/l) 0.18 (0.13, 0.22) 0.33 (0.25, 0.41) 0.21 (0.16, 0.27) 0.34 (0.26, 0.41) 0.22 (0.17, 0.27) 0.23 (0.16, 0.29)
BMI WC WHR
 
 
Sex-specific correlation coefficients were calculated using studies comprising both male and female participants. 
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Table 3.3 Cross-sectional associations of BMI, WC and WHR with various continuous 
variables 
 
BMI (kg/m2) WC (cm) WHR
Adiposity measures
BMI (kg/m2)  -  4.06 (3.95, 4.17)  2.21 (2.05, 2.38)
WC (cm)
 10.05 (9.85, 10.26)  -  9.50 (9.08, 9.91)
WHR  0.03 (0.03, 0.03)  0.05 (0.05, 0.06)  -
BP and fasting glucose
Systolic BP (mmHg)  4.40 (4.00, 4.81)  4.41 (4.02, 4.80)  3.37 (3.08, 3.67)
Diastolic BP (mmHg)  2.95 (2.60, 3.31)  2.93 (2.59, 3.27)  2.09 (1.83, 2.35)
Fasting glucose (mmol/l)  0.29 (0.26, 0.32)  0.33 (0.28, 0.37)  0.29 (0.22, 0.36)
Lipid markers
Total cholesterol (mmol/l)  0.09 (0.06, 0.11)  0.09 (0.07, 0.12)  0.12 (0.10, 0.14)
Non-HDL-cholesterol (mmol/l)  0.19 (0.16, 0.22)  0.21 (0.18, 0.24)  0.22 (0.19, 0.25)
HDL-cholesterol (mmol/l)  -0.11 (-0.11, -0.10)  -0.12 (-0.12, -0.11)  -0.10 (-0.11, -0.09)
Loge triglycerides (mmol/l)  0.16 (0.14, 0.18)  0.18 (0.17, 0.20)  0.18 (0.16, 0.19)
Apo AI (g/l)  -0.05 (-0.06, -0.04)  -0.05 (-0.06, -0.04)  -0.04 (-0.06, -0.03)
Apo B (g/l)  0.05 (0.03, 0.06)  0.05 (0.04, 0.07)  0.05 (0.03, 0.07)
Loge Lp(a) (mg/dl)  0.01 (-0.02, 0.04)  -0.01 (-0.04, 0.01)  -0.04 (-0.07, -0.01)
Inflammatory markers
Fibrinogen (µmol/l)  0.33 (0.27, 0.39)  0.35 (0.28, 0.41)  0.30 (0.24, 0.37)
Loge CRP (mg/l)  0.33 (0.29, 0.37)  0.36 (0.32, 0.40)  0.31 (0.26, 0.35)
Albumin (g/l)  -0.11 (-0.25, 0.03)  -0.10 (-0.22, 0.03)  0.02 (-0.06, 0.10)
Loge leukocyte count (x109 per l)  0.03 (0.02, 0.03)  0.03 (0.03, 0.04)  0.04 (0.03, 0.05)
Loge Interleukin 6 (ng/l)  0.15 (0.11, 0.19)  0.16 (0.12, 0.21)  0.14 (0.10, 0.19)
Difference (95% CI) in row variables per 1-SD higher level of 
adiposity measures¶ 
 
 ¶Change in row variable (adiposity measure or potential mediating risk factor) per 1-SD higher BMI, WC or WHR, adjusted 
for age and sex, pooled across studies using random effects meta-analysis. SDs were 4.56 kg/m2 for BMI, 12.6 cm for WC 
and 0.083 for WHR. 
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Table 3.4 Cross-sectional associations of Z-transformed values of BMI, WC and WHR with 
various categorical variables and age at baseline 
 
BMI (kg/m2) WC (cm) WHR
Age at survey (yrs) 0.02 (-0.02, 0.06) 0.11 (0.08, 0.14) 0.15 (0.12, 0.17)
Categorical variables
Sex
    Female 0.04 (-0.04, 0.11) -0.63 (-0.74, -0.52) -1.15 (-1.27, -1.03)
    Male Reference Reference Reference
Ethnicity
    Non-white 0.24 (0.13, 0.35) 0.10 (0.00, 0.20) 0.10 (0.01, 0.18)
    White Reference Reference Reference
Smoking status
    Current -0.21 (-0.24, -0.18) -0.12 (-0.15, -0.09) 0.05 (0.02, 0.07)
    Not current Reference Reference Reference
Alcohol status
    Current -0.13 (-0.17, -0.09) -0.08 (-0.12, -0.04) -0.02 (-0.05, 0.01)
    Not current Reference Reference Reference
History of diabetes
    Yes 0.43 (0.37, 0.49) 0.46 (0.40, 0.52) 0.36 (0.32, 0.41)
    No Reference Reference Reference
Physical activity
    Active -0.15 (-0.28, -0.03) -0.18 (-0.30, -0.06) -0.16 (-0.24, -0.08)
    Not active Reference Reference Reference
Level of education reached
    Tertiary -0.29 (-0.34, -0.23) -0.24 (-0.29, -0.19) -0.26 (-0.30, -0.21)
    Secondary -0.17 (-0.21, -0.13) -0.14 (-0.18, -0.11) -0.13 (-0.16, -0.10)
    No schooling/Primary Reference Reference Reference
Difference (95% CI) in Z-score of adiposity measures per 1-SD higher 
level in row variable or compared to reference category ‡
 
 ‡Difference in mean Z-score of adiposity measure per 1-SD higher levels of the row variable or compared to reference 
category, adjusted for age and sex, pooled across studies using random effects meta-analysis. Differences by sex were not 
adjusted for sex. To obtain the original scale of adiposity measures, Z-scores have to be multiplied by the standard deviation 
(SD) of relevant adiposity measure. SDs were 4.56 kg/m2 for BMI, 12.6 cm for WC and 0.083 for WHR.  
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Table 3.5 Cross-sectional associations of Z-transformed values of BMI, WC and WHR with various categorical variables, stratified by 
sex 
 
Males Females Males Females Males Females
Ethnicity
    Non-white -0.01 (-0.06, 0.03) 0.48 (0.29, 0.66) -0.23 (-0.31, -0.14) 0.34 (0.15, 0.54) -0.16 (-0.31, -0.01) 0.23 (0.09, 0.36)
    White Reference Reference Reference Reference Reference Reference
Smoking status
    Current -0.18 (-0.21, -0.14) -0.29 (-0.33, -0.24) -0.13 (-0.17, -0.10) -0.20 (-0.25, -0.15) -0.00 (-0.03, 0.02) -0.01 (-0.05, 0.03)
    Not current Reference Reference Reference Reference Reference Reference
Alcohol status
    Current -0.03 (-0.06, 0.00) -0.24 (-0.30, -0.18) -0.01 (-0.04, 0.02) -0.22 (-0.27, -0.16) 0.01 (-0.02, 0.04) -0.14 (-0.19, -0.10)
    Not current Reference Reference Reference Reference Reference Reference
History of diabetes
    Yes 0.32 (0.25, 0.38) 0.61 (0.52, 0.69) 0.35 (0.30, 0.41) 0.68 (0.61, 0.76) 0.31 (0.26, 0.37) 0.57 (0.50, 0.64)
    No Reference Reference Reference Reference Reference Reference
Physical activity
    Active -0.11 (-0.19, -0.02)  -0.24 (-0.48, -0.01) -0.20 (-0.29, -0.10) -0.22 (-0.42, -0.01)
-0.19 (-0.26, -0.13) -0.17 (-0.31, -0.02)
    Not active Reference Reference Reference Reference Reference Reference
Education reached
    Vocat/Uni -0.16 (-0.22, -0.09) -0.52 (-0.63, -0.40) -0.19 (-0.25, -0.12) -0.51 (-0.61, -0.40) -0.32 (-0.40, -0.24) -0.43 (-0.52, -0.34)
    Secondary -0.09 (-0.13, -0.04) -0.33 (-0.41, -0.24) -0.13 (-0.17, -0.08) -0.33 (-0.39, -0.26) -0.17 (-0.23, -0.11) -0.28 (-0.32, -0.23)
    Primary Reference Reference Reference Reference Reference Reference
BMI (kg/m2) WC (cm) WHR
Difference (95% CI) in Z-score of adiposity measures compared to reference category
 
 
Analyses were restricted to studies comprising both male and female participants. Difference (95% CI) in mean Z-score of adiposity measure compared to reference category, 
adjusted for age, pooled across studies using random effects meta-analysis. To obtain the original scale of adiposity measures, Z-scores have to be multiplied by the standard 
deviation (SD) of relevant adiposity measure. SDs were 4.56 kg/m2 for BMI, 12.6 cm for WC and 0.083 for WHR.  
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Table 3.6 Cross-sectional associations of Z-transformed values of BMI, WC and WHR with various categorical variables, adjusted for 
potential confounders 
 
Adjusted for age 
and sex
Further adjusted for 
potential confounders†
Adjusted for age 
and sex
Further adjusted for 
potential confounders†
Adjusted for age 
and sex
Further adjusted for 
potential confounders†
Sex
    Female -0.04 (-0.14, 0.05) -0.10 (-0.19, -0.02) -0.78 (-1.02, -0.54) -0.82 (-1.06, -0.59) -1.30 (-1.51, -1.09) -1.32 (-1.53, -1.11)
    Male Reference Reference Reference Reference Reference Reference
Race
    Non-white 0.40 (0.09, 0.70) 0.33 (0.04, 0.62) 0.26 (0.09, 0.44) 0.18 (0.01, 0.34) 0.05 (-0.11, 0.20) -0.01 (-0.19, 0.18)
    White Reference Reference Reference Reference Reference Reference
Smoking status
    Current -0.21 (-0.27, -0.15) -0.22 (-0.28, -0.17) -0.09 (-0.14, -0.05) -0.10 (-0.15, -0.06) 0.07 (0.03, 0.10) 0.05 (0.02, 0.08)
    Not current Reference Reference Reference Reference Reference Reference
Alcohol status
    Current -0.19 (-0.26, -0.12) -0.14 (-0.21, -0.08) -0.13 (-0.20, -0.06) -0.10 (-0.16, -0.03) -0.05 (-0.10, -0.00) -0.03 (-0.08, 0.01)
    Not current Reference Reference Reference Reference Reference Reference
History of diabetes
    Yes 0.50 (0.40, 0.60) 0.46 (0.36, 0.55) 0.51 (0.42, 0.60) 0.48 (0.39, 0.57) 0.42 (0.34, 0.50) 0.40 (0.33, 0.47)
    No Reference Reference Reference Reference Reference Reference
Physical activity
    Active -0.22 (-0.34, -0.11) -0.22 (-0.33, -0.10) -0.25 (-0.37, -0.13) -0.24 (-0.37, -0.11) -0.19 (-0.29, -0.09) -0.17 (-0.27, -0.07)
    Not active Reference Reference Reference Reference Reference Reference
Level of education
    Tertiary -0.31 (-0.38, -0.24) -0.31 (-0.37, -0.24) -0.26 (-0.32, -0.21) -0.26 (-0.31, -0.20) -0.28 (-0.33, -0.22) -0.26 (-0.31, -0.21)
    Secondary -0.22 (-0.27, -0.17) -0.21 (-0.26, -0.15) -0.16 (-0.21, -0.12) -0.15 (-0.19, -0.11) -0.14 (-0.18, -0.10) -0.13 (-0.17, -0.09)
    No schooling/Primary Reference Reference Reference Reference Reference Reference
BMI (kg/m2) WC (cm) WHR
Difference (95% CI) in Z-score of adiposity measures compared to reference category
 
 †Potential confounders are smoking status, alcohol status, physical activity and education.  
Analysis is restricted to participants with complete information on height, weight, waist and hip circumference, smoking status, alcohol consumption, physical activity and 
education. Difference in mean Z-score of adiposity measure compared to reference category, adjusted as shown, pooled across studies using random effects meta-analysis. To 
obtain the original scale of adiposity measures, Z-scores have to be multiplied by the standard deviation (SD) of relevant adiposity measure. Differences by sex were not 
adjusted for sex. SDs were 4.56 kg/m2 for BMI, 12.6 cm for WC and 0.083 for WHR.  
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Figure 3.1 Mean values of adiposity measure according to studies (panel A) and within 5-year age bands adjusted for studies (panel 
B)  
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Figure 3.2 Cross-sectional associations between values of adiposity measures with each other 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean adiposity measure values were adjusted to age 50 years. The values presented above each figure correspond to the age and sex adjusted partial correlation coefficient 
(95% CI) between adiposity measures in males and females combined. Y-axes are standardised to correspond to SD differences. 
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Figure 3.3 Cross-sectional associations of adiposity measures with blood pressure and fasting 
glucose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean risk factor values were adjusted to age 50 years. The values presented above each figure correspond to the age and 
sex adjusted partial correlation coefficient (95% CI) between adiposity measures and BP/fasting glucose in males and 
females combined. Y-axes are standardised to correspond to ½-SD differences.  
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Figure 3.4 Cross-sectional associations of adiposity measures with lipid markers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean risk factor values were adjusted to age 50 years. The values presented above each figure correspond to the age and 
sex adjusted partial correlation coefficient (95% CI) between adiposity measures and lipid markers in males and females 
combined. Y-axes are standardised to correspond to ½-SD differences. 
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Figure 3.5 Cross-sectional associations of adiposity measures with apolipoproteins and Lp(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean risk factor values were adjusted to age 50 years. The values presented above each figure correspond to the age and 
sex adjusted partial correlation coefficient (95% CI) between adiposity measures and apolipoproteins/Lp(a) in males and 
females combined. Y-axes are standardised to correspond to ½-SD differences. 
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Figure 3.6 Cross-sectional associations of adiposity measures with inflammatory markers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean risk factor values were adjusted to age 50 years. The values presented above each figure correspond to the age and 
sex adjusted partial correlation coefficient (95% CI) between adiposity measures and inflammatory markers in males and 
females combined. Y-axes are standardised to correspond to ½-SD differences. 
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CHAPTER 4: Within-person variability in adiposity measures 
 
Summary 
Within-person variability in risk factors can bias aetiological associations with disease risk. 
While within-person variability in directly measured risk factors has been extensively studied, 
less is known about within-person variability in calculated risk factors, such as sums or ratios, 
of measured variables. This chapter illustrates the extent of within-person variability in 
calculated variables and reports on such variability in body-mass index (BMI), waist 
circumference (WC) and waist-to-hip ratio (WHR), using data on over 79,000 serial 
measurements taken on average of 6 years apart in over 42,000 participants from 12 
prospective studies. Within-person variability was assessed by the regression dilution ratio 
(RDR). The findings show that the extent of within-person variability in calculated risk factors 
can be considerably larger (or smaller) than the within-person variability in its components. 
Furthermore, the present data demonstrate that the reproducibility (ie, low within-person 
variability) of BMI (RDR 0.96 [95% confidence interval [CI] 0.94-0.98]) is superior to that of WC 
(RDR 0.88 [95% CI 0.86-0.91]) and WHR (RDR 0.66 [95% CI 0.59-0.72]). The within-person 
variability in adiposity measures is not materially influenced by several characteristics, although 
the RDR of WHR varies somewhat by sex, diabetes status and baseline WHR values. These 
findings suggest that the degree of underestimation of the magnitude of association with 
disease risk is smaller for BMI than for WC and WHR in analyses using baseline values.  
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Background 
Epidemiological analyses often aim to estimate the aetiological association between error-free 
levels of risk factors and the likelihood of disease. Because most risk factors are measured 
with error and are subject to fluctuations within individuals, analyses that use only one single 
measurement of a risk factor may produce biased estimates of such associations.1,2 Such bias 
can be caused by technical measurement error and/or within-person variation.3,4 These 
sources of variability are classed together as "within-person variability" in the present chapter. 
In regression analyses with only a single risk factor, within-person variability leads to an 
underestimation of the true magnitude of the association between long-term average levels of 
the risk factor and disease (regression dilution bias),5,6 whereas in analyses with multiple error-
prone risk factors the association may be either over- or underestimated.7 Various methods 
have been proposed to quantify and to correct the effect of within-person variability in 
aetiological associations estimated from a single measurement of the risk factor.2,8  
 
While within-person variability in directly measured risk factors (eg, blood pressure9 or 
fibrinogen10) has been extensively studied, less is known about within-person variability in 
calculated risk factors, such as sums and differences (eg, change in height) or ratios (eg, body-
mass index [BMI] or waist-to-hip ratio [WHR]) of measured variables. This chapter will show 
that the extent of within-person variability in calculated risk factors can often appear higher or 
lower than expected in comparison to the within-person variability in the components that 
comprise the calculated risk factor. 
 
Current information on variability in adiposity measures is mostly based on studies conducted 
in a small number of individuals over a short time period (<6 months).11-14 A relatively small 
study with repeat measurements taken over three years in almost 2,000 participants, 
investigated long-term within-person variability in adiposity ratios and anthropometric indicators 
by use of the intra-class correlation coefficient.15 The findings of that study suggested that the 
within-person variability in BMI is lower than that of waist circumference (WC) and WHR. 
 
The objectives of this chapter are to (i) illustrate the extent of within-person variability in 
calculated variables; (ii) produce reliable estimates that quantify the within-person variability of 
BMI, WC and WHR; and (iii) identify important determinants of such variability. This chapter 
reports data from 79,145 serial measurements made in 42,300 participants from 12 studies in 
the Emerging Risk Factors Collaboration (ERFC).  
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Methods  
Study design 
Details of data on adiposity measures in the ERFC are given in Chapter 2. Briefly, the current 
analysis involves individual records from 12 prospective studies. A total of 42,300 participants 
without known history of cardiovascular disease at the initial ("baseline") examination had 
concomitant information on height, weight, waist and hip circumference at baseline 
examination and at resurvey. 
 
Regression dilution ratios 
The within-person variability in adiposity ratios and anthropometric indicators was quantified by 
the regression dilution ratio (RDR).5,9,10 The RDR estimates the extent to which an individual’s 
adiposity measurements vary around a long-term average adiposity level. The assumption is 
that knowledge of the long-term average level of an adiposity measure would completely 
capture the risk of disease associated with that adiposity measure.16 
 
The RDR is a ratio of the between-person variance over the total-variance (= between-person 
variance + within-person variance).17 Values of the RDR close to one suggest a small degree 
of within-person variability, and values closer to zero imply greater levels of within-person 
variability. Using Rosner’s regression approach,8 RDRs were estimated by regressing a repeat 
measurement of adiposity measures on their baseline values. Study and resurvey-specific 
RDRs were estimated from separate linear regression models in each study and at each 
resurvey. So, for each study Ss K1= , with individuals sni K1= , and repeat measurements 
sirr K1= , the model can be written as 
 
 
 
where ),0(~ 2srsir N σε  and srβ  is the study and resurvey-specific RDR. sirE  and siE represent 
repeat and baseline measurements of adiposity measure E , respectively. srα  represents the 
study and resurvey-specific intercept. Overall RDRs were estimated from a single linear mixed 
model of the repeat measurement on the baseline measurement, adjusted for study and 
resurvey (to allow for general differences in mean levels between studies and at different 
resurveys) and with allowance for between-study heterogeneity in the RDR and between-
(4.1),sirsisrsrsir EE εβα ++=
 87
person heterogeneity in mean levels (to account for multiple repeat measurements per 
individual).  
 
The overall RDR was obtained using the following model 
 
 
 
where ),0(~),,0(~ 22 wsius NwNu σσ  and ).,0(~ 2esir N σε  Between-study heterogeneity on the 
estimated RDR value β  is represented by 2uσ . The parameters 2wσ  and 2eσ  represent 
individual-specific and residual variation, respectively. Overall within and between-person 
variances were estimated from a further single linear mixed model, using all baseline and 
resurvey measurements as the dependent variable, adjusted for study and resurvey.  
 
Adjusting RDR for covariates 
To assess the impact of confounders (or mediators) on the RDR of adiposity measures, 
baseline covariates siX  (eg, age, sex, smoking status, systolic blood pressure [SBP], high-
density lipoprotein [HDL] and non-HDL cholesterol, and loge triglyceride) were included 
progressively in regression model (4.2) as fixed coefficient terms. The adjusted Rosner 
regression model is given by 
 
 
 
where ),0(~),,0(~ 22 wsius NwNu σσ  and ).,0(~ 2esir N σε  β  represents the overall RDR, 
adjusted for covariates siX . 
 
Determinants of variability 
Investigation of potential determinants of variability (ie, time since baseline, age, sex, smoking 
status, history of diabetes, SBP, HDL and non-HDL cholesterol, BMI, WC and WHR) was done 
by fitting an interaction term between baseline values of the determinant and the relevant 
adiposity measure in regression model (4.2), also allowing for additional study random effects. 
 
All analyses were performed using Stata release 11 (StataCorp LP, College Station, Texas 
USA). 
(4.2),)( sirsisissrsir wEuE εβα ++++=
(4.3),)( sirsisisissrsir wXEuE ελβα +++++=
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Within-person variability in calculated variables 
Whereas the within-person variability of WHR is considerably greater than that of waist and hip 
circumference, the within-person variability of BMI is similar to that of its components (see 
below section Extent of within-person variability in adiposity measures). The following two 
sections, therefore, investigate possible explanations why the within-person variability of ratios 
can be larger than expected in comparison to the within-person variability of the components. 
 
Within-person variability in ratios – algebraic formula 
Assume the classical additive measurement error models for two correlated normally 
distributed variables T1 and T2 in a single study,  
 
 
 
Q1i and Q2i represent the observed variables measured with error for individual i. Within and 
between-person variances for Q1 are represented by 21υ  and 21σ  respectively, and likewise for 
Q2i. The parameter ρ represents the correlation between the error-free values T1 and T2, 
whereas the parameter τ  represents the correlation between the within-person errors of T1 
and T2, which is often assumed to be zero.  
 
The RDRs for Q1 and Q2 are simply 
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Now suppose one is interested in the calculated variable T2-T1. For example, T1 and T2 may be 
true measures of height at two subsequent ages and one is interested in the change in growth 
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and 22σ , a strong correlation ρ, and similar but uncorrelated within-person variances 21υ  and 
2
2υ . 
 
The within and between-individual variances for the observed difference Q2-Q1 are given by 
 
 
 
The value of the between-person variance is important here. If T1 and T2 are similarly 
distributed with equal variances (say σ2) then the between-person variance for Q2-Q1 is simply 
22 22 ρσσ − , which becomes close to zero as the correlation ρ approaches 1. It is unlikely that 
the within-individual variance for Q2-Q1 will similarly shrink, as τ  is typically closer to 0. This 
can result in a relatively larger within-person variance and consequently low RDR in the 
calculated variable. For example, there is relatively large within-person variability in measures 
of growth change in comparison to the within-person variability in height measures. 
 
The algebraic forms for the within and between-person variances are simple for summations 
and differences of variables. For ratios of variables, say *1*2 /TTR = , it is easier to consider its 
loge-transformation, *1*2 logloglog TTR eee −= , to which the above equations can be applied 
(replacing T with logeT*) under assumption of normality. Below it is illustrated how the RDRs of 
Q1+Q2 and Q2-Q1 vary with the crucial parameters ρ, τ  and comparative variances of T1 and 
T2. 
 
Numerical results 
Figure 4.1 displays the calculated RDRs for Q1+Q2 and Q2-Q1, under the scenarios (i) 
RDR(Q1)=RDR(Q2) equal to 0.95, 0.80 and 0.60, (ii) ρ varying from -1 to 1 and (iii) ratios of the 
between-person variances 21σ  and 22σ  equal to 1, 0.75, 0.5 and 0.25. First, it is assumed that 
there is no correlation between the within-person errors (ie, 0=τ ). Under these scenarios, the 
RDR(Q2-Q1) (dotted line) decreases with higher correlation ρ because of the reduction in the 
between-person variance and the increase in the relative within-person variance. The decline 
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in RDR(Q2-Q1) becomes particularly important with ρ in the positive range. Depending on the 
RDRs of Q1 and Q2, the decrease can occur mainly at high correlations ρ or stretch also over 
lower correlations. For instance, for RDR(Q1)=RDR(Q2)=0.95, ρ>0.8 leads to a sudden drop in 
the RDR(Q2-Q1), while for lower RDRs of Q1 and Q2, the RDR(Q2-Q1) decreases earlier and 
less remarkably. Greater discrepancy in the distributions of T1 and T2 attenuates that effect by 
limiting the RDR(Q2-Q1) to decrease beyond a certain boundary value. A similar, but reversed 
situation is observed for RDR(Q1+Q2) (dashed line). 
 
Figure 4.2 plots the calculated RDRs for Q1+Q2 and Q2-Q1, under the scenarios (i) 
RDR(Q1)=RDR(Q2) equal to 0.95, 0.80 and 0.60, (ii) ρ varying from -1 to 1 and (iii) τ equal to 
0, 0.3, 0.6 and 0.9. The variances are now assumed to be equal 21σ = 22σ . RDR(Q2-Q1) 
declines with higher correlation ρ. However, RDR(Q2-Q1) becomes more stable with increasing 
τ , except at very high values of ρ.  
 
These numerical findings provide a useful insight for the observed RDRs of adiposity 
measures presented below.  
 
Extent of within-person variability in adiposity measures 
Available data from repeat measurements in the ERFC 
Baseline characteristics of studies and participants with concomitant repeat measurements on 
weight, height, waist and hip circumference are summarised in Table 4.1. A total of 42,300 out 
of 58,271 participants in 12 studies had one or more repeat measurements, and 21,360 
participants from 4 studies had more than two repeats. The participants with repeat 
measurements were not formally random samples from each cohort, although in general they 
were selected with the intention of being fairly representative of all individuals in the cohorts of 
interest. Individuals with repeat measurements of adiposity measures generally had somewhat 
higher baseline adiposity measures, were younger and were more likely to be non-smokers 
than individuals in the same studies without repeats (data not shown). A total of 79,145 repeat 
measurements were available derived from 18 different resurvey times spanning between 2 to 
10 years after the baseline survey. The mean time interval between baseline and repeat was 
5.9 years (Table 4.2 panel B). Mean (SD) values of adiposity measures among those with 
repeats were generally similar at baseline and follow-up resurveys (Table 4.2). For instance, 
the overall mean values (SD) at baseline examination were 27 kg/m2 (5.0) for BMI, 92 cm (13) 
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for WC and 0.90 (0.08) for WHR. Corresponding overall mean values (SD) at resurvey were 27 
kg/m2 (5.2) for BMI, 94 cm (14) for WC and 0.91 (0.08) for WHR. 
 
Regression dilution ratios for adiposity measures 
Overall unadjusted RDRs of adiposity measures, combined across studies and time intervals, 
were 0.96 (95% confidence interval [CI] 0.93-0.98) for BMI, 0.72 (95% CI 0.65-0.80) for WHR 
and 0.87 (95% CI 0.85-0.90) for waist-to-height ratio (WHtR) (Figure 4.3). Corresponding 
RDRs of components of these ratios were 0.87 (95% CI 0.85-0.90) for WC, 0.90 (95% CI 0.86-
0.93) for hip circumference, 0.99 (95% CI 0.99-1.00) for height and 0.97 (95% CI 0.96-0.98) for 
weight. There was considerable heterogeneity between the study and resurvey-specific RDRs 
of WHR, with RDRs ranging from 0.48 to 0.87. The total heterogeneity between RDRs had a 
standard deviation of 0.04 (95% CI 0.02-0.06) with BMI, 0.04 (95% CI 0.03-0.07) with WC and 
0.13 (95% CI 0.08-0.19) with WHR.  
 
Illustration of the extent of within-person variability in adiposity ratios 
Correlations and ratios of the between-person variances for the components of BMI, WHR and 
WHtR are shown in Table 4.3. Overall, waist and hip circumference were more strongly 
correlated than either waist circumference and height or weight and height. Additionally, the 
errors for waist and hip circumference were strongly correlated, which is likely to be due to the 
same measuring procedure for waist and hip circumference. Figure 4.4 illustrates that studies 
with low RDRs of WHR had generally lower RDRs of waist and hip circumference, larger ratios 
of variances for loge waist and hip circumference, and higher correlations between waist and 
hip circumference. There was large between-study variation in the correlations between waist 
and hip circumference and the ratios of between-person variances of loge waist and hip 
circumference, resulting in the observed heterogeneity in the RDRs of WHR. 
 
Determinants of within-person variability in adiposity measures 
Adjusting for potential confounders and mediators 
While the overall RDRs of BMI and WC remained virtually unchanged after adjustment for sex, 
the RDR decreased to 0.66 (95% CI 0.59-0.74) for WHR (Table 4.4). The within-person 
variability of adiposity measures did not materially change upon further adjustment for baseline 
values of age, smoking status, SBP, history of diabetes, and HDL and non-HDL cholesterol 
(Table 4.4). 
 
 92
Time trends in RDRs 
The length of the time between baseline and repeat measurement did not materially affect 
within-person variability of BMI and WC (Table 4.5) (although the time trend was formally 
significant, the overall RDR of WC did not vary materially with time interval). The within-person 
variability of WHR decreased with time since baseline, with the overall RDRs of 0.76 (95% CI 
0.69-0.84) at 1 year, 0.67 (95% CI 0.59-0.75) at 5 years and 0.58 (95% CI 0.50-0.66) at 10 
years (Table 4.5). However, these findings were dominated by the ARIC study (as seen from 
the decline in RDRs of ARIC [ie, the three biggest data markers] over time in Figure 4.3). After 
excluding the ARIC study, the decline over time in the overall RDR of WHR was not significant 
anymore (-0.01 [95% CI -0.03 to 0.01] for the RDR time trend per 5-year change). 
 
Predictors of variability 
The variability in BMI and WC was not materially affected by age, sex, smoking status, 
baseline SBP, HDL and non-HDL cholesterol (Table 4.6) (although some formally significant 
interactions with these variables were observed, the RDRs did not vary materially). There was 
some evidence that within-person variability of WHR was somewhat greater in women than in 
men and in people with a history of diabetes than in those without such a history. Similarly, 
there was evidence that the within-person variability of WHR was greater at higher baseline 
WHR values (Table 4.6). The non-linear relationship between baseline WHR and repeat 
measurements was reduced but not removed on loge-transformation of WHR. The overall RDR 
for loge WHR, adjusted for age and sex, was 0.65 (95% CI 0.58-0.72), with the standard 
deviation of the total heterogeneity of 0.12 (95% CI 0.08-0.18). 
 
RDR for other cardiovascular risk factors 
To compare the within-person variability for adiposity measures with that of other 
cardiovascular risk factors, estimates were calculated using repeat information in up to 42,300 
participants with complete information on BMI, WC and WHR. The age and sex adjusted 
RDRs were 0.57 (95% CI 0.52-0.62) for SBP, 0.75 (95% CI 0.69-0.80) for HDL cholesterol, 
0.63 (95% CI 0.59-0.67) for non-HDL cholesterol and 0.66 (95% CI 0.60-0.72) for loge 
triglyceride (Figure 4.5).  
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Discussion 
This chapter presented data on serial measurements of adiposity measures from 42,300 
participants in 12 prospective studies, providing the most comprehensive and detailed 
assessment of long-term within-person variability in adiposity measures. Furthermore, the 
current chapter illustrated the extent of within-person variability in calculated risk factors. The 
data demonstrate that the within-person variability of BMI is lower than that of WC and WHR. 
The within-person variability in adiposity measures is not materially influenced by several 
individual-level characteristics, although the RDR of WHR varies somewhat by sex and 
diabetes status, and is somewhat lower at higher baseline WHR values. This chapter has also 
shown that for given regression dilution ratios in two directly measured risk factors, the effect of 
within-person variability in corresponding calculated variables depends mostly on the strength 
of correlations and similarity of the between-person variances of the directly measured risk 
factors. 
 
The current data demonstrate that the reproducibility (ie, low within-person variability) of BMI 
(RDR 0.96) is superior to that of WC (RDR 0.88) or WHR (RDR 0.66), suggesting that for long-
term epidemiological studies of disease outcomes, regression dilution bias is less important for 
BMI than for WC or WHR. While the length of time between baseline and repeat measurement 
did not materially affect the variability of BMI and WC, the RDR of WHR decreased somewhat 
with longer follow-up. This suggestion should, however, be interpreted carefully, because only 
a few studies provided more than one repeat per individual. The observed findings are highly 
dependent on the data of the ARIC study. Indeed, the apparent time trend in the variability of 
WHR was abolished when the ARIC study was excluded from the analysis. Therefore, further 
studies are required to investigate this time trend, as corrections for regression dilution bias 
require stronger assumptions when RDRs vary substantially over time.16 
 
The variability of adiposity measures was not materially influenced by several individual 
characteristics, such as age, smoking status, blood pressure and lipids, although the variability 
in WHR was somewhat greater in females than in males and in people with a history of 
diabetes than in those without such a history. The current data showed that the within-person 
variability in WHR increased at higher baseline WHR values, suggesting that there is a non-
linear relationship between baseline and repeats of WHR. This increase in variability is 
probably due to the difficulty in measuring accurately WHR in obese people. As increasing 
WHR values are continuously associated with risk of cardiovascular disease (Chapter 6) and 
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as the RDR of WHR is lower at higher WHR values, use of an overall RDR may underestimate 
the true aetiological association.10 To allow for the non-linear relationship between repeats of 
WHR measures, regression calibration models1 can be used to assess the association 
between WHR and disease risk. Because there was considerable between-study heterogeneity 
in the RDRs of WHR, the observed differences in RDRs should, however, be interpreted 
carefully, as it is uncertain how much these observed differences are due to study differences 
rather than true differences in sex, diabetes status and levels of baseline WHR.  
 
The estimated RDRs of BMI and WC were unaffected by adjustment for age at baseline, sex 
and other established risk factors, suggesting that unadjusted RDRs for correcting relative risks 
associated with BMI and WC may generally be used. The RDR of WHR reduced somewhat 
upon adjustment for sex, but otherwise the RDR did not materially change with further 
adjustments. Using an unadjusted RDR to estimate the adjusted underlying association of 
WHR with disease risk will underestimate the true association.  
 
The current analysis has also shown that for given regression dilution biases in directly 
measured risk factors, the effect of within-person variability in corresponding calculated 
variables depends on the strength of correlations and the similarity of the between-person 
variances of the directly measured risk factors. The overall RDR of WHR was considerably 
lower than that of BMI, WHtR and its components. The main explanation for this finding is that 
overall waist and hip circumference are more strongly correlated and have – at least for some 
studies – more similar between-person variances than height and weight or waist 
circumference and height, respectively. Study and resurvey-specific correlations and between-
person variances of waist and hip circumference varied considerably across studies, explaining 
the observed heterogeneity in the RDRs of WHR.  
 
The limitations of regression dilution methods for correction for within-person variability are 
well-known.10 Firstly, regression dilution correction methods assume that the confounders (and 
mediators) are perfectly measured.17 As these factors are generally measured with error, 
correction methods would need to be extended for such analyses, for example, using a 
multivariate Rosner regression model.2 This approach has been implemented for analyses on 
associations of adiposity with disease risk (Chapters 5-6). Secondly, regression dilution 
correction methods assume that disease risk depends on a single underlying error-corrected 
exposure level. In a more realistic model with time-dependent true underlying exposure, 
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regression dilution corrections are valid if disease risk depends only on current true underlying 
exposure, or if RDRs are constant over life course.16 Except possibly for WHR, there was no 
important time trend in RDRs over a 10-year time span, suggesting the corrections are likely to 
be appropriate for adiposity measures. Thirdly, the observed exposure-disease association 
may reflect residual bias due to unmeasured confounders (eg, dietary intake or physical 
activity) rather than being causal associations. Corrections for the extent of within-person 
variability amplify the effect of such non-causal associations with no epidemiological value.18 
 
Conclusion 
The extent of within-person variability in calculated risk factors can be considerably larger (or 
smaller) than the within-person variability in its components. The present data demonstrate that 
the reproducibility of BMI is superior to that of WC and WHR. The within-person variability of 
adiposity measures is not materially influenced by several characteristics, although the RDR of 
WHR varies somewhat by sex, diabetes status and baseline WHR values. These findings 
suggest that the degree of underestimation of the magnitude of association with disease risk is 
smaller for BMI than for WC and WHR in analyses using baseline values. 
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Table 4.1 Characteristics of studies and individuals with serial measurements of adiposity measures 
 
Study
No of 
individuals 
with baseline 
values 
No of 
individuals 
No of 
re-
surveys
No of 
individuals 
with >2 
repeats
Male % Age
 (yrs)
WC 
(cm)
Hip 
(cm)
Height 
(cm)
Weight 
(kg) WHR WHtR 
BMI 
(kg/m2)
ARIC 14383 13414 3 12065 43 54 (6) 97 (14) 105 (10) 168 (9) 78 (17) 0.92 (0.08) 0.57 (0.08) 28 (5)
AUSDIAB 9204 5280 1  - 44 53 (11) 91 (14) 105 (10) 169 (9) 77 (16) 0.86 (0.09) 0.54 (0.08) 27 (5)
CHS1 3881 3265 1  - 38 72 (5) 93 (13) 101 (9) 164 (9) 72 (14) 0.92 (0.09) 0.57 (0.08) 26 (4)
COPEN 8166 4332 1  - 42 54 (13) 86 (13) 99 (8) 169 (10) 73 (14) 0.86 (0.09) 0.51 (0.07) 25 (4)
EPICNOR 1417 792 1  - 67 65 (8) 92 (11) 103 (7) 168 (9) 75 (12) 0.90 (0.08) 0.55 (0.06) 27 (3)
HOORN 2226 1359 1  - 45 60 (7) 90 (10) 102 (6) 169 (9) 75 (11) 0.88 (0.09) 0.53 (0.06) 26 (3)
IKNS 1942 86 1  - 83 63 (8) 83 (8) 91 (6) 158 (7) 59 (8) 0.92 (0.06) 0.53 (0.06) 23 (3)
LASA 1806 1124 2 707 44 70 (7) 97 (11) 103 (8) 167 (9) 75 (12) 0.94 (0.08) 0.58 (0.07) 27 (4)
MESA 6768 6373 3 6002 48 62 (10) 98 (14) 106 (11) 167 (10) 79 (17) 0.93 (0.08) 0.59 (0.09) 28 (5)
RANCHO 1784 882 1  - 40 65 (10) 84 (12) 100 (8) 167 (10) 70 (14) 0.83 (0.09) 0.50 (0.06) 25 (4)
SHS 4135 3482 2 2586 37 56 (8) 106 (15) 111 (13) 165 (9) 84 (18) 0.95 (0.06) 0.64 (0.10) 31 (6)
TARFS 2559 1911 1  - 50 47 (11) 93 (12) 105 (10) 163 (9) 74 (13) 0.89 (0.09) 0.57 (0.08) 28 (5)
Overall 58271 42300  - 21360 44 61 (9) 92 (13) 103 (10) 166 (9) 74 (16) 0.90 (0.08) 0.56 (0.08) 27 (5.0)
Among individuals with at least one repeat
Baseline mean (SD)
 
Appendix 4 lists study acronyms.  
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Table 4.2 Comparison of means and standard deviations (SD) of adiposity measures, grouped by study, between baseline 
measurements (panel A) and repeat measurements (panel B)  
 
A Baseline measurements
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
ARIC 13414 97 14 105 10 168 9 78 17 0.92 0.08 0.57 0.08 28 5.3
AUSDIAB 5280 91 14 105 10 169 9 77 16 0.86 0.09 0.54 0.08 27 4.8
CHS1 3265 93 13 101 9 164 9 72 14 0.92 0.09 0.57 0.08 26 4.4
COPEN 4332 86 13 99 8 169 10 73 14 0.86 0.09 0.51 0.07 25 4.0
EPICNOR 792 92 11 103 7 168 9 75 12 0.9 0.08 0.55 0.06 27 3.4
HOORN 1359 90 10 102 6 169 9 75 11 0.88 0.09 0.53 0.06 26 3.3
IKNS 86 83 8 91 6 158 7 59 8 0.92 0.06 0.53 0.06 23 3.1
LASA 1124 97 11 103 8 167 9 75 12 0.94 0.08 0.58 0.07 27 4.1
MESA 6373 98 14 106 11 167 10 79 17 0.93 0.08 0.59 0.09 28 5.4
RANCHO 882 84 12 100 8 167 10 70 14 0.83 0.09 0.5 0.06 25 3.6
SHS 3482 106 15 111 13 165 9 84 18 0.95 0.06 0.64 0.10 31 6.3
TARFS 1911 93 12 105 10 163 9 74 13 0.89 0.09 0.57 0.08 28 5.1
Overall 42300 92 13 103 10 166 9 74 16 0.90 0.08 0.56 0.08 27 5.0
Study No ofindividuals
WHR WHtR BMIWC Hip Height Weight
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Table 4.2 con’t Comparison of means and standard deviations (SD) of adiposity measures, grouped by study, between baseline 
measurements (panel A) and repeat measurements (panel B)  
 
B Repeat measurements
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
ARIC 13079 2.9 98 14 106 10 168 9 79 17 0.92 0.08 0.58 0.09 28 5.4
11841 6.0 100 14 107 11 168 9 80 17 0.94 0.07 0.6 0.09 28 5.6
10787 8.9 102 14 107 11 168 9 81 17 0.95 0.07 0.61 0.09 29 5.6
AUSDIAB 5280 5.0 93 14 106 10 168 10 78 16 0.88 0.09 0.55 0.08 28 5.1
CHS1 3265 2.9 97 13 102 10 164 9 71 14 0.94 0.08 0.59 0.08 27 4.5
COPEN 4332 9.4 89 13 102 8 169 10 74 15 0.87 0.09 0.53 0.07 26 4.3
EPICNOR 792 3.8 93 11 104 8 168 9 76 13 0.89 0.08 0.55 0.06 27 3.8
HOORN 1359 6.4 93 11 102 8 169 9 76 12 0.91 0.08 0.55 0.06 27 3.6
IKNS 86 3.7 85 8 90 5 158 7 58 8 0.94 0.07 0.54 0.06 23 3.0
LASA 931 3.1 95 11 103 9 166 9 74 13 0.92 0.09 0.57 0.07 27 4.2
900 6.1 97 11 103 8 166 9 75 12 0.94 0.08 0.58 0.07 27 4.2
MESA 6091 1.6 98 14 105 11 166 10 78 17 0.93 0.08 0.59 0.09 28 5.5
5868 3.2 98 14 105 11 166 10 78 17 0.93 0.08 0.59 0.09 28 5.5
5698 4.8 99 15 106 12 166 10 78 18 0.94 0.07 0.6 0.09 28 5.6
RANCHO 882 8.3 86 13 101 9 166 10 70 15 0.85 0.09 0.52 0.07 25 4.0
SHS 3268 3.9 107 15 112 14 164 9 84 19 0.96 0.06 0.65 0.10 31 6.5
2775 7.9 106 15 112 14 164 9 84 19 0.95 0.07 0.65 0.10 31 6.6
TARFS 1911 9.2 96 12 105 11 162 10 77 14 0.92 0.09 0.6 0.08 30 5.3
Overall 5.9 94 14 103 11 166 9 75 16 0.91 0.08 0.57 0.09 27 5.2
Mean 
time (yrs)Study
No of
individuals
WC Hip Height Weight WHR WHtR BMI
 
Appendix 4 lists study acronyms.  
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Table 4.3 Overall correlations and comparative distributions of components of WHR, WHtR and BMI 
 
T2/T1
Correlation (95% CI) of 
measures between 
subjects
Correlation (95% CI) of 
within-subjects errors SDLog T2 SDLog T1 VarLog T1/VarLog T2
Waist/hip ratio 0.810 (0.806, 0.813) 0.574 (0.569, 0.578) 0.131 0.090 0.47
Waist/height ratio 0.227 (0.198, 0.217)  -0.084 (-0.091, -0.077) 0.131 0.056 0.18
BMI (Weight/Height2) 0.524 (0.516, 0.531) 0.050 (0.043, 0.057) 0.199 0.112 0.32
 
 
Abbreviations: SD = standard deviation; Var = variance. 
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Table 4.4 Regression dilution ratios (95% CI) for BMI, WC, WHR and WHtR, progressively adjusted for baseline values of 
conventional risk factors 
 
Adjusted for baseline levels of
Body-mass 
index
Waist
circumference
Waist/hip 
ratio
Waist/height 
ratio
Unadjusted 0.97 (0.94, 0.98) 0.88 (0.85, 0.90) 0.72 (0.64, 0.80) 0.88 (0.86, 0.91)
Sex 0.96 (0.34, 0.98) 0.88 (0.86, 0.91) 0.66 (0.59, 0.74) 0.88 (0.86, 0.91)
plus age 0.96 (0.94, 0.98) 0.89 (0.86, 0.91) 0.66 (0.59, 0.73) 0.89 (0.87, 0.92)
plus smoking status 0.96 (0.94, 0.98) 0.89 (0.86, 0.91) 0.66 (0.59, 0.73) 0.89 (0.87, 0.92)
plus systolic blood pressure 0.97 (0.95, 0.99) 0.89 (0.87, 0.92) 0.66 (0.58, 0.73) 0.89 (0.87, 0.92)
plus history of diabetes 0.97 (0.95, 0.99) 0.89 (0.87, 0.92) 0.65 (0.58, 0.72) 0.89 (0.87, 0.92)
plus Non-HDL cholesterol 0.97 (0.95, 0.99) 0.89 (0.87, 0.92) 0.65 (0.57, 0.72) 0.89 (0.87, 0.92)
plus HDL cholesterol 0.97 (0.95, 0.99) 0.89 (0.86, 0.91) 0.63 (0.56 (0.70) 0.89 (0.87, 0.92)
 
 
Analyses were restricted to participants with complete information on age, sex, systolic blood pressure, smoking status, history of diabetes and non-HDL and HDL cholesterol 
(75731 repeats in 40023 individuals in 11 studies). 
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Table 4.5 Regression dilution ratios for BMI, WC, WHR and WHtR at different time points since baseline measurement 
 
Body-mass 
index
Waist 
circumference
Waist/hip 
ratio
Waist/height 
ratio
Overall RDR (95% CI) 0.96 (0.94, 0.98) 0.88 (0.86, 0.91) 0.66 (0.59, 0.72) 0.88 (0.85, 0.91)
RDR (95% CI) time trend per 5 year change  -0.013 (-0.029, 0.001)  -0.040 (-0.062, -0.018)  -0.093 (-0.111, -0.076)  -0.015 (-0.034, 0.002)
RDR (95% CI) at 1 year 0.97 (0.97, 0.98) 0.92 (0.90, 0.96) 0.76 (0.69, 0.84) 0.90 (0.87, 0.93)
RDR (95% CI) at 5 years 0.96 (0.95, 0.98) 0.89 (0.86, 0.92) 0.67 (0.59, 0.75) 0.88 (0.85, 0.92)
RDR (95% CI) at 10 years 0.95 (0.92, 0.98) 0.85 (0.80, 0.90) 0.58 (0.50, 0.66) 0.87 (0.83, 0.91)
 
 
Analyses were adjusted for age at baseline and sex. 
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Table 4.6 Regression dilution ratios for BMI, WC and WHR by levels of several individual-level 
characteristics at baseline 
 
RDR (95% CI) Interactionp-value RDR (95% CI)
Interaction
p-value RDR (95% CI)
Interaction
p-value
Age at baseline (yrs)
40-59 0.97 (0.94, 0.99) 0.89 (0.87, 0.92) 0.68 (0.61, 0.75)
60-69 0.95 (0.93, 0.98) 0.87 (0.85, 0.90) 0.64 (0.57, 0.72)
70+ 0.94 (0.91, 0.96) <0.001 0.87 (0.84, 0.90) 0.003 0.62 (0.55, 0.69) <0.001
Per 8.76 years increase  -0.013 (-0.017, -0.008 <0.001  -0.013 (-0.018, -0.007) <0.001  -0.026 (-0.032, -0.021) <0.001
Sex
Males 0.96 (0.94, 0.98) 0.89 (0.86, 0.92) 0.68 (0.61, 0.75)
Females 0.96 (0.94, 0.98) 0.647 0.86 (0.83, 0.89) <0.001 0.58 (0.51, 0.65) <0.001
Smoking status
Current 0.95 (0.92, 0.97) 0.87 (0.85, 0.90) 0.68 (0.61, 0.74)
Not current 0.96 (0.94, 0.98) 0.016 0.89 (0.86, 0.91) 0.026 0.65 (0.58, 0.72) 0.037
History of diabetes
Yes 0.91 (0.89, 0.94) 0.86 (0.83, 0.89) 0.58 (0.51, 0.64)
No 0.97 (0.95, 0.99) <0.001 0.89 (0.86, 0.91) <0.001 0.66 (0.59, 0.72) <0.001
Systolic blood pressure
<116 mmHg 0.98 (0.96, 1.00) 0.89 (0.87, 0.92) 0.68 (0.60, 0.75)
116-132 mmHg 0.97 (0.94, 0.99) 0.89 (0.86, 0.91) 0.65 (0.58, 0.73)
≥133 mmHg 0.95 (0.92, 0.97) <0.001 0.88 (0.86, 0.91) 0.1226 0.63 (0.56, 0.71) <0.001
Per 19.5 mmHg increase  -0.010 (-0.015, -0.007) <0.001  -0.006 (-0.011, -0.002) 0.008  -0.018 (-0.023, -0.013) <0.001
Non-HDL cholesterol
<3.6 mmol/l 0.97 (0.95, 0.99) 0.89 (0.86, 0.92) 0.67 (0.60, 0.74)
3.6-4.53 mmol/l 0.97 (0.95, 0.99) 0.89 (0.86, 0.92) 0.65 (0.58, 0.72)
≥4.54 mmol/l 0.95 (0.93, 0.97) <0.001 0.86 (0.83, 0.89) <0.001 0.62 (0.55, 0.69) <0.001
Per 1.09 mmol/l increase  -0.010 (-0.014, -0.006) <0.001  -0.012 (-0.017, -0.008) <0.001  -0.016 (-0.022, -0.011) <0.001
HDL cholesterol
<1.15 mmol/l 0.95 (0.93, 0.97) 0.88 (0.85, 0.91) 0.62 (0.56, 0.69)
1.15-1.49 mmol/l 0.96 (0.94, 0.98) 0.87 (0.84, 0.90) 0.62 (0.55, 0.69)
≥1.50 mmol/l 0.98 (0.96, 1.00) <0.001 0.88 (0.85, 0.91) 0.115 0.65 (0.58, 0.72) <0.001
Per 0.41 mmol/l increase 0.014 (0.010, 0.019) <0.001 0.000 (-0.004, 0.005) 0.886 0.007 (0.001, 0.013) 0.015
Body-mass index
<24.8 kg/m2 0.98 (0.96, 1.01) 0.79 (0.74, 0.83) 0.62 (0.55, 0.69)
24.8-28.7 kg/m2 0.96 (0.93, 1.00) 0.74 (0.69, 0.78) 0.61 (0.54, 0.68)
≥28.8 kg/m2 0.94 (0.92, 0.97) <0.001 0.82 (0.77, 0.86) <0.001 0.57 (0.50, 0.64) <0.001
Per 4.56 kg/m2 increase NA NA  -0.014 (-0.022, -0.006) <0.001  -0.037 (-0.042, -0.031) <0.001
Waist circumference
<87 cm 0.97 (0.93, 1.01) 0.86 (0.83, 0.89) 0.58 (0.51, 0.65)
88-99 cm 0.94 (0.90, 0.98) 0.89 (0.86, 0.93) 0.55 (0.48, 0.63)
≥100 cm 0.94 (0.89, 0.98) <0.001 0.89 (0.87, 0.92) 0.023 0.53 (0.46, 0.61) <0.001
Per 13.3 cm increase  -0.003 (-0.010, 0.004) 0.371 NA NA  -0.026 (-0.032, -0.020) <0.001
Waist/hip ratio
<0.88 0.97 (0.95, 1.00) 0.98 (0.94, 1.02) 0.68 (0.62, 0.74)
0.88-0.95 0.95 (0.93, 0.98) 0.96 (0.93, 1.00) 0.70 (0.63, 0.77)
≥0.96 0.95 (0.92, 0.97) <0.001 0.90 (0.86, 0.94) <0.001 0.51 (0.44, 0.57) <0.001
Per 0.08 increase
 -0.012 (-0.016, -0.008) <0.001  -0.010 (-0.017, -0.002) 0.010 NA NA
BMI WC WHR
Baseline characteristics
 
Analyses were adjusted for age at baseline and sex. Continuous variables were divided intro thirds based on the overall 
distribution in males and females combined. 
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Figure 4.1 Changes in regression dilution ratios according to correlation ρ and different ratios of comparative between-person 
variances of components 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression dilution ratios (RDRs) for Q1+Q2 (dashed line) and Q2-Q1 (dotted line) shown for RDR(Q1) = RDR(Q2) = 0.95 (top row), = 0.8 (middle row), = 0.6 (bottom row) (solid 
lines). Assumption: τ  = 0 
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Figure 4.2 Changes in regression dilution ratios according to correlation ρ and different correlations of within-person errors of 
components 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression dilution ratios (RDRs) for Q1+Q2 (dashed line) and Q2-Q1 (dotted line) shown for RDR(Q1) = RDR(Q2) = 0.95 (top row), = 0.8 (middle row), = 0.6 (bottom row) (solid 
lines). Assumption: Var(T2) = Var(T1)  
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Figure 4.3 Unadjusted regression dilution ratios for adiposity measures and anthropometric indicators plotted against time since 
baseline measurement by study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The sizes of data markers are proportional to the inverse of the variance of the regression dilution ratios (RDRs).  
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Figure 4.4 Unadjusted study and resurvey-specific regression dilution ratios of WHR by 
influential properties of waist and hip circumference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A shows the study and resurvey-specific RDRs of WHR according to individual RDRs of waist and hip circumference. 
Panel B shows RDRs of WHR according to the comparative between-person variances of loge waist and loge hip 
circumference. Panel C shows the RDRs of WHR according to the correlation ρ of waist and hip circumference. Panel D 
shows the RDRs of WHR according to the correlations of within-person errors τ  of waist and hip circumference. The sizes 
of data markers are proportional to the inverse of the variance in panel A and proportional to number of individuals in panel 
B, C and D. 
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Figure 4.5 Age and sex adjusted regression dilution ratios for adiposity measures and different 
cardiovascular risk factors 
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CHAPTER 5: Associations of body-mass index with risk of coronary heart 
disease, stroke, and cause-specific mortality  
 
Summary 
Although various prospective studies and collaborative analyses have reported on the 
associations of body-mass index (BMI) with coronary heart disease, stroke and/or non-vascular 
outcomes, the aetiological relevance of these relationships is still unclear. For instance, it is 
uncertain how much of the effect of BMI on disease risk can be accounted by confounders and 
biological mediators; whether associations with cardiovascular disease differ importantly at 
different levels of such risk factors, and how the shape of associations is characterised in 
associations with site-specific cancers and non-vascular conditions other than cancer. This 
chapter reports prospective analyses of individual participant data from over 1 million 
participants without known history of cardiovascular disease in 118 prospective studies, based 
mostly in Western countries. During 15.0 million person-years at risk, there were 31,909 non-
fatal myocardial infarctions or strokes and 129,994 deaths. In analyses adjusted for age, sex 
and smoking status, and excluding participants with BMI values below 20 kg/m2, there were 
approximately loge-linear associations with risk of coronary heart disease, ischaemic stroke 
and all cardiovascular mortality. Risk ratios per 5 kg/m2 higher baseline BMI, adjusted for age, 
sex and smoking status, were 1.31 (95% confidence interval [CI] 1.26-1.36) for coronary heart 
disease and 1.23 (95% CI 1.18-1.29) for ischaemic stroke. These associations were largely 
explained by long-term average levels of mediating risk factors, such as blood pressure, history 
of diabetes and lipids. Risk ratios for coronary heart disease were significantly greater in some 
groups at lower absolute risk – ie, in people without history of diabetes, at early middle age and 
at lower-than-average systolic blood pressure. Across the full range of BMI values, BMI had 
curvilinear associations with all-cause mortality, including most site-specific cancers and non-
vascular conditions not attributed to cancer. In participants with BMI values of 25 kg/m2 or 
higher, BMI was positively associated with a range of non-vascular mortality outcomes. 
Particularly strong relationships were observed with risk of death from diabetes and renal 
disease. By contrast, among participants with BMI values below 25 kg/m2, the negative 
association of BMI was predominantly due to the strong negative associations with respiratory 
disease and cancers of the lung and upper aerodigestive tract. These inverse associations 
were much stronger in smokers than in never smokers. In participants with BMI values of 25 
kg/m2 or higher, associations of BMI with non-vascular mortality attenuated somewhat after 
accounting for long-term levels of the intermediate factors noted above. 
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Background 
Although several large prospective studies1-10 and individual participant data meta-analyses of 
observational studies in Western11-13 and Asian14-16 populations have reported on associations 
of body-mass index (BMI) with risk of coronary heart disease, stroke and/or non-vascular 
mortality, the aetiological relevance of these relationships remains uncertain. Because previous 
studies involved a moderate number of outcomes,2 relied on self-reported weight and 
height,2,12 and/or lacked measurement of mediating and other established risk factors,10-12 it is 
uncertain how much of the effect of BMI on disease risk can be accounted by confounders and 
biological mediators, such as blood pressure, diabetes, lipids, inflammation, alcohol 
consumption, physical activity and socioeconomic indicators; whether associations with 
cardiovascular disease differ importantly at different levels of such risk factors, and how the 
shape of associations is characterised in associations with site-specific cancers and non-
vascular conditions other than cancer. Furthermore, two relatively small studies17,18 have 
suggested that BMI is more strongly related to fatal cardiovascular disease than non-fatal 
cardiovascular disease. Previous collaborative analyses,10-12 however, were not able to 
evaluate this suggestion, because they did not record non-fatal outcomes.  
 
The objective of this chapter is to produce reliable estimates of the associations of BMI with 
subsequent risk of coronary heart disease, stroke and cause-specific mortality, incorporating 
adjustment for potential confounders and biological mediators using data from the Emerging 
Risk Factors Collaboration (ERFC).19 
 
Methods 
Study design 
Details of study selection, data collection and harmonisation have been described in Chapter 
2. Briefly, the current analyses included individual participant data on BMI from 118 prospective 
studies involving 1,064,541 participants without known history of cardiovascular disease at the 
initial ("baseline") examination. The general characteristics of these studies, including methods 
for measurement of weight and height, were described in Chapter 2.  
 
Analytical approach 
Associations of BMI were assessed in relation to fatal or first-ever non-fatal coronary heart 
disease or stroke and cause-specific mortality, including deaths from vascular disease, cancer, 
and non-vascular conditions not attributed to cancer, as well as to further subdivisions of these 
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outcomes. Analyses involved a two-stage approach with estimates of association calculated 
separately within each study before pooling across studies by random effects meta-analysis.20 
The main analyses were based on Cox proportional-hazards regression models, estimated for 
each study separately. The Cox models were stratified, where appropriate, by sex and trial 
arm.21 The Cox proportional hazards model for each study ,1 Ss K=  with strata sKk K1=  (for 
most studies 2=SK  just for two sexes) and individuals sni K1= , with exposure of interest 
siE  and other covariates siX , can be written as 
 
 
 
where ),|( sisiski XEth  is the hazard at time t after baseline, )(0 th sk  is the baseline hazard at 
time t, and sβ  the parameter of interest, being the loge hazard ratio per unit increase in the 
exposure of study s, adjusted for confounding and/or mediating effects of the covariates siX . 
The estimated loge hazard ratios were subsequently combined over studies using random 
effects meta-analysis (ie, allowing for heterogeneity between studies).22 The random effects 
meta-analysis model with variance sν  for the estimate sβ  is given by  
 
 
 
 
β  represents the pooled loge hazard ratio and the variance 2τ  represents the extent of 
heterogeneity between studies.23 Parallel analyses were conducted using fixed-effect 
models.11,24-26  
 
Participants contributed only their first non-fatal outcome or death recorded at age 40 years or 
older (ie, deaths preceded by non-fatal coronary heart disease or stroke were not included in 
the analyses). The assumptions of proportionality of hazards were evaluated within each study 
by including an interaction term between exposure and time since baseline measurement.20 
Study-specific interaction terms were then pooled by random effects meta-analysis across 
studies to provide the average interaction term and corresponding test statistic. A significant 
correlation between time and loge hazard ratio would indicate that the proportional hazards 
assumption is violated. The proportional hazards assumptions were satisfied.  
(5.1),)(log)),|((log 0 sississkesisiskie XEthXEth γβ ++=
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For the five contributing "nested" case-control studies within prospective cohorts, odds ratios 
were calculated with logistic regression models.27 Provided the disease is relatively rare, 
hazard ratios and odds ratios were assumed to approximate the same relative risk and are 
collectively described as "risk ratios".28 The risk ratios were combined as described in (5.2).  
 
To avoid over-fitting of the statistical models, studies with fewer than five incident cases of an 
outcome were excluded from the analysis of that particular outcome. Risk ratios were initially 
adjusted for age, sex and smoking status only. To explore confounding and potential biological 
pathways underlying associations, risk ratios were further adjusted for systolic blood pressure 
(SBP), history of diabetes, total and high-density lipoprotein (HDL) cholesterol, triglyceride, C-
reactive protein (CRP), fibrinogen, alcohol consumption, or socioeconomic indicators (ie, 
educational attainment and occupational category). To limit potential bias due to pre-existing 
disease (ie, reverse causality), the first five years of follow-up were excluded in analyses 
involving associations with non-vascular outcomes and BMI values below 25 kg/m2 (see 
Results).  
 
Heterogeneity and reporting biases 
Between-study heterogeneity in loge risk ratio was estimated by calculating the Q statistic for 
testing heterogeneity and its corresponding transformation to the I2 statistic for quantifying the 
extent of heterogeneity  
 
 
 
where S represents the number of studies.29,30 Confidence intervals for the I2 statistic were 
calculated as recommended by Higgins and Thompson.30 The I2 statistic describes the 
percentage of variance in the estimated loge risk ratios from each study that is attributable to 
between-study variation as opposed to sampling variation. Values of I2 close to 0 correspond 
to lack of heterogeneity. Potential bias from small study effects was assessed by funnel plots 
and use of Egger’s test for publication bias.31 
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Shape of associations 
To characterise shapes of associations, study-specific risk ratios calculated within categories of 
baseline BMI values were pooled on a loge scale by multivariate random effects meta-analysis 
and plotted against mean BMI values within each category.32,33 BMI categories were defined as 
multiples of 2.5 kg/m2 (ie, <20, 20 to <22.5, 22.5 to <25.0, 25.0 to <27.5, 27.5 to <30.0, 30.0 to 
<32.5, 32.5 to <35.0, 35.0 to <37.5, 37.5 to <40.0, ≥40.0 kg/m2). 95% confidence intervals 
(CIs) were estimated from floated variances that reflect the amount of information underlying 
each group (including the reference group).34 This allows the values to be compared 
informatively between any pair of exposure categories, rather than only with the arbitrary 
chosen reference group. In the figures presented, sizes of data markers are proportional to the 
inverse of the variance of the loge risk ratios. Because associations with vascular outcomes 
were nearly loge-linear (except at low values of BMI: see Results), regression coefficients were 
calculated to estimate the risk ratios associated with 5 kg/m2 higher baseline BMI in 
participants with baseline BMI values of 20 kg/m2 or higher. Because association with non-
vascular conditions (and all-cause mortality) were curvilinear (with the lowest risk ratios at 
about 22.5 to 27.5 kg/m2), risk ratios of these outcomes were estimated within two ranges of 
baseline BMI – (i) in participants with BMI values below 25 kg/m2 and (ii) in participants with 
BMI values of 25 kg/m2 or higher. Associations with non-vascular mortality outcomes were 
approximately loge-linear in these two ranges of baseline BMI.  
 
Effect modification 
Effect modification by individual characteristics, such as age or other risk markers, was 
assessed using within-study information.35,36 Using a two-stage approach, study-specific 
interaction estimates sδ  for the potential effect modifier siX  were estimated using model (5.4) 
and subsequently combined by random effects meta-analysis, as described in (5.2).  
 
 
The overall interaction term was then based on only within-study information. Model (5.4) was 
further extended to include adjustments for other confounders, such as age and smoking 
status. Effect modification at the study-level, such as geographical region or study design, were 
assessed entirely on between-study comparisons using random effects meta-regression.37  
(5.4).)(log)),|((log 0 sisissississkesisiskie XEXEthXEth δγβ +++=
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Using the estimates of sβ  from model (5.1), model (5.2) was extended to include a study-level 
covariate sX , so that 
 
 
 
Bδ  is the between-study interaction term allowing for between-study variance 2τ . Effect 
modifications with variables that can have both within-study and between-study information 
(eg, sex or ethnicity) depending on the individual study, were based on within-study information 
only. Differences between associations with coronary deaths and non-fatal myocardial 
infarction were examined in competing risk models.38 
 
Within-person variability  
As discussed in Chapter 4, within-person variability in exposures can underestimate the true 
magnitude of exposure-disease association,39,40 while within-person variability in confounders 
can bias the association in either direction.41 To take into account the impact of within-person 
variability in BMI and potential confounders and biological mediators, regression dilution ratios 
(RDRs) were calculated by use of regression calibration models that allow for between-study 
and between-individual heterogeneity.23,42 For each error-prone variable, the regression 
calibration model with studies Ss K1= , individuals sni K1= , and repeat measurements 
sirr K1= , can be written as 
 
 
 
where ),0(~),,0(~ 22 wsius NwNu σσ  and ).,0(~ 2esir N σε  sirE  and siE represent repeat and 
baseline measurements of the error-prone variable, respectively, and siX  represents other 
baseline covariates. Between-study heterogeneity on the estimated RDR value β  is 
represented by the variance 2uσ . The parameters 2wσ  and 2eσ  represent individual-specific and 
residual variation, respectively. The regression calibration model shown in (5.6) was used to 
predict conditional expectations of long-term average ("usual") levels of BMI (and potential 
confounders and intermediate risk factors), which were then used in assessments of 
associations with disease risk.23,43,44 
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Censoring for outcomes 
For participants who had multiple events (eg, two coronary events at separate time points, or a 
coronary event followed by another type of event such as a stroke or death from cancer), 
analyses in the ERFC focused on first events (Chapter 2). Thus, in analysis of coronary heart 
disease events, participants were followed until their first coronary event, or censored at the 
time of other non-fatal cardiovascular events, such as stroke, or death from other causes. The 
rationale for this was that major cardiovascular events, such as first non-fatal myocardial 
infarction or stroke, may lead to lifestyle and other modifications (eg, medication use) that may 
alter levels of risk factors and so disrupt the association between risk factors and subsequent 
disease risk. Subsidiary analyses were done for fatal outcomes without censoring previous 
non-fatal outcomes. 
 
All analyses were performed using Stata release 11 (StataCorp LP, College Station, Texas 
USA). 
 
Results 
Characteristics of the 118 studies contributing to the analyses are summarised in Table 2.2 in 
Chapter 2 on pages 45-46 and in Tables 5.1-5.2. Mean (SD) age at baseline of the 1,064,541 
participants without known history of cardiovascular disease at baseline was 56 (9) years; 47% 
were women. Participants were mainly from Europe (63%), North America (30%) or Japan 
(3%). During 15.0 million person-years at risk (median 13.5 years to first outcome), there were 
a total of 161,903 deaths or major non-fatal vascular outcomes, comprising: 20,150 non-fatal 
myocardial infarctions, 23,210 coronary deaths, 11,759 non-fatal and 8,586 fatal strokes; 
12,088 deaths from other vascular diseases, 45,643 deaths from cancer, 30,684 deaths from 
non-vascular non-cancer cause and 9,783 deaths of unknown or ill-defined cause (Table 5.2).  
 
Associations with coronary heart disease, ischaemic stroke and other vascular outcomes  
In analyses adjusted for age, sex, and smoking status only, there were J-shaped associations 
of baseline BMI with risk of coronary heart disease, ischaemic stroke and all vascular mortality 
across the range of values (Figure 5.1). To account for non-linear associations at lower values 
of BMI, further analyses excluded the 61,682 (5.8%) participants with BMI values below 20 
kg/m2. Loge-linear associations of baseline BMI with various vascular outcomes per 5 kg/m2 
higher baseline BMI are shown in Figure 5.2. After adjustment for age, sex and smoking 
status, baseline BMI was significantly associated with all specific vascular outcomes, except 
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subarachnoid haemorrhage. Risk ratios per 5 kg/m2 higher baseline BMI, adjusted for age, sex 
and smoking only, were 1.31 (95% CI 1.26-1.36) for coronary heart disease, 1.23 (95% CI 
1.18-1.29) for ischaemic stroke, 1.16 (95% CI 1.08-1.26) for haemorrhagic stroke, 1.18 (95% 
CI 1.12-1.23) for unclassified stroke and 1.31 (95% CI 1.26-1.36) for all cardiovascular 
mortality. Particularly strong associations were also observed for hypertensive disease (RR 
1.67 [95% CI 1.47-1.90]), pulmonary embolism (RR 1.63 [95% CI 1.45-1.84]), heart failure (RR 
1.41 [95% CI 1.29-1.55]) and sudden death (RR 1.40 [95% CI 1.26-1.55]).  
 
Risk ratios for coronary heart disease and ischaemic stroke reduced considerably after 
additional adjustment for baseline values of potential intermediate risk factors such as blood 
pressure, history of diabetes, lipids, CRP, fibrinogen, or fasting glucose (Table 5.3). For 
example, in analyses restricted to participants with complete information on relevant 
covariates, risk ratios – initially adjusted for age, sex and smoking status only and then further 
adjusted for baseline values of SBP, history of diabetes, HDL and non-HDL cholesterol, and 
triglyceride – were, respectively, 1.26 (95% CI 1.21-1.32) and 1.08 (95% CI 1.04-1.11) for 
coronary heart disease, and 1.24 (95% CI 1.19-1.29) and 1.07 (95% CI 1.02-1.11) for 
ischaemic stroke.  
 
In regression dilution corrected analyses, the observed association between BMI and risk of 
coronary heart disease and ischaemic stroke was largely explained by long-term average 
levels of these potential intermediate risk factors (Table 5.4 & Figure 5.3). For example, in 
analyses restricted to participants with complete information on relevant covariates, risk ratios 
– initially adjusted for age, sex and smoking status only and then further adjusted for usual 
levels of SBP, history of diabetes, HDL and non-HDL, triglyceride and CRP – were, 
respectively, 1.24 (95% CI 1.17-1.32) and 0.93 (95% CI 0.87-1.00) for coronary heart disease, 
and 1.19 (95% CI 1.10-1.29) and 0.92 (95% CI 0.84-1.00) for ischaemic stroke. 
 
Among the contributing studies, between-study heterogeneity tended to decrease with 
increasing adjustment of risk ratios for intermediate risk factors. Risk ratios were not 
appreciably altered after further adjustment for potential confounding factors, such as alcohol 
consumption, physical activity or indicators of socioeconomic status (Table 5.3). 
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In analyses restricted to studies providing data on both outcomes, risk ratios were slightly 
stronger for coronary death (RR 1.33 [95% CI 1.27-1.40]) than for non-fatal myocardial 
infarction (RR 1.26 [95% CI 1.21-1.31], p=0.006 for the difference; Figures 5.2 and 5.4). The 
association with coronary death remained stronger compared to that with non-fatal myocardial 
infarction, even after further adjustment for biological, socioeconomic and behavioural risk 
factors (Table 5.5). Analyses involving fatal myocardial infarction rather than coronary death 
yielded similar results, albeit lower power (data not shown). 
 
Qualitatively similar results to those reported here were also observed in analyses that 
excluded: the initial five years of follow-up (Table 5.6 & Figure 5.5), current smokers (Table 
5.6 & Figure 5.6); participants who were not of European descent (Table 5.6); or the 
participants who had self-reported height and weight (rather than measured by a trained 
person) (data not shown); or participants known to be receiving lipid-lowering, blood pressure-
lowering or other cardiovascular medication at baseline (data not shown). Risk ratios were also 
broadly similar using fixed-effect models (Figures 5.7-5.8) and after additional adjustment for 
cigarette pack-years (in addition to smoking status) (data not shown). There was no evidence 
of bias due to small studies (data not shown).  
 
Risk ratios for coronary heart disease and ischaemic stroke associated with BMI were around 
three times stronger at ages 40-59 years than at 70 years or older (although the absolute risk 
is much higher at older ages; Figure 5.9), but risk ratios did not otherwise vary importantly by 
sex, ethnicity, geographical region, educational level, HDL and non-HDL cholesterol, 
triglyceride, CRP or fasting glucose (Figures 5.9-5.10). Associations with coronary heart 
disease were somewhat stronger in people without history of diabetes, but were similar by 
smoking status (Figures 5.10-5.11). Risk ratios for coronary heart disease were greater at 
lower-than-average SBP levels (Figure 5.9). Associations of BMI and risk of coronary death 
and non-fatal myocardial infarction separately were broadly similar in subgroups defined by 
sex, smoking status and age groups (Figure 5.12). 
 
Associations with non-vascular mortality outcomes and all-cause mortality 
In analyses adjusted for age, sex and smoking status only, there were curvilinear associations 
between baseline BMI and risk of all cancer mortality, all non-vascular non-cancer mortality, 
and all-cause mortality (Figure 5.13). Because risk ratios at low BMI values were potentially 
confounded by weight loss due to pre-existing disease (ie, reverse causality), further shape 
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analyses excluded the first five years of follow-up (Figure 5.14 & Results below). For both 
sexes, the relative risks for all-cause mortality were lowest at about 22.5 to 25 kg/m2 (Figure 
5.15). Associations between baseline BMI and risk of death from cause-specific non-vascular 
outcomes are shown in Figures 5.16-5.17.  
 
In participants with BMI values of 25 kg/m2 or higher, the risk ratios per 5 kg/m2 higher baseline 
BMI, adjusted for age, sex and smoking status only, were 1.12 (95% CI 1.09-1.15) for all 
cancer mortality, 1.32 (95% CI 1.26-1.38) for all non-vascular non-cancer mortality and 1.26 
(95% CI 1.23-1.29) for all-cause mortality (Table 5.7). These risk ratios were reduced after 
additional adjustment for baseline values of blood pressure, history of diabetes, lipids, CRP, 
fibrinogen or fasting glucose (Table 5.8). In regression dilution corrected analyses, long-term 
average levels of these biological risk factors reduced the risk ratios even further (data not 
shown). However, associations were not altered after additional adjustment for alcohol 
consumption, physical activity or indicators of socioeconomic status (Table 5.8). As regard to 
site-specific cancer deaths, in people with BMI values of 25 kg/m2 or higher, baseline BMI was 
positively associated with cancers of the liver, oesophagus, pancreas, stomach, blood, 
colorectum, prostate, renal, endocrine and nervous systems, and breast (Figure 5.18). There 
were non-significant associations of BMI with some site-specific cancers (eg, melanoma, 
bladder, ovary and lung). Aside from cancer, baseline BMI was also positively associated with 
death due to diabetes mellitus, renal disease, digestive diseases, infections, liver disease, 
chronic obstructive pulmonary disease, external causes and mental disorders (Figure 5.18). 
There was modest heterogeneity among contributing studies (I2 12% [95% CI 0% to 33%] for 
all cancer deaths and I2 53% [95% CI 40% to 63%] for all deaths not attributed to vascular 
disease or cancer; Table 5.7). Findings were qualitatively similar after exclusion of the first five 
years of follow-up (Table 5.9).  
 
In participants with BMI values below 25 k/m2, baseline BMI was negatively associated with all 
cancer mortality, all non-vascular non-cancer mortality and all-cause mortality. Exclusion of the 
first five years of follow-up attenuated these associations (Tables 5.7 and 5.9), and hence, the 
results described below relate to analyses with such exclusions. In analyses adjusted for age, 
sex and smoking status, and restricted to participants with BMI values below 25 kg/m2, the risk 
ratios per 5 kg/m2 higher baseline BMI were 0.82 (95% CI 0.76-0.87) for all cancer mortality, 
0.53 (95% CI 0.48-0.57) for all non-vascular non-cancer mortality and 0.74 (95% CI 0.70-0.78) 
for all-cause mortality (Table 5.9). Baseline BMI was negatively associated with risk of oral 
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cancer and cancers of the lung, oesophagus, stomach and ovary (Figure 5.19). There were 
strong inverse associations between baseline BMI and death due to respiratory disease, which 
remained even after exclusion of ten years of follow-up (Figures 5.19-5.20). Baseline BMI 
below 25 kg/m2 was inversely associated with all other specific non-vascular non-cancer 
conditions, except with diabetes mellitus and liver disease (Figure 5.19). There was modest 
heterogeneity among contributing studies (I2 34% [95% CI 13% to 50%] for all cancer deaths 
and I2 49% [95% CI 33% to 61%] for all deaths not attributed to vascular disease or cancer; 
Table 5.9). Associations with non-vascular mortality outcomes were weakened in analyses 
restricted to never-smokers only (Table 5.9).  
 
Qualitatively similar results to those reported here were observed in a range of subsidiary 
analyses, such as those that: were restricted to participants with measured (rather than self-
reported) height and weight (data not shown), omitted participants of non European descent 
(Table 5.9); analysed associations with fatal outcomes without censoring previous non-fatal 
outcomes (Table 5.10); or used fixed effect models (data not shown). 
 
Discussion 
The current analysis of 1,064,541 participants in 118 prospective studies assessed the shape, 
specificity, magnitude and independence of associations of BMI with risk of vascular morbidity 
and cause-specific mortality. After exclusion of participants with BMI values below 20 kg/m2, 
there were approximately loge-linear associations with risk of coronary heart disease and all 
cardiovascular mortality, although somewhat weaker associations were observed with stroke. 
The observed associations with coronary heart disease and ischaemic stroke were largely 
explained by long-term average levels of mediating risk factors, such as blood pressure, history 
of diabetes and lipids. Across the full range of BMI values, BMI had curvilinear associations 
with all-cause mortality, including most site-specific cancers and non-vascular conditions not 
attributed to cancer. In participants with BMI values of 25 kg/m2 or higher, BMI was positively 
associated with a range of non-vascular mortality outcomes. Particularly strong relationships 
were observed with risk of death from diabetes and renal disease. By contrast, among 
participants with BMI values below 25 kg/m2, the negative association of BMI was 
predominantly due to the strong negative associations with death due to respiratory disease 
and cancers of the lung and upper aerodigestive tract. In participants with BMI values of 25 
kg/m2 or higher, associations between BMI and non-vascular mortality attenuated somewhat 
after accounting for long-term average levels of intermediate factors noted above.  
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The current analysis has shown that the observed association of BMI with coronary heart 
disease and ischaemic stroke is largely explained by long-term average levels of blood 
pressure, history of diabetes, lipids and inflammatory markers. Because excess adiposity is a 
major determinant of these intermediate risk factors noted above (Chapter 3),45 the current 
findings underscore the importance of controlling adiposity to help prevent coronary heart 
disease and stroke. For instance, effective interventions for weight loss have shown to reduce 
blood pressure levels, favourably affect the lipid profile and to increase insulin sensitivity.45 
While there is increasing evidence that blood pressure, lipids and diabetes contribute to the 
pathogenesis of cardiovascular disease, the role of inflammation is controversial.46 For 
instance, a recent study with almost 200,000 participants used to principle of "Mendelian 
randomisation" to show that CRP itself is unlikely to be a causal factor for coronary heart 
disease.47 Nevertheless, there is considerable evidence showing that other markers of 
inflammation may well contribute to cardiovascular disease.46,48,49  
 
The current data also suggest the relevance of controlling intermediate risk factors by use of 
lipid-lowering or blood pressure-lowering medication for instance, in order to combat the 
detrimental vascular effects of overweight and obesity.50-53 Furthermore, these data have 
shown that in participants with BMI values of 25 kg/m2 or higher, the association between BMI 
and non-vascular conditions is partly mediated by such risk factors, suggesting that some of 
the adverse effects of BMI may be reversible for non-vascular mortality too. The associations 
of BMI with vascular and non-vascular outcomes were, however, not altered after adjustment 
for confounding factors, such as alcohol consumption, physical activity or socioeconomic 
indicators. In contrast to previous much smaller studies,17,18 which observed much stronger 
associations of BMI with risk of fatal than non-fatal cardiovascular disease, BMI was only 
slightly more strongly related to coronary death than to non-fatal myocardial infarction in the 
current study. Although statistically significant, this difference is probably too small to have any 
meaningful clinical implications. Similar, but larger differential associations between fatal and 
non-fatal cardiovascular disease have been observed for other cardiovascular risk factors, 
such as diabetes54 or CRP.55,56 
 
There was strong modification of the effects of BMI by age, with about three-fold higher excess 
risk for coronary heart disease and ischaemic stroke with higher BMI in early middle age than 
at older ages. This finding must be interpreted appropriately, acknowledging that absolute 
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cardiovascular risk increases with age. Hence, studies that found greater risk ratios associated 
with BMI in younger compared to older adults have found the opposite relationship when age 
groups were compared using absolute risk differences rather than risk ratios.57,58 Nevertheless, 
the weakening of the associations between BMI and cardiovascular disease risk at older ages 
might be due to the weaker associations at older ages of intermediate risk factors,11 such as 
blood pressure25 or cholesterol measures.26 Also, BMI at older ages might be affected by loss 
of muscle mass.59,60 Risk ratios for coronary heart disease were also significantly greater in 
some other groups at lower absolute risk of vascular disease – ie, in people without diabetes 
and at lower-than-average SBP. Further investigation is needed to identify possible 
mechanisms of such effect modification. Otherwise, there were no important modifications of 
the effect of BMI on risk of coronary heart disease and ischaemic stroke by other subgroups 
assessed. 
 
The current analysis demonstrated curvilinear associations of BMI with risk of death from a 
range of site-specific cancers and non-vascular conditions other than cancer. In the BMI range 
of 25 kg/m2 or higher, BMI was positively and moderately associated with mortality from 
cancers of the liver, oesophagus, pancreas, stomach, blood, and colorectum, and somewhat 
less strongly with cancers of the prostate, kidney, endocrine and nervous system, and breast. 
Aside from cancers, BMI was positively and strongly associated with mortality due to diabetes, 
renal disease and digestive diseases. There were moderately strong associations of BMI with 
death due to infections, liver disease, chronic obstructive pulmonary disease, external causes 
and mental disorders. In participants with BMI values below 25 kg/m2, BMI was negatively and 
strongly associated with death from oral and lung cancer, and somewhat less strongly with 
mortality from cancers of the oesophagus, stomach and ovary. Among non-vascular non-
cancer outcomes, there were strong inverse associations between BMI and death due to 
respiratory diseases. Although the relationship remained strong even after exclusion of the first 
ten years of follow-up, the observed inverse association might still be due to reverse causality, 
as chronic obstructive pulmonary disease can cause weight loss over many years.11 In 
participants with BMI values below 25 k/m2, BMI was also inversely associated with death due 
to infections, falls, Alzheimer’s disease, renal disease, nervous system disorders, external 
causes, intentional self-harm, mental disorders and digestive diseases. The inverse 
associations weakened in analyses restricted to never-smokers. Because smoking is strongly 
related to outcomes, such as lung cancer or chronic obstructive pulmonary disease, the 
observed differences in the associations might be due to imprecisely measured confounding by 
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smoking (eg, smoking intensity). Further research is required to investigate the inverse 
associations with various outcomes among never-smokers. The observed findings are broadly 
consistent with those of the Prospective Studies Collaboration (PSC).11 For instance, among 
participants with BMI values of 25 kg/m2 or higher, the risk ratios for all-cause mortality and all 
cancer mortality were 1.26 and 1.12 per 5 kg/m2 higher baseline BMI in the current study, 
compared to 1.29 and 1.10 in the PSC. Corresponding risk ratios in participants with BMI 
values below 25 kg/m2 were 0.74 and 0.82 in the current study, compared to 0.79 and 0.82 in 
the PSC.  
 
There was some between-study heterogeneity in the risk ratios, although it was only partly 
explained by the variables recorded here. Much of the inverse association of BMI with non-
vascular outcomes in particiapants with low BMI values was explained by pre-existing disease 
and/or confounding (eg, smoking). Therefore, if the inverse association at low BMI is partly 
non-causal, the real optimum for BMI might be somewhat lower than the optimum observed in 
the current study.11 The generalisability of the current findings, at least to Western populations, 
is supported by broadly consistent results across the 118 studies in 24 countries. As more than 
90% of the participants were adults of European ancestry in high-income countries, the current 
study could not assess the effect of obesity on disease risk in children, or in adults of other 
ethnic groups or in low-income countries.61-63  
 
Conclusion 
BMI had positive and nearly loge-linear associations with coronary heart disease and ischaemic 
stroke (except at BMI values below 20 kg/m2), which were largely explained by intermediate 
risk factors, such as blood pressure, diabetes and lipids. The association between BMI and 
non-vascular mortality was curvilinear. 
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Table 5.1 Summary of data contributing to the analysis of BMI  
 
Variable No of 
studies
No of 
subjects
Mean (SD) 
or %
BMI (kg/m2) 118 1064541 26 (4)
Age at survey (yrs) 118 1064541 56 (9)
BP and fasting glucose
SBP (mmHg) 114 823757 136 (19)
DBP (mmHg) 114 825230 82 (11)
Fasting glucose (mmol/l) 57 301749 5.5 (1.6)
Lipid markers
Total cholesterol (mmol/l) 114 807182 5.9 (1.1)
Non-HDL-C (mmol/l) 97 448087 4.49 (1.12)
HDL-C (mmol/l) 97 448500 1.34 (0.37)
Loge triglyceride (mmol/l) 96 656203 0.33 (0.52)
Inflammatory markers
Loge CRP (mg/l) 48 136455 0.66 (1.11)
Fibrinogen (µmol/l) 45 222258 9.2 (2.1)
Categorical veriables
Sex 118 1064541
    Female 503748 47%
    Male 560793 53%
Ethnicity 89 506969
    East Asian 36925 7%
    Black 26042 5%
    Other 10380 2%
    White 433622 86%
Smoking status 117 988239
    Current 305761 31%
    Not current 682478 69%
Alcohol status 89 506600
    Current 325398 64%
    Not current 181202 36%
History of diabetes 105 781253
    Yes 38652 5%
    No 742601 95%
Physical activity 60 325038
    Active 126770 39%
    Not active 198268 61%
Education 58 334746
    Tertiary 90389 27%
    Secondary 164903 49%
    Primary 65659 20%
    No schooling 13795 4%
Occupation or job 56 345571
    Other 47100 14%
    Office 116753 34%
    Manual 93101 27%
    Not working 88617 26%
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Table 5.2 Summary of events of individual studies with complete information on BMI, age and sex 
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AMORIS 3677 734 2011 1583 428 1421 938 212 120 135 11 12 26 3 60 27 4 1390 13 174 118 23 60 32 108 221 111 38 5 27 61 123 61 43 19 92 707 230 35 30 43 84 61 33 65 48 8 46 2877
ARIC 1643 427 875 675 200 565 456 56 33 16 21 51 12 0 13 13 7 692 6 58 44 11 14 7 45 228 31 20 2 18 12 68 21 7 16 61 352 55 24 28 10 33 20 11 75 20 15 36 1507
ATENAb 30 9 18 17 1 4 1 2 1 0 2 3 0 0 1 0 0 22 0 0 0 0 1 1 4 4 0 2 0 1 1 3 0 0 0 4 8 4 0 0 0 1 2 0 0 0 0 1 40
ATS_SARc 34 34 21 0 21 8 0 1 1 6 0 0 0 0 1 0 0 56 1 5 4 0 2 4 3 14 0 2 0 1 1 5 5 0 0 4 30 12 0 0 0 1 4 2 2 2 3 4 124
ATTICA 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 1 0 0 0 0 0 0 0 0 0 0 50
AUSDIAB 181 138 65 24 41 47 14 7 2 18 6 16 2 0 0 18 2 106 1 12 6 3 1 0 3 13 9 2 0 1 1 6 11 1 2 2 139 5 25 19 9 17 4 12 4 3 5 54 437
BHS 931 931 519 0 519 221 23 21 4 144 14 22 9 0 37 35 9 547 6 83 67 12 23 6 22 87 60 16 3 17 15 47 18 13 6 34 478 53 4 38 28 63 11 32 106 45 22 17 1973
BRHS 1857 775 1214 674 540 516 7 13 10 475 7 5 12 0 50 11 8 745 11 84 52 34 45 20 29 248 62 0 0 39 18 39 23 6 2 0 305 33 5 4 6 28 18 44 95 27 8 134 1959
BRUN 101 56 54 23 31 40 24 15 0 0 0 0 4 0 3 0 0 68 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 55 12 2 0 3 1 2 22 5 5 1 1 180
BUPA 1505 1505 1012 0 1012 254 31 37 12 145 3 14 23 0 94 30 2 1383 11 189 137 72 67 21 86 287 158 0 0 48 50 132 64 32 15 0 618 115 12 4 35 91 50 61 92 56 30 37 3543
BWHHS 197 30 90 77 13 91 0 1 0 90 0 1 3 0 4 1 2 116 1 13 10 3 7 1 6 18 0 10 4 6 0 5 4 0 1 14 69 4 2 1 1 12 3 10 12 8 0 3 218
CAPS 291 152 251 139 112 18 3 3 1 9 0 4 7 0 3 1 1 127 1 18 15 5 12 1 5 46 4 0 0 3 3 8 5 1 1 0 63 11 1 0 2 4 5 3 21 7 2 0 342
CASTEL 521 521 95 0 95 107 0 0 0 107 0 0 29 74 0 216 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 299 0 59 0 0 0 28 0 37 0 0 18 1116
CHARL 950 585 522 223 299 264 30 34 5 186 32 21 11 0 11 13 5 297 4 26 22 14 16 2 14 88 20 1 3 5 5 17 9 3 2 19 282 17 16 32 12 17 17 36 43 34 16 60 1224
CHS1a 1116 271 593 380 213 467 368 62 0 37 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 809 1080
CHS2a 111 29 56 33 23 49 40 5 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 67 96
COPEN 1371 352 513 472 41 592 368 73 16 122 10 22 26 13 15 58 0 529 7 47 40 21 13 9 31 141 31 17 3 22 7 28 11 6 5 44 642 58 41 28 25 44 30 135 80 47 18 150 1673
DISCOc 12 12 9 0 9 3 1 1 0 1 0 0 0 0 0 0 0 11 0 2 2 0 0 0 0 3 0 2 0 1 0 1 0 0 0 0 6 3 0 1 0 0 2 0 0 0 0 0 29
DRECE 29 29 15 0 15 6 0 1 0 4 0 1 1 0 0 2 0 63 2 12 10 1 4 1 5 13 1 1 1 2 0 3 1 1 2 6 42 5 3 5 0 6 6 1 6 3 0 0 134
DUBBO 541 135 283 220 63 192 76 20 3 87 4 0 5 0 6 28 0 169 2 18 11 3 3 2 8 28 16 4 1 6 5 18 2 1 0 7 169 24 12 1 9 16 6 26 24 14 8 18 491
EAS 169 80 82 41 41 68 0 3 2 60 1 2 1 0 4 3 0 126 1 17 12 6 9 1 5 33 14 3 0 1 1 7 0 1 0 8 70 2 2 0 5 11 0 12 16 6 3 8 284
EMOFRIb 8 4 2 2 0 3 2 1 0 0 3 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 0 0 0 0 0 0 0 0 0 1 9
EPESEBOS 91 35 38 30 8 26 17 6 2 1 19 0 2 0 0 1 0 22 0 3 3 2 2 1 1 2 4 0 0 0 1 1 0 2 0 0 26 3 2 0 1 2 0 6 1 2 4 8 91
EPESEIOW 152 68 57 33 24 58 22 6 2 26 12 2 1 0 1 14 0 23 0 1 1 1 0 1 3 5 2 1 0 2 0 3 0 0 0 3 46 5 6 1 0 1 3 8 3 2 7 25 162
EPESENCA 120 46 48 28 20 50 30 5 0 15 12 0 0 0 0 7 0 34 0 5 5 1 1 0 1 14 5 0 1 1 0 2 0 0 0 0 33 5 4 1 0 2 1 9 2 3 3 16 129
EPESENHA 87 51 21 17 4 21 10 2 0 9 31 1 0 0 0 4 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 20 2 2 0 0 1 2 7 2 1 1 20 94
ESTHER 243 22 88 77 11 151 3 1 1 146 0 0 0 0 2 0 0 55 1 6 4 1 1 1 5 17 2 1 0 1 0 3 3 1 2 3 17 1 1 2 0 2 2 0 3 4 0 7 101
FINE_FIN 111 62 70 33 37 29 8 1 0 16 0 2 2 0 0 4 0 39 0 5 3 0 2 0 1 13 11 0 0 0 1 3 0 0 0 0 44 9 1 4 8 2 0 11 5 2 0 1 146
FINE_IT 210 142 67 18 49 104 4 5 0 85 1 5 0 2 1 19 1 108 2 22 15 2 11 3 5 17 19 0 0 6 3 7 5 0 1 0 47 15 0 1 0 3 4 5 4 9 1 32 329
FINRISK92 296 60 150 119 31 124 84 36 1 0 1 1 6 2 1 4 0 82 1 8 3 2 9 4 6 17 3 3 2 0 2 2 5 2 3 10 101 47 5 0 2 7 6 13 1 7 4 1 244
FINRISK97 224 59 109 75 34 95 75 19 1 0 0 2 10 0 1 2 0 69 1 5 3 3 6 3 6 12 4 3 0 0 3 6 3 2 0 4 79 29 5 1 2 2 4 21 3 5 0 2 209
FRAMOFF 207 21 127 114 13 72 62 8 2 0 0 0 0 0 0 0 0 135 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 79 0 0 0 0 0 0 0 0 0 0 34 269
GOH 593 593 277 0 277 134 2 12 3 72 66 13 9 15 4 19 4 334 8 43 33 3 19 10 24 39 15 9 1 8 3 33 17 1 2 26 322 45 19 46 15 17 20 16 42 29 28 692 1941
GOTO13 369 43 213 211 2 116 0 1 0 115 0 0 6 5 3 18 0 115 1 14 5 7 8 3 8 18 24 0 0 4 8 6 2 3 1 0 50 2 2 1 8 4 6 14 5 4 1 43 251
GOTO33 44 22 27 14 13 8 0 0 0 8 2 0 2 0 0 0 0 27 1 3 3 0 6 0 1 7 2 0 0 0 1 2 1 0 0 0 29 9 0 1 7 4 2 2 2 0 0 3 81
GOTO43 42 4 28 27 1 12 9 1 1 1 0 0 0 0 1 0 0 16 0 0 0 0 1 0 0 3 0 0 0 0 2 4 3 0 1 0 4 2 0 0 0 0 2 0 0 0 0 1 25
GOTOW 369 131 148 94 54 179 0 0 0 179 0 0 0 0 0 0 0 154 0 0 0 0 0 0 0 14 0 15 0 0 0 19 0 1 0 17 116 82 25 0 0 0 0 0 0 0 0 6 407
GREPCOc 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5
GRIPS 449 47 299 299 0 103 0 0 0 103 0 0 13 17 3 10 0 108 2 18 11 0 11 3 6 34 3 0 0 5 1 10 7 1 1 0 69 30 4 0 0 2 7 3 3 16 3 1 225
GUBBIOc 107 107 69 0 69 29 11 2 1 13 0 2 1 0 0 0 1 95 2 8 7 1 12 9 5 12 3 5 0 2 0 8 3 0 3 9 34 15 0 0 0 3 6 2 5 0 0 3 239
HBS 131 131 87 0 87 27 0 0 0 27 0 0 0 0 0 0 0 158 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 112 27 0 0 0 0 0 0 0 0 0 10 411
HELSINAG 106 106 42 0 42 41 21 3 0 3 2 2 7 0 3 1 2 38 0 3 2 1 4 1 3 4 2 1 0 3 0 2 0 0 0 2 72 2 0 0 12 2 0 42 1 6 1 15 231
HISAYAMA 356 76 77 67 10 220 148 49 21 0 1 10 2 0 12 2 2 154 1 19 14 4 22 25 11 30 2 2 0 0 0 12 3 0 0 2 154 23 7 0 0 3 13 42 11 19 5 2 386
HONOL 314 110 156 114 42 133 12 40 2 75 3 4 1 0 7 0 1 182 3 17 12 9 28 1 9 41 29 0 0 0 2 26 2 0 2 0 156 18 7 6 37 17 1 16 27 8 1 87 535
HOORN 171 69 73 60 13 53 3 4 0 46 11 0 3 13 4 12 0 85 1 9 8 3 6 2 5 19 3 4 0 2 2 2 4 0 0 2 18 5 1 0 1 0 0 6 3 0 1 40 212
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HPFS 4424 4424 2575 0 2575 740 100 129 37 176 57 14 45 354 146 206 12 4400 67 477 422 141 95 68 342 782 649 0 0 179 137 719 209 127 45 0 3604 668 154 86 326 799 128 307 382 198 184 362 12790
IKNS 495 154 84 37 47 344 158 71 25 90 2 0 1 0 3 57 0 297 4 24 15 12 72 27 32 18 7 1 0 3 0 10 3 2 1 4 250 59 6 4 3 0 14 88 11 13 17 59 760
ISRAEL 987 987 723 0 723 264 0 0 0 264 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1544 2531
KARELIA 3136 987 1983 1387 596 931 69 48 40 768 22 21 41 3 18 44 3 692 9 46 24 12 54 22 38 156 20 28 11 9 30 69 19 11 9 55 825 238 40 22 27 54 27 238 38 48 23 13 2517
LASA 54 0 34 34 0 20 0 0 0 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 536 536
MALMO 2418 1185 2047 1233 814 143 36 49 21 16 6 6 17 1 46 18 3 1274 27 108 70 25 69 21 91 335 74 38 5 36 50 106 59 36 19 52 667 169 14 25 51 61 87 45 93 53 7 163 3289
MATISS83b 336 196 83 47 36 99 26 10 3 57 71 11 1 0 0 54 0 90 1 3 2 0 2 3 1 12 0 0 0 0 0 6 3 0 3 2 60 9 0 9 3 5 11 3 6 3 4 65 411
MATISS87b 175 95 45 22 23 58 9 8 2 39 36 3 0 1 1 27 0 46 0 2 2 0 3 1 1 7 1 1 0 0 0 1 2 0 2 0 33 11 0 1 2 1 4 0 1 2 5 33 207
MATISS93b 31 13 14 11 3 7 1 2 1 3 4 1 0 0 0 5 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 1 0 1 0 1 1 0 0 1 2 5 29
MCVDRFP 457 457 197 0 197 97 15 31 14 32 19 8 8 8 16 27 4 852 8 82 59 23 32 6 48 247 26 27 5 12 15 60 19 18 16 97 358 70 13 23 13 41 22 19 73 45 8 113 1780
MESA 173 21 83 69 14 84 68 13 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 122 143
MICOLc 150 150 105 0 105 33 7 3 0 20 0 0 3 0 3 0 2 248 5 25 22 5 20 15 16 75 2 7 1 3 5 16 10 4 5 14 94 20 0 3 0 3 41 4 8 6 3 24 516
MOGERAUG1 108 61 79 47 32 5 0 2 0 2 0 0 5 2 2 10 1 40 1 7 4 1 5 1 3 8 1 0 0 1 2 1 2 0 0 0 25 7 0 2 3 2 1 3 4 2 0 0 126
MOGERAUG2 129 66 104 63 41 7 1 1 1 3 0 1 4 1 0 8 0 77 3 14 10 0 4 2 6 16 2 4 2 1 4 6 2 1 1 5 53 11 2 2 7 3 7 2 10 5 2 3 199
MOGERAUG3 36 25 18 11 7 5 2 1 0 2 0 3 2 0 0 3 0 20 1 5 4 0 1 1 1 2 1 1 0 0 1 3 2 0 0 0 9 2 0 1 2 0 1 1 0 0 0 0 54
MONFRI86b 107 62 28 20 8 25 14 4 2 5 44 0 2 1 1 4 0 41 0 0 0 1 2 3 0 5 0 0 0 0 1 1 1 0 0 1 22 6 0 1 0 1 5 1 0 1 2 42 167
MONFRI89b 82 43 28 22 6 20 10 5 0 5 23 0 2 0 1 6 0 16 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 23 4 1 0 0 0 6 2 0 3 1 18 100
MONFRI94b 40 13 11 11 0 17 6 7 1 2 9 0 0 1 1 0 0 7 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 7 1 0 0 0 0 3 1 0 1 0 13 40
MONICAc 38 38 28 0 28 8 0 1 0 5 0 0 0 0 0 0 0 45 0 2 1 1 8 4 0 10 0 2 0 1 5 1 1 1 0 1 17 5 0 0 0 0 3 0 2 1 2 0 100
MORGEN 149 149 77 0 77 24 3 10 7 4 4 2 3 4 6 5 0 317 6 32 22 10 10 5 23 80 8 10 1 6 7 19 7 4 6 33 95 25 7 5 4 12 9 5 9 8 0 26 587
MOSWEGOT 280 67 143 104 39 117 66 17 18 15 2 0 7 0 2 1 1 109 1 10 8 1 5 3 7 15 6 5 1 0 1 10 5 1 4 16 56 14 1 1 6 9 3 0 10 5 2 4 236
MRCOLD 2636 2636 1148 0 1148 843 52 61 13 519 62 50 47 0 92 170 47 1386 15 165 107 56 69 30 63 219 141 25 11 62 22 89 11 15 16 98 2077 83 59 50 45 334 17 540 293 252 44 210 6309
NCS1 548 548 375 0 375 67 9 17 26 12 5 13 2 43 12 8 0 560 10 76 49 8 37 3 29 75 13 32 9 4 15 69 32 15 4 49 247 89 7 21 10 19 16 9 31 11 5 83 1438
NCS2 280 280 193 0 193 28 2 7 11 6 5 8 1 20 4 1 1 327 5 66 44 3 27 1 13 44 12 18 3 8 12 17 18 12 3 30 143 61 3 7 11 11 8 10 9 4 4 54 804
NCS3 465 465 287 0 287 86 8 24 22 23 6 19 0 38 5 3 0 286 5 19 12 1 31 5 22 62 6 25 4 4 12 18 10 1 1 25 142 45 4 4 17 14 9 4 25 7 2 96 989
NFRc 124 124 90 0 90 27 2 9 1 11 0 0 1 0 4 0 0 151 1 12 7 3 14 8 4 39 8 0 0 7 4 17 6 3 3 0 41 13 0 0 0 1 15 3 2 4 2 15 331
NHANESI 1757 1112 930 330 600 499 135 46 18 274 48 58 11 1 20 38 5 702 6 92 71 18 26 14 37 143 55 15 3 23 15 74 15 7 4 63 636 82 41 49 27 31 33 88 110 60 31 52 2502
NHANESIII 854 854 471 0 471 171 0 0 0 171 0 43 0 0 14 50 0 542 74 0 0 8 17 17 26 144 53 7 0 3 0 50 4 8 0 32 624 71 37 57 0 45 38 64 95 5 20 12 2032
NHS 5247 5247 2290 0 2290 1341 23 106 654 235 152 15 101 345 150 219 155 10367 101 965 765 97 158 91 614 2212 0 726 279 116 184 1079 370 163 85 2216 6320 924 257 331 1126 552 374 274 471 379 89 1495 23429
NPHSI 196 88 154 85 69 23 0 0 0 23 0 0 0 0 0 0 0 85 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 40 0 0 0 0 0 0 0 0 0 0 3 216
NPHSII 297 56 194 175 19 73 39 7 7 20 0 4 2 16 6 0 0 117 1 21 15 11 9 2 6 26 5 0 0 2 3 12 4 3 2 0 25 5 1 0 0 3 4 1 7 2 0 3 201
NSHS 87 40 24 0 24 51 1 1 1 48 5 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 40
OB43c 24 24 15 0 15 8 1 1 1 4 0 0 0 0 1 0 0 36 1 6 6 0 0 2 2 5 0 0 1 3 0 3 1 0 2 5 14 2 0 0 0 0 3 0 4 3 1 3 77
OSAKA 261 106 42 26 16 144 57 27 16 44 1 3 0 1 4 62 0 220 3 15 8 9 37 30 18 10 7 5 0 2 1 10 7 0 0 6 146 22 11 1 8 2 17 43 6 12 9 155 627
OSLO 2613 2613 1604 0 1604 379 56 79 29 170 35 51 15 119 158 61 5 2016 46 310 184 42 125 23 115 504 225 0 0 47 60 179 74 51 22 0 1073 182 29 67 60 106 98 90 226 101 27 188 5890
OYABE 198 57 26 0 26 141 88 30 22 1 0 7 0 0 0 19 0 181 0 7 0 7 46 5 11 28 0 0 0 0 0 4 0 0 0 2 97 26 7 1 0 3 7 34 5 5 0 41 376
PARIS1 601 601 341 0 341 100 0 0 0 100 0 0 0 0 0 0 0 918 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 479 150 0 0 0 0 0 0 0 153 0 83 2081
PREVEND 219 71 146 124 22 31 0 17 7 7 3 1 2 1 10 5 1 180 3 23 21 4 12 1 8 42 8 1 1 8 8 7 3 2 3 10 42 12 0 3 2 5 3 2 7 4 0 13 306
PRHHP 384 245 213 125 88 84 54 20 3 5 0 28 4 24 8 0 1 159 9 12 8 18 29 0 4 24 15 0 0 1 1 18 4 0 1 0 181 76 12 7 4 9 39 6 6 8 3 9 594
PRIME 208 37 146 129 17 42 33 6 0 3 0 0 0 17 0 0 0 99 3 15 9 4 4 3 4 29 2 0 0 2 3 8 6 1 2 0 34 24 0 0 0 2 3 1 1 1 1 15 185
PROCAM 741 301 486 367 119 106 77 22 0 7 4 0 13 97 8 13 0 440 15 56 29 6 25 10 33 97 22 0 0 13 0 43 17 0 0 28 206 64 21 0 6 5 22 48 7 10 2 50 997
QUEBEC 43 10 31 28 3 5 0 0 0 5 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 31 41
RANCHO 507 113 222 219 3 185 0 1 0 175 9 16 1 0 5 10 5 173 0 21 18 2 3 0 11 36 28 3 3 6 4 20 4 6 1 10 200 10 7 6 31 21 7 40 22 15 4 1 487
REYK 4538 2510 3249 2028 1221 768 183 162 45 243 45 52 78 12 71 82 6 2424 22 281 226 43 182 44 173 532 202 68 13 64 92 169 93 20 38 199 1656 77 62 41 15 360 27 276 278 130 35 92 6682
RF2c 90 90 64 0 64 18 2 7 0 8 0 0 2 0 1 0 0 149 4 12 9 1 10 9 10 27 3 4 1 1 4 7 10 3 6 20 53 15 0 3 2 1 14 2 2 3 4 28 320
ROTT 652 441 244 211 33 144 38 23 3 63 1 0 3 55 21 77 2 450 3 69 51 14 15 5 29 92 27 6 5 18 11 46 11 3 17 43 319 43 19 0 1 117 6 34 44 28 8 169 1379
SHHEC 682 182 459 325 134 184 56 21 21 81 2 4 2 2 7 3 1 405 7 48 27 17 17 10 21 122 12 8 1 6 9 18 13 5 3 36 152 11 21 6 5 8 18 25 27 11 1 26 765
SHS 784 311 451 303 148 214 8 10 0 190 24 12 6 4 2 15 4 224 5 17 13 4 7 15 14 39 8 5 1 1 15 28 4 0 1 15 609 89 34 154 29 6 124 36 31 27 18 19 1163
SPEED 353 194 252 98 154 77 66 2 1 5 1 2 5 0 9 0 0 205 4 30 16 8 15 0 6 69 11 0 0 7 7 13 6 1 0 0 77 11 1 1 1 7 3 12 22 4 4 1 477
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Table 5.2 con’t Summary of events of individual studies with complete information on BMI, age and sex 
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TARFS 316 255 217 53 164 62 1 0 0 61 0 0 2 12 1 11 0 35 0 4 4 0 2 2 1 3 1 0 0 0 0 0 1 0 0 1 25 7 0 2 1 4 0 0 3 1 0 174 489
TOYAMA 92 8 34 33 1 51 24 17 10 0 0 0 0 0 0 4 0 28 1 2 2 0 7 4 0 6 1 1 0 0 0 4 0 0 2 0 15 10 0 0 0 1 2 1 0 0 1 32 83
TROMSØ 1877 281 1009 889 120 727 537 88 45 52 13 12 1 30 28 19 2 592 9 76 59 14 39 9 37 127 42 27 8 12 12 54 15 10 11 28 354 82 12 7 13 54 12 35 66 33 8 34 1261
ULSAM 996 252 593 446 147 316 195 56 19 41 3 10 7 0 18 13 3 394 3 35 18 12 22 11 32 65 85 0 0 16 16 29 12 9 2 0 203 49 6 11 3 29 10 13 31 22 6 7 856
USPHS2 643 104 310 282 28 259 217 40 0 2 0 0 0 38 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 688 792
VHMPP 3281 3281 1683 0 1683 783 81 122 24 443 61 60 45 1 57 184 34 2297 45 264 193 30 184 69 149 460 135 76 15 55 67 172 87 40 19 181 1284 363 4 98 42 115 164 69 169 127 34 67 6929
VITA 66 21 38 30 8 19 15 2 1 1 5 0 0 0 1 1 0 44 2 3 3 1 2 4 3 7 1 0 0 3 1 4 4 1 0 3 17 6 0 2 0 1 4 0 1 1 0 4 86
WHITEI 473 473 218 0 218 141 19 14 4 75 12 7 6 0 40 20 4 400 2 50 41 19 13 3 20 62 84 0 0 22 5 43 11 5 3 0 348 9 9 7 10 44 5 114 47 31 11 14 1235
WHITEII 348 94 316 254 62 10 2 2 2 4 0 2 4 0 3 1 1 160 2 23 17 7 7 2 7 15 6 6 2 3 8 13 8 5 3 21 72 25 2 1 0 10 10 4 7 4 1 3 329
ZARAGOZA 100 24 50 35 15 50 9 0 0 41 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 24
ZUTE 124 56 57 37 20 39 1 1 0 34 2 0 1 0 8 14 0 56 0 4 3 2 4 0 6 10 10 0 0 5 0 4 1 1 0 0 32 2 2 1 2 2 1 6 7 4 2 17 161
SUBTOTAL 67607 42242 37732 15763 21969 18065 5585 2229 1426 7323 1078 765 739 1401 1359 2158 354 44162 632 4584 3383 949 2004 789 2611 8935 2675 1344 412 1007 1058 4011 1502 723 452 3775 30160 5082 1240 1379 2199 3417 1834 3266 3515 2299 838 9646 126210
Clinical trials
AFTCAPS 191 26 147 143 4 23 22 0 0 1 0 0 0 12 0 0 0 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 16 4 0 0 0 0 0 0 0 0 0 0 57
ALLHAT 1666 6 1124 1119 5 542 0 0 0 542 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 11
LEADER 181 95 99 36 63 66 51 3 0 12 1 0 1 0 3 6 3 49 1 4 1 2 2 2 1 25 2 0 0 2 2 2 0 0 0 0 32 0 4 0 1 0 1 11 5 4 0 7 183
MRFIT 896 256 767 583 184 80 5 4 8 61 8 7 6 0 5 0 0 141 6 10 8 5 9 2 7 62 4 0 0 2 4 9 3 5 1 0 84 50 1 1 0 3 11 3 4 7 0 3 484
PROSPER 395 88 266 201 65 115 0 0 0 115 0 0 0 0 0 0 0 113 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 42 0 0 0 0 0 0 0 0 0 0 0 243
TPT 1638 585 1213 776 437 337 187 37 19 93 5 3 17 0 30 15 1 787 11 84 51 37 47 7 31 246 66 0 0 27 30 38 33 4 6 0 189 40 7 1 4 20 2 29 50 16 4 22 1583
WHS 606 93 237 229 8 288 241 26 19 2 0 0 0 52 0 0 0 373 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 159 46 0 0 0 0 0 0 31 0 0 0 625
WOSCOPS 447 80 368 297 71 70 0 0 0 70 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 105 185
SUBTOTAL 6020 1229 4221 3384 837 1521 506 70 46 896 14 10 24 64 38 21 4 1481 18 98 60 44 58 11 39 333 72 0 0 31 36 49 36 9 7 0 524 141 12 2 5 23 14 43 90 27 4 137 3371
Nested case-control studies
EPICNOR  -  - 481 257 224  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
FIA  -  - 611 469 142  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
GLOSTRUP  -  - 70 54 16  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
USPHS  -  - 245 223 22  - 153  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
WHIHABPS  -  -  -  -  -  - 606  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
SUBTOTAL  -  - 1407 1003 404  - 759  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
TOTAL 73627 43471 43360 20150 23210 19586 6850 2299 1472 8219 1092 775 763 1465 1397 2179 358 45643 650 4682 3443 993 2062 800 2650 9268 2747 1344 412 1038 1094 4060 1538 732 459 3775 30684 5223 1252 1381 2204 3440 1848 3309 3605 2326 842 9783 129581
 
 
Study acronyms are provided in Appendix 4.  
*Includes both fatal and non-fatal events. 
aCHS included an original cohort (here termed CHS1) and a supplemental African-American cohort (here termed CHS2), which were analysed separately. 
bProgetto CUORE was analysed as 8 different studies (ie, ATENA, EMOFRI, MATISS83, MATISS87, MATISS93, MONFRI86, MONFRI89 and MONFRI94).  
cRIFLE Study was analysed as 9 different studies (ie, ATS_SAR, DISCO, GREPCO, GUBBIO, MICOL, MONICA, NFR, OB43 and RF2).  
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Table 5.3 Risk ratios for coronary heart disease and ischaemic stroke per 5 kg/m2 higher 
baseline BMI, adjusted for baseline values of biological, socioeconomic and behavioural risk 
factors 
 
Progressive adjustment No of
cases
RR (95% CI) I2 (95% CI) No ofcases RR (95% CI) I
2
 (95% CI)
Age, sex & smoking 26198 1.30 (1.26 to 1.35) 74 (68 to 78) 4496 1.23 (1.18 to 1.29) 10 (0 to 35)
Plus systolic blood pressure 26198 1.21 (1.18 to 1.25) 56 (45 to 65) 4496 1.13 (1.09 to 1.17) 0 (0 to 31)
Plus history of diabetes 26198 1.19 (1.16 to 1.23) 59 (48 to 67) 4496 1.09 (1.05 to 1.13) 0 (0 to 31)
Plus total cholesterol 26198 1.17 (1.14 to 1.21) 52 (39 to 62) 4496 1.09 (1.05 to 1.13) 0 (0 to 31)
Additional adjustment
Lipids
Age, sex & smoking 12137 1.26 (1.21 to 1.32) 61 (49 to 70) 3460 1.24 (1.19 to 1.29) 0 (0 to 36)
Plus conventional risk factorsl† 12137 1.16 (1.12 to 1.20) 39 (18 to 54) 3460 1.09 (1.05 to 1.14) 0 (0 to 36)
Plus non-HDL-C, HDL-C & loge triglyceride‡ 12137 1.08 (1.04 to 1.11) 26 (0 to 45) 3460 1.07 (1.02 to 1.11) 0 (0 to 36)
Inflammatory markers
Age, sex & smoking 7458 1.23 (1.17 to 1.29) 41 (13 to 60) 2218 1.20 (1.11 to 1.30) 32 (0 to 61)
Plus conventional risk factorsl† 7458 1.14 (1.08 to 1.19) 39 (10 to 59) 2218 1.09 (1.01 to 1.18) 31 (0 to 61)
Plus loge CRP 7458 1.06 (1.01 to 1.12) 40 (12 to 60) 2218 1.05 (0.97 to 1.13) 28 (0 to 59)
Age, sex & smoking 7112 1.28 (1.22 to 1.34) 53 (33 to 67) 2515 1.25 (1.17 to 1.33) 24 (0 to 53)
Plus conventional risk factorsl† 7112 1.16 (1.11 to 1.21) 38 (9 to 58) 2515 1.09 (1.03 to 1.14) 1 (0 to 43)
Plus fibrinogen 7112 1.13 (1.08 to 1.18) 38 (8 to 57) 2515 1.07 (1.02 to 1.12) 0 (0 to 43)
Fasting glucose
Age, sex & smoking 12527 1.26 (1.20 to 1.33) 71 (61 to 78) 2116 1.22 (1.12 to 1.32) 32 (0 to 58)
Plus conventional risk factorsl† 12527 1.14 (1.10 to 1.19) 43 (19 to 60) 2116 1.08 (1.01 to 1.15) 9 (0 to 42)
Plus fasting glucose 12527 1.13 (1.09 to 1.18) 42 (18 to 59) 2116 1.07 (0.99 to 1.15) 15 (0 to 47)
Lifestyle factors 
Age, sex & smoking 16415 1.28 (1.22 to 1.34) 75 (68 to 81) 3230 1.20 (1.15 to 1.26) 11 (0 to 41)
Plus education 16415 1.27 (1.21 to 1.32) 74 (66 to 80) 3230 1.20 (1.15 to 1.25) 0 (0 to 38)
Age, sex & smoking 14964 1.35 (1.31 to 1.40) 46 (25 to 61) 1848 1.29 (1.22 to 1.36) 0 (0 to 41)
Plus occupation/job 14964 1.35 (1.30 to 1.39) 46 (24 to 61) 1848 1.29 (1.22 to 1.36) 0 (0 to 41)
Age, sex & smoking 20435 1.28 (1.24 to 1.33) 62 (53 to 70) 4185 1.23 (1.18 to 1.29) 11 (0 to 37)
Plus alcohol consumption 20435 1.28 (1.24 to 1.32) 61 (51 to 70) 4185 1.22 (1.17 to 1.28) 9 (0 to 35)
Age, sex & smoking 15851 1.36 (1.30 to 1.42) 61 (47 to 71) 1921 1.25 (1.16 to 1.35) 28 (0 to 54)
Plus physical activity 15851 1.35 (1.30 to 1.41) 59 (45 to 70) 1921 1.24 (1.16 to 1.34) 26 (0 to 53)
Coronary heart disease Ischaemic stroke
 †Systolic blood pressure, history of diabetes and total cholesterol. 
‡Total cholesterol was not included in further adjustments.  
Risk ratios were adjusted as shown, and stratified, where appropriate, by sex and trial arm. Analyses were restricted to 
subsets with complete information and BMI values ≥20kg/m2.  
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Table 5.4 Risk ratios for coronary heart disease and ischaemic stroke per 5 kg/m2 higher usual 
levels of BMI, adjusted for usual levels of potential intermediate risk factors 
 
RR (95% CI) I2 (95% CI) RR (95% CI) I2 (95% CI)
Adjusted for age, sex and smoking 1.29 (1.24 to 1.35) 60 (48 to 69) 1.24 (1.17 to 1.32) 33 (0 to 57)
Plus systolic blood pressure 1.18 (1.14 to 1.23) 36 (14 to 52) 1.15 (1.09 to 1.22) 21 (0 to 50)
Plus history of diabetes 1.14 (1.09 to 1.18) 41 (21 to 56) 1.10 (1.04 to 1.17) 25 (0 to 52)
Plus non-HDL-cholesterol 1.10 (1.06 to 1.15) 40 (20 to 55) 1.07 (1.01 to 1.14) 26 (0 to 53)
Plus HDL-cholesterol 1.06 (1.01 to 1.10) 47 (30 to 60) 1.01 (0.95 to 1.08) 32 (0 to 57)
Plus loge triglyceride 1.04 (1.01 to 1.08) 18 (0 to 40) 1.02 (0.95 to 1.08) 28 (0 to 54)
Plus loge CRP 0.93 (0.87 to 1.00) 28 (0 to 55)
Ischaemic stroke
Adjusted for age, sex and smoking 1.27 (1.21 to 1.32) 0 (0 to 36) 1.19 (1.10 to 1.29) 26 (0 to 61)
Plus systolic blood pressure 1.11 (1.06 to 1.16) 0 (0 to 36) 1.07 (0.99 to 1.16) 19 (0 to 56)
Plus history of diabetes 1.04 (0.99 to 1.09) 0 (0 to 36) 1.01 (0.93 to 1.10) 23 (0 to 59)
Plus non-HDL-cholesterol 1.03 (0.97 to 1.09) 14 (0 to 42) 1.01 (0.93 to 1.11) 28 (0 to 62)
Plus HDL-cholesterol 1.02 (0.97 to 1.07) 0 (0 to 36) 1.02 (0.91 to 1.14) 45 (0 to 71)
Plus loge triglyceride 1.02 (0.98 to 1.07) 0 (0 to 36) 1.00 (0.91 to 1.09) 25 (0 to 60)
Plus loge CRP 0.92 (0.84 to 1.00) 13 (0 to 51)
Coronary heart disease 68 studies & 12137 cases 29 studies & 3961 cases 
40 studies & 3460 cases 14 studies & 1764 cases 
 
 
Risk ratios (RRs) were adjusted as shown, and stratified, where appropriate, by sex and trial arm. Analyses were restricted 
to BMI values ≥20kg/m2.  
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Table 5.5 Risk ratios for coronary deaths and non-fatal myocardial infarction (MI) per 5 kg/m2 
higher baseline BMI, adjusted for baseline values of biological, socioeconomic and behavioural 
risk factors 
 
Progressive adjustment No of
cases
RR (95% CI) I2 (95% CI) No ofcases RR (95% CI) I
2
 (95% CI)
Age, sex & smoking 6298 1.33 (1.26 to 1.40) 43 (23 to 58) 12928 1.27 (1.22 to 1.31) 48 (31 to 62)
Plus systolic blood pressure 6298 1.23 (1.17 to 1.29) 31 (6 to 50) 12928 1.20 (1.16 to 1.24) 37 (15 to 54)
Plus history of diabetes 6298 1.20 (1.14 to 1.26) 30 (4 to 49) 12928 1.18 (1.13 to 1.22) 42 (21 to 57)
Plus total cholesterol 6298 1.19 (1.14 to 1.25) 26 (0 to 46) 12928 1.16 (1.12 to 1.20) 36 (12 to 53)
Additional adjustment
Lipids
Age, sex & smoking 2836 1.32 (1.23 to 1.41) 39 (13 to 57) 7266 1.25 (1.19 to 1.31) 48 (26 to 63)
Plus conventional risk factorsl† 2836 1.20 (1.12 to 1.28) 30 (0 to 51) 7266 1.15 (1.10 to 1.20) 31 (1 to 52)
Plus non-HDL-C, HDL-C & loge triglyceride‡ 2836 1.13 (1.06 to 1.21) 26 (0 to 49) 7266 1.06 (1.02 to 1.11) 26 (0 to 49)
Inflammatory markers
Age, sex & smoking 1936 1.29 (1.17 to 1.43) 40 (6 to 61) 4963 1.21 (1.14 to 1.29) 45 (14 to 64)
Plus conventional risk factorsl† 1936 1.19 (1.07 to 1.32) 39 (4 to 61) 4963 1.12 (1.05 to 1.19) 40 (6 to 62)
Plus loge CRP 1936 1.10 (0.98 to 1.24) 45 (15 to 64) 4963 1.06 (0.99 to 1.12) 39 (5 to 61)
Age, sex & smoking 1781 1.34 (1.23 to 1.47) 44 (16 to 62) 4505 1.27 (1.20 to 1.34) 41 (11 to 60)
Plus conventional risk factorsl† 1781 1.21 (1.11 to 1.32) 36 (4 to 58) 4505 1.16 (1.10 to 1.22) 33 (0 to 56)
Plus fibrinogen 1781 1.17 (1.07 to 1.28) 38 (6 to 59) 4505 1.13 (1.07 to 1.19) 34 (0 to 56)
Fasting glucose
Age, sex & smoking 3485 1.35 (1.25 to 1.46) 54 (31 to 70) 6984 1.21 (1.15 to 1.27) 44 (13 to 64)
Plus conventional risk factorsl† 3485 1.22 (1.14 to 1.30) 35 (0 to 59) 6984 1.12 (1.09 to 1.16) 0 (0 to 41)
Plus fasting glucose 3485 1.21 (1.13 to 1.30) 35 (0 to 59) 6984 1.12 (1.08 to 1.15) 0 (0 to 41)
Lifestyle factors 
Age, sex & smoking 4481 1.28 (1.21 to 1.36) 41 (11 to 61) 10595 1.25 (1.19 to 1.32) 71 (60 to 80)
Plus education 4481 1.27 (1.20 to 1.35) 39 (7 to 60) 10595 1.27 (1.20 to 1.35) 39 (7 to 60)
Age, sex & smoking 4250 1.37 (1.30 to 1.44) 24 (0 to 51) 7065 1.32 (1.26 to 1.38) 32 (0 to 56)
Plus occupation/job 4250 1.36 (1.29 to 1.43) 24 (0 to 51) 7065 1.31 (1.25 to 1.37) 31 (0 to 55)
Age, sex & smoking 4932 1.34 (1.27 to 1.43) 46 (26 to 61) 11160 1.26 (1.21 to 1.31) 47 (27 to 61)
Plus alcohol consumption 4932 1.34 (1.26 to 1.42) 45 (25 to 60) 11160 1.25 (1.21 to 1.30) 46 (26 to 60)
Age, sex & smoking 3655 1.41 (1.32 to 1.49) 25 (0 to 52) 7542 1.27 (1.21 to 1.33) 41 (8 to 62)
Plus physical activity 3655 1.39 (1.31 to 1.48) 27 (0 to 53) 7542 1.27 (1.20 to 1.33) 38 (4 to 60)
Non-fatal MICoronary deaths
 †Systolic blood pressure, history of diabetes and total cholesterol. 
‡Total cholesterol was not included in further adjustments. 
Risk ratios were adjusted as shown, and stratified, where appropriate, by sex and trial arm. Analyses were restricted to studies 
contributed data to both outcomes and BMI values ≥20kg/m2.  
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Table 5.6 Supplementary analyses for coronary heart disease and ischaemic stroke per 5 
kg/m2 higher baseline BMI, adjusted for age, sex and smoking status 
 
Description of 
supplementary analysis Outcome
No of 
cases
RR (95% CI) I2 (95% CI)
Excluding 5 years of follow-up Coronary heart disease 27519 1.36 (1.30 to 1.42) 81 (77 to 84)
Ischaemic stroke 3335 1.26 (1.19 to 1.33) 22 (0 to 45)
Excluding current smokers Coronary heart disease 24975 1.31 (1.25 to 1.36) 80 (77 to 83)
Ischaemic stroke 4809 1.25 (1.21 to 1.30) 4 (0 to 28)
Excluding non-European descents Coronary heart disease 36985 1.31 (1.26 to 1.37) 72 (64 to 78)
Ischaemic stroke 4474 1.24 (1.18 to 1.29) 11 (0 to 36)
 
 
Risk ratios were adjusted for age at baseline and smoking status and stratified, where appropriate, by sex and trial arm. 
Analyses were restricted to BMI values ≥20kg/m2.  
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Table 5.7 Risk ratios for major causes of death per 5 kg/m2 higher baseline BMI, adjusted for 
age, sex and smoking status 
 
Cause of death No ofdeaths RR (95% CI) I
2
 (95% CI) No ofdeaths RR (95% CI) I
2
 (95% CI)
All cancer deaths 22500 0.75 (0.70 to 0.81) 50 (37 to 61) 20870 1.12 (1.09 to 1.15) 12 (0 to 33)
All non-cancer non-vascular deaths 15446 0.48 (0.45 to 0.53) 57 (45 to 66) 13702 1.32 (1.26 to 1.38) 53 (40 to 63)
Death of unknown cause or
ill-defined cause 4581 0.64 (0.57 to 0.73) 42 (18 to 59) 4756 1.21 (1.14 to 1.28) 21 (0 to 44)
All-cause mortality 60638 0.68 (0.65 to 0.72) 67 (60 to 73) 63628 1.26 (1.23 to 1.29) 64 (56 to 71)
BMI <25kg/m2 BMI ≥25kg/m2
 
 
Risk ratios were adjusted as shown, and stratified, where appropriate, by sex and trial arm.  
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Table 5.8 Risk ratios for all cancer mortality, non-vascular non-cancer mortality and all-cause mortality per 5 kg/m2 higher baseline 
BMI in the BMI range ≥25kg/m2, adjusted for baseline values of biological, socioeconomic and behavioural risk factors 
 
Progressive adjustment No ofdeaths RR (95% CI) I
2
 (95% CI) No ofdeaths RR (95% CI) I
2
 (95% CI) No ofdeaths RR (95% CI) I
2
 (95% CI)
Age, sex & smoking 10497 1.12 (1.08 to 1.16) 6 (0 to 29) 6448 1.34 (1.26 to 1.42) 47 (31 to 60) 32631 1.27 (1.23 to 1.31) 59 (48 to 67)
Plus systolic blood pressure 10497 1.11 (1.07 to 1.15) 11 (0 to 34) 6448 1.29 (1.22 to 1.36) 39 (19 to 54) 32631 1.22 (1.18 to 1.25) 48 (34 to 59)
Plus history of diabetes 10497 1.10 (1.06 to 1.14) 10 (0 to 33) 6448 1.25 (1.18 to 1.33) 41 (23 to 55) 32631 1.20 (1.16 to 1.23) 52 (39 to 62)
Plus total cholesterol 10497 1.10 (1.06 to 1.14) 11 (0 to 33) 6448 1.24 (1.17 to 1.32) 43 (25 to 57) 32631 1.19 (1.16 to 1.23) 53 (40 to 63)
Additional adjustment
Lipids
Age, sex & smoking 4489 1.11 (1.06 to 1.15) 0 (0 to 32) 2944 1.35 (1.24 to 1.47) 57 (42 to 69) 13128 1.24 (1.19 to 1.29) 45 (26 to 59)
Plus conventional risk factors† 4489 1.09 (1.04 to 1.14) 4 (0 to 29) 2944 1.28 (1.17 to 1.40) 60 (45 to 70) 13128 1.19 (1.14 to 1.23) 47 (30 to 60)
Plus non-HDL-C, HDL-C & loge triglyceride‡ 4489 1.07 (1.02 to 1.12) 2 (0 to 24) 2944 1.28 (1.16 to 1.41) 60 (46 to 71) 13128 1.17 (1.12 to 1.22) 44 (25 to 58)
Inflammatory markers
Age, sex & smoking 1990 1.06 (0.99 to 1.14) 0 (0 to 44) 1370 1.26 (1.15 to 1.38) 10 (0 to 44) 6945 1.21 (1.15 to 1.27) 24 (0 to 50)
Plus conventional risk factors† 1990 1.05 (0.98 to 1.13) 0 (0 to 44) 1370 1.21 (1.11 to 1.31) 0 (0 to 45) 6945 1.17 (1.12 to 1.22) 19 (0 to 47)
Plus loge CRP 1990 1.01 (0.94 to 1.09) 0 (0 to 44) 1370 1.15 (1.06 to 1.25) 0 (0 to 45) 6945 1.11 (1.05 to 1.16) 21 (0 to 48)
Age, sex & smoking 2968 1.08 (1.01 to 1.15) 17 (0 to 46) 2066 1.34 (1.20 to 1.50) 59 (41 to 72) 8766 1.23 (1.17 to 1.30) 54 (34 to 68)
Plus conventional risk factors† 2968 1.06 (0.99 to 1.13) 19 (0 to 48) 2066 1.26 (1.12 to 1.42) 63 (46 to 74) 8766 1.17 (1.11 to 1.24) 55 (36 to 69)
Plus fibrinogen 2968 1.03 (0.96 to 1.10) 24 (0 to 50) 2066 1.21 (1.08 to 1.36) 59 (40 to 72) 8766 1.14 (1.08 to 1.20) 55 (36 to 69)
Fasting glucose
Age, sex & smoking 4498 1.13 (1.08 to 1.18) 0 (0 to 38) 3094 1.32 (1.20 to 1.45) 54 (32 to 69) 14075 1.26 (1.20 to 1.32) 61 (46 to 72)
Plus conventional risk factors† 4498 1.10 (1.05 to 1.15) 0 (0 to 38) 3094 1.23 (1.12 to 1.34) 51 (26 to 67) 14075 1.18 (1.12 to 1.24) 57 (40 to 69)
Plus fasting glucose 4498 1.09 (1.04 to 1.14) 0 (0 to 38) 3094 1.20 (1.10 to 1.32) 48 (23 to 66) 14075 1.16 (1.11 to 1.22) 54 (36 to 67)
Lifestyle factors 
Age, sex & smoking 5883 1.08 (1.04 to 1.13) 12 (0 to 40) 4380 1.29 (1.21 to 1.38) 52 (31 to 66) 18252 1.22 (1.18 to 1.27) 58 (43 to 69)
Plus education 5883 1.08 (1.03 to 1.13) 13 (0 to 41) 4380 1.28 (1.19 to 1.37) 53 (32 to 67) 18252 1.22 (1.17 to 1.26) 60 (46 to 71)
Age, sex & smoking 6427 1.09 (1.05 to 1.13) 0 (0 to 35) 3891 1.35 (1.28 to 1.44) 22 (0 to 47) 20359 1.27 (1.23 to 1.30) 27 (0 to 49)
Plus occupation/job 6427 1.09 (1.05 to 1.13) 0 (0 to 35) 3891 1.34 (1.26 to 1.42) 19 (0 to 45) 20359 1.26 (1.22 to 1.30) 27 (0 to 49)
Age, sex & smoking 8832 1.09 (1.05 to 1.13) 9 (0 to 32) 6228 1.29 (1.22 to 1.37) 47 (30 to 60) 27709 1.29 (1.22 to 1.37) 47 (30 to 60)
Plus alcohol consumption 8832 1.09 (1.05 to 1.13) 7 (0 to 31) 6228 1.28 (1.21 to 1.36) 45 (28 to 59) 27709 1.28 (1.21 to 1.36) 45 (28 to 59)
Age, sex & smoking 7117 1.13 (1.09 to 1.17) 0 (0 to 34) 4318 1.34 (1.25 to 1.44) 45 (21 to 61) 20633 1.30 (1.26 to 1.35) 53 (36 to 66)
Plus physical activity 7117 1.12 (1.08 to 1.17) 0 (0 to 34) 4318 1.33 (1.24 to 1.43) 43 (19 to 60) 20633 1.30 (1.25 to 1.35) 52 (34 to 65)
All cancer deaths All non-cancer non-vascular deaths All-cause mortality
 
 †Systolic blood pressure, history of diabetes and total cholesterol. ‡Total cholesterol was not included in further adjustments. 
Risk ratios were adjusted as shown, and stratified, where appropriate, by sex and trial arm. Analyses were restricted to subsets with complete information.  
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Table 5.9 Risk ratios per 5 kg/m2 higher baseline BMI, adjusted for age, sex and smoking status 
 
Description of 
supplementary analysis Outcome
No of 
deaths RR (95% CI) I
2
 (95% CI) No of deaths RR (95% CI) I
2
 (95% CI)
Excluding 5 years of follow-up All cancer deaths 18678 0.82 (0.76 to 0.87) 34 (13 to 50) 16567 1.14 (1.11 to 1.18) 20 (0 to 40)
All non-cancer non-vascular deaths 12901 0.53 (0.48 to 0.57) 49 (33 to 61) 11309 1.31 (1.26 to 1.38) 42 (24 to 56)
Respiratory disease 4257 0.40 (0.35 to 0.45) 40 (15 to 57) 2918 1.20 (1.10 to 1.32) 40 (17 to 57)
All-cause mortality 49769 0.74 (0.70 to 0.78) 58 (47 to 66) 51108 1.29 (1.25 to 1.32) 58 (47 to 66)
Including never-smokers only All cancer deaths 5809 0.94 (0.84 to 1.05) 24 (0 to 45) 6257 1.13 (1.10 to 1.17) 0 (0 to 28)
Lung cancer 329 0.86 (0.57 to 1.30) 19 (0 to 57) 293 1.06 (0.88 to 1.26) 0 (0 to 58)
All non-cancer non-vascular deaths 4261 0.61 (0.54 to 0.69) 27 (0 to 48) 4531 1.32 (1.24 to 1.42) 43 (24 to 58)
Respiratory disease 861 0.47 (0.38 to 0.58) 20 (0 to 50) 861 1.08 (0.96 to 1.22) 16 (0 to 47)
All-cause mortality 16787 0.80 (0.74 to 0.86) 37 (18 to 52) 20405 1.28 (1.24 to 1.33) 49 (35 to 60)
Excluding non-European descents All cancer deaths 21382 0.76 (0.70 to 0.82) 53 (39 to 63) 20095 1.13 (1.10 to 1.16) 8 (0 to 30)
All non-cancer non-vascular deaths 14464 0.49 (0.45 to 0.54) 52 (39 to 63) 12819 1.33 (1.28 to 1.39) 32 (12 to 48)
All-cause mortality 57242 0.70 (0.66 to 0.73) 64 (56 to 71) 60700 1.28 (1.25 to 1.30) 51 (38 to 61)
BMI <25kg/m2 BMI ≥25kg/m2
 
 
Risk ratios (RRs) were adjusted for age at baseline and smoking status and stratified, where appropriate, by sex and trial arm.  
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Table 5.10 Risk ratios for all cancer mortality, non-cancer non-vascular mortality and all-cause 
mortality per 5 kg/m2 higher baseline BMI without censoring for previous non-fatal outcomes, 
adjusted for age, sex and smoking status 
 
Cause of death No ofdeaths HR (95% CI) I
2
 (95% CI) No ofdeaths HR (95% CI) I
2
 (95% CI)
All cancer deaths 19732 0.83 (0.77 to 0.88) 36 (15 to 52) 23158 1.11 (1.08 to 1.14) 21 (0 to 40)
All non-cancer non-vascular deaths 14012 0.55 (0.51 to 0.60) 49 (33 to 61) 15804 1.30 (1.25 to 1.36) 54 (41 to 64)
All-cause mortality 55704 0.76 (0.73 to 0.80) 52 (39 to 63) 75505 1.25 (1.22 to 1.28) 73 (68 to 78)
BMI <25kg/m2 BMI ≥25kg/m2
 
 
Analyses involving participants with BMI below 25 kg/m2 excluded the first five years of follow-up. Risk ratios were adjusted 
for age and smoking, and stratified, where appropriate, by sex and trial arm.  
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Figure 5.1 Risk ratios for coronary heart disease, ischaemic stroke and all vascular mortality across categories of baseline BMI, 
adjusted for age, sex and smoking status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Reference groups are the second category (ie, 20 to <22.5 kg/m2). 
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Figure 5.2 Risk ratios for vascular outcomes per 5 kg/m2 higher baseline BMI, adjusted for 
age, sex and smoking status (in participants with BMI values of 20kg/m2 or higher) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Includes both fatal and non-fatal events. 
†Restricted to studies contributing to both outcomes. 
 
Causes of other vascular deaths are ordered by their strength of association. Risk ratios (RRs) were adjusted for age at 
baseline and smoking status and stratified, where appropriate, by sex and trial arm. Analyses were restricted to participant 
with BMI values ≥20 kg/m2. There was evidence of heterogeneity in risk ratios between different vascular outcomes (P-value 
for heterogeneity <0.001). P-value = 0.006 for test of difference between associations with coronary deaths and non-fatal 
myocardial infarction (MI). 
 
For comparison with results in Chapter 6, risk ratios per 4.56 kg/m2 were 1.28 (95% CI 1.23-1.32) for coronary heart disease 
and 1.21 (95% CI 1.16-1.26) for ischaemic stroke. 
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Figure 5.3 Risk ratios for coronary heart disease and ischaemic stroke across categories of 
usual levels of BMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression analyses were stratified, where appropriate, by sex and trial arm. Values with further adjustments were adjusted 
for age, sex and usual levels of smoking status, SBP, history of diabetes, total and HDL cholesterol, and loge triglyceride. 
Reference groups are the second category (ie, 20 to <22.5 kg/m2). 
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Figure 5.4 Risk ratios for coronary deaths and non-fatal myocardial infarction (MI) by 
categories of baseline BMI, restricted to studies providing data on both outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Analyses 
involved 62 studies with 7853 coronary deaths and 15649 non-fatal MIs. Reference groups are the second category (ie, 20 
to <22.5 kg/m2). 
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Figure 5.5 Risk ratios for coronary heart disease, ischaemic stroke and all vascular mortality across categories of baseline BMI, after 
excluding the first five years of follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Reference groups are the second category (ie, 20 to <22.5 kg/m2). 
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Figure 5.6 Risk ratios for coronary deaths and non-fatal myocardial infarction (MI) by 
categories of baseline BMI, restricted to studies providing data on both outcomes and on 
never-smokers only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age, and stratified, where appropriate, by sex and trial arm. Analyses involved 30 studies with 
1696 coronary deaths and 3051 non-fatal MIs. Reference groups are the second category (ie, 20 to <22.5 kg/m2). 
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Figure 5.7 Study-specific risk ratios for coronary heart disease per 5 kg/m2 higher baseline 
BMI, adjusted for age, sex and smoking status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were restricted to participants with BMI values ≥20 kg/m2.  
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Figure 5.8 Study-specific risk ratios for ischaemic stroke per 5 kg/m2 higher baseline BMI, 
adjusted for age, sex and smoking status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were restricted to participants with BMI values ≥20 kg/m2.  
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Figure 5.9 Risk ratios for coronary heart disease and ischaemic stroke per 5 kg/m2 higher baseline BMI, according to various 
characteristics of continuous variables  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk ratios were adjusted for age and smoking, and stratified, where appropriate, by sex and trial arm. Analyses involved baseline values of BMI and interaction variables. 
Analyses were restricted to participants with BMI values ≥20 kg/m2. P-values for interaction were calculated from analyses using continuous variable, where appropriate.  
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Figure 5.10 Risk ratios for coronary heart disease and ischaemic stroke per 5 kg/m2 higher baseline BMI, according to various 
characteristics of categorical variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk ratios were adjusted for age and smoking, and stratified, where appropriate, by sex and trial arm. Analyses were restricted to participant with BMI values ≥20 kg/m2.  
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Figure 5.11 Risk ratios for coronary heart disease by baseline smoking and diabetes status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis by baseline smoking status was based on 279,473 current smokers and 389,196 never smokers from 96 studies 
with 26609 cases. Analysis by baseline diabetes status was based on 42,913 people with diabetes and 714,442 people 
without diabetes from 95 studies with 32573 cases.  
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Figure 5.12 Risk ratios for coronary deaths and non-fatal myocardial infarction (MI) per 5 kg/m2 higher baseline BMI, according to 
sex, smoking status and age at baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were restricted to studies providing data to both outcomes. Risk ratios were adjusted for age and smoking, and stratified, where appropriate, by sex and trial arm. 
Analyses involved baseline values of BMI and interaction variables. Analyses were restricted to participant with BMI values ≥20 kg/m2. P-values for interaction were calculated 
from analyses using continuous variable, where appropriate.  
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Figure 5.13 Risk ratios for all cancer mortality, non-vascular non-cancer mortality and all-cause mortality across categories of 
baseline BMI, adjusted for age, sex and smoking status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Reference group is the category including the mean BMI value (ie, 
25 to <27.5 kg/m2). 
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Figure 5.14 Risk ratios for all cancer mortality, non-vascular non-cancer mortality and all-cause mortality across categories of 
baseline BMI, after excluding the first five years of follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Analyse excluded participants with less than 5 years. Reference 
group is the category including the mean BMI value (ie, 25 to <27.5 kg/m2). 
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Figure 5.15 Risk ratios for all-cause mortality across categories of baseline BMI, among men 
and women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis was restricted to studies contributing information on both men and women. Analysis was adjusted for age and 
smoking status, and stratified, where appropriate, by trial arm. Analyse excluded participants with less than five years of 
follow-up. Reference group is the category including the mean BMI value in women (ie, 25 to <27.5 kg/m2 in women). 
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Figure 5.16 Risk ratios for site-specific cancer mortality across categories of baseline BMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Analyses 
excluded participants with less than five years of follow-up. Reference group is the category including the mean BMI value 
(ie, 25 to <27.5 kg/m2). Other cancer outcomes are not shown, because there were generally too few deaths to characterise 
reliably shape of associations. 
20 25 30 35 40 20 25 30 35 40 20 25 30 35 40
20 25 30 35 40 20 25 30 35 40 20 25 30 35 40
Oesophagus: 707 cases Colorectum: 3607 cases Stomach: 1393 cases
Pancreas: 2034 cases Lung: 7184 cases Prostate: 2065 cases
0.7
1.0
1.5
2.0
2.5
3.0
3.5
0.7
1.0
1.5
2.0
2.5
3.0
3.5
0.7
1.0
1.5
2.0
2.5
3.0
3.5
0.7
1.0
1.5
2.0
2.5
3.0
3.5
20 25 30 35 40 20 25 30 35 40 20 25 30 35 40
20 25 30 35 40 20 25 30 35 40
Ovary: 1062 cases Bladder: 769 cases Haematological: 3186 cases
Endocrine / nervous: 
1115 cases
Breast (female): 3104 cases
R
is
k 
ra
tio
 
(95
%
 
CI
)
Baseline BMI (kg/m2)
 156
Figure 5.17A Risk ratios for non-vascular non-cancer specific mortality across categories of 
baseline BMI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Analyses 
excluded participants with less than five years of follow-up. Reference group is the category including the mean BMI value 
(ie, 25 to <27.5 kg/m2). Other non-vascular non-cancer outcomes are not shown, because there were generally too few 
deaths to characterise reliably shape of associations. 
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Figure 5.17B Risk ratios for non-vascular non-cancer specific mortality outcomes across 
categories of baseline BMI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age and smoking status, and stratified, where appropriate, by sex and trial arm. Analyses 
excluded participants with less than five years of follow-up. Reference group is the category including the mean BMI value 
(ie, 25 to <27.5 kg/m2). Other non-vascular non-cancer outcomes are not shown, because there were generally too few 
deaths to characterise reliably shape of associations. 
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Figure 5.18 Risk ratios for cause-specific non-vascular mortality outcomes per 5 kg/m2 higher 
baseline BMI in the BMI range ≥25kg/m2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With the exception of "Other/Unspecified", causes of deaths are presented in descending order of their estimated risk ratios 
(RRs). All analyses are adjusted for age and smoking status, and stratified by sex and trial arm. There was evidence of 
heterogeneity in risk ratios between different cancer sites and between different non-cancer non-vascular causes of death 
(P-value for heterogeneity <0.001 for both).  
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Figure 5.19 Risk ratios for cause-specific non-vascular mortality per 5 kg/m2 higher baseline 
BMI in the BMI range <25kg/m2, after excluding the first five years of follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses excluded the first five years of follow-up. With the exception of "Other/Unspecified", causes of deaths are 
presented in ascending order of their estimated risk ratios (RRs). All analyses are adjusted for age and smoking status, and 
stratified by sex and trial arm. There was evidence of heterogeneity in risk ratios between different cancer sites and between 
different non-cancer non-vascular causes of death (P-value for heterogeneity <0.001 for both).  
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Figure 5.20 Risk ratios for death due to respiratory disease across categories of baseline BMI, (a) without exclusion of follow-up or 
excluding (b) the first five years of follow-up or (c) the first ten years of follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were restricted to 42 studies involving 7906 deaths in (a), 6861 deaths in (b) and 5282 deaths in (c). Analyses were adjusted for age and smoking status, and 
stratified, where appropriate, by sex and trial arm. Reference group is the category including the mean BMI value (ie, 25 to <27.5 kg/m2). 
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CHAPTER 6: Associations of adiposity measures with risk of coronary heart 
disease and ischaemic stroke 
 
Summary 
Although several epidemiological studies have reported on the associations of body-mass 
index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) with risk of cardiovascular 
disease, the relative importance of overall versus abdominal adiposity is still unclear. A large 
retrospective case-control study has reported that baseline measurement of WHR is three 
times more strongly associated with risk of acute myocardial infarction than is BMI, 
recommending that WHR replaces BMI as the principal clinical measure of adiposity. After 
reliably characterising the association of BMI with cardiovascular morbidity and cause-specific 
mortality in Chapter 5, this chapter reports prospective analyses of individual records from 
221,934 participants in 58 mostly Western prospective studies with complete information on 
BMI, WC and WHR, and without known history of cardiovascular disease at baseline 
examination. During 1.87 million person-years at risk, there were 11,196 first-ever non-fatal 
and fatal coronary heart disease and ischaemic stroke outcomes. In analyses adjusted for age, 
sex and smoking status only, nearly loge-linear associations were observed between BMI, WC 
and WHR, and risk of coronary heart disease and ischaemic stroke across the range of values, 
except at low BMI values. After excluding participants with BMI values below 20 kg/m2, age, 
sex and smoking status adjusted risk ratios for coronary heart disease and ischaemic stroke 
were broadly similar with BMI, WC and WHR. These risk ratios reduced considerably, after 
further adjustment for intermediate risk factors, such as blood pressure, history of diabetes, 
total and high-density lipoprotein cholesterol. The effect of abdominal adiposity on the risk of 
coronary heart disease and ischaemic stroke was largely independent of BMI. The risk ratios 
were about three-to-four fold stronger in participants at early middle age than at older ages, but 
otherwise did not vary materially by sex, method of adiposity assessment (ie, self-reported 
versus assessed by a trained person) and other characteristics recorded. These findings refute 
previous recommendations to adopt WHR instead of BMI as the principal clinical measure of 
adiposity.  
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Background 
Although several epidemiological studies have reported on the associations of body-mass 
index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) with risk of coronary heart 
disease,1-24 the relative importance of overall versus abdominal adiposity is still unclear 
(Chapter 1). A large retrospective case-control study has reported that baseline measurement 
of WHR is three times more strongly associated with risk of acute myocardial infarction than is 
BMI, recommending that WHR replaces BMI as the principal clinical measure of adiposity.23 
Prospective studies have, however, been unable to evaluate reliably this suggestion because 
most involved a moderate number of incident vascular disease outcomes,2,4,21,25 relied only on 
self-reported adiposity measures,4 lacked measurement of both BMI and abdominal adiposity 
in the same participants,26-28 and/or lacked measurement of lipids and other established risk 
factors.9,27 Moreover, previous studies were unable to investigate whether measures of 
abdominal adiposity are more strongly related to risk of ischaemic stroke than is BMI, primarily 
because there has been a paucity of published information.21,29-31 Because of these limitations, 
previous prospective studies with concomitant data on weight, height, waist and hip 
circumference were not able to examine reliably the magnitude of associations of BMI, WC and 
WHR with risk of coronary heart disease and ischaemic stroke; characterise the shape of any 
dose-response relationship; explore the degree to which associations can be explained by 
correlations with other cardiovascular risk factors (notably intermediate risk factors; Chapter 
3); or assess whether associations differ importantly under different circumstances, such as at 
different levels of BMI, in different age groups, or by sex. Consequently, the relevance of 
clinical measures of adiposity to the vascular disease aetiology remains uncertain, and 
important aspects of its epidemiology have yet to be characterised in detail.  
 
The objective of this chapter is to produce reliable estimates of the associations of BMI, WC 
and WHR with risk of coronary heart disease and ischaemic stroke under different 
circumstances, incorporating adjustment for potential confounders and biological mediators 
using data from the Emerging Risk Factors Collaboration (ERFC).32 
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Methods 
Study design 
Details of study selection, data collection and harmonisation have been described in Chapter 
2. Briefly, the current analysis involves individual records from 58 prospective studies. A total of 
221,934 participants without known history of cardiovascular disease at the initial ("baseline") 
examination had information on height, weight, and waist and hip circumference. 155,938 
(70%) of these participants also had data on smoking status, history of diabetes, systolic blood 
pressure (SBP), and total and high-density lipoprotein (HDL) cholesterol.  
 
Analytical approach 
The statistical methods have been described in detail in Chapter 5 on pages 111-116. The 
principal measures of adiposity studied were BMI, WC and WHR. Associations of these 
measures were assessed in relation to fatal or first-ever coronary heart disease and ischaemic 
stroke. Analyses involved a two-stage approach with estimates of association calculated 
separately within each study before pooling across studies by random effects meta-analysis.33 
Hazard ratios were calculated using Cox proportional-hazards regression models stratified by 
sex.34 The proportional hazards assumptions were met. Participants contributed only first non-
fatal outcome or death recorded at age 40 years or older (ie, deaths preceded by non-fatal 
coronary event or stroke were not included). For the four contributing individually-matched 
nested case-control studies within prospective cohorts, odds ratios were calculated with 
conditional logistic regression models. Provided the disease is relatively rare, hazard ratios and 
odds ratios were assumed to approximate the same relative risk and are collectively described 
as "risk ratios".35 The incidence of coronary heart disease and ischaemic stroke is higher than 
that of many endpoints reported in Chapter 5. Therefore, to avoid over-fitting of the statistical 
models, studies with fewer than ten incident cases (rather than five cases) of an outcome were 
excluded from the analysis of that particular outcome.  
 
Shape analysis 
To characterise shapes of associations, study-specific risk ratios calculated within overall 
quantiles (ie, quantile groups defined across all studies) of baseline adiposity values were 
pooled on a loge scale by multivariate random effects meta-analysis and plotted against mean 
values of the relevant adiposity measure within each quantile.36,37 Whereas shape analysis in 
relation to coronary heart disease were based on deciles, corresponding analyses with 
ischaemic stroke used quintiles only, since there were considerably fewer incident stroke 
events than coronary events. 95% confidence intervals (CIs) were estimated from floated 
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variances that reflect the amount of information underlying each group (including the reference 
group).38 Because associations were nearly loge-linear (except at low values of BMI: see 
Results), regression coefficients were calculated to estimate the risk ratios associated with one 
standard deviation (SD) higher baseline values: 4.56 kg/m2 higher BMI, 12.6 cm higher WC 
and 0.083 higher WHR, thereby allowing for direct comparisons between adiposity measures. 
Risk ratios with clinically defined categories of BMI and WC in combination were also 
calculated.39 Risk ratios were initially adjusted for age, sex and smoking status only. To explore 
potential biological pathways underlying associations, risk ratios were further adjusted for SBP, 
history of diabetes, total and HDL cholesterol. Effect modification was investigated with formal 
tests of interaction, and p-values for interaction were calculated with continuous variables, 
when appropriate. Diversity between studies was investigated by grouping studies by recorded 
characteristics and meta-regression. Extent of heterogeneity was indicated by the I2 
statistic.40,41  
 
Within-person variability 
Correction for within-person variability in adiposity measures and in potential confounders and 
biological mediators was achieved by use of conditional expectations of long-term average 
("usual") levels of adiposity measures and potential confounders and mediators predicted from 
Rosner regression calibration models,42,43 and used in assessments of associations with 
disease risk. As described in Appendix 2, regression coefficients were calculated to estimate 
the risk ratios associated with 1-SD higher usual levels adjusted for age, sex and smoking 
status: 4.36 kg/m2 higher BMI, 10.98 cm higher WC and 0.059 higher WHR. These SDs in 
usual levels remained unchanged after further adjustment for intermediate risk factors (ie, SBP, 
history of diabetes, and total and HDL cholesterol). Sensitivity analyses involved regression 
calibration models allowing variability of WHR to vary by sex, history of diabetes and baseline 
WHR values (Chapter 4).  
 
All analyses were performed using Stata release 11 (StataCorp LP, College Station, Texas 
USA). 
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Results 
Characteristics of individual studies are summarised in Table 2.3 in Chapter 2 on page 47 and 
in Table 6.1. Mean (SD) age of participants at baseline was 58 (9) years, 124,189 (56%) were 
women, and 129,326 (58%) were in Europe, 73,707 (33%) were in North America, 9,204 (4%) 
were in Australia and 9,697 (4%) were in Japan. During 1.87 million person-years at risk 
(median 5.7 years to first outcome, IQR 3.0-9.0), there were 8,290 coronary heart disease 
outcomes (4,982 non-fatal myocardial infarctions and 3,308 coronary deaths) and 2,906 
incident ischaemic stroke outcomes (2,764 non-fatal and 142 fatal outcomes).  
 
Associations with coronary heart disease  
In analyses adjusted for age, sex and smoking status only, there were nearly loge-linear 
associations of BMI, WC and WHR and risk of coronary heart disease, except at low BMI 
values (Figure 6.1). These associations were similar when clinically defined categories of BMI 
and WC were combined (Figure 6.2). To account for the non-linear association at low BMI 
values, further analyses excluded the 9,355 participants (4%) with BMI values below 20 kg/m2. 
In analyses restricted to participants with complete information on relevant covariates, risk 
ratios for coronary heart disease per one standard deviation higher baseline values – initially 
adjusted for age, sex and smoking status only, and then further adjusted for baseline values of 
intermediate risk factors (ie, SBP, history of diabetes and total and HDL cholesterol) – 
respectively, were 1.29 (95% CI 1.22-1.37) and 1.11 (95% CI 1.05-1.17) with BMI, 1.32 (95% 
CI 1.24-1.40) and 1.12 (95% CI 1.06-1.19) with WC, and 1.30 (95% CI 1.22-1.38) and 1.14 
(95% CI 1.09-1.18) with WHR (Table 6.2). Risk ratios for coronary heart disease reduced even 
more after additional adjustment for C-reactive protein (CRP) (Table 6.3). In regression dilution 
corrected analyses, long-term average levels of blood pressure, diabetes and lipids accounted 
for more than two-thirds of the coronary risk associated with adiposity measures (Table 6.4). 
The proportion in risk reduction was possibly somewhat larger for BMI than for WHR (ie, 74% 
risk reduction for BMI versus 62% risk reduction for WHR). Among the contributing studies, 
heterogeneity between studies tended to decrease after adjustment of risk ratios for 
intermediate risk factors (Table 6.2).  
 
Associations with ischaemic stroke 
Associations with ischaemic stroke were approximately loge-linear, with possible attenuation at 
low BMI values (Figure 6.1). After exclusion of participants with BMI values below 20 kg/m2, 
age, sex and smoking status adjusted risk ratios for ischaemic stroke with BMI, WC and WHR 
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were broadly similar to those for coronary heart disease (Table 6.2). Risk ratios for ischaemic 
stroke per one standard deviation higher baseline values – initially adjusted for age, sex and 
smoking status only and then further adjusted for baseline values of intermediate risk factors – 
respectively, were 1.20 (95% CI 1.12-1.28) and 1.06 (95% CI 0.99-1.13) with BMI, 1.25 (95% 
CI 1.18-1.33) and 1.11 (95% CI 1.05-1.17) with WC, and 1.25 (95% CI 1.18-1.32) and 1.14 
(95% CI 1.09-1.20) with WHR (Table 6.2). Risk ratios for ischaemic stroke reduced even more 
after additional adjustment for CRP (Table 6.3). In regression dilution corrected analyses, 
blood pressure, diabetes and lipids accounted for at least half of the association between 
adiposity measures and ischaemic stroke (Table 6.4). The proportion in risk reduction was 
possibly somewhat larger for BMI than for WHR (ie, 89% risk reduction for BMI versus 53% 
risk reduction for WHR). Between-study heterogeneity tended to decrease after adjustment of 
risk ratios for intermediate risk factors (Table 6.2).  
 
Sensitivity analyses 
Qualitatively similar results to those reported here were also observed in analyses that 
excluded: the initial five or ten years of follow-up, current smokers; participants who were not of 
European descent; or the 29,905 participants who had only self-reported adiposity measures 
(Table 6.5); the few studies with the most discrepant findings (Figure 6.3); or the 21,139 
participants known to be receiving lipid-lowering, blood pressure-lowering or other 
cardiovascular medication at baseline (data not shown). Risk ratios were also broadly similar 
using fixed-effect models (Figure 6.3) and after additional adjustment for: cigarette pack-years 
(in addition to smoking status), alcohol consumption or measures of socioeconomic status 
(data not shown). The risk ratio with WHR corrected for regression dilution was somewhat 
higher when regression calibration models were allowed to vary by sex, history of diabetes and 
baseline WHR (data not shown). Risk ratios with waist-to-height ratio (WHtR) were similar to 
those of WC because of the strong correlation between WC and WHtR (r = 0.95, 95% CI 0.94-
0.96) (Table 6.2). There was no evidence of bias due to small studies (Figure 6.4).  
 
Assessment of joint effects  
Risk ratios for coronary heart disease and ischaemic stroke associated with adiposity 
measures were around three-to-four times stronger at ages 40-59 years than at older than 70 
years, but similar in men and women (Figures 6.5-6.6). Risk ratios for coronary heart disease 
were possibly higher at lower-than-average systolic blood pressure, but otherwise did not vary 
importantly by baseline levels of smoking status, history of diabetes, HDL and non-HDL 
 167
cholesterol, CRP or ethnicity (Figure 6.7). Risk ratios for coronary heart disease with BMI and 
WC were similar at different triglyceride levels, but risk ratios with WHR were somewhat 
stronger at lower-than-average triglyceride levels (Figures 6.7-6.8). There were no important 
variations in risk ratios of studies using self-reported adiposity measures values versus 
adiposity measures assessed by a trained person, or with other features recorded at the study-
level (Figure 6.7). 
 
Combined analyses of adiposity measures 
Further analyses investigated joint effects and independence between adiposity measures. 
Risk ratios with WC and WHR were generally similar at different BMI levels and slightly 
reduced after adjustment for BMI (Table 6.6 & Figures 6.5 and 6.9). For example, risk ratios 
for coronary heart disease – initially adjusted for age, sex and smoking status, and then 
additionally adjusted for BMI – respectively, were 1.31 (95% CI 1.24-1.37) and 1.23 (95% CI 
1.15-1.32) with WC, and 1.29 (95% CI 1.23-1.35) and 1.21 (95% CI 1.16-1.26) with WHR 
(Table 6.6). Corresponding risk ratios for ischaemic stroke were 1.26 (95% CI 1.19-1.33) and 
1.26 (95% CI 1.16-1.36) with WC, and 1.25 (95% CI 1.19-1.32) and 1.18 (95% CI 1.13-1.24) 
with WHR (Table 6.6). By contrast, associations with BMI reduced considerably and 
disappeared after adjustment for WHR or WC, respectively (Table 6.6).  
 
Discussion 
The current analysis of individual data from 221,934 people without initial cardiovascular 
disease in 58 mostly Western prospective studies assessed the shape, specificity and 
independence of associations of BMI, WC and WHR with risk of coronary heart disease and 
ischaemic stroke. These data demonstrate that: (i) BMI, WC and WHR have nearly loge-linear 
associations with risk of coronary heat disease and ischaemic stroke (after exclusion of the 4% 
of people with BMI values below 20 kg/m2); (ii) BMI and measures of abdominal adiposity each 
have a similar magnitude of association with risk of coronary heart disease; (iii) excess 
adiposity is broadly similarly related to risk of coronary heart disease and ischaemic stroke; (iv) 
much of the risk of coronary heart disease and ischaemic stroke is explained by intermediate 
risk factors such as blood pressure, history of diabetes, and total and HDL cholesterol; (v) 
measures of abdominal adiposity increase cardiovascular risk largely independent of BMI; and 
(vi) age strongly modifies the impact of adiposity on coronary heart disease and ischaemic 
stroke. 
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Contrary to a report from INTERHEART23 (a large case-control study with 12,000 cases of first 
myocardial infarction and 14,000 controls) that WHR is three times more strongly related to 
myocardial infarction than is BMI, the current analysis has shown that BMI, WC and WHR each 
have a similar strength of association with cardiovascular disease risk, arguing against the idea 
of replacing BMI with WC or WHR as the principal measure of adiposity in clinical practice. 
Whereas INTERHEART observed an odds ratio for myocardial infarction of only 1.12 per 5 
kg/m2 higher baseline BMI, the corresponding risk ratio for coronary heart disease was 1.32 in 
the current analysis. This discrepancy might be due to the greater susceptibility of retrospective 
studies of acute myocardial infarction to some biases (eg, selection biases, reverse causality) 
than long-term prospective studies of people without an initial history of cardiovascular 
disease. Because visceral fat is believed to be more metabolically active than other fat depots 
such as subcutaneous fat,44-46 abdominal adiposity measures such as WC and WHR are 
expected to be more strongly associated with metabolic abnormalities and cardiovascular 
disease risk than is BMI, since BMI is a measures of general adiposity. However, the current 
findings indicate that BMI, WC and WHR each have similar associations with risk of coronary 
heart disease and ischaemic stoke. This might be due to the fact that these measures of 
abdominal adiposity are poor surrogates of visceral adiposity, as they do not distinguish 
visceral adipose tissue from abdominal subcutaneous adipose tissue, which is only possible by 
use of imaging techniques.44,47 The similarity of effect of adiposity on coronary heart disease 
and ischaemic stroke contrasts with results previously reported for pro-atherogenic lipids 
(which are four times more strongly related to coronary heart disease than ischaemic stroke48) 
and systolic blood pressure (which is more strongly related to ischaemic stroke than coronary 
heart disease49). The current data, therefore, highlight the potential importance of reducing 
adiposity for both coronary heart disease and ischaemic stroke. 
 
The current analysis has shown that at least half of the risk with coronary heart disease and 
ischaemic stroke associated with adiposity measures is explained by baseline values of blood 
pressure, history of diabetes, and total and HDL cholesterol – with an even larger proportion of 
this risk explained by long-term average levels of these intermediate risk factors. The findings 
observed for BMI in this chapter are very similar to those observed in Chapter 5, which 
involves five times more participants. The proportion in risk reduction was possibly somewhat 
larger for BMI than for WHR. Nevertheless, as discussed in Chapter 5, the current findings 
underscore the importance of controlling adiposity to help prevent coronary heart disease and 
stroke, as well as potential added benefits of controlling these intermediate risk factors to 
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combat the detrimental vascular effects of overweight and obesity.50 The current findings have 
shown that the effect of abdominal adiposity on risk of coronary heart disease and ischaemic 
stroke is largely independent of BMI and not modified by BMI. However, the association of BMI 
with these outcomes was reduced and even disappeared after adjustment for WC or WHR, 
respectively, suggesting that these measures of abdominal adiposity provide useful information 
on cardiovascular disease beyond that of BMI. Furthermore, the risk ratios were not greatly 
different between studies using self-reported adiposity measures and adiposity measures 
assessed by a trained person, or different locations of WC assessment. By contrast, there was 
a strong modification of the effects of adiposity by age, with three-to-four higher excess risk for 
coronary heart disease and ischaemic stroke in early middle age than at older ages. Possible 
explanations of that interaction have been discussed in Chapter 5. Otherwise, there were no 
important modifications of the effect of adiposity on risk of coronary heart disease and 
ischaemic stroke by subgroups assessed.  
 
The data in this chapter are likely to represent a substantial proportion of available data from 
prospective studies of overall and abdominal adiposity and incident disease risk, at least in 
Western populations, and include data from several studies that have not previously reported 
such associations. The data complements previous analyses of large prospective studies. In 
contrast with the Prospective Studies Collaboration26 (PSC) and the National Cancer Institute 
Cohort Consortium27 (NCICC) which lacked information on WC and WHR, the ERFC had 
concomitant data for each participant on BMI, WC and WHR. In contrast with NCICC and the 
European Prospective Investigation into Cancer9 (EPIC) which lacked information on lipids, the 
ERFC had concomitant information on lipids, blood pressure and other conventional risk 
factors. Whereas the PSC, NCICC and EPIC all lacked non-fatal cardiovascular outcomes, the 
ERFC involved fatal or first-onset non-fatal myocardial infarctions and ischaemic stokes 
recorded during 1.87 million person-years at risk. Whereas the EPIC aggregated 
cardiovascular outcomes, the ERFC reported associations with coronary heart disease and 
ischaemic stroke separately. There was some heterogeneity in risk ratios with adiposity 
measures. However, the generalisability of the current findings, at least to Western 
populations, is supported by broadly consistent results across 58 cohorts in 17 countries. 
Although the analysis could only use a fifth of the coronary events available in the previous 
chapter, the current findings with BMI were consistent with those observed in Chapter 5. For 
instance, the risk ratio for coronary heart disease, adjusted for age, sex and smoking status, 
was 1.31 per 5 kg/m2 higher baseline BMI in Chapter 5, while the corresponding risk ratio was 
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1.32 in the current chapter. Contrary to previous suggestions,51-53 WHtR was associated to a 
similar extent with risk of coronary heart disease and ischaemic stroke as were other clinical 
measures of adiposity. As most of the participants in this study were of European descent, 
further studies are needed in people of non-European descent.21,54,55 
 
Conclusion 
Excess adiposity is substantially and similarly related to risk of coronary heart disease and 
ischaemic stroke. BMI, WC and WHR each have a similar magnitude of associations with risk 
of coronary heart disease and ischaemic stroke, with much the risk explained by intermediate 
risk factors, such as blood pressure, history of diabetes, total and HDL cholesterol. These 
findings refute previous recommendations to adopt WHR instead of BMI as the principal clinical 
measure of adiposity. 
 171
Chapter 6 – References  
 1. Aekplakorn W, Pakpeankitwatana V, Lee CM et al. Abdominal obesity and coronary heart 
disease in Thai men. Obesity. 2007;15:1036-1042. 
 2. Canoy D, Boekholdt SM, Wareham N et al. Body fat distribution and risk of coronary heart 
disease in men and women in the European Prospective Investigation Into Cancer and 
Nutrition in Norfolk cohort: a population-based prospective study. Circulation. 
2007;116:2933-2943. 
 3. Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and 
coronary heart disease incidence in African Americans and whites. Atherosclerosis Risk in 
Communities Study Investigators. Am J Epidemiol. 1998;148:1187-1194. 
 4. Gelber RP, Gaziano JM, Orav EJ, Manson JE, Buring JE, Kurth T. Measures of obesity and 
cardiovascular risk among men and women. J Am Coll Cardiol. 2008;52:605-615. 
 5. Gruson E, Montaye M, Kee F et al. Anthropometric assessment of abdominal obesity and 
coronary heart disease risk in men : the PRIME study. Heart. 2009;96:136-140. 
 6. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with 
increased risk of acute coronary events in men. Eur Heart J. 2002;23:706-713. 
 7. Lawlor DA, Davey Smith G, Ebrahim S. Does the new International Diabetes Federation 
definition of the metabolic syndrome predict CHD any more strongly than older definitions? 
Findings from the British Women's Heart and Health Study. Diabetologia. 2006;49:41-48. 
 8. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose 
tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in 
the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed). 
1984;289:1257-1261. 
 9. Pischon T, Boeing H, Hoffmann K et al. General and abdominal adiposity and risk of death 
in Europe. N Engl J Med. 2008;359:2105-2120. 
 10. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose 
tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up 
of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984;288:1401-
1404. 
 11. Li C, Engstrom G, Hedblad B, Calling S, Berglund G, Janzon L. Sex differences in the 
relationships between BMI, WHR and incidence of cardiovascular disease: a population-
based cohort study. Int J Obes. 2006;30:1775-1781. 
 12. Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary artery 
disease mortality in older women. Ann Epidemiol. 1993;3:35-41. 
 13. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary 
heart disease in men. Int J Obes Relat Metab Disord. 2001;25:1047-1056. 
 14. Rexrode KM, Carey VJ, Hennekens CH et al. Abdominal adiposity and coronary heart 
disease in women. JAMA. 1998;280:1843-1848. 
 15. Rimm EB, Stampfer MJ, Giovannucci E et al. Body size and fat distribution as predictors of 
coronary heart disease among middle-aged and older US men. Am J Epidemiol. 
1995;141:1117-1127. 
 16. Silventoinen K, Jousilahti P, Vartiainen E, Tuomilehto J. Appropriateness of anthropometric 
obesity indicators in assessment of coronary heart disease risk among Finnish men and 
women. Scand J Public Health. 2003;31:283-290. 
 172
 17. Terry RB, Page WF, Haskell WL. Waist/hip ratio, body mass index and premature 
cardiovascular disease mortality in US Army veterans during a twenty-three year follow-up 
study. Int J Obes Relat Metab Disord. 1992;16:417-423. 
 18. Welborn TA, Dhaliwal SS, Bennett SA. Waist-hip ratio is the dominant risk factor predicting 
cardiovascular death in Australia. Med J Aust. 2003;179:580-585. 
 19. Yang L, Kuper H, Weiderpass E. Anthropometric characteristics as predictors of coronary 
heart disease in women. J Intern Med. 2008;264:39-49. 
 20. Zhang X, Shu XO, Gao YT et al. Anthropometric predictors of coronary heart disease in 
Chinese women. Int J Obes Relat Metab Disord. 2004;28:734-740. 
 21. Asia Pacific Cohort Studies Collaboration. Central obesity and risk of cardiovascular 
disease in the Asia Pacific Region. Asia Pac J Clin Nutr. 2006;15:287-292. 
 22. Huang B, Rodreiguez BL, Burchfiel CM, Chyou PH, Curb JD, Sharp DS. Associations of 
adiposity with prevalent coronary heart disease among elderly men: the Honolulu Heart 
Program. Int J Obes Relat Metab Disord. 1997;21:340-348. 
 23. Yusuf S, Hawken S, Ounpuu S et al. Obesity and the risk of myocardial infarction in 27,000 
participants from 52 countries: a case-control study. Lancet. 2005;366:1640-1649. 
 24. Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist 
circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the 
literature. Eur J Clin Nutr. 2009;64:16-22. 
 25. Taylor AE, Ebrahim S, Ben-Shlomo Y et al. Comparison of the associations of body mass 
index and measures of central adiposity and fat mass with coronary heart disease, 
diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr. 
2010;91:547-556. 
 26. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 
000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096. 
 27. Berrington de Gonzalez A, Hartge P, Cerhan JR et al. Body-mass index and mortality 
among 1.46 million white adults. N Engl J Med. 2010;363:2211-2219. 
 28. Jacobs EJ, Newton CC, Wang Y et al. Waist circumference and all-cause mortality in a 
large US cohort. Arch Intern Med. 2010;170:1293-1301. 
 29. Kizer JR, Biggs ML, Ix JH et al. Measures of adiposity and future risk of ischemic stroke 
and coronary heart disease in older men and women. Am J Epidemiol. 2010;173:10-25. 
 30. Toss F, Wiklund P, Franks PW et al. Abdominal and gynoid adiposity and the risk of stroke. 
Int J Obes. 2011. 
 31. Hu G, Tuomilehto J, Silventoinen K, Sarti C, Mannisto S, Jousilahti P. Body mass index, 
waist circumference, and waist-hip ratio on the risk of total and type-specific stroke. Arch 
Intern Med. 2007;167:1420-1427. 
 32. Emerging Risk Factors Collaboration. The Emerging Risk Factors Collaboration: analysis of 
individual data on lipid, inflammatory and other markers in over 1.1 million participants in 
104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22:839-869. 
 33. Emerging Risk Factors Collaboration. Statistical methods for the time-to-event analysis of 
individual participant data from multiple epidemiological studies. Int J Epidemiol. 
2010;39:1345-1359. 
 34. Cox DR. Regression models and life tables. J Roy Stat Soc B. 1972;74:187-220. 
 173
 35. Kirkwood BR, Sterne AC. Probability, risk and odds (of disease). Essential Medical 
Statistics. 2 ed. Oxford: Blackwell Science; 2006. 
 36. White IR. Multivariate random-effects meta-analysis. Stata Jounral. 2009;9(1):40-56. 
 37. Berkey CS, Hoaglin DC, ntczak-Bouckoms A, Mosteller F, Colditz GA. Meta-analysis of 
multiple outcomes by regression with random effects. Stat Med. 1998;17:2537-2550. 
 38. Easton D, Peto J, Babiker A. Floating absolute risk: an alternative to relative risk in survival 
and case-control analysis avoiding an arbitrary reference group. Stat Med. 1991;10:1025-
1035. 
 39. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and 
Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6 
Suppl 2:51S-209S. 
 40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
analyses. BMJ. 2003;327:557-560. 
 41. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 
2002;21:1539-1558. 
 42. Fibrinogen Studies Collaboration. Regression dilution methods for meta-analysis: assessing 
long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int 
J Epidemiol. 2006;35:1570-1578. 
 43. Fibrinogen Studies Collaboration. Correcting for multivariate measurement error by 
regression calibration in meta-analyses of epidemiological studies. Stat Med. 
2009;28:1067-1092. 
 44. Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly 
hazardous and how do we measure them? Int J Epidemiol. 2006;35:83-92. 
 45. Ross R, Aru J, Freeman J, Hudson R, Janssen I. Abdominal adiposity and insulin 
resistance in obese men. Am J Physiol Endocrinol Metab. 2002;282:E657-E663. 
 46. Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition, and 
insulin resistance in premenopausal women. J Clin Endocrinol Metab. 2002;87:5044-5051. 
 47. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic 
syndrome. Endocr Rev. 2000;21:697-738. 
 48. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular 
disease. JAMA. 2009;302:1993-2000. 
 49. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to 
vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective 
studies. Lancet. 2002;360:1903-1913. 
 50. Logue J, Thompson L, Romanes F, Wilson DC, Thompson J, Sattar N. Management of 
obesity: summary of SIGN guideline. BMJ. 2010;340:c154. 
 51. Schneider HJ, Glaesmer H, Klotsche J et al. Accuracy of anthropometric indicators of 
obesity to predict cardiovascular risk. J Clin Endocrinol Metab. 2007;92:589-594. 
 52. Ashwell M, Gibson S. Waist to height ratio is a simple and effective obesity screening tool 
for cardiovascular risk factors: Analysis of data from the British National Diet And Nutrition 
Survey of adults aged 19-64 years. Obes Facts. 2009;2:97-103. 
 53. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a 
screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a 
suitable global boundary value. Nutr Res Rev. 2010;23:247-269. 
 174
 54. Whincup PH, Gilg JA, Papacosta O et al. Early evidence of ethnic differences in 
cardiovascular risk: cross sectional comparison of British South Asian and white children. 
BMJ. 2002;324:635. 
 55. Colin BA, Adair LS, Popkin BM. Ethnic differences in the association between body mass 
index and hypertension. Am J Epidemiol. 2002;155:346-353. 
 
 
 175
Table 6.1 Descriptive summaries, grouped by study, of individuals with concomitant information 
on BMI, WC, WHR, age and sex 
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ARIC 14383 54 (6) 6213 (43) 28 (5) 97 (14) 0.92 (0.08) 14.0 (4.9 to 15.7) 865 198 667 455 2 453
ATENAb 4741 50 (7) 0 (0) 27 (4) 85 (10) 0.82 (0.07) 6.7 (5.2 to 8.1) 18 1 17 1 0 1
ATTICA 1503 51 (11) 769 (51) 27 (4) 93 (14) 0.88 (0.11) 5.0 (5.0 to 5.0) 0 0 0 0 0 0
AUSDIAB 9204 53 (13) 4079 (44) 27 (5) 91 (14) 0.87 (0.09) 5.0 (4.8 to 8.5) 65 41 24 13 2 11
BRHS 3466 68 (5) 3466 (100) 27 (4) 97 (10) 0.95 (0.06) 5.0 (1.9 to 5.0) 160 92 68 3 3 0
BRUN 817 58 (11) 398 (49) 25 (4) 87 (11) 0.89 (0.07) 15.3 (3.9 to 15.5) 54 31 23 24 9 15
BWHHS 2779 68 (5) 0 (0) 27 (5) 85 (12) 0.81 (0.07) 7.3 (3.2 to 8.4) 89 13 76 0 0 0
CAPS 1062 62 (4) 1062 (100) 27 (4) 93 (10) 0.93 (0.06) 3.1 (1.8 to 3.3) 29 16 13 0 0 0
CHARL 428 71 (7) 179 (42) 27 (5) 95 (13) 0.94 (0.08) 11.8 (1.3 to 12.9) 56 28 28 2 2 0
CHS1a 3881 72 (5) 1489 (38) 26 (5) 93 (13) 0.92 (0.09) 12.1 (1.9 to 12.9) 593 213 380 368 0 368
CHS2a 480 72 (5) 181 (38) 29 (5) 99 (15) 0.94 (0.07) 9.1 (1.7 to 9.5) 56 23 33 40 0 40
COPEN 8166 58 (15) 3502 (43) 26 (4) 87 (13) 0.87 (0.10) 13.2 (2.7 to 14.9) 509 41 468 368 3 365
DRECE 497 57 (11) 222 (45) 28 (4) 95 (13) 0.92 (0.11) 1.5 (1.5 to 1.5) 0 0 0 0 0 0
EMOFRIb 360 55 (6) 176 (49) 26 (4) 91 (11) 0.90 (0.07) 6.8 (6.5 to 7.2) 2 0 2 2 0 2
EPESENCA 1001 77 (5) 333 (33) 27 (5) 93 (13) 0.88 (0.08) 4.0 (1.4 to 4.6) 45 17 28 30 1 29
FINRISK92 5276 46 (10) 2446 (46) 26 (4) 88 (13) 0.86 (0.10) 11.8 (7.1 to 11.9) 150 31 119 84 0 84
FINRISK97 6382 52 (11) 3167 (50) 27 (4) 90 (13) 0.87 (0.09) 6.8 (6.0 to 6.9) 109 34 75 75 0 75
FRAMOFF 2685 60 (9) 1183 (44) 28 (5) 99 (14) 0.94 (0.08) 5.2 (3.1 to 7.0) 51 4 47 24 0 24
GOH 634 70 (7) 305 (48) 28 (5) 99 (11) 1.03 (0.12) 3.9 (0.3 to 6.9) 0 0 0 0 0 0
GOTO13 756 54 (0) 756 (100) 25 (3) 87 (9) 0.93 (0.05) 23.5 (5.0 to 30.5) 211 2 209 0 0 0
GOTO33 729 51 (0) 729 (100) 26 (3) 95 (9) 0.93 (0.06) 12.8 (5.8 to 13.1) 27 13 14 0 0 0
GOTO43 762 50 (0) 762 (100) 26 (3) 95 (9) 0.99 (0.06) 10.0 (7.9 to 10.7) 28 1 27 9 1 8
GOTOW 1401 47 (7) 0 (0) 24 (4) 74 (9) 0.74 (0.05) 32.2 (8.7 to 32.7) 147 54 93 0 0 0
HBS 1268 60 (4) 1268 (100) 26 (3) 97 (9) 0.97 (0.06) 20.5 (6.0 to 20.5) 85 85 0 0 0 0
HISAYAMA 2515 59 (11) 1068 (42) 23 (3) 81 (9) 0.91 (0.07) 14.0 (3.2 to 14.0) 77 10 67 146 1 145
HOORN 2226 61 (7) 979 (44) 27 (4) 91 (11) 0.89 (0.09) 8.8 (3.7 to 9.9) 73 13 60 3 3 0
IKNS 1942 59 (10) 830 (43) 24 (3) 83 (9) 0.90 (0.07) 7.1 (4.1 to 14.6) 11 5 6 23 2 21
LASA 1806 69 (8) 827 (46) 27 (4) 97 (11) 0.94 (0.08) 9.9 (1.8 to 10.4) 33 0 33 0 0 0
MATISS83b 1317 61 (9) 614 (47) 29 (4) 94 (10) 0.91 (0.09) 8.7 (3.7 to 9.7) 20 3 17 13 0 13
MATISS87b 1077 58 (9) 510 (47) 29 (4) 94 (11) 0.91 (0.09) 8.5 (5.0 to 9.5) 12 5 7 4 0 4
MATISS93b 1206 49 (9) 579 (48) 28 (5) 91 (11) 0.91 (0.08) 8.3 (7.0 to 9.3) 14 3 11 1 0 1
MESA 6768 62 (10) 3190 (47) 28 (5) 98 (14) 0.93 (0.08) 4.8 (2.5 to 5.2) 83 14 69 68 0 68
MOGERAUG2 3934 53 (12) 1935 (49) 27 (4) 90 (12) 0.87 (0.08) 7.9 (2.3 to 8.4) 102 41 61 1 1 0
MOGERAUG3 3368 55 (10) 1663 (49) 28 (4) 92 (12) 0.88 (0.09) 3.0 (1.8 to 3.6) 18 7 11 2 2 0
MONFRI89b 1330 49 (8) 658 (49) 26 (4) 88 (12) 0.87 (0.09) 13.6 (6.6 to 13.7) 28 6 22 10 0 10
MONFRI94b 1291 49 (8) 627 (49) 26 (4) 90 (12) 0.88 (0.09) 8.5 (7.2 to 8.8) 11 0 11 5 0 5
MORGEN 17707 46 (9) 8046 (45) 26 (4) 88 (12) 0.86 (0.09) 10.8 (8.5 to 13.1) 77 77 0 3 3 0
MOSWEGOT 4132 47 (11) 1966 (48) 25 (4) 85 (12) 0.86 (0.09) 12.9 (7.6 to 18.6) 141 39 102 65 3 62
MRCOLD 9933 80 (4) 3747 (38) 26 (4) 90 (12) 0.88 (0.08) 8.7 (1.2 to 11.7) 1118 1118 0 52 52 0
NHANESIII 10450 53 (16) 4859 (46) 27 (6) 95 (14) 0.93 (0.09) 8.8 (4.2 to 11.7) 320 320 0 0 0 0
NSHS 1608 54 (15) 765 (48) 27 (6) 90 (15) 0.87 (0.10) 9.7 (3.7 to 10.0) 24 24 0 1 1 0
OSAKA 717 49 (7) 602 (84) 23 (3) 84 (8) 0.90 (0.05) 7.7 (3.9 to 16.8) 4 2 2 3 0 3
PREVEND 7368 50 (12) 3583 (49) 26 (4) 89 (13) 0.88 (0.09) 8.2 (6.7 to 8.9) 145 22 123 0 0 0
PRIME 9563 55 (3) 9563 (100) 27 (3) 95 (10) 0.96 (0.06) 5.2 (5.0 to 7.3) 145 17 128 33 0 33
RANCHO 1784 68 (11) 739 (41) 25 (4) 85 (12) 0.84 (0.09) 14.2 (2.0 to 18.1) 222 3 219 0 0 0
ROTT 4607 68 (8) 1752 (38) 26 (4) 90 (11) 0.90 (0.09) 11.9 (3.2 to 14.1) 235 33 202 37 37 0
SHHEC 3489 49 (11) 1625 (47) 26 (5) 86 (13) 0.85 (0.10) 10.0 (4.8 to 10.0) 119 44 75 26 0 26
SHS 4135 56 (8) 1615 (39) 31 (6) 105 (15) 0.95 (0.06) 12.4 (2.1 to 14.3) 449 147 302 8 8 0
TARFS 2559 49 (12) 1270 (50) 28 (5) 93 (12) 0.89 (0.09) 9.0 (2.0 to 10.0) 102 68 34 1 1 0
TOYAMA 4523 46 (7) 2907 (64) 23 (3) 78 (9) 0.85 (0.07) 12.7 (7.8 to 12.8) 34 1 33 24 0 24
TROMSØ 1573 60 (10) 811 (52) 26 (4) 91 (11) 0.87 (0.08) 11.1 (2.6 to 11.3) 146 18 128 78 0 78
ULSAM 962 71 (1) 962 (100) 26 (3) 94 (9) 0.94 (0.05) 12.2 (2.3 to 14.9) 137 43 94 83 0 83
WHITEII 7862 49 (6) 5414 (69) 25 (4) 85 (11) 0.87 (0.09) 7.6 (3.8 to 8.2) 167 22 145 1 1 0
WHS 24138 60 (7) 0 (0) 27 (5) 89 (14) 0.83 (0.08) 4.7 (3.0 to 5.6) 115 4 111 117 0 117
SUBTOTAL 218551 58 (9) 96391 (44) 27 (4.56) 91 (12.6) 0.90 (0.08) 7.9 (2.9 to 14.7) 7531 3047 4484 2306 138 2168
Nested case-control studies
EPICNOR 1417 66 (8) 960 (68) 27 (4) 93 (11) 0.90 (0.08) 7.1 (2.2 to 9.3) 479 224 255  -  -  -
HPFS 394 66 (8) 394 (100) 26 (4) 99 (10) 0.96 (0.06) 4.0 (0.8 to 4.0) 129 21 108  -  -  -
NHS 372 58 (6) 0 (0) 25 (4) 81 (11) 0.79 (0.07) 12.0 (5.2 to 12.0) 151 16 135  -  -  -
WHIHABPS 1200 68 (6) 0 (0) 27 (6) 86 (13) 0.82 (0.09) 6.8 (1.2 to 9.3)  -  -  - 600 4 596
SUBTOTAL 3383 64 (7) 1354 (40) 26 (4.46) 90 (11.8) 0.87 (0.08) 6.9 (1.5 to 12.0) 759 261 498 600 4 596
TOTAL 221934 58 (9) 97745 (44) 27 (4.56) 91 (12.6) 0.90 (0.08) 7.9 (2.9 to 14.7) 8290 3308 4982 2906 142 2764
Cohort studies
 
aCHS included an original cohort (here termed CHS1) and a supplemental African-American cohort (here termed CHS2), 
which were analysed separately; bProgetto CUORE was analysed as 7 different studies (ie, ATENA, EMOFRI, MATISS83, 
MATISS87, MATISS93, MONFRI89 and MONFRI94); Study acronyms are provided in Appendix 4.  
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Table 6.2 Associations of baseline values of adiposity measures with coronary heart disease 
and ischaemic stroke risk, adjusted for baseline values of potential confounders and 
intermediate risk factors 
 
RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index 1.29 (1.22 to 1.37) 65 (52 to 75) 1.11 (1.05 to 1.17) 45 (20 to 62)
Waist circumference 1.32 (1.24 to 1.40) 64 (50 to 75) 1.12 (1.06 to 1.19) 49 (25 to 65)
Waist/hip ratio 1.30 (1.22 to 1.38) 65 (51 to 75) 1.14 (1.09 to 1.18) 14 (0 to 42)
Waist/height ratio 1.34 (1.27 to 1.42) 64 (49 to 74) 1.15 (1.09 to 1.21) 43 (17 to 61)
Body-mass index 1.20 (1.12 to 1.28) 39 (0 to 64) 1.06 (0.99 to 1.13) 26 (0 to 57)
Waist circumference 1.25 (1.18 to 1.33) 21 (0 to 54) 1.11 (1.05 to 1.17) 9 (0 to 43)
Waist/hip ratio 1.25 (1.18 to 1.32) 21 (0 to 53) 1.14 (1.09 to 1.20) 0 (0 to 47)
Waist/height ratio 1.27 (1.18 to 1.35) 33 (0 to 61) 1.13 (1.05 to 1.22) 32 (0 to 61)
Coronary heart disease
(39 studies, 143710 individuals & 5259 cases)
Ischaemic stroke
(21 studies, 85169 individuals & 2431 cases)
Adjusted for age, sex and smoking Adjusted for age, sex, smoking 
and intermediate risk factors†
 
 †Intermediate risk factors were systolic blood pressure, history of diabetes, and total and HDL cholesterol. 
 
Risk ratios (RRs) are presented per 4.56 kg/m2 higher BMI, 12.6 cm higher WC, 0.083 higher WHR and 0.075 higher WHtR 
(1-SD higher baseline values). RRs were adjusted as shown, and stratified, where appropriate by sex. Analyses were 
restricted to participants with BMI values ≥20kg/m2. 
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Table 6.3 Risk ratios for coronary heart disease and ischaemic stroke per 1-SD higher 
baseline BMI, WC and WHR values, with adjustment for baseline values of potential 
intermediate risk factors 
 
Outcome / adjusted variables† Body-massindex
Waist 
circumference Waist/hip ratio
Coronary heart disease
(34 studies, 114083 participants & 4800 cases)
Adjusted for age, sex and smoking 1.28 (1.21 to 1.36) 1.30 (1.23 to 1.37) 1.30 (1.22 to 1.38)
plus intermediate risk factors 1.10 (1.05 to 1.16) 1.11 (1.06 to 1.17) 1.14 (1.10 to 1.18)
plus loge triglyceride 1.10 (1.05 to 1.15) 1.11 (1.06 to 1.16) 1.15 (1.11 to 1.19)
(21 studies, 50492 participants & 2854 cases)
Adjusted for age, sex and smoking 1.26 (1.17 to 1.35) 1.28 (1.19 to 1.38) 1.28 (1.19 to 1.37)
plus intermediate risk factors 1.10 (1.02 to 1.18) 1.11 (1.03 to 1.20) 1.12 (1.07 to 1.17)
plus loge C-reactive protein 1.04 (0.97 to 1.12) 1.05 (0.98 to 1.13) 1.08 (1.04 to 1.13)
(21 studies, 82557 participants & 3568 cases)
Adjusted for age, sex and smoking 1.25 (1.16 to 1.34) 1.26 (1.17 to 1.35) 1.27 (1.18 to 1.37)
plus intermediate risk factors 1.08 (1.01 to 1.14) 1.08 (1.02 to 1.15) 1.13 (1.09 to 1.18)
plus fibrinogen 1.06 (1.00 to 1.12) 1.06 (1.00 to 1.12) 1.13 (1.09 to 1.18)
Ischaemic stroke
(20 studies, 81017 participants & 2395 cases)
Adjusted for age, sex and smoking 1.19 (1.11 to 1.28) 1.25 (1.18 to 1.33) 1.25 (1.18 to 1.33)
plus intermediate risk factors 1.06 (0.99 to 1.13) 1.11 (1.05 to 1.17) 1.15 (1.09 to 1.21)
plus loge triglyceride 1.06 (0.99 to 1.13) 1.11 (1.05 to 1.18) 1.15 (1.09 to 1.21)
(12 studies, 30758 participants & 1656 cases)
Adjusted for age, sex and smoking 1.16 (1.08 to 1.25) 1.21 (1.13 to 1.29) 1.22 (1.13 to 1.31)
plus intermediate risk factors 1.07 (0.98 to 1.16) 1.11 (1.03 to 1.20) 1.15 (1.06 to 1.25)
plus loge C-reactive protein 1.02 (0.95 to 1.10) 1.11 (1.03 to 1.20) 1.13 (1.04 to 1.23)
(15 studies, 59328 participants & 1856 cases)
Adjusted for age, sex and smoking 1.21 (1.12 to 1.31) 1.26 (1.18 to 1.34) 1.28 (1.17 to 1.39)
plus intermediate risk factors 1.08 (1.00 to 1.16) 1.12 (1.05 to 1.18) 1.17 (1.08 to 1.25)
plus fibrinogen 1.06 (0.99 to 1.13) 1.11 (1.05 to 1.17) 1.16 (1.08 to 1.24)
RR (95% CI) 
 
 †Intermediate risk factors were systolic blood pressure, history of diabetes, and total and HDL cholesterol. 
 
Risk ratios (RRs) are presented per 4.56 kg/m2 higher BMI, 12.6 cm higher WC and 0.083 higher WHR (ie, 1-SD higher 
baseline values). Analyses are restricted to participants with BMI values ≥20 kg/m2 and complete information on age, sex, 
smoking status and intermediate risk factors plus triglyceride, CRP or fibrinogen in turn.  
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Table 6.4 Associations of usual levels of BMI, WC and WHR with coronary heart disease and 
ischaemic stroke risk, adjusted for usual levels of potential confounders and intermediate risk 
factors 
 
RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index 1.30 (1.23 to 1.38) 66 (52 to 76) 1.07 (1.02 to 1.13) 40 (12 to 59)
Waist circumference 1.32 (1.25 to 1.41) 65 (50 to 75) 1.09 (1.03 to 1.15) 45 (20 to 62)
Waist/hip ratio 1.35 (1.26 to 1.44) 58 (40 to 71) 1.12 (1.07 to 1.17) 5 (0 to 33)
Body-mass index 1.20 (1.12 to 1.28) 42 (2 to 65) 1.02 (0.96 to 1.08) 20 (0 to 53)
Waist circumference 1.26 (1.18 to 1.34) 26 (0 to 57) 1.07 (1.02 to 1.13) 3 (0 to 49)
Waist/hip ratio 1.30 (1.23 to 1.37) 2 (0 to 48) 1.13 (1.06 to 1.20) 0 (0 to 47)
Coronary heart disease
(39 studies, 143710 individuals & 5259 cases)
Ischaemic stroke
(21 studies, 85169 individuals & 2431 cases)
Adjusted for age, sex and smoking Adjusted for age, sex, smoking 
and intermediate risk factors†
 
 †Intermediate risk factors were systolic blood pressure, history of diabetes, and total and HDL cholesterol. 
 
Risk ratios (RRs) are presented per 4.36 kg/m2 higher BMI, 10.98 cm higher WC and 0.059 higher WHR (ie, 1-SD higher 
usual levels). RRs were adjusted as shown, and stratified, where appropriate, by sex. Analyses were restricted to 
participants with BMI values ≥20kg/m2. 
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Table 6.5 Age, sex and smoking status adjusted associations of baseline values of BMI, WC 
and WHR with coronary heart disease and ischemic stroke risk, under various exclusion 
circumstances 
 
Adiposity measure
RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index 1.31 (1.23 to 1.39) 59 (40 to 71) 1.24 (1.13 to 1.35) 40 (0 to 66)
Waist circumference 1.36 (1.28 to 1.45) 56 (36 to 70) 1.27 (1.16 to 1.39) 42 (0 to 67)
Waist/hip ratio 1.31 (1.23 to 1.38) 51 (27 to 66) 1.24 (1.15 to 1.35) 36 (0 to 64)
Adiposity measure
RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index 1.23 (1.16 to 1.29) 60 (44 to 71) 1.21 (1.13 to 1.30) 41 (0 to 65)
Waist circumference 1.27 (1.20 to 1.34) 62 (47 to 72) 1.24 (1.17 to 1.32) 22 (0 to 54)
Waist/hip ratio 1.24 (1.17 to 1.32) 22 (0 to 54) 1.23 (1.15 to 1.31) 21 (0 to 54)
Adiposity measure
RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index 1.30 (1.23 to 1.37) 64 (51 to 74) 1.21 (1.13 to 1.29) 32 (0 to 60)
Waist circumference 1.29 (1.22 to 1.36) 64 (50 to 73) 1.25 (1.17 to 1.33) 35 (0 to 62)
Waist/hip ratio 1.33 (1.26 to 1.40) 65 (52 to 74) 1.26 (1.18 to 1.34) 24 (0 to 55)
Adiposity measure
RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index 1.27 (1.21 to 1.34) 69 (59 to 77) 1.20 (1.13 to 1.29) 41 (3 to 64)
Waist circumference 1.30 (1.23 to 1.37) 67 (55 to 75) 1.25 (1.18 to 1.33) 32 (0 to 59)
Waist/hip ratio 1.29 (1.23 to 1.36) 65 (52 to 74) 1.25 (1.18 to 1.33) 27 (0 to 56)
Coronary heart disease
(47 studies, 178300 individuals & 7391 cases)
Ischaemic stroke
(21 studies, 92594 individuals & 1985 cases)
D Excluding studies involving self-reported anthropometric 
measurements
C Excluding known participants of non-European descent
Coronary heart disease
(47 studies, 178532 individuals & 6752 cases)
Ischaemic stroke
(21 studies, 104996 individuals & 2130 cases)
Coronary heart disease
(45 studies, 147963 individuals & 5561 cases)
Ischaemic stroke
(18 studies, 63356 individuals & 1479 cases)
Ischaemic stroke
(23 studies, 98973 individuals & 2524 cases)
B Excluding smokers
A Excluding data from first 5 years of follow-up
Coronary heart disease
(36 studies, 123685 individuals & 4028 cases)
 
Risk ratios (RRs) are presented per 4.56 kg/m2 higher BMI, 12.6 cm higher WC and 0.08 higher WHR (ie, 1-SD higher 
baseline values). RRs were adjusted for age at baseline and smoking status and stratified, where appropriate, by sex. All 
analyses were restricted to participants with BMI values ≥20 kg/m2.  
 180
Table 6.6 Associations of baseline values of BMI, WC and WHR with coronary heart disease 
and ischaemic stroke risk, adjusted for baseline values of adiposity measures 
 
1-SD
Adiposity measure RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index* 4.56 1.27 (1.21 to 1.34) 67 (56 to 76) 1.06 (0.99 to 1.13) 37 (11 to 55)
Waist circumference 12.6 1.31 (1.24 to 1.37) 65 (53 to 74) 1.23 (1.15 to 1.32) 33 (6 to 53)
Hip circumference 9.44 1.16 (1.11 to 1.21) 47 (26 to 62) 0.87 (0.82 to 0.93) 28 (0 to 49)
Waist/hip ratio 0.08 1.29 (1.23 to 1.35) 3 (50 to 73) 1.21 (1.16 to 1.26) 37 (12 to 55)
Adiposity measure 1-SD RR (95%CI) I2 (95% CI) RR (95%CI) I2 (95% CI)
Body-mass index† 4.56 1.21 (1.13 to 1.29) 44 (10 to 65) 1.00 (0.92 to 1.08) 0 (0 to 44)
Waist circumference 12.6 1.26 (1.19 to 1.33) 31 (0 to 58) 1.26 (1.16 to 1.36) 0 (0 to 44)
Hip circumference 9.44 1.13 (1.07 to 1.20) 31 (0 to 58) 0.91 (0.84 to 0.98) 0 (0 to 44)
Waist/hip ratio 0.08 1.25 (1.19 to 1.32) 20 (0 to 51) 1.18 (1.13 to 1.24) 0 (0 to 44)
Coronary heart disease
(51 studies & 7750 cases) Adjusted for age, sex and smoking
Adjusted for age, sex, smoking 
and BMI (or WC for association with 
BMI)
Ischaemic stroke
(25 studies & 2661 cases) Adjusted for age, sex and smoking
Adjusted for age, sex, smoking 
and BMI (or WC for association with 
BMI)
 
 
*Associations with BMI were adjusted for WC. RR = 1.18 (1.13 to 1.24) after adjustment for age, sex, smoking and WHR. 
†Associations with BMI were adjusted for WC. RR = 1.13 (1.07 to 1.20) after adjustment for age, sex, smoking and WHR. 
 
Risk ratios (RRs) are presented per 1-SD higher baseline values of adiposity measures. RRs were adjusted as shown, and 
stratified, where appropriate, by sex. Analyses were restricted to participants with BMI values ≥20kg/m2. 
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Figure 6.1 Risk ratios for coronary heart disease and ischaemic stroke across quantiles of 
baseline BMI, WC and WHR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression analyses were stratified, where appropriate, by sex. Values with further adjustments were adjusted for age, 
smoking status, systolic blood pressure, history of diabetes and total and HDL cholesterol. Referent groups are the second 
deciles in the plots for coronary heart disease and the first quintiles in the plots for ischaemic stroke. 
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Figure 6.2 Risk ratios for coronary heart disease by clinically defined categories of baseline 
BMI and WC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis was based on 214,169 participants (involving 8097 cases) from 52 studies. Risk ratios were adjusted for age and 
smoking status, and stratified, where appropriate, by sex. High WC was defined as WC >102 cm in men and WC >88 cm in 
women. 
 
 
 
0.8 1 2 4
Risk ratio (95% CI)
<18.5 kg/m2 1232601 (1.2%) 1.70 (1.42 to 2.05)
18.5-24.9 kg/m2 260885116 (39.7%) 1.00 (0.91 to 1.10)
25.0-29.9 kg/m2 & normal WC 223356224 (26.3%) 1.25 (1.18 to 1.33)
25.0-29.9 kg/m2 & high WC 129528773 (13.4%) 1.46 (1.33 to 1.61)
30.0-34.9 kg/m2 & normal WC 1553894 (1.8%) 1.77 (1.51 to 2.09)
30.0-34.9 kg/m2 & high WC 121226186 (12.2%) 1.82 (1.71 to 1.95)
35.0-39.9 kg/m2 3348164 (3.8%) 2.21 (1.93 to 2.54)
≥40 kg/m2 1373211 (1.5%) 2.98 (2.47 to 3.60)
Classification of overweight by
BMI and WC
Number of
cases
Number of 
Participants (%)
RR (95%)
 183
Figure 6.3 Study-specific risk ratios for coronary heart disease per 1-SD higher baseline BMI, WC and WHR, adjusted for age, sex 
and smoking status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were restricted to participants with BMI values ≥20 kg/m2 and complete information on age, sex, smoking status, history of diabetes, systolic blood pressure, and total 
and HDL cholesterol. In the BMI analysis, after excluding the 6 most discrepant studies (CHARL, MATISS87, NHANESIII, MORGEN, TOYOMA, WHITEII) the risk ratio was 
1.26 (95% CI 1.20-1.33) and the I2 was reduced to 45% (95% CI 17% to 64%). In the WC analysis, after excluding the 6 most discrepant studies (CHARL, NHANESIII, ROTT, 
ATENA, GOTO43, MORGEN) the risk ratio was 1.31 (95% CI 1.25-1.38) and the I2 was reduced to 40% (95% CI 9% to 61%). In the waist/hip ratio analysis, after excluding the 
6 most discrepant studies (MATISS83, MATISS87, ROTT, GOTO43, MATISS93, MORGEN) the risk ratio was 1.30 (95% CI 1.22-1.37) and the I2 was reduced to 61% (95% CI 
43% to 73%). 
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Figure 6.4 Funnel plots assessing potential bias from small-study effects in the meta-analysis of adiposity measures with coronary 
heart disease risk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were restricted to participants with BMI values ≥20 kg/m2 and complete information on age, sex, smoking status, history of diabetes, systolic blood pressure, and total 
and HDL cholesterol.  
 
There was no evidence of bias from small-study effects for BMI (p = 0.123), waist circumference (p = 0.211) and waist/hip ratio (p = 0.414) using Egger’s test from small-study 
effects. 
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Figure 6.5 Risk ratios for coronary heart disease and ischaemic stroke per 1-SD higher 
baseline BMI, WC and WHR, according age, sex and BMI at baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk ratios (RRs) are presented per 4.56 kg/m2 higher BMI, 12.6 cm higher WC and 0.083 higher WHR (ie, 1-SD higher 
baseline values). Study-specific risk ratios were adjusted for age at baseline and smoking status, and stratified, where 
appropriate, by sex. Analyses were restricted to participants with BMI values ≥20 kg/m2.  
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Figure 6.6 Risk ratios for coronary heart disease and ischaemic stroke across quintiles of 
baseline BMI, WC and WHR, among men and women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were restricted to studies with data on both males and females. Regression analyses were adjusted for age and 
smoking status. Referent groups are the first quintile in women in the plots. 
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Figure 6.7 Risk ratios for coronary heart disease per 1-SD higher baseline BMI, WC and WHR, according to several individual and 
study level characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study-specific risk ratios were adjusted for age and smoking status, and stratified, where appropriate, by sex. Analyses were restricted to participant with BMI values ≥20 kg/m2. 
Abbreviation: NA = not applicable.  
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Bottom third 1213 1.24 (1.15, 1.35) p=0.486 1.28 (1.17, 1.39) 1.31 (1.21, 1.43)
Middle third 1828 1.25 (1.17, 1.35) 1.32 (1.21, 1.42) 1.29 (1.20, 1.38)
Top third 2640 1.25 (1.17, 1.34) 1.25 (1.17, 1.33) 1.22 (1.14, 1.30)
p=0.265 p=0.054
HDL-C (mmol/l)
Bottom third 2756 1.20 (1.12, 1.29) p=0.073 1.21 (1.13, 1.30) 1.23 (1.15, 1.31)
Middle third 1754 1.19 (1.13, 1.25) 1.22 (1.14, 1.29) 1.24 (1.16, 1.34)
Top third 1174 1.32 (1.20, 1.45) 1.35 (1.24, 1.46) 1.31 (1.21, 1.43)
p=0.043 p=0.405
Loge triglyceride
Bottom third 1256 1.24 (1.14, 1.35) p=0.644 1.29 (1.19, 1.40) 1.32 (1.24, 1.40)
Middle third 1831 1.23 (1.14, 1.33) 1.24 (1.18, 1.30) 1.26 (1.19, 1.33)
Top third 2360 1.20 (1.14, 1.26) 1.19 (1.14, 1.26) 1.19 (1.12, 1.27)
p=0.130 p=0.001
Ethnicity
Non-white 995 1.23 (1.10, 1.39) p=0.267 1.33 (1.17, 1.51) 1.42 (1.17, 1.73)
White 3690 1.30 (1.22, 1.39) 1.35 (1.27, 1.44) 1.32 (1.23, 1.42)
p=0.746 p=0.418
Geographical region
Western Europe 4565 1.32 (1.23, 1.42) p<0.001 1.34 (1.25, 1.44) 1.30 (1.22, 1.38)
North America 2938 1.16 (1.08, 1.24) 1.24 (1.14, 1.34) 1.27 (1.15, 1.40)
Australasia 247 1.45 (1.26, 1.66) 1.38 (1.18, 1.60) 1.20 (1.03, 1.40)
p=0.065 p=0.622
Adiposity assessment
Assessed 7391 1.27 (1.21, 1.34) p=0.610 1.30 (1.23, 1.37) 1.29 (1.23, 1.36)
Self-reported 359 1.26 (1.12, 1.43) 1.38 (1.19, 1.59) 1.25 (1.04, 1.50)
p=0.206 p=0.731
Waist circumference assessment
Midway bet. lower rib margin and iliac crest 1.31 (1.21, 1.42) 1.29 (1.20, 1.38)3731 NA
1.29 (1.18, 1.40) 1.31 (1.18, 1.44)Umbilical level 2534
1.38 (1.19, 1.59) 1.25 (1.04, 1.50)Self-reported 359
1013 1.25 (1.00, 1.57) 1.29 (1.07, 1.55)Other
p=0.448 p=0.980
Interaction
p-value
BMI Waist circumference Waist/hip ratio
Loge CRP
Bottom third 729 1.24 (1.12, 1.38) p=0.341 1.20 (1.09, 1.32) 1.20 (1.11, 1.31)p=0.236 p=0.618
Middle third 979 1.14 (1.03, 1.27) 1.16 (1.07, 1.26) 1.19 (1.11, 1.28)
Top third 1393 1.15 (1.05, 1.25) 1.21 (1.12, 1.30)1.19 (1.10, 1.29)
1.0 1.2 1.4 1.6 1.0 1.2 1.4 1.6 1.0 1.2 1.4 1.6
RR (95% CI) per 4.56 kg/m2
higher baseline BMI levels
RR (95% CI) per 12.6 higher 
baseline waist circumference levels
RR (95% CI) per 0.083 higher
baseline waist/hip ratio levels
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Figure 6.8 Risk ratios for coronary heart disease across thirds of WC and WHR by baseline 
values of triglyceride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis was based on 141,203 participants (involving 5684 cases) from 41 studies. Regression analyses were adjusted for 
age at baseline and smoking status, and stratified, where appropriate, by sex. Referent groups are the lowest third of WC or 
WHR in the lower level of triglyceride.  
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Figure 6.9 Risk ratios for coronary heart disease across thirds of WC and WHR, stratified by 
thirds of BMI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis was based on 203,388 participants (involving 7750 cases) from 51 studies. Analyses were restricted to participants 
with BMI values ≥20kg/m2. Risk ratios were adjusted for age at baseline and smoking status, and stratified, where 
appropriate, by sex. Reference groups are the lowest third of waist circumference or waist-to-hip ratio in the bottom third of 
BMI. Similar findings were observed with BMI categories were <25, 25-29.9 and ≥30 kg/m2 using the full range of BMI 
values.  
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CHAPTER 7: Adiposity measures in cardiovascular disease risk prediction 
 
Summary 
Findings from a previous systematic review of 27 guideline statements showed substantial 
variation in recommendations about the value of inclusion of clinical measures of adiposity in 
risk scores for the primary prevention of cardiovascular disease in developed countries. 
Furthermore, a relatively small study suggested replacing assessment of lipid measures with 
that of adiposity measures in resource-limited settings where cholesterol testing is not feasible 
for cardiovascular disease risk assessment. This chapter reports on the incremental predictive 
ability of adiposity measures, assessed singly or in combination, under a wide range of 
circumstances in 144,795 healthy participants from the Emerging Risk Factors Collaboration. 
Additional information on body-mass index (BMI), waist circumference, and waist-to-hip ratio 
(WHR) to a cardiovascular disease risk prediction model containing conventional risk factors 
did not importantly improve risk discrimination, nor classification of participants to risk 
categories of predicted 10-year risk. Regarding the replacement of lipids with adiposity 
measures, the current data has shown that a combination of BMI and WHR provides only 
about one-quarter of the predictive information provided by total and high-density lipoprotein 
cholesterol combined. These findings indicates that for population-wide assessment of 
cardiovascular disease risk, simple adiposity measures provide little or no additional 
information about cardiovascular disease risk prediction given knowledge about risk factors 
used in standard risk scores. They also highlight the desirability of supporting the development 
of lipid assessment in resource-limited settings. 
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Background 
For the prevention of cardiovascular disease, clinicians depend on risk scores that correctly 
and easily identify patients at high risk of cardiovascular disease, so that they can provide 
targeted preventative interventions.1-3 Over the past three decades, many cardiovascular 
disease risk prediction models have been proposed, each including different risk factors.4 
While analyses of the type presented in Chapters 5 and 6 involving measures of associations 
(such as relative risks) are informative for aetiological purposes, they do not directly assess the 
ability of a risk marker for cardiovascular disease risk prediction.5-8 Therefore, specific 
measures (eg, measures of risk discrimination and reclassification) have been developed to 
assess the predictive accuracy of a risk maker.1  
 
National and international guideline statements have provided differing recommendations 
about the value of assessment of clinical measures of adiposity for cardiovascular risk 
prediction in primary prevention.4 Recommendations range from omission of adiposity 
measures to their inclusion as additional screening tests to their formal inclusion as risk factors 
in prediction models. For example, whereas the World Health Organization9 and the US 
National Heart, Lung and Blood Institute10 recommend body-mass index (BMI) measurement 
as well as assessment of waist circumference (WC) in people with a BMI between 25.0 and 
34.9 kg/m2, several commonly-used cardiovascular disease risk scores omit adiposity 
measures (eg, Framingham11, PROCAM12, SCORE13, ASSIGN14 or Reynolds15), but others 
include BMI (eg, QRISK16) (Table 7.1). Furthermore, some data suggest that BMI can serve as 
a simple alternative in settings where cholesterol testing is not feasible for cardiovascular 
disease risk assessment.17 This suggestion, however, requires larger-scale evaluation, with 
inclusion of measures of abdominal adiposity. 
 
This divergence in guideline recommendations noted above may reflect, in part, uncertainties 
in relation to data from previous studies. As described in Chapter 1 on pages 10-13, previous 
prospective studies with assessment of BMI, WC and waist-to-hip ratio (WHR) in the same 
people have reported inconsistent findings regarding the relative importance of overall and 
abdominal adiposity to the risk of cardiovascular disease.18-41 Furthermore, prospective studies 
of adiposity have often lacked concomitant measurement of lipids and other conventional risk 
factors. This feature has made it difficult for such studies to evaluate adiposity measures in the 
context of standard risk prediction scores.26,42 Furthermore, because studies have often 
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reported on measures of association rather than on specific measures of predictive ability, they 
may not have been able to make an optimum assessment of predictive ability.7,8 
 
The objective of this chapter is to quantify the incremental gain in predictive ability that can be 
attributed to addition of BMI, WC and WHR, singly or in combination, to cardiovascular risk 
prediction models under a wide range of circumstances, using data from the Emerging Risk 
Factors Collaboration (ERFC).43 
 
Methods 
Study design 
Details of data on adiposity measures in the ERFC are given in Chapter 2. The current 
analysis involved individual records from 144,795 participants in 39 prospective cohort studies 
with the following features: (1) participants were not selected on the basis of having previous 
cardiovascular disease; (2) participants had BMI values of 20 kg/m2 or higher; (3) concomitant 
information was provided at baseline on weight, height, waist and hip circumference, smoking 
status, systolic blood pressure (SBP), history of diabetes, and total and high-density lipoprotein 
(HDL) cholesterol; (4) individual studies recorded at least ten cardiovascular outcomes; and (5) 
at least 1 year of follow-up had been accrued.  
 
Analyses involved participants with baseline BMI, WC and WHR plus conventional risk factors 
(ie, smoking status, SBP, history of diabetes, and total and HDL cholesterol). The study 
outcome was cardiovascular disease, defined as first-ever myocardial infarction or coronary 
death or any cerebrovascular disease event.  
 
Risk prediction model 
The risk prediction models were based on a Cox proportional regression model stratified by 
study and sex (ie, allowing for separate baseline hazards by study and sex), but common 
coefficients (ie, loge hazard ratios) across studies.44 For each stratum Kk K1=  (ie, distinct 
combinations of study and sex), with kni K1=  individuals in stratum K, and baseline 
covariates iX , the probability of surviving without a cardiovascular disease event to at least 
time t years after baseline is given by 
 
 
 
(7.1),)()|( )exp(0 iXkiki tSXtS β=
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where )(0 tS k  is the baseline survival at time t. The probability of a cardiovascular event within t 
years is given by 
 
 
 
Deaths from non-cardiovascular causes were censored. Parallel analyses involved multivariate 
random effects meta-analyses, allowing for between-study heterogeneity. The random effects 
model yielded similar point estimates for β  but with wider confidence intervals. Since only the 
point estimates were necessary for making the absolute risk predictions and calculating 
measures of discrimination, the simpler stratified Cox proportional regression model was used 
for derivation of the risk prediction model. The models were fitted to data from all participants 
and then the predictive ability was assessed using measures of discrimination and 
reclassification. 
 
Measures of discrimination 
Discrimination refers to the ability of a risk prediction model to separate those who do and do 
not have the disease of interest.7 Discrimination was assessed using Harrell’s C-index for 
censored time-to-event data.45,46 The C-index is the probability, that for a randomly selected 
pair of participants, the individual who develops cardiovascular disease first has the higher 
value of the linear predictor iXβ  (ie, the worse prognosis).46 A C-index of 0.5 indicates that the 
model has no discriminatory power (ie, the model does no better than chance alone), while a 
value of 1 implies perfect discrimination. It is estimated by examining within each stratum all 
possible pairs of participants for which the participant who has the shorter participation time 
fails. It classifies each pair as concordant (ie, matching in rank according to the magnitude of 
the linear predictor and the order of failure), discordant (ie, opposite in such ranking), or 
undecided (ie, tied in either category). The overall measures is given by 
 
 
 
where cn , dn  and un  are the number of concordant, discordant and undecided pairs, 
respectively.  
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To deal with the multi-study structure of the data, the overall C-index was calculated in two 
stages, with estimation within each study separately before pooling results to obtain an overall 
average estimate. Within each study, pair-wise comparisons were constrained to allow only 
pairing of participants within the same strata (ie, concordance/discordance counts did not 
include comparison of males to females). So, for each study Ss K,1= , the C-index sθˆ  with 
variance 2
ˆsθσ
)
 was calculated, the variance being estimated using an efficient jackknife 
approach for rank statistics.47  
 
Subsequently, the C-indices and corresponding variances were combined across studies using 
a weighted average: 
 
 
where sw  is the study-specific weight (ie, weighted according to the number of cardiovascular 
events in each study). Alternative weights were considered, including inverse-variance weights 
in fixed and random effects meta-analysis models.48 However, weighting by the number of 
events in a study was considered the most appropriate, as it best matches the weighting 
applied across studies in the derivation of the original stratified Cox proportional regression 
model described in (7.1). As described in detail in Chapter 5, the extent of heterogeneity 
between studies was indicated by the I2 statistic.49,50  
 
To investigate the change in C-index on addition of a new risk factor, two risk prediction 
models were fitted, one model with the core risk factors only (eg, age, sex, smoking status, 
blood pressure, history of diabetes and lipids), and the second model with the core risk factors 
plus the new risk factor (eg, BMI). The C-index sθˆ  for both models, their difference s∆ˆ , and 
corresponding jackknife standard errors47 were calculated within each study. The study-
specific C-index changes and the corresponding variances were then combined using models 
described in (7.4; 7.5), replacing θ  with ∆ . Between-study heterogeneity in C-index changes 
were quantified by the I2 statistic.49,50 
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Risk reclassification 
Risk reclassification was assessed by comparing the predicted 10-year cardiovascular disease 
risk from the model containing conventional risk factors to the predicted risk from models that 
contained also – either assessed separately or combined – BMI, WC and WHR. The 10-year 
risk predictions were calculated using model (7.2). Participants were placed into standard 10-
year risk categories (0% to <5%, 5% to <10%, 10% to <20% and ≥20%) based on the Third 
Adult Treatment Panel of the National Cholesterol Education Program (NCEP ATP-III) 
guidelines,51 and movement between risk categories on addition of adiposity measures was 
quantified by the Net Reclassification Improvement52 (NRI) that summarises whether 
movement between risk categories is in the correct direction. The reclassification of individuals 
was deemed appropriate for cardiovascular disease cases occurring before 10 years moving 
up the risk categories, and for event free individuals at 10 years moving down the risk 
categories on addition of adiposity measures. The NRI and the corresponding standard error 
are given by 
 
where eventsup,pˆ  and eventsdown,pˆ  are probabilities of moving up or down a category among 
events calculated as )events#events(# ↑  and )events#events#( ↓  and likewise for 
noneventsup,pˆ  and noneventsdown,pˆ  among non-events. 
 
Because risk categories are inherently arbitrary, the Integrated Discrimination Improvement52 
(IDI) was also used, which estimates the average absolute improvement in predicted risk 
between different models. The IDI can be estimated as 
 
where eventsnew,pˆ  and eventsold,pˆ  are the average estimated 10-year risks among events 
according to the new and the old model, respectively, and similarly for noneventsnew,pˆ  and 
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The standard error of the IDI is given by 
 
 
 
where eventsse  and noneventsse  are the standard errors of the paired differences between new 
and old model-based predicted probabilities across all events and non-events, respectively.  
 
In order to calculate 10-year risk predictions, studies with less than 10 year of follow-up and 
participants who were censored before 10 years were not able to contribute to the 
reclassification analyses, while individuals whose cardiovascular events occurred after 10 
years were considered as non-cases.  
 
All analyses were performed using Stata release 11 (StataCorp LP, College Station, Texas 
USA). 
 
Results 
Information on age, sex, weight, height, waist and hip circumference, smoking status, SBP, 
history of diabetes, total and HDL cholesterol was available in 144,795 participants from 39 
cohorts, yielding 8,347 first-onset cardiovascular disease outcomes (4,839 coronary heart 
disease and 3,508 cerebrovascular outcomes) during 1.3 million person-years at risk (median, 
5.7 [IQR 3.0-9.0] years to first outcome). The baseline characteristics of the 144,795 
participants were broadly similar to those participants from the larger dataset with information 
on age, sex, weight, height, and waist and hip circumference only (Chapter 2). Table 7.2 
shows adjusted hazard ratios for cardiovascular disease with baseline values of BMI, WC, 
WHR, total and HDL cholesterol and other conventional risk factors. In models with 
conventional risk factors plus one measure of adiposity, hazard ratios of adiposity measure 
were 1.07 (95% confidence interval [CI] 1.03-1.11) for BMI, 1.10 (95% CI 1.06-1.15) for WC 
and 1.12 (95% CI 1.08-1.15) for WHR. In models including conventional risk factors plus two 
adiposity measures (ie, BMI plus either WC or WHR), hazard ratios were, respectively, 0.97 
(95% CI 0.92-1.02) and 1.13 (95% CI 1.07-1.20) for BMI and WC, and 1.04 (95% CI 1.00-1.08) 
and 1.11 (95% CI 1.07-1.14) for BMI and WHR.  
 
(7.9),)se()se( 2nonevents2events +
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Addition of adiposity measures to age and sex only 
Compared to a risk prediction model containing age and sex only, addition of adiposity 
measures, whether assessed singly or in combination, achieved modest increases in C-index 
(Figure 7.1). The C-index increases with additional information of adiposity measures were 
0.0051 (95% CI 0.0031-0.0072) with BMI, 0.0077 (95% CI 0.053-0.0100) with WC and 0.0102 
(95% CI 0.0080-0.0125) with WHR. This translates, for example on addition of WHR to correct 
prediction of the order of cardiovascular disease events in an extra 102 pairs out of 10,000 
pairs of participants screened (6,843 as opposed to 6,741 pairs per 10,000). By contrast, 
addition of conventional risk factors (ie, smoking status, SBP, history of diabetes, and total and 
HDL cholesterol) improved risk prediction more substantially, giving an increase in the C-index 
about five times greater than that seen on addition BMI and WHR together (0.0584 versus 
0.0108). Compared to a risk prediction model containing age, sex and BMI, addition of WC or 
WHR significantly improved risk discrimination (p<0.001 for both). Broadly similar findings to 
those reported above were observed in analyses that used 10-year risk reclassification metrics 
(Table 7.3). 
 
Replacement of total and HDL cholesterol with adiposity measures 
When information on adiposity measures was added to a risk prediction containing non-lipid 
variables (ie, age, sex, smoking, systolic blood pressure and history of diabetes), WC and 
WHR significantly improved risk discrimination, however, less than did total and HDL 
cholesterol combined (Figure 7.2). For example, the incremental gain in predictive value 
provided by a combination of BMI and WHR was about one-quarter of the predictive gain 
provided by total and HDL cholesterol (C-index change of 0.0022 versus 0.0087). Additional 
information on BMI, WC or WHR, however, did not significantly change cardiovascular disease 
reclassification of participants to 10-year predicted risk categories (net reclassification 
improvement [NRI] of 0.17% [95% CI -0.57% to 0.91%], 0.13% [95% CI -0.71% to 0.97%], 
0.52% [95% CI -0.33% to 1.38%], respectively), whereas total and HDL cholesterol combined 
did (NRI of 2.83 [95% CI 1.56% to 4.11%]; Table 7.4). Assessment of combinations of 
adiposity measures revealed no important improvement in risk discrimination (Figure 7.2) or 
reclassification (Table 7.4). Qualitatively similar results to those for risk discrimination were 
observed in analyses that assessed integrated discrimination improvement (Table 7.4). 
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Addition of adiposity measures to conventional risk factors 
When information on lipids and other conventional risk factors was available, additional 
information on BMI, WC or WHR did not importantly change cardiovascular disease risk 
discrimination (C-index changes of -0.0001, -0.0001 and 0.0008, respectively; Table 7.5) nor 
reclassification of participants to 10-year predicted risk categories (NRIs of -0.19%, -0.05% and 
-0.05%, respectively; Tables 7.5-7.6). To assess any incremental gain in predictive ability 
provided by adiposity measures irrespective of the sequence of their addition to a risk model, 
the effect of one-at-a-time omission of each risk factor was assessed from a full model. The 
impact of omission of BMI and WC was nearly zero and that for WHR was small (Figure 7.3). 
This result applied in analyses that either included or omitted people with diabetes at baseline 
(Figure 7.4) and for a wide range of other circumstances (Figure 7.5). It was not possible to 
assess risk prediction at different ages because studies differed considerably in age 
distributions. Qualitatively similar results to those noted above were observed in analyses that 
assessed integrated discrimination improvement (Table 7.5). Whereas there was considerable 
between-study heterogeneity in the absolute values of the C-index (mainly reflecting the 
differing age distributions of contributing studies; Figure 7.6), there was only little between-
study heterogeneity in C-index changes (Figure 7.7).  
 
Discussion 
In high-income countries, the common situation is for individuals to have information available 
on several conventional risk factors, including lipids. In this situation, the current analysis of 
individual data from a total of 144,795 people without a history of cardiovascular disease in 39 
prospective cohort studies has shown that BMI, WC and WHR, assessed singly or in 
combination, do not importantly improve prediction of cardiovascular disease risk when 
additional information is available on blood pressure, history of diabetes and cholesterol 
measures. This is because much of the association between adiposity and cardiovascular 
disease is explained by these intermediate risk factors. This main finding does not, of course, 
diminish the importance of adiposity as a major modifiable determinant of cardiovascular 
disease. Because excess adiposity is major determinant of the intermediate risk factors, the 
findings in Chapter 5 have underscored the importance of controlling adiposity to help prevent 
cardiovascular disease, as well as the relevance of controlling these intermediate risk factors to 
combat the detrimental vascular effects of overweight and obesity.53 However, the findings of 
the current analysis indicate that for population-wide assessment of cardiovascular disease 
risk, simple adiposity measures provide little or no additional information about cardiovascular 
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disease risk prediction given knowledge about risk factors used in standard risk scores. Even 
so, there could be other reasons to include adiposity measures in risk assessment (such as 
promotion of behaviour change54 or improvement of risk communication).  
 
Previous smaller studies (and World Health Organization guidelines) have suggested that for 
situations in which there is no information on lipids for cardiovascular disease risk prediction 
(such as in resource-limited settings, where lipid measurement is not possible, too expensive, 
or inconvenient) assessment of simple adiposity measures can be used instead, with only a 
modest loss of predictive ability.55-57 However, data from the current analysis indicate that a 
combination of BMI and WHR provides only about one-quarter of the predictive information 
provided by total and HDL cholesterol. This gain in assessment is equivalent to correct 
prediction of the order of cardiovascular disease outcomes in an extra 65 pairs out of 10,000 
pairs of participants screened. This finding highlights, therefore, the desirability of supporting 
the development of lipid assessment in resource-poor settings in parallel with implementing 
interim strategies that dispense with this need. 
 
The current analysis also assessed the predictive ability of adiposity measures for assessment 
of adiposity related cardiovascular disease risk, ignoring intermediate risk factors on the 
pathway between adiposity and cardiovascular disease. The findings indicate that adiposity 
measures significantly improve risk discrimination and risk reclassification (except the NRI for 
BMI) when taking into account information on age and sex only. However, the gain in risk 
discrimination is more than five times smaller than that achieved by measurement of 
intermediate risk factors (ie, SBP, history of diabetes and lipids) and smoking status. The 
analyses have also shown that WC and WHR further significantly improve risk discrimination in 
models including additionally BMI. Consistent with the findings from the European Prospective 
Investigation into Cancer26 (EPIC), the current data suggest measurement of WC or WHR in 
addition of BMI for assessment of adiposity related cardiovascular disease risk. 
 
The strength and potential limitations of the available data merit consideration. Compared to 
previous reports investigating the predictive ability of adiposity measures,19,26,58-60 the current 
analysis had concomitant information on BMI, WC, WHR, lipids and other conventional risk 
factors and/or included several times more incident first-onset cardiovascular disease 
outcomes. Whereas previous analyses have often reported only on measures of association, 
the current analysis considered several measures of risk reclassification and discrimination, 
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and found broadly concordant results among them. Discrimination was assessed using the C-
index, which acknowledges time-to-event data and makes allowance for censoring (in contrast 
to reclassification methods). However, this measure has been criticised of being insensitive to 
modest but potentially important improvements in predicted risk that fail to alter the ranking of 
predicted survival probabilities.7 Furthermore, because the probability of correct ordering of 
risks may not be of great clinical relevance, some researchers consider the C-index 
inappropriate for the evaluation of risk markers.61 The current analysis included reclassification 
analyses, which examine movement of participants between clinically relevant risk categories, 
upon addition of a new marker of interest to a risk model containing (conventional) risk 
factors.15 Although reclassification metric are clinically more intuitive than discrimination 
methods, they are sensitive to the landmark time, number of risk categories, as well as choice 
of risk categories.62 The current analysis quantified the incremental gain of adiposity measures 
in context of several conventional risk factors, as well as irrespective of the sequence of 
addition of risk factors to the model. Adiposity measures contributed relatively little to the 
heterogeneity in the results observed, which was mostly due to the differing age ranges across 
cohorts. The data showed that adiposity measures provide less predictive information than 
total and HDL cholesterol combined. Because this finding is based on data from adults from 
mostly European ancestry living in high-income countries, further study is needed in resource-
limited settings.  
 
Conclusions 
Whether assessed singly or in combination, BMI, WC and WHR do not importantly improve 
cardiovascular disease risk prediction in Western people when additional information exists on 
blood pressure, history of diabetes and cholesterol measures. Because a combination of BMI 
and WHR provides only about one-quarter of the predictive information provided by total and 
HDL cholesterol, the development of lipid assessment should be supported in resource-poor 
settings. 
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Table 7.1 Comparison of some features of commonly-used cardiovascular risk scores 
 
PROCAM SCORE Reynolds ASSIGN QRISK2 Framingham
2002 2003 2007 (Women),
2008 (Men)
2007 2008 2008
Derivation dataset
Location Germany Europe US Scotland England & Wales US
No of cohorts/centres 1 cohort 12 cohorts 2 controlled trials 1 cohort 531 centres 2 cohorts
Age range 20-75 40-65 45-80 30-74 35-75 30-74
Age, sex, smoking 
& blood pressure      
Ethnicity 
Family history of CVD   
History of diabetes     
Rheumatoid arthritis 
Chronic renal disease 
Atrial fibrillation 
Socioeconomic status  
hsCRP 
History of premature MI 
(parent<age 60)

HbA1c if diabetic 
BMI 
Total cholesterol   
HDL-cholesterol    
LDL-cholesterol 
Total / HDL cholesterol ratio  
Triglyceride 
Antihypertensive  
Fatal / non-fatal  MI Fatal CVD Fatal / non-fatal  CVD Fatal / non-fatal  CVD Fatal / non-fatal  CVD Fatal / non-fatal  CVD
Population source
Interview based
General
(random)
13297
(6540 men, 
6757 women)
Industrial employees
(volunteer, not random)
26975
(18460 men,
 8515 women)
Age range
Marker currently used
General
(mostly random)
No of participants
Physical measurements
Lipid measurements
Current treatment
Outcome definition
General
(volunteer, random)
GP
(not random)
Health service employees
(volunteer, not random)
205178
(117098 men, 
88080 women)
8491
(3969 men, 
4522 women)
35282
(10724 men, 
24558 women; )
2.3 M
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Table 7.2 Summary of available data and hazard ratios for cardiovascular disease with baseline values of risk factors 
 
Mean (SD) or
No (%) BMI
HR (95% CI)† HR (95% CI)† HR (95% CI)‡ HR (95% CI)† HR (95% CI)‡
Males NA* NA* NA* NA* NA*
Age at survey (years) 57.29 (9.20) 1.99 (1.87, 2.12) 1.98 (1.86, 2.11) 1.97 (1.85, 2.09) 1.96 (1.84, 2.08) 1.97 (1.85, 2.09)
Current smokers 71538 (49.4) 1.86 (1.69, 2.04) 1.86 (1.70, 2.04) 1.84 (1.68, 2.02) 1.81 (1.66, 1.98) 1.84 (1.68, 2.02)
SBP (mmHg) 135.2 (19.6) 1.31 (1.27, 1.36) 1.30 (1.26, 1.35) 1.31 (1.26, 1.35) 1.30 (1.26, 1.35) 1.30 (1.26, 1.35)
History of diabetes 10508 (7.3) 1.97 (1.83, 2.13) 1.94 (1.80, 2.10) 1.97 (1.82, 2.13) 1.94 (1.80, 2.10) 1.94 (1.79, 2.10)
Total cholesterol (mmol/l) 5.79 (1.09) 1.17 (1.14, 1.21) 1.17 (1.14, 1.21) 1.17 (1.14, 1.21) 1.17 (1.14, 1.21) 1.17 (1.13, 1.20)
HDL cholesterol (mmol/l) 1.38 (0.40) 0.80 (0.76, 0.84) 0.81 (0.77, 0.85) 0.81 (0.77, 0.85) 0.81 (0.77, 0.85) 0.81 (0.77, 0.85)
BMI (kg/m2) 26.94 (4.56) 1.07 (1.03, 1.11)  - 0.97 (0.92, 1.02)  - 1.04 (1.00, 1.08)
WC (cm) 91.5 (12.6)  - 1.10 (1.06, 1.15) 1.13 (1.07, 1.20)  -  -
WHR 0.90 (0.08)  -  -  - 1.12 (1.08, 1.15) 1.11 (1.07, 1.14)
WC WHR
 
 †Hazard ratios (HRs) were adjusted, where appropriate, for age, sex, smoking status, systolic blood pressure, history of diabetes, total cholesterol, HDL cholesterol plus either 
BMI, WC or WHR. 
‡Hazard ratios were adjusted, where appropriate, for age, sex, smoking status, systolic blood pressure, history of diabetes, total cholesterol, HDL cholesterol, BMI plus either 
WC or WHR. 
*Models were stratified by sex. 
Standard deviations (SDs) were calculated without excluding individuals with BMI values <20kg/m2. Hazard ratios are presented per 1-SD measured level or compared to 
relevant reference category.  
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Table 7.3 Reclassification of 10-year predicted risk of cardiovascular disease after addition of 
adiposity measure(s) or conventional risk factors to a model including age and sex only 
 
NRI [%]
 (95% CI)
IDI
 (95% CI)
Addition of adiposity measures 
BMI 0.55% (-0.42%, 1.53%) 0.0015 (0.0009, 0.0022)
WC 1.29% (0.17%, 2.42%) 0.0027 (0.0018, 0.0035)
WHR 2.66% (1.58%, 3.75%) 0.0029 (0.0021, 0.0037)
BMI & WC 1.11% (-0.02%, 2.23%) 0.0027 (0.0018, 0.0035)
BMI & WHR 2.56% (1.39%, 3.74%) 0.0036 (0.0026, 0.0045)
Weight & height 0.81% (-0.24%, 1.85%) 0.0021 (0.0014, 0.0026)
WC & hip 2.55% (1.33%, 3.77%) 0.0041 (0.0031, 0.0051)
Weight & height & WC & hip 2.93% (1.68%, 4.18%) 0.0048 (0.0038, 0.0059)
Addition of cardiovascular risk factors
Non-lipid variables‡ 15.30% (13.52%, 17.08%) 0.0275 (0.0250, 0.0301)
Conventional risk factors¶ 17.36% (15.49%, 19.23%) 0.0334 (0.0306, 0.0362)
Reclassification
(20 studies, 4777 cases, 43944 controls)
 
 ‡Smoking status, systolic blood pressure and history of diabetes. 
¶Smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol. 
 
Model included age and was stratified by sex. Abbreviations: NRI = Net Reclassification Improvement; IDI = Integrated 
Discrimination Improvement. 
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Table 7.4 Reclassification of 10-year predicted risk of cardiovascular disease after addition of adiposity measure(s) or total and HDL 
cholesterol measures to a non-lipid-based model  
 
Body-mass index Waist circumference Waist/hip ratio Body-mass index& Waist circumference
Body-mass index
& Waist/hip ratio
Total & HDL
cholesterol
Reclassification (20 studies, 4777 cases, 43944 controls)
Participants who developed CVD at 10 years
Appropriately reclassified 159 (3.33%) 201 (4.21%) 211 (4.42%) 205 (4.29%) 243 (5.09%) 509 (10.66%)
Inappropriately reclassified 137 (2.87%) 180 (3.77%) 189 (3.96%) 184 (3.85%) 217 (4.54%) 381 (7.98%)
No change 4481 (93.80%) 4777 (92.02%) 4377 (91.63%) 4388 (91.86%) 4317 (90.37%) 3887 (81.37%)
Participants event free at 10 years
Appropriately reclassified 1033 (2.35%) 1402 (3.19%) 1572 (3.58%) 1435 (3.27%) 1735 (3.95%) 3095 (7.04)
Inappropriately reclassified 1161 (2.64%) 1538 (3.5%) 1544 (3.51%) 1533 (3.49%) 1752 (3..99%) 3027 (6.89%)
No change 41750 (95.01%) 41004 (93.31%) 40828 (92.91%) 40976 (93.25%) 40457 (92.06%) 37822 (86.07%)
NRI (95% CI) 0.17% (-0.57%, 0.91%) 0.13% (-0.71%, 0.97%) 0.52% (-0.33%, 1.38%) 0.22% (-0.63%, 1.06%) 0.51% (-0.41%, 1.42%) 2.83% (1.56%, 4.11%)
p-value 0.652 0.76 0.231 0.615 0.281 <0.0001
IDI (95% CI) 0.0005 (0.0001, 0.0010) 0.0012 (0.0006, 0.0018) 0.0019 (0.0012, 0.0026) 0.0013 (0.0007, 0.0019) 0.0019 (0.0012, 0.0027) 0.0059 (0.0046, 0.0072)
p-value 0.022 <0.001 <0.001 <0.001 <0.001 <0.0001
 
 
Non-lipid-based variables were age, smoking status, systolic blood pressure and history of diabetes. Model was stratified by sex. Abbreviations: NRI = Net Reclassification 
Improvement; IDI = Integrated Discrimination Improvement. 
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Table 7.5 Reclassification of 10-year predicted risk and changes in risk discrimination for cardiovascular disease after addition of 
adiposity measure(s) to a model including conventional risk factors 
 
Body-mass index Waist circumference Waist/hip ratio Body-mass index &Waist circumference
Body-mass index &
Waist/hip ratio
Discrimination (39 studies, 8347 cases, 144795 participants)
Reference C-Index 0.7325 (0.7274, 0.7376)
C-Index change (95% CI)  -0.0001 (-0.0005, 0.0002)  -0.0001 (-0.0006, 0.0005) 0.0008 (0.0001, 0.0014)  -0.0000 (-0.0005, 0.0006) 0.0006 (-0.0000, 0.0013)
p-value† 0.430 0.816 0.027 0.933 0.068
p-value‡ Ref 0.627 0.006 0.454 0.009
Reclassification (20 studies, 4777 cases, 43944 controls)
Participants who developed CVD at 10 years
Appropriately reclassified 68 (1.42%) 111 (2.32%) 132 (2.76%) 106 (2.22%) 141 (2.95%)
Inappropriately reclassified 73 (1.53%) 110 (2.30%) 136 (2.85%) 116 (2.43%) 142 (2.97%)
No change 4636 (97.05%) 4556 (95.37%) 4509 (94.39%) 4555 (95.35%) 4494 (94.08%)
Participants event free at 10 years
Appropriately reclassified 507 (1.15%) 806 (1.83%) 1091 (2.48%) 856 (1.95%) 1111 (2.53%)
Inappropriately reclassified 545 (1.24%) 839 (1.91%) 1078 (2.45%) 847 (1.93%) 1116 (2.54%)
No change 42892 (97.61%) 42299 (96.26%) 41775 (95.06%) 42241 (96.12%) 41717 (94.93%)
NRI (95% CI)  -0.19% (-0.70%, 0.32%)  -0.05% (-0.69%. 0.58%)  -0.05% (-0.76%, 0.65%)  -0.19% (-0.83%, 0.45%)  -0.03% (-0.75%, 0.69%)
p-value 0.461 0.867 0.88 0.562 0.93
IDI (95% CI) 0.0001 (-0.0002, 0.0003) 0.0004 (0.0000, 0.0007) 0.0010 (0.0004, 0.0015) 0.0005 (0.0001, 0.0008) 0.0009 (0.0004, 0.0015)
p-value 0.654 0.043 <0.001 0.016 0.001
 
 †p-value is for changes in C-index as compared with a model including conventional risk factors. 
‡p-value is for changes in C-index as compared with addition of BMI alone. 
 
Conventional risk factors include age, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol. The number of individuals classified according 
to their predicted 10-year cardiovascular risk are reported in Table 7.6. Abbreviations: NRI = Net Reclassification Improvement; IDI = Integrated Discrimination Improvement. 
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Table 7.6 Reclassification of individuals between predicted 10-year cardiovascular disease risk 
categories upon addition of BMI, WC or WHR to a model including conventional risk factors 
 
a) BMI 
 
0-5% 5-10% 10-20% >20% Lower Higher
0-5%
Cases, n 528 12 0 0 0 12
Non-cases, n 24025 242 0 0 0 242
5-10%
Cases, n 15 907 26 0 15 26
Non-cases, n 261 9058 189 0 261 189
10-20%
Cases, n 0 28 1373 30 28 30
Non-cases, n 0 170 6669 114 170 114
>20%
Cases, n 0 0 30 1828 30 0
Non-cases, n 0 0 76 3140 76 0
Total
Cases, n 543 947 1429 1858 73 68
Non-cases, n 24286 9470 6934 3254 507 545
Model without
BMI
Model with BMI Reclassified into
new risk categories
 
 
b) WC 
 
0-5% 5-10% 10-20% >20% Lower Higher
0-5%
Cases, n 517 23 0 0 0 23
Non-cases, n 23902 365 0 0 0 365
5-10%
Cases, n 20 895 33 0 20 33
Non-cases, n 400 8808 300 0 400 300
10-20%
Cases, n 0 44 1332 55 44 55
Non-cases, n 0 264 6515 174 264 174
>20%
Cases, n 0 0 46 1812 46 0
Non-cases, n 0 0 142 3074 142 0
Total
Cases, n 537 962 1411 1867 110 111
Non-cases, n 24302 9437 6957 3248 806 839
Model without
WC
Model with waist circumference Reclassified into
new risk categories
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c) WHR 
 
0-5% 5-10% 10-20% >20% Lower Higher
0-5%
Cases, n 512 28 0 0 0 28
Non-cases, n 23811 456 0 0 0 456
5-10%
Cases, n 26 880 42 0 26 42
Non-cases, n 501 8627 378 2 501 380
10-20%
Cases, n 0 48 1321 62 48 62
Non-cases, n 0 374 6337 242 374 242
>20%
Cases, n 0 0 62 1796 62 0
Non-cases, n 0 0 216 3000 216 0
Total
Cases, n 538 956 1425 1858 136 132
Non-cases, n 24312 9457 6931 3244 1091 1078
Model without
WHR
Model with waist/hip ratio Reclassified into
new risk categories
 
 
Conventional risk factors include age, smoking status, systolic blood pressure, history of diabetes, and total and HDL 
cholesterol. 
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Figure 7.1 Changes in C-index for cardiovascular disease risk prediction on addition of 
adiposity measures or conventional risk factors to a model containing age and sex only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Reference model includes age and is stratified by sex.  
‡Smoking status, systolic blood pressure and history of diabetes. 
¶Smoking status, systolic blood pressure, history of diabetes and total and HDL cholesterol. 
§p<0.001 for change in C-index after addition of WC or WHR into the reference model plus BMI. 
 
 
0 0.01 0.02 0.03 0.04 0.05 0.06
C-index change (95% CI) upon addition of variable(s)
Reference model + conventional risk factors¶
Reference model + non-lipid-based model‡
Reference model + weight & height & WC & hip
Reference model + WC & hip
Reference model + weight & height
Reference model + BMI & WHR
Reference model + BMI & WC
Reference model + WHR
Reference model + WC
Reference model + BMI
Reference model†
Reference C-Index  0.6741 (0.6685, 0.6798)
Reference model \
Variable added in turn
C-index change (95% CI)
0.0584 (0.0539, 0.0628)
0.0497 (0.0455, 0.0538
0.0121 (0.0093, 0.0148)
0.0108 (0.0082, 0.0133)
0.0064 (0.0041, 0.0086)
0.0108 (0.0083, 0.0134)§
0.0077 (0.0054, 0.0101)§
0.0102 (0.0080, 0.0125)
0.0077 (0.0053, 0.0100)
0.0051 (0.0031, 0.0072)
Reference
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Figure 7.2 Changes in C-index for cardiovascular disease risk prediction on addition of 
adiposity measures or lipid markers to a non-lipid-based model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Non-lipid-base model includes age, smoking status, systolic blood pressure and history of diabetes. Model was stratified by 
sex.  
§p=0.175 for change in C-index after addition of WC  into the reference model plus BMI. 
¶p<0.001 for change in C-index after addition of WHR into the reference model plus BMI. 
 
 
Reference model + Total and HDL-cholesterol
Reference model + HDL-cholesterol
Reference model + Total cholesterol
Reference model + weight & height & WC & hip
Reference model + WC & hip
Reference model + weight & height
Reference model + BMI & WHR
Reference model + BMI & WC
Reference model + WHR
Reference model + WC
Reference model + BMI
0 0.002 0.004 .006 .008 .01 .012
0.0087 (0.0068, 0.0106)
0.0051 (0.0037, 0.0066)
0.0030 (0.0018, 0.0041)
0.0026 (0.0014, 0.0038)
0.0020 (0.0009, 0.0031)
0.0011 (0.0002, 0.0019)
0.0022 (0.0011, 0.0033)¶
0.0010 (0.0000, 0.0020)‡
0.0023 (0.0013, 0.0033)
0.0010 (0.0001, 0.0019)
0.0006 (-0.0002, 0.0013)
Non-lipid-based model†
Reference C-Index 0.7238 (0.7186, 0.7291) 
Reference model \
Variable added in turn
Reference
C-index change (95% CI)
C-index change (95% CI) upon addition of variable(s)
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Figure 7.3 Changes in C-index for cardiovascular disease risk prediction on omission of 
individual risk factors from a full model containing conventional risk factors plus BMI, WC or 
WHR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Conventional risk factors include age, smoking status, systolic blood pressure, history of diabetes, and total and HDL 
cholesterol. Model was stratified by sex. 
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Figure 7.4 Changes in C-index for cardiovascular disease risk prediction on omission of 
individual risk factors from a full model containing conventional risk factors plus BMI, WC or 
WHR in participants without diabetes at baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Conventional risk factors include age, smoking status, systolic blood pressure, and total and HDL cholesterol. Model was 
stratified by sex. 
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Figure 7.5 Changes in C-index for cardiovascular disease risk prediction upon addition of BMI, WC or WHR on top of conventional 
risk factors, according to different subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Models contain all conventional risk factors (ie, age, systolic blood pressure, smoking status, history of diabetes, and total and HDL cholesterol) with and without inclusion of 
BMI, WC or WHR. Predictive ability added by BMI, WC or WHR is given, with a p-value testing the null hypothesis of no difference in effect between levels of each subgroup. 
Error bars indicate 95% confidence limits. In each case only studies with information on both subgroup levels are used. Not all studies used had full information across all 
subgroups levels, so comparisons across subgroups (eg, men versus smokers) are not reliable due to inclusion of between study differences.  
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Figure 7.6 Study-specific C-index for cardiovascular disease risk prediction in a model 
including conventional risk factors 
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Figure 7.7 Study-specific changes in C-index for cardiovascular disease risk prediction after addition of BMI, WC or WHR to a model 
including conventional risk factors 
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CHAPTER 8: Discussion 
 
This thesis used individual participant data from mostly Western prospective studies with 
information on body-mass index (BMI) and measures of abdominal adiposity, such as waist 
circumference (WC) and waist-to-hip ratio (WHR), in order to: (i) assess lifestyle and biological 
correlates of BMI, WC and WHR; (ii) determine the long-term within-person variability in BMI, 
WC and WHR; (iii) characterise in detail the association of BMI with risk of cardiovascular 
morbidity and cause-specific mortality under different circumstances in participants with 
information on BMI only; (iv) characterise in detail the associations of BMI, WC and WHR with 
risk of coronary heart disease and ischaemic stroke in participants with concomitant 
information on all three adiposity measures; and (v) investigate the ability of BMI, WC and 
WHR to predict cardiovascular disease. This final chapter summarises the main findings, 
discusses the strengths and limitations of the available data, and highlights further studies that 
are needed to clarify the relevance of adiposity to cardiovascular disease.  
 
Summary of the principal findings 
The Emerging Risk Factors Collaboration (ERFC) is an individual participant meta-analysis of 
more than 120 prospective epidemiological studies with information on lipids, inflammatory 
and/or metabolic markers, other cardiovascular risk factors, as well as major cardiovascular 
morbidity and/or cause-specific mortality (Chapter 2). 118 prospective studies, involving more 
than 1 million participants without known history of cardiovascular disease, had information on 
BMI at baseline examination. 58 of these studies, involving more than 220,000 participants had 
additional information on waist and hip circumference at baseline examination.  
 
Cross-sectional correlates of adiposity measures 
Analyses of individual records from up to 221,934 participants demonstrated that there were 
approximately linear and strong associations between BMI and WC (r = 0.85), and WHR and 
WC (r = 0.70), and only moderately strong correlations between BMI and WHR (r = 0.43) 
(Chapter 3). Adiposity measures had broadly similar and approximately linear associations 
with cardiovascular risk factors, such as blood pressure, fasting glucose and inflammatory 
markers, and slightly curvilinear associations with lipid markers. In both males and females, 
BMI, WC and WHR were most strongly associated with blood pressure, high-density 
lipoprotein (HDL) cholesterol, triglyceride, C-reactive protein (CRP) and interleukin-6 (IL-6). 
Overall, adiposity measures were higher in individuals of non-European descent, physically 
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inactive people, people with diabetes, and people with low levels of education. Whereas mean 
BMI and WC values were somewhat lower in current smokers and current alcohol drinkers, 
mean WC and WHR values were higher in males than in females. These findings demonstrate 
that although the correlations between clinical measures of adiposity differ, BMI, WC and WHR 
are similarly and importantly associated with blood pressure, fasting glucose, lipids and 
inflammatory markers. This finding highlights the importance of intermediate risk factors on the 
pathway between excess body fat and cardiovascular disease. Furthermore, the findings 
suggest possible scope for confounding by lifestyle factors in observational studies of 
associations of adiposity measures with disease risk.  
 
Within-person variability in adiposity measures 
The findings in Chapter 4 showed that the extent of within-person variability in calculated risk 
factors can be considerably larger (or smaller) than the within-person variability in its 
components. Furthermore, analyses of data on over 79,000 serial measurements of BMI, WC 
and WHR taken on average of 6 years apart in over 42,000 participants from 12 prospective 
studies demonstrated that the reproducibility in BMI (regression dilution ratio [RDR] 0.96) was 
superior to that of WC (RDR 0.88) and WHR (RDR 0.66). The within-person variability in 
adiposity measures was not materially influenced by several characteristics (such as age, 
smoking status, blood pressure and lipids), although the RDR of WHR varied somewhat by 
sex, diabetes status and baseline WHR values. These findings suggest that the degree of 
underestimation of the magnitude of association with disease risk is smaller for baseline 
measures of BMI than for WC and WHR. 
 
Associations of BMI with disease risk 
Over 31,000 non-fatal myocardial infarctions or strokes and almost 130,000 deaths were 
recorded during approximately 15.0 million person-years at risk in more than 1 million 
participants from 118 prospective studies, mainly from Western populations (Chapter 5). In 
analyses adjusted for age, sex and smoking status, and excluding participants with BMI values 
below 20 kg/m2, there were nearly loge-linear associations with risk of coronary heart disease, 
ischaemic stroke and all cardiovascular mortality. Risk ratios per 5 kg/m2 baseline BMI change, 
adjusted for age, sex and smoking status, were 1.31 (95% confidence interval [CI] 1.26-1.36) 
for coronary heart disease and 1.23 (95% CI 1.18-1.29) for ischaemic stroke. These 
associations were largely explained by long-term average levels of mediating risk factors, such 
as blood pressure, history of diabetes, lipids and inflammatory markers (although the causal 
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relevance of some inflammatory markers is uncertain). Risk ratios for coronary heart disease 
were significantly greater in some groups at lower absolute risk – ie, in people without history 
of diabetes, at early middle age and at lower-than-average systolic blood pressure (SBP). 
Across the full range of BMI values, BMI had curvilinear associations with all-cause mortality, 
including most site-specific cancers and non-vascular conditions not attributed to cancer. In 
participants with BMI values of 25 kg/m2 or higher, particularly strong positive relationships 
were observed with risk of death from diabetes and renal disease. By contrast, among 
participants with BMI values below 25 kg/m2, the negative association of BMI was 
predominantly due to the strong negative associations with death due to respiratory disease 
and cancers of the lung and upper aerodigestive tract.  
 
Associations of adiposity measures with risk of coronary heart disease and ischaemic stroke 
A large multinational retrospective case-control study has reported that WHR is three times 
more strongly associated to risk of acute myocardial infarction than is BMI, suggesting that 
WHR should replace BMI as the principal clinical measure of adiposity.1 However, in 
prospective analyses that involved 221,934 individuals with concomitant information on height, 
weight, waist and hip circumference, there were nearly loge-linear associations between BMI, 
WC and WHR, and risk of coronary heart disease and ischaemic stroke across the range of 
values, except at low BMI (Chapter 6). After excluding participants with BMI values below 20 
kg/m2, age, sex and smoking status adjusted risk ratios for coronary heart disease and 
ischaemic stroke were broadly similar for one standard deviation change of BMI, WC and 
WHR. These risk ratios reduced considerably after further adjustment for intermediate risk 
factors, such as SBP, history of diabetes, total and HDL cholesterol. Whereas these risk 
factors explained coronary risk to a similar extent, the risk reduction for ischaemic stroke was 
mainly due to blood pressure. The effect of abdominal adiposity on the risk of coronary heart 
disease and ischaemic stroke was largely independent of BMI. The risk ratios were about 
three-to-four fold stronger in participants at early middle age than at older ages, but otherwise 
did not vary materially by sex, method of adiposity assessment (ie, self-reported versus 
assessed by a trained person) and other characteristics recorded. These findings refute 
previous recommendations to adopt WHR instead of BMI as the principal clinical measure of 
adiposity.  
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Adiposity measures in risk prediction 
National and international guidelines have provided differing recommendations about the value 
of clinical measures of adiposity for prediction of cardiovascular risk in primary prevention.2 
Recommendations range from omission of adiposity measures, to inclusion of such measures 
as additional screening tests, to formal inclusion of such measures as risk factors in prediction 
models. Furthermore, it has been suggested to replace assessment of lipid measures with that 
of adiposity measures in resource-limited settings where cholesterol testing is not feasible for 
cardiovascular disease risk assessment.3 In analyses of 114,795 healthy participants with 
concomitant information on weight, height, waist and hip circumference, lipids and other 
conventional risk factors, BMI, WC and WHR did not importantly improve risk discrimination, 
nor classification of participants to risk categories of predicted 10-year risk when information 
was available lipids and other conventional risk factors (Chapter 7). Regarding the 
replacement of lipids with adiposity measures, the results have shown that a combination of 
BMI and WHR provides only about one-quarter of the predictive information provided by total 
and HDL cholesterol. These findings indicate that for population-wide assessment of 
cardiovascular disease risk, simple adiposity measures provide little or no additional 
information about cardiovascular disease risk prediction given knowledge about risk factors 
used in standard risk scores. They also highlight the desirability of supporting the development 
of lipid assessment in resource-limited settings. 
 
Strengths and limitation of current data 
The findings of this thesis differ from previous reports on adiposity measures and 
cardiovascular risk in several important ways that enhance its scientific value and accuracy. 
First, the dataset is large; the data compass 118 prospective studies with information on BMI at 
baseline examination and 58 prospective studies with complete information on weight, height, 
and waist and hip circumference at baseline examination, thereby reducing scope for random 
error and avoiding undue emphasis on the results of any particular study. Second, in contrast 
to previous individual participant data meta-analyses,4-6 the dataset has concomitant 
information on BMI, WC, WHR and conventional risk factors, allowing reliable examination of 
the predictive ability of BMI, WC and WHR in context of standard risk scores. Third, 
harmonisation of individual records has enhanced consistency across studies, allowed use of 
common outcome definitions and consistent approaches to adjustment for potential 
confounders and biological mediators. Fourth, individuals with known history of cardiovascular 
disease were excluded from the analysis, limiting any effects of clinically evident disease on 
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weight or abdominal adiposity (ie, minimising any reverse causality). Fifth, use of data on 
several individuals with repeat measurements has allowed investigation of within-person 
variability in adiposity measures (and other covariates). Sixth, the dataset has enabled to 
reliably examine associations with coronary heart disease, ischaemic stroke and non-vascular 
conditions, and to explore the degree to which any associations can be explained by potential 
confounders and biological mediators. Seventh, the data has allowed detailed investigation of 
potential sources of heterogeneity, including comparison of associations at different levels of 
BMI and other cardiovascular risk factors. Finally, the analyses have used more appropriate 
statistical methods, including use of consistent within-study comparisons and incorporation of 
potential between-study heterogeneity into risk estimates.  
 
The limitations of the current data also merit consideration. Although analyses were restricted 
to individuals without known history of cardiovascular disease at baseline examination, and 
subsidiary analyses excluded the first five years of follow-up, residual biases (ie, reverse 
association) may still remain because of subclinical or unreported prevalent disease. Second, 
not all studies recorded all possible variables of interest. For instance, only a fifth of the 
participants with data available on BMI had also concomitant information on waist and hip 
circumference. Statistical methods such as multiple imputation techniques in meta-analytical 
settings are under development, but beyond the scope of this thesis.7 Third, despite the 
consistency of the results across studies in many countries, participants in the ERFC were 
predominantly from Western populations. Future studies should also investigate whether the 
current findings can be generalised to people from other ethnic groups or from low-income 
countries.8 Fourth, because the ERFC had only information on the severity of adiposity, this 
thesis could not assess the impact of the duration of adiposity on intermediate risk factors and 
disease risk. Furthermore, additional studies are needed to better understand to what extent 
obesity, particularly in children and young adults, relates to the development of intermediate 
risk factors and cardiovascular disease in adulthood. Fifth, despite the large size of the dataset, 
this thesis could not examine associations of BMI, WC and WHR with cause-specific mortality. 
Future prospective studies will be required to examine whether measures of abdominal 
adiposity have different associations with risk of death from specific cancer sites and other 
non-vascular conditions than has BMI. Sixth, this thesis considered single measurements of 
adiposity measures for cardiovascular risk prediction. Future studies should also investigate 
the relevance of changes in body size for prediction of subsequent cardiovascular disease. 
Seventh, any preferential diagnosis of cardiovascular disease in people who were overweight 
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or obese may have tended to overestimate associations. Eighth, the ERFC had information 
only on adiposity estimated indirectly by anthropometric indicators. Large studies are needed 
that concurrently assess several additional adiposity markers not assessed in the current 
analyses, including direct measures of abdominal adiposity or skinfold thickness,9 as well as 
circulating concentrations of adipocytokines.10,11 Lastly, because the current findings are based 
on observational data they cannot, of course, establish any causal relationships of adiposity 
with cardiovascular disease.  
 
Ongoing and future studies 
Further clarification of the role of clinical measures of adiposity for non-vascular conditions 
It has been suggested that measures of abdominal adiposity (eg, WC or WHR) are more 
strongly associated with risk of death from some cancers and other non-vascular conditions 
than is BMI.5,12-20 Because previous studies generally have had limited numbers of specific 
outcomes, adjusted inconsistently for confounders and mediators, or reported on adiposity 
measures in relation to one (or few) selected or aggregated conditions only, there is a need for 
adequately powered, standardised assessment of associations of BMI, WC and WHR with the 
risk of death from a broad range of causes. The ERFC will therefore extend analyses to 
adiposity measures in relation to risk of cause-specific mortality. In order to obtain adequate 
statistical power, I will identify new relevant prospective studies with available data and invite 
them to join the ERFC, as well as ask current ERFC collaborators whether they would like to 
provide further data on adiposity measures and/or cause-specific mortality.  
 
Further clarification on the role of other adiposity measures 
Although the current analyses indicated that BMI and measures of abdominal adiposity, such 
as WC and WHR, are each associated with risk of cardiovascular disease, these relationships 
may have been underestimated due to imprecise assessment of body fat and body 
composition by these indirect measures of adiposity. Several other methods of measurement 
of overall body fatness and body fat distribution have been proposed for large-scale 
epidemiological studies. Skinfold measures the thickness of the skin and subcutaneous fat 
mass which can be used to estimate overall body fatness.21 Because most research on 
skinfold thickness has been focused on children and young adults, less is known on the 
association of skinfold thickness with cardiovascular disease risk in adults. Larger subscapular 
skinfold has been associated with greater risk of coronary heart disease in previous studies,22 
but it is uncertain how skinfold measures relate to cardiovascular disease compared to other 
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measures of adiposity.23,24 Existing population-based prospective studies could help to address 
such uncertainties. For example, triceps, subscapular and abdominal skinfolds, as well as 
weight, height and WC have been measured in 19,000 initially healthy participants in the 
prospective Reykjavik Study. This study was initiated in 1967 and indentified participants 
resident in Reykjavik, Iceland, through population registers.25 All participants were monitored 
subsequently for cause-specific mortality and cardiovascular morbidity, with a loss of follow-up 
of only about 0.6% to date. To enable assessment of any confounding and mediation, the 
study collected data on a range of cardiovascular risk factors, such smoking, blood pressure, 
lipids and inflammatory markers. Analyses of such data should help to examine the association 
of skinfold thickness with risk of cardiovascular disease, and to compare it with that of other 
adiposity measures.  
 
As discussed in Chapter 1 on page 8, Dual-energy X-ray Absorptiometry (DXA) measures total 
and regional body composition, including the estimation of fat-free mass, fat mass and bone 
mineral content.26 The most accurate methods available to measure body composition at the 
tissue level are imaging methods, such as magnetic resonance imaging and computed 
tomography. It has been suggested that visceral adipose fat depot is more strongly associated 
with metabolic disease risk than are other fat depots.27-32 While WC and WHR are reasonably 
good markers of abdominal adiposity, they have been criticised for being poor surrogates of 
visceral adiposity, as they may not distinguish visceral adipose tissue from abdominal 
subcutaneous adipose tissue, which is only possible by use of imaging techniques.33,34 
However, such data from large-scale epidemiological studies are currently lacking. Generation 
of new observational data with accurate measurement of body fat and body fat distribution will 
therefore provide new insights into the association of adiposity with cardiovascular disease. For 
example, adiposity is being assessed in 500,000 people aged 40 to 69 in the UK Biobank 
study.35 This prospective study is a major medical research initiative with the aim of improving 
the prevention, diagnosis and treatment of a wide range of conditions, such as cancer, 
cardiovascular disease or dementia. Following piloting in 2005-2006, UK Biobank started 
recruiting participants with detailed information on lifestyle, environment and genes in 2008. 
While weight, height, waist and hip circumference are measured in all participants, UK Biobank 
also measures amount and distribution of body fat in approximately 100,000 participants using 
DXA and imaging methods.36 New data from this study should substantially advance 
understanding of body fat distribution with risk of cardiovascular disease, as well as non-
vascular conditions. 
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Further clarification of biomarkers of adiposity 
As discussed in detail in Chapter 1 on pages 5-7, adipocytokines released by adipose tissue 
are believed to be involved in development of atherosclerosis via inflammatory processes.37 
Available data from prospective studies on adipocytokines and cardiovascular disease risk, 
however, are sparse.10,11,38,39 For instance, only a few studies, involving a total of about 1,300 
coronary disease cases, have reported associations of adiponectin and/or leptin levels with risk 
of coronary heart disease, yielding largely inconsistent findings.40-46 Observational data on 
adipocytokines from large population-based studies should help to better understand 
mechanisms by which adiposity increases cardiovascular risk. For instance, adiponectin and 
leptin have been measured in a nested case-control study within the prospective Reykjavik 
Study. 1,917 participants had a coronary event during follow-up; 3,618 controls (frequency-
matched to cases with respect to calendar year of recruitment, sex and age) were free from 
coronary heart disease at the end of the study period. In preliminary analyses, lower 
adiponectin was associated with a greater risk of coronary heart disease, even after 
adjustment for several conventional risk factors, including BMI (Table 8.1). By contrast, leptin 
levels were not associated with risk of coronary heart disease. Such analyses on adiponectin, 
leptin and possibly other adipocytokines should advance understanding of the biological 
pathways through which the adverse vascular effects of excess body fat are mediated.  
 
Further clarification on the role of adiposity measures in other ethnic groups 
Since most previous studies were conducted in participants from Western populations,4-6 less 
is known about the relationship between adiposity measures and risk of cardiovascular disease 
in other ethnic groups, such as South-Asians. The Pakistan Risk of Myocardial Infarction Study 
(PROMIS) and the Bangladesh Risk of Acute Vascular Events (BRAVE) study are two case-
control studies based in South Asia. PROMIS has already collected information on BMI, WC 
and WHR, and several other established and emerging risk factors in 10,000 individuals with 
first-ever acute myocardial infarction and 10,000 controls.47 Furthermore, it measured around 
45,000 genetic markers using Illumina "cardiochip" array, and performed a genomewide 
association scan (GWAS) in 20,000 individuals using the Illumina 610-Quad array. Since 
Pakistan generally has a high prevalence of obesity and high rates of cardiovascular disease, 
this study should provide complementary insights into the relevance of adiposity to 
cardiovascular disease as compared with studies in European populations. BRAVE is a new 
global vascular research initiative that is currently in the pilot phase. The target of the study is 
to recruit at least 10,000 individuals with a first-ever confirmed myocardial infarction, and 
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10,000 patients with computer tomography-confirmed stroke events, and one control per case. 
BRAVE will collect information on various cardiovascular risk factors, including BMI, WC and 
WHR. Contrary to observations from Western and East Asian populations, a recent prospective 
study has shown that higher BMI is not associated with greater risk of death in Bangladeshis.48 
BRAVE should provide further insights into the relationship of adiposity measures with 
cardiovascular disease in the Bangladeshi population 
 
Besides studies in South Asians, there are other large prospective studies, such as the 
Kadoorie Study and the Mexico City Study that may provide complementary information on the 
role of adiposity measures to the risk of cardiovascular disease.49,50 The Kadoorie Study of 
Chronic Disease in China (KSCDC) is a prospective blood-based study, involving 500,000 
middle aged adults in 10 different parts of China.49 The Mexico City Prospective Study 
recruited about 150,000 men and women in order to assess the associations of established 
and new risk factors with risk of cause-specific deaths in Mexico City.50 Both studies collected 
information on height, weight, waist and hip circumferences and other established and 
emerging risk factors to enable detailed investigation of the association of adiposity measures 
with risk vascular and non vascular mortality outcomes in non-Western populations. 
 
Further clarification on the role of adiposity in children and young adults  
Evidence on the impact of the duration of obesity on the risk of mortality is sparse.51 
Furthermore, it is unclear to what extent body fatness and body distribution in adolescence 
relates to the development of intermediate risk factors and to increased cardiovascular risk, 
and whether such risk is independent of adiposity in adulthood.52-54 Birth cohorts, such as the 
Avon Longitudinal Study of Parents and Children (ALSPAC),55,56 should address such 
uncertainties in the future. ALSPAC is a longitudinal population based birth cohort that 
recruited 14,000 pregnant women with expected delivery between 1991 and 1992. Since then, 
all offspring are monitored and invited regularly for follow-up examinations to obtain detailed 
information on various characteristics, including body composition. Such data collected 
throughout the life course should help to better understand the relevance adiposity in childhood 
or young adults for the development of cardiovascular disease in later life.57 
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Conclusion 
BMI, WC and WHR each have similar magnitudes of association with risk of cardiovascular 
disease. This argues against previous suggestions to adopt WHR instead of BMI as the 
principal clinical measure of adiposity. Furthermore, these adiposity measures do not 
importantly improve cardiovascular risk prediction when additional information exists on blood 
pressure, history of diabetes and cholesterol measures. To investigate the relevance of 
adiposity to cardiovascular disease, large studies are needed that concurrently assess several 
additional adiposity markers, including direct measures of abdominal adiposity or skinfold 
thickness, as well as circulating concentrations of adipocytokines. 
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Table 8.1 Associations of baseline levels of adiponectin, leptin and BMI with coronary heart disease risk in the Reykjavik Study 
 
Adiposity marker Adjusted for age, 
sex and period
Adjusted for age, sex, period 
and conventional risk factors
Adjusted for age, sex, period, 
conventional risk factors and 
inflammatory markers
Adjusted for age, sex, period, 
conventional risk factors, 
inflammatory markers and BMI
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Loge adiponectin† 1.24 (1.10-1.41) 1.24 (1.09-1.41) 1.22 (1.06-1.41) 1.18 (1.02-1.36)
Loge leptin 1.20 (1.04-1.37) 1.13 (0.98-1.31) 1.07 (0.92-1.26) 0.95 (0.79-1.14)
BMI 1.40 (1.25-1.56) 1.30 (1.15-1.46) 1.22 (1.07-1.39) NA
 
 
Odds ratios (OR) are presented per two standard deviations higher baseline values in adiposity markers. "Period" refers to calendar year of recruitment. Conventional risk 
factors are smoking status, systolic blood pressure, history of diabetes and total cholesterol. Inflammatory markers are C-reactive protein, interleukin 6 and albumin.  
†Odd ratios are presented per two standard deviations lower adiponectin. 
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APPENDIX 2: Rationale for using standard deviation changes in long-term 
average levels for comparing aetiological associations of risk factors with 
different degrees of within-person variability 
 
Introduction 
The extent of within-person variability may be of importance when taking into account 
regression dilution bias and making direct comparisons of the strength of association with 
outcome of risk factors with different degrees of within-person variability. Chapter 6 compares 
the magnitudes of association of adiposity measures, such as body-mass index (BMI), waist 
circumference (WC) and waist-to-hip ratio (WHR) with risk of cardiovascular disease. Such 
comparisons are straightforward when the effect of within-person variability is ignored (ie, 
analyses using measured ["baseline"] values). Assuming loge-linear relationships with 
cardiovascular disease risk, associations are generally compared per standard deviation 
changes in baseline values of adiposity measures.1 Because of different degrees of within-
person variability in adiposity measures, however, the interpretation of these findings becomes 
more complicated when associations are also corrected for regression dilution bias and use of 
baseline standard deviation as unit to compare associations may be inappropriate. 
 
Using data on adiposity measures from the Emerging Risk Factors Collaboration (ERFC), this 
appendix shows how to compare magnitudes of associations of risk factors with different 
degrees of within-person variability taking into account regression dilution bias.  
 
Methods 
Details of data on adiposity measures in the ERFC are given in Chapter 2. The current 
analysis involved individual records from 42,300 participants from 12 prospective studies with 
the following features: (1) participants were not selected on the basis of having previous 
cardiovascular disease; (2) concomitant information was provided on height, weight, waist and 
hip circumference at initial ("baseline") examination and at resurvey; and (3) at least 1 year of 
follow-up had been accrued.  
 
The statistical methods have been described in detail in Chapter 5 on pages 111-116. Risk 
ratios for BMI, WC and WHR were calculated in relation to first-ever non-fatal or fatal coronary 
heart disease. To investigate the impact of different degrees of within-person variability in 
adiposity measures on these associations, risk ratios were corrected for regression dilution 
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bias and presented per one standard deviation higher baseline and long-term average ("usual") 
levels. Correction for the effect of within-person variability in adiposity measures was achieved 
by use of conditional expectations of long-term average levels of adiposity measures adjusted 
for age, sex and smoking status, which were predicted from the Rosner regression calibration 
models.2,3 Usual levels of adiposity ratios were estimated by regressing repeat measurements 
of adiposity ratios on the baseline values of the ratios. Analyses involved a two-stage approach 
with estimates of association calculated separately within each study before pooling across 
studies by random effects meta-analysis.4 Evidence of heterogeneity was indicated by the I2 
statistic.5 
 
All analyses were performed using Stata release 11 (StataCorp LP, College Station, Texas 
USA). 
 
Results 
Concomitant baseline and repeat information on height, weight, and waist and hip 
circumference were available in 42,300 participants from 12 prospective studies, among whom 
there were 3,484 coronary events. Without correction for regression dilution bias, risk ratio of 
coronary heart disease per one standard deviation higher baseline BMI, WC and WHR were 
broadly similar (Table A2.1). Similar results were observed in analyses that corrected for 
regression dilution bias and calculated risk ratios per one standard deviation changes in usual 
levels of adiposity measures. In such corrected analyses that calculated risk ratios per one 
standard deviation higher baseline adiposity measure, however, coronary heart disease was 
distinctly more strongly associated with WHR than with BMI or WC.  
 
Discussion 
Risk ratios for coronary heart disease per one standard deviation higher usual levels of BMI, 
WC and WHR are similar, but quite different conclusions could be drawn had the regression-
dilution-corrected associations been presented per standard deviation of baseline levels. This 
contrast is worthy of further thought. The objectives of many aetiological studies are to 
estimate associations between usual levels of risk factors and the likelihood of disease, 
expressed as risk of ratios for some appropriate unit change in the risk factors. For continuous 
variables, the measure of unit change is often chosen as a standard deviation in the observed 
baseline risk factor, which allows (i) direct comparisons of risk associations for several baseline 
risk factors measured on different scales, uncorrected for within-person variability, and (ii) 
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direct comparisons of risk associations for a single risk factor before and after correction for 
within-person variability. It is arguable, however, whether use of baseline standard deviation as 
the unit of change for comparison between different risk factors would be valid after correction 
for within-person variability. Correcting for within-person variability in a single risk factor can be 
viewed as shrinking the observed distribution of the risk factor to its true usual distribution, and 
the degree of shrinkage will depend on the extent of within-person variability. Thus, for risk 
factors with substantial within-person variability, the standard deviation for the usual levels 
could be much smaller than the standard deviation of the observed baseline levels. Given the 
aetiological objectives, it is more appropriate to present the risk of ratios per standard deviation 
change in the usual levels to allow a direct comparison of risk associations between usual 
levels of several risk factors with different degrees of within-person variability, such as 
presented for the different adiposity measures. These results may closely resemble the risk 
associations uncorrected for within-person variability, as one might expect from using smaller 
unit changes that counteract the effect of correcting for regression dilution bias. Further 
statistical investigations are warranted in this area.  
 
Conclusion 
Aetiological associations of risk factors with different degrees of within-person variability should 
be compared per standard deviation changes in usual levels in analyses corrected for 
regression dilution. 
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Table A2.1 Associations of BMI, WC, WHR and waist-to-height ratio (WHtR) with coronary heart disease risk, with and without 
correction for within-person variability 
 
RDR
1-SD
(BL) RR (95%CI) I
2 (95% CI) 1-SD(BL) RR (95%CI)
1-SD
(UL) RR (95%CI) I
2 (95% CI)
Body-mass index 4.95 1.26 (1.17 to 1.37) 69 (44 to 83) 4.95 1.29 (1.18 to 1.40) 4.76 1.28 (1.17 to 1.38) 69 (45 to 83) 0.96 (0.94, 0.98)
Waist circumference 13.29 1.30 (1.20 to 1.40) 64 (33 to 81) 13.29 1.35 (1.23 to 1.47) 11.65 1.30 (1.20 to 1.40) 65 (34 to 81) 0.88 (0.86, 0.91)
Waist/hip ratio 0.084 1.30 (1.18 to 1.44) 79 (65 to 88) 0.084 1.50 (1.29 to 1.74) 0.061 1.34 (1.20 to 1.50) 79 (65 to 88) 0.66 (0.59, 0.72)
Waist/height ratio 0.080 1.31 (1.21 to 1.42) 66 (38 to 82) 0.080 1.37 (1.25 to 1.50) 0.071 1.32 (1.22 to 1.43) 67 (39 to 82) 0.88 (0.85, 0.91)
Usual levels
Coronary heart disease
(12 studies & 3351 cases)
Baseline levels
 
 
Risk ratios (RRs) and regression dilution ratios (RDRs) were adjusted for age, sex and smoking status. Analyses were restricted to participants with BMI values ≥20kg/m2. 
Abbreviations: BL = baseline levels; UL = usual levels. 
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APPENDIX 3: Adult stature and risk of cause-specific death and vascular 
morbidity in 1 million people  
 
Summary 
The extent to which adult stature, a biomarker of the interplay of genetic endowment and early-
life experiences, is related to risk of diseases of late-onset is uncertain. This appendix reports 
prospective analyses of individual participant data from over 1 million participants in 121 
studies with more than 170,000 deaths or major non-fatal vascular outcomes. The data 
demonstrate that for people born between 1900 and 1960, mean adult height increased by 0.5 
to 1.0 cm with each successive decade of birth. After adjustment for age, sex, smoking status 
and year of birth, risk ratios per 6.5 cm greater height were 0.97 (95% confidence interval [CI] 
0.96-0.99) for death from any cause, 0.94 (95% CI 0.93-0.96) for death from vascular causes, 
1.04 (95% CI 1.03-1.06) for death from cancer and 0.92 (95% CI 0.90-0.94) for death from 
other causes. Height was negatively associated with death from coronary disease, stroke 
subtypes, heart failure, stomach and oral cancers, chronic obstructive pulmonary disease, 
mental disorders, liver-disease and external causes. In contrast, height was positively 
associated with death from ruptured aortic aneurysm, pulmonary embolism, melanoma, and 
cancers of the pancreas, endocrine and nervous systems, ovary, breast, prostate, colorectum, 
blood and lung. At the two extremes, risk of melanoma death was 25% higher per 6.5 cm 
increment in height, whereas risk of death from chronic obstructive pulmonary disease was 
15% lower. Risk ratios were not appreciably altered after further adjustment for adiposity, 
blood pressure, lipids, inflammation, diabetes mellitus, alcohol consumption or socioeconomic 
indicators. These findings demonstrate that adult stature has multiple opposing relationships 
with death from vascular, neoplastic, respiratory and other causes, independent from major 
risk factors. 
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Background 
Because adult stature is a widely available biomarker that reflects the interplay of genetic 
endowment and various early-life experiences and exposures (such as fetal, dietary, social 
and psychological circumstances),1-5 the study of height could reveal insights into patterns of 
shared and differing early determinants of major diseases of later life. Previous studies have 
suggested that there is a weakly negative association between adult height and death from 
any cause, which is mainly due to the well-established inverse association between stature 
and risk of coronary disease.6-9 However, previous studies have been underpowered to 
consider associations of adult height with other common vascular outcomes (such as stroke 
subtypes, heart failure, pulmonary embolism or ruptured aortic aneurysm)10,11 and with a 
broad range of nonvascular causes, such as site-specific cancers and nonvascular diseases 
other than cancer, such chronic obstructive pulmonary disease.12-15 Furthermore, studies 
have not been able to combine adequate statistical power with characterisation of a range of 
risk factors that could be mediators (or confounders) of relationships between height and 
late-onset diseases, such as markers of blood lipids, blood pressure, inflammation, 
dysglycemia and socioeconomic indicators. 
 
The objective of this appendix is to provide estimates of any independent associations of 
baseline adult height with the risk of cause-specific death (as well as major vascular 
morbidity) by analysing data from 1,085,949 people who were at risk for a total of 16.1 million 
person-years. 
 
Methods  
Study design 
The current analyses focus on individual participant data on adult height from 121 prospective 
studies that also had information on age and sex at baseline, that did not select participants on 
the basis of having previous chronic disease, that recorded cause-specific mortality and/or 
vascular morbidity (ie, non-fatal myocardial infarction or stroke) using clearly defined criteria; 
and that accrued more than 1 year of follow-up. Details of the contributing study are presented 
Table A3.1 and corresponding study acronyms are in Appendix 4. There were 1,085,949 
participants who had no known history of cardiovascular disease at the baseline examination. 
For 875,782 (81%) of the participants, height was measured using standardised protocols; for 
the remainder, height was self-reported (Table A3.1). In registering fatal outcomes, all 
contributing studies used coding from the International Classification of Diseases to at least 3 
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digits or study-specific classification systems, and ascertainment was based on death 
certificates. Attribution of death refers to the primary cause (or, in its absence, the underlying 
cause) provided. 80 of the 121 contributing studies also involved medical records, autopsy 
findings and other supplementary sources to help classify deaths. 78 studies used standard 
definitions of myocardial infarction based on World Health Organization criteria. 59 studies 
reported diagnosis of strokes on the basis of typical clinical features and brain imaging and 
attributed stroke subtype. 
 
Statistical analyses 
The statistical methods have been described in detail in Chapter 5 on pages 111-116. Height 
was normally distributed and the pooled within-study standard deviation (SD) was 6.5 cm for 
both males and females. Associations of height were assessed in relation to fatal or first-ever 
non-fatal coronary disease or stroke and cause-specific mortality, including deaths from 
vascular disease, cancer, and nonvascular conditions not attributed to cancer, as well as to 
further subdivisions of these outcomes. Participants contributed only the first non-fatal 
outcome or death recorded at age 40 years or older (ie, deaths preceded by non-fatal coronary 
disease or stroke were not included). Subsidiary analysis was done for fatal outcomes without 
censoring of previous non-fatal outcomes. Analyses involved a two-stage approach with 
estimates of association calculated separately within each study before pooling across studies 
by random effects meta-analysis.16 Hazard ratios were calculated using Cox proportional-
hazards regression models stratified by decades of year of birth, and, where appropriate, by 
sex and trial arm.17 The proportional hazards assumptions were satisfied. For the six 
contributing "nested" case-control studies within prospective cohorts, odds ratios were 
calculated with logistic regression models. Provided the disease is relatively rare, hazard ratios 
and odds ratios were assumed to approximate the same relative risk and are collectively 
describe as "risk ratios".18 To avoid over-fitting of the statistical models, studies with fewer than 
five incident cases of an outcome were excluded from the analysis of that particular outcome. 
 
To assess the shape of association, study and sex-specific risk ratios calculated within 
quantiles of baseline values of height were pooled on a loge scale by multivariate random 
effects meta-analysis and plotted against mean height values within each quantile. 95% 
confidence intervals (CIs) were estimates from variances attributed to the groups to reflect the 
amount of information within each group (including the reference group).19  
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When associations were approximately loge-linear, regression coefficients were calculated to 
estimate the risk ratio per one standard deviation greater baseline height. Parallel analyses 
were done in males and females separately. Unless specified otherwise, risk ratios were 
adjusted for age, sex, year of birth and smoking status only. To explore confounding and 
potential biological pathways underlying associations, risk ratios were further adjusted for 
systolic blood pressure (SBP), history of diabetes, body-mass index (BMI), waist 
circumference (WC), waist-to-hip ratio (WHR), total and high density lipoprotein (HDL) 
cholesterol, triglyceride, C-reactive protein (CRP), fibrinogen, alcohol consumption, or 
socioeconomic indicators (ie, educational attainment and occupational category) and raw lung 
function (ie, forced expiratory volume in one second [FEV1] unstandardised for age or height). 
Evidence of heterogeneity was indicated by the I2 statistic.20 Subsidiary analyses were 
corrected for regression dilution in height and covariates,21,22 using serial measurement in 
355,391 participants from 67 cohorts (mean interval: 5.5 years).  
 
All analyses were performed using Stata release 11 (StataCorp LP, College Station, Texas 
USA). 
 
Results 
Characteristics of the contributing studies are shown in Table A3.1. Among the 1,085,949 
participants included, the mean (SD) age at baseline was 55 (10) years; 48% were women. 
Most participants were in Europe (60%) or North America (33%). Median year of baseline 
survey was 1986 (IQR 1976-1992). Although mean height varied across studies, SDs were 
similar across studies (Figure A3.1). Overall mean (SD) height was 173 (6.5) cm in men and 
160 (6.5) cm in women. For both sexes, mean height decreased with age, but increased by 0.5 
to 1.0 cm per decade of birth between 1900 and 1960 (Figure A3.2). 619,984 of the 
participants had information on smoking status, SBP, diabetes, BMI and total cholesterol.  
 
At baseline, there were modest and positive correlations of height with body weight, waist and 
hip circumference and FEV1, but weakly negative correlations with blood pressure, lipids and 
inflammatory markers (Table A3.2 panel A & Figure A3.3). On average, people of white 
European ancestry were 8.46 cm (95% CI 7.48 to 9.44 cm) taller than East-Asians, alcohol 
drinkers were 0.64 cm (95% CI 0.44 to 0.85 cm) taller than non-drinkers, people without 
diabetes were 0.34 cm (95% CI 0.20 to 0.49 cm) taller than those with diabetes, people with 
more education were 5.09 cm (95% CI 4.54 to 5.63 cm) taller than others, and people with 
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office jobs were 1.55 cm (95% CI 1.27 to 5.63 cm) taller than manual workers (Table A3.2 
panel B).  
 
As would be expected for a trait that is stable in middle-aged people, the regression dilution 
ratio for adult height, adjusted for age, sex and year of birth, was close to 1.0, ie, 0.96 (95% CI 
0.95-0.97; Figure A3.4) during a mean interval of about 6 years.  
 
During 16.1 million person-years at risk (median 11.5 years to first outcome), there were a total 
of 174,374 deaths or major non-fatal vascular outcomes, comprising: 19,768 non-fatal 
myocardial infarctions, 26,102 coronary deaths and 161 unspecified coronary events; 11,757 
non-fatal and 9534 fatal strokes; 13,345 deaths from other vascular diseases, 49,722 deaths 
from cancer, 34,527 deaths from non-vascular non-cancer causes, and 9,458 deaths of 
unknown or ill-defined cause (Table A3.3). The overall association of height with death from 
any cause was weakly inverse and possibly curvilinear (Figure A3.5). 
 
Height and cardiovascular diseases 
There were continuous inverse associations for the risk of each of coronary disease and stroke 
across the range of baseline height values, with possible attenuation at higher values (Figures 
A3.5-A3.6). Crude rates of coronary disease per 1000 person-years in the bottom and top 
fifths of baseline height distribution, respectively, were 5.6 and 2.9 in men and 2.6 and 0.9 in 
women. Associations of baseline height with vascular outcomes are shown in Figure A3.7. 
After adjustment for age, sex, smoking status and birth year, risk ratios per one standard 
deviation higher baseline height were 0.93 (95% CI 0.91-0.94) for coronary disease, 0.94 (95% 
CI 0.90-0.97) for ischaemic stroke, 0.90 (95% CI 0.85-0.95) for haemorrhagic stroke, 0.91 
(95% CI 0.84-0.98) for subarachnoid haemorrhage, 0.95 (95% CI 0.92-0.98) for unclassified 
stroke and 0.94 (95% CI 0.89-0.99) for death from heart failure. In contrast, the corresponding 
risk ratios were 1.12 (95% CI 1.03-1.21) for pulmonary embolism and 1.12 (95% CI 1.05-1.20) 
for ruptured aortic aneurysm (Figure A3.7). Risk ratios were not appreciably altered after 
additional adjustment for blood pressure, diabetes, lipids, CRP, fibrinogen, BMI, WC, WHR, 
alcohol consumption or indicators of socioeconomic status (Tables A3.4-A3.5). However, risk 
ratios became non-significant after adjustment for FEV1. Risk ratios for coronary disease and 
stroke appeared to become more extreme with later decade of birth, but risk ratios did not vary 
materially by the other characteristics recorded (Figure A3.8).  
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Height and cancer mortality and non-vascular non-cancer mortality 
Height was continuously and positively associated with total cancer mortality (Figure A3.5 and 
Figure A3.9), though inversely associated with death from oral and stomach cancers. As 
regards other site-specific cancers, height was positively associated with death from 
melanoma, and cancers of the pancreas, endocrine and nervous systems, breast, ovary, 
prostate, colorectum, blood and lung (Figure A3.10). Risk ratios for breast cancer mortality 
were similar across age-at-risk groups (Figure A3.11). With the exception of adjustment for 
FEV1 (which accentuated risk ratios for total cancer mortality), adjustment for several major 
risk factors for chronic disease did not appreciably vary risk ratios for cancer death (Table 
A3.4-A3.5). There were non-significant associations of height with some site-specific cancers 
(eg, liver, connective tissue, oesophagus and bladder). For every 6.5 cm greater height, risk 
ratios were 0.84 (95% CI 0.80-0.89) for chronic obstructive pulmonary disease, 0.89 (95% CI 
0.83-0.96) for mental disorders, 0.89 (95% CI 0.84-0.93) for liver disease, 0.96 (95% CI 0.92-
1.00) for death from external causes and 0.96 (95% CI 0.92-1.00) for pneumonia (Figure 
A3.10 and Figure A3.12).  
 
Sensitivity analyses 
Qualitatively similar results to those reported here were observed in a range of subsidiary 
analyses, such as those that: restricted attention to participants with measured (rather than 
self-reported) height (data not shown); omitted the initial five years of follow-up, current 
smokers, participants of non-European descent (Table A3.5); included fatal outcomes without 
censoring previous non-fatal outcomes (Table A3.6); used fixed effect (Figure A3.12) or sex-
specific (Table A3.5) models; or corrected concurrently for regression dilution in height and in 
potential confounders and mediators (data not shown).  
 
Discussion 
The current analysis of individual participant data from more than 1 million people 
demonstrated that, whereas the risk of death from any cause is 3% lower per 6.5 cm increment 
in height, disaggregation of this overall association reveals stronger and opposing relationships 
with death from a variety of vascular, neoplastic, respiratory and other causes, independent 
from major risk factors. At the two extremes, the risk of death from melanoma is about 25% 
higher per 6.5 cm increment in height, whereas the risk of death from chronic obstructive 
pulmonary disease is about 15% lower for the same difference in height. Because the disease 
associations of height were not appreciably altered after adjustment for long-term levels of 
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smoking, adiposity, blood pressure, lipids, diabetes and inflammation, it reduces the likelihood 
that such factors are major mediators of the associations in this study. Hence, the results of 
our study suggest that variations in adult stature (and, by implication, the determinants of 
height) have pleiotropic effects on major diseases of later life. Furthermore, the current data 
demonstrate that mean adult height in developed countries has increased by 0.5 to 1.0 cm per 
decade for those born between 1900 and 1960.6,13 Consequently, although height is 80 to 90% 
heritable,23,24 these population-wide increases in height have most likely been due to non-
genetic factors. 
 
The current data showed that taller people have a lower risk of death from coronary disease, 
major pathological subtypes of stroke, heart failure, oral and gastric cancers, chronic 
obstructive pulmonary disease, mental disorders, liver diseases and external causes. Some of 
these conditions have been previously associated with height.6,25-28 For example, the inverse 
association between height and coronary disease has been proposed to be due to taller 
people having larger coronary vessel diameters, elevated insulin-like growth factors and/or 
greater lung capacity.6,11,29,30 The last of these mechanisms is supported by the current data, 
since the association of height and coronary disease was markedly attenuated after 
adjustment for FEV1 (though this interpretation is complicated by the fact that lung function is 
itself strongly correlated with body size). In contrast with earlier less powerful studies, the 
current study demonstrated negative associations of similar magnitude between adult stature 
and risk of major pathological subtypes of stroke, a pattern that differs from the differential 
associations previously observed of certain conventional risk factors (eg, pro-atherogenic 
lipids31) with stroke subtypes. The negative association observed between height and death 
from gastric cancer is consistent with the known relevance to this malignancy of Helicobacter 
pylori infection, acquisition of which is related to poorer socioeconomic circumstances in 
childhood.11,32 
 
In contrast with the negative associations observed between height and death from coronary 
disease and stroke, there were positive associations between adult stature and risk of death 
from pulmonary embolism (which could be due to greater propensity to venous thrombosis 
owing to greater venous surface area or more venous valves in taller people33) and ruptured 
aortic aneurysm (which could be due to longer arteries being more prone to rupture34). The 
current data also indicate that taller people have greater risk of death from several common 
malignancies. For some cancers, it has been proposed that because taller people have larger 
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organs, they have greater numbers of cells at risk of malignant transformation and/or 
proliferation.35 For breast and other hormone-related cancers, it has been proposed that taller 
people have tumour-inducing biochemical alterations6,12 and/or genes linked with both skeletal 
growth and cancer risk.36 
 
The current study has several strengths. These include the large sample size (174,374 deaths 
or major non-fatal vascular outcomes recorded during more than 16 million person-years at 
risk), standardised approaches to adjust for potential confounding factors, serial assessment of 
risk factors in 355,000 participants, extended period of follow-up and information about a 
variety of disease outcomes. Furthermore, the current study investigated several factors that 
could mediate associations of height and disease. The current study minimised potential bias 
by involving data from only prospective cohort studies. The generalisability of the current 
findings to populations in economically developed Western countries is supported by broadly 
consistent results across 121 prospective cohorts in 24 countries. Due to the wide age ranges 
and periods of recruitment of the participants in our study, the current study was able to 
quantify reliably the trend toward increasing height in successive birth cohorts.  
 
Despite this study’s strengths, residual bias could persist due to unmeasured or imprecisely 
measured confounding factors (eg, dietary factors and socioeconomic factors, respectively). 
Apart from for coronary disease and stroke, the current study studied only fatal outcomes. 
Future studies will seek to investigate whether height-related genetic loci5 are associated with 
the height-related diseases identified in this report, and to determine whether ethnic or 
geographical variation in genetic make-up could explain the current results. However, the 
scope for the latter explanation has been reduced because more than 90% of the participants 
in this study were of white European descent. Further studies are also needed to investigate 
more specific early-life exposures6 in relation to adult-onset diseases. Although the 
associations observed of height with major disease are generally too weak to inform disease 
prediction, the current results suggest avenues for new aetiological insights. 
 
Conclusion 
Adult stature, which is an indicator of the interplay of genetic and early-life factors, has 
opposing relationships with a variety of vascular, neoplastic, respiratory and other causes, 
independent from major risk factors. These data underscore the pleiotropy and potential 
importance of early-life influences on major adult-onset diseases. 
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Table A3.1 Characteristics of individuals studies with complete information on height, age and 
sex  
 
Males Females 
AFTCAPS 6605 USA Assessed 179 (7) 164 (6) 58 (7) 5608 (85) 5.1 (4.3 to 6.7)
ALLHAT 28087 USA/Canada/Puerto 
Rico/US Virgin Islands
Assessed 174 (9) 160 (9) 66 (8) 13775 (49) 4.4 (0.8 to 6.7)
AMORIS 58117 Sweden Assessed 178 (7) 165 (6) 46 (10) 33287 (57) 13.2 (6.6 to 17.0)
ARIC 14604 USA Assessed 176 (7) 162 (6) 54 (6) 6303 (43) 14.0 (5.0 to 15.7)
ATENA 4750 Italy Assessed  - 156 (6) 50 (7) 0 (0) 6.7 (5.2 to 8.1)
ATS_SAR 4264 Italy Assessed 165 (7) 153 (6) 46 (8) 2066 (48) 8.7 (5.7 to 8.7)
ATTICA 1533 Greek Assessed 174 (7) 162 (7) 51 (11) 786 (51) 5.0 (5.0 to 5.0)
AUSDIAB 8794 Australia Assessed 176 (7) 162 (7) 53 (12) 3873 (44) 5.0 (4.9 to 8.5)
BHS 5991 Australia Assessed 174 (7) 161 (6) 45 (16) 2829 (47) 26.3 (7.1 to 33.2)
BRHS 6810 UK Assessed 173 (7)  - 50 (6) 6810 (100) 24.5 (4.7 to 25.4)
BRUN 817 Italy Assessed 172 (7) 160 (6) 58 (11) 398 (49) 20.2 (3.9 to 20.5)
BUPA 20889 UK Assessed 177 (7)  - 47 (8) 20889 (100) 23.7 (11.3 to 26.7)
BWHHS 2797 UK Assessed  - 159 (6) 68 (5) 0 (0) 7.3 (3.1 to 8.4)
CAPS 2134 UK Assessed 171 (6)  - 52 (5) 2134 (100) 13.0 (4.0 to 13.0)
CASTEL 2504 Italy Assessed 168 (7) 155 (6) 73 (5) 955 (38) 11.2 (2.4 to 14.0)
CHA 34250 USA Assessed 176 (7) 163 (7) 41 (13) 19894 (58) 32.0 (11.6 to 35.6)
CHARL 2031 USA Assessed 175 (7) 162 (6) 50 (11) 952 (47) 24.1 (3.5 to 39.9)
CHS1 3787 USA Assessed 173 (6) 159 (6) 72 (5) 1441 (38) 12.1 (2.0 to 12.9)
CHS2 464 USA Assessed 173 (7) 160 (7) 72 (5) 173 (37) 9.1 (1.9 to 9.5)
COPEN 8197 Denmark Assessed 176 (7) 163 (7) 58 (15) 3509 (43) 13.2 (2.7 to 14.9)
DISCO 1925 Italy Assessed 165 (7) 154 (6) 50 (11) 843 (44) 5.5 (5.5 to 9.5)
DRECE 2818 Spain Assessed 170 (8) 158 (6) 41 (11) 1360 (48) 16.4 (15.5 to 16.6)
DUBBO 2071 Australia Assessed 173 (6) 160 (6) 68 (7) 867 (42) 14.1 (1.8 to 14.9)
EAS 1036 Scotland Assessed 173 (7) 160 (6) 64 (6) 515 (50) 15.2 (2.8 to 15.8)
EMOFRI 360 Italy Assessed 174 (6) 161 (6) 55 (6) 176 (49) 6.8 (6.5 to 7.2)
EPESEBOS 770 USA Self-reported 170 (8) 157 (7) 77 (4) 263 (34) 4.0 (1.1 to 4.5)
EPESEIOW 1229 USA Assessed 171 (8) 157 (8) 78 (5) 369 (30) 4.8 (1.6 to 4.9)
EPESENCA 1025 USA Self-reported 173 (7) 158 (6) 77 (5) 338 (33) 4.0 (1.3 to 4.6)
EPESENHA 606 USA Self-reported 172 (8) 160 (6) 78 (5) 230 (38) 4.4 (1.5 to 4.7)
EPICNOR 1426 UK Assessed 173 (7) 159 (6) 66 (8) 967 (68) 7.1 (2.2 to 9.3)
ESTHER 8164 Germany Assessed 174 (7) 162 (6) 62 (7) 3447 (42) 5.0 (2.0 to 5.9)
FIA 2509 Sweden Assessed 176 (7) 162 (6) 54 (8) 2026 (81) 4.2 (0.5 to 9.6)
FINE_FIN 278 Finland Assessed 169 (7)  - 77 (5) 278 (100) 6.9 (1.1 to 10.0)
FINE_IT 461 Italy Assessed 166 (7)  - 72 (4) 461 (100) 9.8 (1.9 to 21.4)
FINRISK92 5776 Finland Assessed 176 (7) 162 (6) 44 (11) 2667 (46) 16.9 (7.9 to 16.9)
FINRISK97 7224 Finland Assessed 175 (7) 162 (6) 49 (12) 3538 (49) 11.8 (6.7 to 11.9)
FLETCHER 686 New Zealand Assessed 175 (7) 162 (6) 52 (14) 545 (79) 5.6 (2.2 to 6.4)
FRAMOFF 2711 USA Assessed 175 (7) 161 (6) 60 (9) 1192 (44) 5.2 (3.1 to 7.0)
FUNAGATA 2751 Japan Assessed 161 (7) 150 (6) 57 (12) 1208 (44) 10.2 (4.7 to 12.0)
GLOSTRUP 210 Denmark Assessed 175 (7) 162 (8) 50 (9) 171 (81) 4.5 (0.5 to 10.5)
GOH 5647 Israel Assessed 168 (7) 157 (7) 43 (8) 2750 (49) 29.0 (11.9 to 36.0)
GOTO13 769 Sweden Assessed 175 (6)  - 54 (2) 769 (100) 23.3 (4.5 to 30.5)
GOTO33 733 Sweden Assessed 178 (6)  - 51 (0) 733 (100) 12.8 (5.8 to 13.1)
GOTO43 775 Sweden Assessed 178 (7)  - 50 (0) 775 (100) 11.0 (7.9 to 11.7)
GOTOW 1425 Sweden Assessed  - 164 (6) 47 (6) 0 (0) 32.2 (10.6 to 32.7)
GREPCO 794 Italy Assessed  - 159 (6) 44 (8) 0 (0) 7.9 (7.7 to 8.4)
GRIPS 5785 Germany Assessed 175 (6)  - 48 (5) 5785 (100) 9.8 (4.8 to 10.0)
GUBBIO 3412 Italy Assessed 167 (7) 155 (6) 55 (13) 1515 (44) 8.4 (5.6 to 9.4)
HBS 1300 Finland Assessed 177 (6)  - 60 (4) 1300 (100) 20.5 (6.0 to 20.5)
HELSINAG 432 Finland Assessed 172 (5) 159 (6) 79 (4) 109 (25) 9.1 (1.9 to 11.0)
HISAYAMA 2576 Japan Assessed 162 (6) 149 (6) 59 (12) 1088 (42) 14.0 (3.2 to 14.0)
HONOL 2530 USA Assessed 162 (6)  - 78 (4) 2530 (100) 6.2 (1.4 to 7.6)
HOORN 2231 Netherlands Assessed 176 (7) 163 (6) 61 (7) 983 (44) 8.8 (3.6 to 9.9)
HPFS 48810 USA Self-reported 178 (7)  - 54 (10) 48810 (100) 20.2 (6.2 to 21.9)
IKNS 8048 Japan Assessed 167 (7) 150 (6) 58 (10) 3302 (41) 11.1 (5.1 to 18.6)
ISRAEL 7826 Israel Assessed 172 (7)  - 49 (7) 7826 (100) 23.3 (7.9 to 23.9)
KARELIA 10784 Finland Assessed 173 (6) 159 (6) 41 (10) 5199 (48) 36.7 (6.7 to 36.9)
KIHD 2063 Finland Assessed 162 (6)  - 53 (5) 2063 (100) 20.1 (3.0 to 24.1)
LASA 1861 Netherlands Assessed 174 (7) 162 (6) 69 (9) 839 (45) 9.8 (1.5 to 10.4)
LEADER 927 UK Assessed 172 (7)  - 68 (9) 927 (100) 4.2 (0.9 to 6.2)
MALMO 32486 Sweden Assessed 177 (7) 164 (6) 46 (7) 21916 (67) 18.2 (7.9 to 22.6)
Follow-up (yrs)
 median (5th & 95th 
percentiles)
Age at survey 
(yrs) mean (sd)
Height (cm) 
mean (sd)
Study design/
studya
Male (%)Measurement
of height
CountryTotal No. with 
height 
measured
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Table A3.1 con’t Characteristics of individuals studies with complete information on height, age 
and sex 
 
Males Females 
MATISS83 2562 Italy Assessed 164 (6) 154 (6) 51 (10) 1202 (47) 18.7 (6.8 to 19.5)
MATISS87 2117 Italy Assessed 165 (6) 153 (6) 52 (10) 937 (44) 15.6 (6.8 to 16.2)
MATISS93 1214 Italy Assessed 167 (6) 155 (6) 49 (9) 587 (48) 8.3 (7.1 to 9.3)
MCVDRFP 23169 Netherlands Assessed 177 (7) 165 (7) 42 (10) 10727 (46) 16.8 (13.6 to 18.9)
MESA 6768 USA Assessed 174 (8) 160 (7) 62 (10) 3190 (47) 4.8 (2.5 to 5.2)
MICOL 19401 Italy Assessed 169 (7) 157 (7) 51 (10) 10865 (56) 5.9 (4.5 to 7.1)
MOGERAUG1 871 Germany Assessed 172 (6)  - 54 (6) 871 (100) 13.0 (3.6 to 13.4)
MOGERAUG2 3974 Germany Assessed 173 (7) 161 (7) 53 (12) 1953 (49) 7.9 (2.3 to 8.4)
MOGERAUG3 3378 Germany Assessed 173 (7) 160 (6) 55 (10) 1667 (49) 3.0 (1.8 to 3.6)
MONFRI86 1413 Italy Assessed 172 (7) 160 (6) 49 (9) 695 (49) 16.7 (7.6 to 16.9)
MONFRI89 1346 Italy Assessed 172 (6) 160 (6) 49 (8) 666 (49) 13.6 (7.5 to 13.7)
MONFRI94 1294 Italy Assessed 173 (7) 161 (6) 49 (8) 630 (49) 8.5 (8.0 to 8.8)
MONICA 3663 Italy Assessed 170 (7) 158 (6) 49 (9) 1830 (50) 6.5 (2.1 to 10.5)
MORGEN 17737 Netherlands Assessed 178 (7) 165 (7) 46 (9) 8060 (45) 10.8 (8.5 to 13.1)
MOSWEGOT 4170 Sweden Assessed 178 (7) 166 (6) 47 (11) 1983 (48) 13.9 (7.6 to 19.6)
MRCOLD 10233 UK Assessed 169 (7) 155 (7) 80 (4) 3861 (38) 8.7 (1.2 to 11.7)
MRFIT 12846 USA Assessed 176 (7)  - 47 (6) 12846 (100) 6.9 (4.4 to 7.8)
NCS1 24201 Norway Assessed 176 (6) 163 (6) 42 (4) 11915 (49) 16.1 (13.5 to 16.7)
NCS2 13056 Norway Assessed 176 (6) 163 (5) 42 (4) 6654 (51) 17.2 (12.8 to 17.8)
NCS3 10029 Norway Assessed 173 (7) 160 (6) 42 (4) 5203 (52) 18.1 (12.1 to 18.8)
NFR 3102 Italy Assessed 169 (6)  - 55 (5) 3102 (100) 10.2 (6.1 to 11.2)
NHANESI 9355 USA Assessed 174 (7) 161 (6) 50 (16) 3646 (39) 19.0 (4.0 to 21.1)
NHANESIII 14658 USA Assessed 175 (8) 161 (7) 50 (18) 6765 (46) 14.4 (4.0 to 17.7)
NHS 119546 USA Self-reported  - 164 (6) 43 (7) 0 (0) 28.6 (12.0 to 30.3)
NPHSI 1389 UK Assessed 172 (7)  - 52 (7) 1389 (100) 14.6 (4.4 to 18.6)
NPHSII 2965 UK Assessed 174 (7)  - 57 (3) 2965 (100) 8.3 (3.4 to 10.4)
NSHS 1651 Canada Assessed 174 (7) 160 (7) 54 (15) 790 (48) 9.7 (3.7 to 10.0)
OB43 3618 Italy Assessed 169 (7) 157 (7) 47 (8) 1737 (48) 7.5 (5.1 to 9.1)
OSAKA 12379 Japan Assessed 167 (6) 152 (6) 52 (10) 8414 (68) 10.2 (3.9 to 18.8)
OSLO 17257 Norway Assessed 178 (7)  - 44 (6) 17257 (100) 29.5 (10.9 to 30.5)
OYABE 5088 Japan Assessed 161 (7) 149 (6) 57 (11) 1568 (31) 10.4 (5.3 to 10.6)
PARIS1 7073 France Assessed 174 (5)  - 47 (2) 7073 (100) 22.9 (7.6 to 26.1)
PREVEND 6934 Netherlands Assessed 179 (7) 167 (7) 50 (11) 3380 (49) 7.6 (4.7 to 8.2)
PRHHP 6344 Caribbean Assessed 165 (7)  - 54 (6) 6344 (100) 8.3 (5.2 to 12.0)
PRIME 9581 France / NI Assessed 173 (7)  - 55 (3) 9581 (100) 5.2 (5.0 to 7.3)
PROCAM 20174 Germany Assessed 175 (7) 163 (7) 44 (10) 14608 (72) 10.0 (3.9 to 18.9)
PROSPER 3253 Scotland/Ireland/Netherland Assessed 173 (7) 159 (7) 75 (3) 1351 (42) 3.2 (1.1 to 3.8)
QUEBEC 988 Canada Assessed 171 (7)  - 56 (7) 988 (100) 5.3 (3.4 to 5.6)
RANCHO 1785 USA Assessed 175 (7) 161 (6) 68 (11) 739 (41) 14.2 (2.0 to 18.1)
REYK 16814 Iceland Assessed 177 (6) 163 (6) 52 (9) 8046 (48) 24.7 (6.3 to 37.1)
RF2 5433 Italy Assessed 169 (7) 157 (7) 44 (9) 2551 (47) 13.7 (11.3 to 14.1)
ROTT 4751 Netherlands Assessed 175 (7) 162 (7) 68 (8) 1801 (38) 12.0 (3.1 to 14.2)
SHHEC 13533 UK Assessed 173 (7) 160 (6) 49 (8) 6587 (49) 10.0 (6.3 to 10.0)
SHS 4148 USA Assessed 173 (6) 160 (6) 56 (8) 1622 (39) 12.4 (2.0 to 14.3)
SPEED 2126 UK Assessed 172 (7)  - 55 (4) 2126 (100) 16.7 (3.3 to 18.2)
TARFS 3287 Turkey Assessed 169 (7) 156 (7) 46 (13) 1636 (50) 12.9 (2.3 to 17.6)
TOYAMA 4523 Japan Assessed 168 (6) 154 (6) 46 (7) 2907 (64) 12.7 (7.8 to 12.8)
TROMSØ 21861 Norway Assessed 177 (7) 164 (6) 43 (14) 10326 (47) 18.8 (5.1 to 19.3)
ULSAM 2284 Sweden Assessed 176 (6)  - 50 (1) 2284 (100) 28.0 (6.5 to 35.9)
USPHS 936 USA Self-reported 178 (7)  - 60 (9) 936 (100) 0.0 (0.0 to 0.0)
USPHS2 10716 USA Self-reported 179 (8)  - 64 (8) 10716 (100) 10.9 (4.9 to 11.5)
VHMPP 120581 Austria Assessed 174 (7) 162 (6) 48 (14) 55110 (46) 13.1 (2.2 to 16.7)
VITA 8996 Italy Assessed 174 (7) 162 (6) 51 (8) 4031 (45) 3.3 (1.7 to 5.3)
WHIHABPS 1222 USA Assessed  - 161 (6) 68 (6) 0 (0) 6.8 (1.2 to 9.3)
WHITEI 4019 UK Assessed 174 (7)  - 76 (5) 4019 (100) 8.2 (2.0 to 8.4)
WHITEII 10201 UK Assessed 176 (7) 162 (7) 45 (6) 6805 (67) 12.4 (4.9 to 14.1)
WHS 27758 USA Self-reported  - 164 (6) 55 (7) 0 (0) 10.2 (8.4 to 10.8)
WOSCOPS 6192 UK Assessed 172 (7)  - 55 (6) 6192 (100) 4.8 (2.9 to 6.0)
ZARAGOZA 2920 Spain Assessed 165 (7) 153 (7) 59 (12) 1205 (41) 5.1 (3.8 to 5.1)
ZUTE 391 Netherlands Assessed 173 (7)  - 76 (4) 391 (100) 8.6 (1.0 to 10.1)
TOTAL 1085949 173 (6.5) 160 (6.5) 55 (10) 563692 (52) 13.7 (3.3 to 30.1)
Study design/
studya
Total No. with 
height 
measured
Country Measurement
of height
Height (cm) 
mean (sd)
Age at survey 
(yrs) mean (sd)
Male (%) Follow-up (yrs)
median (5th & 95th 
percentiles)
 
aAppendix 4 lists study acronyms. Abbreviations: Assessed = height was assessed using standardised protocol; Self-
reported = height was measured by the subject itself. 
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Table A3.2 Summary of data available and associations with height 
 
A 
 
No of 
studies
No of 
subjects
Mean (SD) 
or %
Height (cm) 121 1085949 167 (6.5*)  -
Physical measurements
BMI (kg/m2) 121 1081839 26 (4)  -0.32 (-0.35 to -0.28)
Weight (kg) 121 1081839 73 (13) 4.82 (4.74 to 4.91)
Waist circumference (cm) 54 176957 90 (12) 1.40 (1.29 to 1.50)
Hip circumference (cm) 50 174252 101 (9) 1.86 (1.76 to 1.96)
Waist-to-hip ratio 50 174150 0.89 (0.08)  -0.003 (-0.003 to -0.002)
SBP (mmHg) 117 840352 136 (19)  -0.31 (-0.41 to -0.22)
DBP (mmHg) 117 841842 82 (11) 0.14 (0.09 to 0.20)
Fasting glucose (mmol/l) 62 313423 5.5 (1.6)  -0.01 (-0.02 to 0.00)
FEV1 (l/1min) 10 72480 2.75 (0.77) 0.21 (0.19 to 0.24)
Lipid markers
Total cholesterol (mmol/l) 117 824332 5.8 (1.1)  -0.05 (-0.06 to -0.04)
LDL cholesterol (mmol/l) 13 61006 3.67 (0.87)  -0.04 (-0.05 to -0.02)
Non-HDL cholesterol (mmol/l) 100 452696 4.48 (1.11)  -0.04 (-0.05 to -0.03)
HDL cholesterol (mmol/l) 100 453106 1.34 (0.37)  -0.01 (-0.01 to -0.00)
Loge triglyceride (mmol/l) 99 661385 0.33 (0.52)  -0.01 (-0.01 to -0.01)
Apo AI (g/l) 30 124035 1.47 (0.27)  -0.01 (-0.01 to -0.00)
Apo B (g/l) 31 126523 1.10 (0.28)  -0.01 (-0.02 to -0.02)
Loge Lp(a) (mg/dl) 31 104007 2.29 (1.25)  -0.00 (-0.02 to 0.01)
Inflammatory markers
Loge CRP (mg/l) 49 138177 0.64 (1.10)  - 0.04 (-0.05 to -0.03)
Fibrinogen (µmol/l) 46 201724 9.3 (2.1)  -0.08 (-0.10 to -0.07)
Albumin (g/l) 39 150324 43 (4)  -0.01 (-0.04 to 0.01)
Loge leukocyte count(x10^9/l) 37 135340 1.84 (0.27)  -0.02 (-0.02 to -0.01)
Loge Interleukin 6 (ng/l) 10 19417 0.47 (0.66)  -0.02 (-0.03 to 0.00)
Summary of available data
on height
Difference (95% CI) in row 
variables per 1-SD (6.5cm) 
higher height values†
 
 
*Same pooled standard deviation (SD) in males and females. 
†Change in row variable per 1-SD (6.5 cm) higher height levels, adjusted for age, sex and year of birth, pooled across 
studies using random effects meta-analysis. 
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Table A3.2 con’t Summary of data available and associations with height 
 
B 
 
No of 
studies
No of 
subjects
Mean (SD) 
or %
Age at survey (yrs) 121 1085949 55 (10)  -1.48 (-1.60 to -1.36)
Sex 121 1085949
    Female 522257 48%  -12.9 (-13.0 to -12.7)
    Male 563692 52% Reference
Ethnicity 93 549459
    East Asian 39800 7% -8.46 (-9.44 to -7.48)
    Black 29895 5% -0.30 (-1.12 to 0.52)
    Other 11369 2% -5.28 (-6.14 to -4.42)
    White 468395 85% Reference
Smoking status 120 1010302
    Current 315789 31% -0.01 (-0.10 to 0.08)
    Not current 694513 69% Reference
Alcohol status 92 511895
    Current 325781 64% 0.64 (0.44 to 0.85)
    Not current 186114 36% Reference
History of diabetes 110 833766
   Yes 39106 5% -0.34 (-0.49 to -0.20)
    No 794660 95% Reference
Level of education reached 61 374737
    Tertiary 106396 28% 5.09 (4.54 to 5.63)
    Secondary 187779 50% 3.64 (3.19 to 4.09)
    Primary 66758 18% 2.05 (1.62 to 2.47)
    No schooling 13804 4% Reference
Occupation or job 59 360531
    Office 127181 35% 1.55 (1.27 to 1.84)
    Not working 90013 25% 0.26 (-0.11 to 0.62)
    Other 47468 13% 0.87 (0.48 to 1.25)
    Manual 95869 27% Reference
Summary of available data
on height
Difference (95% CI) in 
height per 1 SD higher 
level of row variable or 
compared to reference 
category (cm)‡
 
 ‡Change in height levels per 1 standard deviation (SD) higher levels of row variables or compared to reference category, 
adjusted for age, sex and year of birth, pooled across studies using random effects meta-analysis.  
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Table A3.3 Summary of events of individual studies with complete information on height, age and sex 
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ATTICA 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0 13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 1 0 0 0 0 0 0 0 0 0 0 50
AUSDIAB 136 76 80 40 12 2 5 17 3 1 1 0 3 2 3 116 0 16 3 1 1 6 22 2 3 2 10 13 7 5 8 60 10 1 4 0 9 2 1 13 4 3 36 288
BHS 931 931 519 221 23 21 4 144 11 22 9 0 37 38 9 547 6 83 12 23 6 22 87 60 16 17 47 18 13 6 34 478 53 4 38 28 41 11 32 106 45 22 17 1973
BRHS 1858 776 1215 516 7 13 10 475 7 5 12 0 50 11 8 745 11 84 34 45 20 29 248 62 0 39 39 23 6 2 0 305 33 5 4 6 5 18 44 95 27 8 134 1960
BRUN 151 80 66 63 43 19 0 0 0 0 7 0 5 9 0 83 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 74 12 3 0 11 0 3 26 8 5 3 3 240
BUPA 1509 1509 1016 254 31 37 12 145 3 14 23 0 94 30 2 1383 11 189 72 67 21 86 287 158 0 48 132 64 32 15 0 618 115 12 4 35 16 50 61 92 56 30 37 3547
BWHHS 197 30 90 91 0 1 0 90 0 1 3 0 4 1 2 116 1 13 3 7 1 6 18 0 10 6 5 4 0 1 14 69 4 2 1 1 9 3 10 12 8 0 3 218
CAPS 291 152 251 18 3 3 1 9 0 4 7 0 3 1 1 127 1 18 5 12 1 5 46 4 0 3 8 5 1 1 0 63 11 1 0 2 1 5 3 21 7 2 0 342
CASTEL 522 522 95 107 0 0 0 107 0 0 29 74 0 217 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 299 0 59 0 0 0 28 0 37 0 0 18 1117
CHA 4820 4820 3000 786 116 154 39 375 119 126 62 3 88 174 32 3630 38 403 73 103 73 211 940 253 95 73 395 122 36 46 269 2774 346 195 146 114 181 184 323 436 177 105 389 11613
CHARL 950 585 522 264 30 34 5 186 32 21 11 0 11 13 5 297 4 26 14 16 2 14 88 20 1 5 17 9 3 2 19 282 17 16 32 12 5 17 36 43 34 16 60 1224
CHS1a 1066 258 571 443 346 62 0 35 0 0 0 0 0 0 0 385 0 41 7 13 10 24 95 33 13 6 41 9 2 0 25 392 47 19 1 69 48 8 45 33 37 16 11 1046
CHS2a 107 28 53 48 39 5 0 4 0 0 0 0 0 0 0 34 0 4 0 2 0 4 15 4 0 1 0 0 0 0 1 26 2 2 1 5 1 0 4 1 2 2 1 89
COPEN 1372 352 514 592 368 73 16 122 9 22 26 13 15 59 0 531 7 47 21 13 9 31 141 31 17 22 28 11 6 5 45 643 58 41 28 25 27 30 135 80 47 18 150 1676
DISCOc 12 12 9 3 1 1 0 1 0 0 0 0 0 0 0 11 0 2 0 0 0 0 3 0 2 1 1 0 0 0 0 6 3 0 1 0 0 2 0 0 0 0 0 29
DRECE 29 29 15 6 0 1 0 4 0 1 1 0 0 2 0 63 2 12 1 4 1 5 13 1 1 2 3 1 1 2 6 43 5 4 5 0 0 6 1 6 3 0 0 135
DUBBO 542 135 284 192 76 20 3 87 4 0 5 0 6 28 0 169 2 18 3 3 2 8 28 16 4 6 18 2 1 0 7 169 24 12 1 9 12 6 26 24 14 8 18 491
EAS 169 80 82 68 0 3 2 60 1 2 1 0 4 3 0 126 1 17 6 9 1 5 33 14 3 1 7 0 1 0 8 70 2 2 0 5 5 0 12 16 6 3 8 284
EMOFRIb 8 4 2 3 2 1 0 0 3 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 0 0 0 0 0 0 0 0 0 1 9
EPESEBOS 94 38 38 26 17 6 2 1 19 1 2 0 0 2 0 22 0 3 2 2 1 1 2 4 0 0 1 0 2 0 0 26 3 2 0 1 0 0 6 1 2 4 9 95
EPESEIOW 153 69 57 58 22 6 2 26 12 2 1 0 1 14 0 24 0 2 1 0 1 3 5 2 1 2 3 0 0 0 3 46 5 6 1 0 0 3 8 3 2 7 25 164
EPESENCA 122 47 49 51 30 6 0 15 12 0 0 0 0 7 0 35 0 5 1 1 0 1 14 5 0 1 3 0 0 0 0 33 5 4 1 0 0 1 9 2 3 3 11 126
EPESENHA 88 52 21 21 10 2 0 9 31 1 0 0 0 4 0 4 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 20 2 2 0 0 1 2 7 2 1 1 21 97
ESTHER 244 22 89 151 3 1 1 146 0 0 0 0 2 0 0 55 1 6 1 1 1 5 17 2 1 1 3 3 1 2 3 17 1 1 2 0 0 2 0 3 4 0 7 101
FINE_FIN 112 63 71 29 8 1 0 16 0 2 2 0 0 4 0 40 0 5 0 2 0 1 14 11 0 0 3 0 0 0 0 45 9 1 4 8 0 0 12 5 2 0 1 149
FINE_IT 210 142 67 104 4 5 0 85 1 5 0 2 1 19 1 108 2 22 2 11 3 5 17 19 0 6 7 5 0 1 0 47 15 0 1 0 2 4 5 4 9 1 32 329
FINRISK92 325 80 163 137 86 39 3 6 1 2 6 2 1 6 0 85 2 9 2 9 4 6 18 3 3 0 2 5 2 3 10 104 48 5 0 2 2 6 14 1 8 4 1 270
FINRISK97 259 69 121 109 76 19 1 13 0 2 11 0 1 10 0 70 1 5 3 6 3 6 12 5 3 0 6 3 2 0 4 80 29 5 1 2 0 4 22 3 5 0 2 221
FRAMOFF 77 4 52 25 24 1 0 0 0 0 0 0 0 0 0 51 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 27 0 0 0 0 0 0 0 0 0 0 18 100
FUNAGATA 171 63 27 138 69 19 4 46 0 0 0 0 2 1 1 105 1 17 5 20 5 7 22 0 1 2 4 0 0 0 5 57 13 4 1 0 0 3 19 0 5 5 7 232
GOH 602 602 281 138 2 12 3 76 67 13 9 15 4 19 4 337 8 43 3 19 10 24 40 16 9 8 33 17 1 2 26 329 45 19 46 15 4 21 17 45 30 29 701 1969
GOTO13 373 43 217 116 0 1 0 115 0 0 6 5 3 18 0 115 1 14 7 8 3 8 18 24 0 4 6 2 3 1 0 50 2 2 1 8 0 6 14 5 4 1 43 251
GOTO33 44 22 27 8 0 0 0 8 2 0 2 0 0 0 0 27 1 3 0 6 0 1 7 2 0 0 2 1 0 0 0 29 9 0 1 7 0 2 2 2 0 0 3 81
GOTO43 47 4 29 16 12 1 1 2 0 0 0 0 1 0 0 16 0 0 0 1 0 0 3 0 0 0 4 3 0 1 0 4 2 0 0 0 0 2 0 0 0 0 1 25
GOTOW 369 131 146 178 2 0 0 175 2 0 0 0 1 1 1 154 0 1 0 1 0 0 14 0 15 0 19 0 1 0 19 118 76 21 1 0 4 0 2 2 1 0 4 407
GREPCOc 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5
GRIPS 449 47 299 103 0 0 0 103 0 0 13 17 3 10 0 108 2 18 0 11 3 6 34 3 0 5 10 7 1 1 0 69 30 4 0 0 0 7 3 3 16 3 1 225
GUBBIOc 109 109 71 29 11 2 1 13 0 2 1 0 0 0 1 95 2 8 1 12 9 5 12 3 5 2 8 3 0 3 9 35 15 0 0 0 0 6 2 5 0 1 3 242
HBS 131 131 87 27 0 0 0 27 0 0 0 0 0 0 0 158 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 112 27 0 0 0 0 0 0 0 0 0 10 411
HELSINAG 109 109 42 43 22 3 0 3 2 2 8 0 3 1 2 38 0 3 1 4 1 3 4 2 1 3 2 0 0 0 2 75 2 0 0 12 1 0 44 1 6 1 16 238
HISAYAMA 356 76 77 220 148 49 21 0 1 10 2 0 12 2 2 154 1 19 4 22 25 11 30 2 2 0 12 3 0 0 2 155 24 7 0 0 1 13 42 11 19 5 2 387
HONOL 314 110 156 133 12 40 2 75 3 4 1 0 7 0 1 183 3 17 9 28 1 9 41 30 0 0 26 2 0 2 0 158 18 7 7 37 0 1 17 27 8 1 88 539
HOORN 172 70 73 53 3 4 0 46 12 0 3 13 4 12 0 85 1 9 3 6 2 5 19 3 4 2 2 4 0 0 2 18 5 1 0 1 0 0 6 3 0 1 40 213
HPFS 4543 4543 2634 767 102 133 40 180 59 14 45 366 149 218 12 4527 70 499 145 99 68 355 804 667 0 181 740 211 130 45 0 3722 688 158 93 337 363 131 313 391 204 190 373 13165
IKNS 495 154 84 344 158 71 25 90 2 0 1 0 3 57 0 297 4 24 12 72 27 32 18 7 1 3 10 3 2 1 4 250 59 6 4 3 0 14 88 11 13 17 59 760
ISRAEL 1000 1000 732 268 0 0 0 268 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1572 2572
KARELIA 3273 1040 2036 971 71 48 40 804 16 25 41 3 18 89 3 695 9 46 12 54 22 38 156 20 28 9 70 19 11 9 55 840 239 42 22 27 27 27 244 41 49 23 12 2587
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Table A3.3 con’t Summary of events of individual studies with complete information on height, age and sex 
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KIHD 586 61 404 153 111 35 2 3 0 3 2 0 5 2 1 146 3 14 2 6 5 19 34 15 0 3 12 8 6 3 0 131 43 3 1 2 14 20 8 6 12 2 7 345
LASA 52 0 33 19 0 0 0 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 490 490
MALMO 2418 1185 2047 143 36 49 21 16 6 6 17 1 46 18 3 1274 27 108 25 69 21 91 335 74 38 36 106 59 36 19 52 667 169 14 25 51 10 87 45 93 53 7 163 3289
MATISS83b 336 196 83 99 26 10 3 57 71 11 1 0 0 54 0 90 1 3 0 2 3 1 12 0 0 0 6 3 0 3 2 60 9 0 9 3 2 11 3 6 3 4 65 411
MATISS87b 175 95 45 58 9 8 2 39 36 3 0 1 1 27 0 46 0 2 0 3 1 1 7 1 1 0 1 2 0 2 0 33 11 0 1 2 1 4 0 1 2 5 33 207
MATISS93b 31 13 14 7 1 2 1 3 4 1 0 0 0 5 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 1 0 1 0 0 1 0 0 1 2 5 29
MCVDRFP 457 457 197 97 15 31 14 32 19 8 8 8 16 27 4 852 8 82 23 32 6 48 247 26 27 12 60 19 18 16 97 358 70 13 23 13 12 22 19 73 45 8 113 1780
MESA 173 21 83 84 68 13 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 122 143
MICOLc 150 150 105 33 7 3 0 20 0 0 3 0 3 0 2 248 5 25 5 20 15 16 75 2 7 3 16 10 4 5 14 94 20 0 3 0 0 41 4 8 6 3 24 516
MOGERAUG1 108 61 79 5 0 2 0 2 0 0 5 2 2 10 1 40 1 7 1 5 1 3 8 1 0 1 1 2 0 0 0 25 7 0 2 3 1 1 3 4 2 0 0 126
MOGERAUG2 130 67 105 7 1 1 1 3 0 1 4 1 0 8 0 77 3 14 0 4 2 6 16 2 4 1 6 2 1 1 5 53 11 2 2 7 0 7 2 10 5 2 3 200
MOGERAUG3 36 25 18 5 2 1 0 2 0 3 2 0 0 3 0 21 1 5 0 2 1 1 2 1 1 0 3 2 0 0 0 9 2 0 1 2 0 1 1 0 0 0 0 55
MONFRI86b 108 62 28 26 14 5 2 5 44 0 2 1 1 4 0 41 0 0 1 2 3 0 5 0 0 0 1 1 0 0 1 22 6 0 1 0 1 5 1 0 1 2 42 167
MONFRI89b 82 43 28 20 10 5 0 5 23 0 2 0 1 6 0 16 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 23 4 1 0 0 0 6 2 0 3 1 18 100
MONFRI94b 39 13 10 17 6 7 1 2 9 0 0 1 1 0 0 7 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 7 1 0 0 0 0 3 1 0 1 0 13 40
MONICAc 38 38 28 8 0 1 0 5 0 0 0 0 0 0 0 45 0 2 1 8 4 0 10 0 2 1 1 1 1 0 1 17 5 0 0 0 0 3 0 2 1 2 0 100
MORGEN 149 149 77 24 3 10 7 4 4 2 3 4 6 5 0 317 6 32 10 10 5 23 80 8 10 6 19 7 4 6 33 95 25 7 5 4 2 9 5 9 8 0 26 587
MOSWEGOT 307 67 155 132 75 19 22 15 2 0 7 0 2 1 1 109 1 10 1 5 3 7 15 6 5 0 10 5 1 4 16 56 14 1 1 6 5 3 0 10 5 2 4 236
MRCOLD 2661 2661 1159 850 54 61 14 522 64 50 48 0 94 171 47 1390 15 166 57 69 30 63 221 143 25 59 90 9 15 17 98 2120 100 65 50 46 262 17 547 296 254 46 201 6372
NCS1 548 548 375 67 9 17 26 12 5 13 2 43 12 8 0 560 10 76 8 37 3 29 75 13 32 4 69 32 15 4 49 247 89 7 21 10 1 16 9 31 11 5 83 1438
NCS2 280 280 193 28 2 7 11 6 5 8 1 20 4 1 1 327 5 66 3 27 1 13 44 12 18 8 17 18 12 3 30 143 61 3 7 11 0 8 10 9 4 4 54 804
NCS3 465 465 287 86 8 24 22 23 6 19 0 38 5 3 0 286 5 19 1 31 5 22 62 6 25 4 18 10 1 1 25 142 45 4 4 17 2 9 4 25 7 2 96 989
NFRc 125 125 91 27 2 9 1 11 0 0 1 0 4 0 0 151 1 12 3 14 8 4 39 8 0 7 17 6 3 3 0 41 13 0 0 0 1 15 3 2 4 2 15 332
NHANESI 1746 1104 926 493 132 46 18 272 48 58 11 1 20 38 5 701 6 92 18 26 14 37 143 55 15 23 74 15 7 4 62 634 82 40 49 27 9 33 88 110 59 31 51 2490
NHANESIII 1464 1464 794 280 0 0 0 280 0 76 0 0 18 104 0 915 110 0 17 36 27 44 249 81 16 9 75 10 11 0 63 1141 105 68 106 0 71 62 127 161 12 42 71 3591
NHS 5295 5295 2315 1350 24 106 657 236 1 15 103 347 151 374 157 10457 101 972 98 161 91 621 2230 0 733 118 1086 374 167 85 2231 6376 934 260 334 1138 0 379 276 476 383 89 1508 23636
NPHSI 196 88 154 23 0 0 0 23 0 0 0 0 0 0 0 85 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 40 0 0 0 0 0 0 0 0 0 0 3 216
NPHSII 298 57 195 73 39 7 7 20 0 4 2 16 6 0 0 117 1 21 11 9 2 6 26 5 0 2 12 4 3 2 0 25 5 1 0 0 1 4 1 7 2 0 3 202
NSHS 89 41 25 52 1 1 1 49 5 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 41
OB43c 24 24 15 8 1 1 1 4 0 0 0 0 1 0 0 36 1 6 0 0 2 2 5 0 0 3 3 1 0 2 5 14 2 0 0 0 0 3 0 4 3 1 3 77
OSAKA 261 106 42 144 57 27 16 44 1 3 0 1 4 62 0 220 3 15 9 37 30 18 10 7 5 2 10 7 0 0 6 146 22 11 1 8 0 17 43 6 12 9 155 627
OSLO 2615 2615 1604 379 56 79 29 170 36 51 15 119 159 61 5 2017 46 310 42 125 23 115 504 225 0 47 179 74 51 22 0 1072 182 29 66 60 15 98 90 226 101 27 188 5892
OYABE 198 57 26 141 88 30 22 1 0 7 0 0 0 19 0 181 0 7 7 46 5 11 28 0 0 0 4 0 0 0 2 97 26 7 1 0 0 7 34 5 5 0 41 376
PARIS1 480 480 195 100 4 30 5 49 22 4 0 25 8 3 4 918 32 37 37 19 4 24 120 16 0 18 35 18 1 12 0 465 150 2 4 9 1 80 4 6 71 0 218 2081
PRHHP 384 245 213 84 54 20 3 5 0 28 4 24 8 0 1 159 9 12 18 29 0 4 24 15 0 1 18 4 0 1 0 182 76 12 7 4 0 39 6 6 8 3 9 595
PRIME 208 37 146 42 33 6 0 3 0 0 0 17 0 0 0 99 3 15 4 4 3 4 29 2 0 2 8 6 1 2 0 34 24 0 0 0 0 3 1 1 1 1 15 185
PROCAM 741 301 486 106 77 22 0 7 4 0 13 97 8 13 0 441 15 56 6 25 10 33 97 23 0 13 43 17 0 0 28 206 64 21 0 6 3 22 48 7 10 2 49 997
QUEBEC 45 10 32 6 0 0 0 6 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 32 42
RANCHO 507 113 222 185 0 1 0 175 9 16 1 0 5 10 5 173 0 21 2 3 0 11 36 28 3 6 20 4 6 1 10 200 10 7 6 31 11 7 40 22 15 4 1 487
REYK 4550 2518 3258 768 183 162 45 243 47 52 78 12 71 82 6 2426 22 281 43 182 44 173 533 203 68 64 169 93 20 38 199 1663 77 62 41 15 217 27 278 281 130 35 91 6698
RF2c 90 90 64 18 2 7 0 8 0 0 2 0 1 0 0 149 4 12 1 10 9 10 27 3 4 1 7 10 3 6 20 53 15 0 3 2 1 14 2 2 3 4 28 320
ROTT 652 441 244 144 38 23 3 63 1 0 3 55 21 77 2 450 3 69 14 15 5 29 92 27 6 18 46 11 3 17 43 319 43 19 0 1 79 6 34 44 28 8 169 1379
SHHEC 683 182 460 184 56 21 21 81 2 4 2 2 7 3 1 405 7 48 17 17 10 21 122 12 8 6 18 13 5 3 36 152 11 21 6 5 2 18 25 27 11 1 26 765
SHS 785 312 451 214 8 10 0 190 24 12 6 4 2 15 4 224 5 17 4 7 15 14 39 8 5 1 28 4 0 1 15 611 89 34 155 29 0 124 36 31 27 19 19 1166
SPEED 355 196 254 77 66 2 1 5 1 2 5 0 9 0 0 205 4 30 8 15 0 6 69 11 0 7 13 6 1 0 0 77 11 1 1 1 2 3 12 22 4 4 1 479
TARFS 318 257 220 61 1 0 0 60 0 0 2 12 1 11 0 34 0 4 0 1 2 1 3 1 0 0 0 1 0 0 1 25 7 0 2 1 4 0 0 3 1 0 173 489
TOYAMA 92 8 34 51 24 17 10 0 0 0 0 0 0 4 0 28 1 2 0 7 4 0 6 1 1 0 4 0 0 2 0 15 10 0 0 0 0 2 1 0 0 1 32 83
TROMSØ 1875 281 1007 727 537 88 45 52 13 12 1 30 28 19 2 592 9 76 14 39 9 37 127 42 27 12 54 15 10 11 28 352 80 12 7 13 36 12 35 66 33 8 34 1259
ULSAM 996 252 593 316 195 56 19 41 2 10 7 0 18 14 3 394 3 35 12 22 11 32 65 85 0 16 29 12 9 2 0 203 49 6 11 3 17 10 13 31 22 6 7 856
USPHS2 643 104 310 259 217 40 0 2 0 0 0 38 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 688 792
VHMPP 3277 3277 1683 781 81 122 24 442 61 60 45 1 57 184 34 2300 45 264 30 184 69 149 460 138 76 55 172 87 40 19 181 1282 362 4 96 42 20 165 69 170 127 34 64 6923
VITA 66 21 38 19 15 2 1 1 5 0 0 0 1 1 0 44 2 3 1 2 4 3 7 1 0 3 4 4 1 0 3 17 6 0 2 0 0 4 0 1 1 0 4 86
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Table A3.3 con’t Summary of events of individual studies with complete information on height, age and sex 
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WHITEI 473 473 218 141 19 14 4 75 12 7 6 0 40 20 4 403 2 50 19 13 3 20 63 85 0 22 43 11 5 3 0 351 9 9 7 10 17 5 114 48 31 12 14 1241
WHITEII 349 94 317 10 2 2 2 4 0 2 4 0 3 1 1 160 2 23 7 7 2 7 15 6 6 3 13 8 5 3 21 72 25 2 1 0 0 10 4 7 4 1 3 329
ZARAGOZA 100 24 50 50 9 0 0 41 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 24
ZUTE 124 56 57 39 1 1 0 34 2 0 1 0 8 14 0 56 0 4 2 4 0 6 10 10 0 5 4 1 1 0 0 32 2 2 1 2 0 1 6 7 4 2 17 161
SUBTOTAL 73792 47869 41363 19310 5875 2454 1483 7861 1062 921 809 1442 1470 2612 396 48855 742 5115 1084 2184 897 2935 10283 3038 1469 1111 4551 1667 782 514 4118 34150 5599 1484 1574 2419 1634 2159 3755 4099 2469 1002 9330 140204
Clinical trials
AFTCAPS 191 26 147 23 22 0 0 1 0 0 0 12 0 0 0 15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 16 4 0 0 0 0 0 0 0 0 0 0 57
ALLHAT 1667 6 1124 543 0 0 0 543 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 0 11
LEADER 181 95 99 66 51 3 0 12 1 0 1 0 3 6 3 49 1 4 2 2 2 1 25 2 0 2 2 0 0 0 0 32 0 4 0 1 0 1 11 5 4 0 7 183
MRFIT 902 256 773 80 5 4 8 61 8 7 6 0 5 0 0 141 6 10 5 9 2 7 62 4 0 2 9 3 5 1 0 84 50 1 1 0 0 11 3 4 7 0 3 484
PREVEND 206 61 140 30 0 17 7 6 3 1 2 1 9 4 1 166 3 22 3 11 0 6 39 7 1 8 7 3 2 3 9 41 12 0 3 2 3 3 2 6 4 0 13 281
PROSPER 396 88 267 115 0 0 0 115 0 0 0 0 0 0 0 113 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 42 0 0 0 0 0 0 0 0 0 0 0 243
WHS 611 93 240 290 243 26 19 2 0 0 0 52 0 0 0 380 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 160 47 0 0 0 0 0 0 31 0 0 0 633
WOSCOPS 448 80 369 70 0 0 0 70 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 105 185
SUBTOTAL 4602 705 3159 1217 321 50 34 810 12 8 9 65 17 10 4 867 10 36 10 22 4 14 126 13 1 12 18 6 7 4 9 377 114 5 4 3 3 15 16 46 15 0 128 2077
Nested case-control studies
EPICNOR  -  - 481  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
FIA  -  - 551  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
FLETCHER  -  - 161  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
GLOSTRUP  -  - 71  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
USPHS  -  - 245  - 153  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
WHIHABPS  -  -  -  - 611  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -
SUBTOTAL  -  - 1509  - 764  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
TOTAL 78394 48574 46031 20527 6960 2504 1517 8671 1074 929 818 1507 1487 2622 400 49722 752 5151 1094 2206 901 2949 10409 3051 1470 1123 4569 1673 789 518 4127 34527 5713 1489 1578 2422 1637 2174 3771 4145 2484 1002 9458 142281
Study design/
study†
Cardiovascular outcomes Cancer deaths Non-cancer, non-cardiovascular deaths
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*includes fatal and non-fatal events; †Appendix 4  lists study acronyms; ‡Ill-defined causes of death were non-vascular deaths defined according to study-specific read-codes for mortality; 
aCHS included an original cohort (here termed CHS1) and a supplemental African-American cohort (here termed CHS2), which were analysed separately; bProgetto CUORE was 
analysed as 8 different studies (ie, ATENA, EMOFRI, MATISS83, MATISS87, MATISS93, MONFRI86, MONFRI89 and MONFRI94); cRIFLE Study was analysed as 9 different studies (ie, 
ATS_SAR, DISCO, GREPCO, GUBBIO, MICOL, MONICA, NFR, OB43 and RF2).  
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Table A3.4 Risk ratios of coronary heart disease, stroke and cancer mortality per 1-SD (6.5 cm) higher baseline height, adjusted for baseline 
levels of biological, socioeconomic and behavioural risk factors 
 
Progressive adjustment No ofparticipants
No of
events RR (95% CI)
No of
participants
No of
events RR (95% CI)
No of
participants
No of
deaths RR (95% CI)
Age, sex and year of birth 615842 30893 0.92 (0.90 to 0.94) 600605 12726 0.92 (0.90 to 0.95) 548327 25195 1.04 (1.02 to 1.06)
Plus smoking status 615842 30893 0.92 (0.91 to 0.94) 600605 12726 0.92 (0.90 to 0.95) 548327 25195 1.05 (1.03 to 1.06)
Plus systolic blood pressure 615842 30893 0.93 (0.91 to 0.95) 600605 12726 0.94 (0.91 to 0.96) 548327 25195 1.05 (1.03 to 1.06)
Plus history of diabetes 615842 30893 0.93 (0.91 to 0.95) 600605 12726 0.94 (0.91 to 0.96) 548327 25195 1.05 (1.03 to 1.06)
Plus body-mass index 615842 30893 0.94 (0.92 to 0.96) 600605 12726 0.94 (0.91 to 0.96) 548327 25195 1.05 (1.03 to 1.07)
Plus total cholesterol 615842 30893 0.95 (0.93 to 0.97) 600605 12726 0.94 (0.91 to 0.96) 548327 25195 1.05 (1.03 to 1.06)
Additional adjustment
Lipids
Basic model† 315881 13448 0.95 (0.94 to 0.97) 304657 7295 0.95 (0.92 to 0.98) 280379 9037 1.04 (1.01 to 1.07)
Plus non-HDL-C, HDL-C & loge triglyceride‡ 315881 13448 0.95 (0.93 to 0.97) 304657 7295 0.95 (0.92 to 0.98) 280379 9037 1.04 (1.01 to 1.07)
Inflammatory markers
Basic model† 126314 8473 0.93 (0.91 to 0.95) 117054 3659 0.98 (0.94 to 1.03) 97634 4483 1.05 (1.01 to 1.09)
Plus loge CRP 126314 8473 0.94 (0.91 to 0.96) 117054 3659 0.99 (0.94 to 1.03) 97634 4483 1.05 (1.01 to 1.10)
Basic model† 179250 8020 0.94 (0.91 to 0.97) 171161 4392 0.95 (0.91 to 1.00) 166313 6226 1.04 (1.01 to 1.07)
Plus fibrinogen 179250 8020 0.95 (0.92 to 0.97) 171161 4392 0.96 (0.92 to 1.00) 166313 6226 1.04 (1.01 to 1.07)
Lifestyle factors & FEV1
Age, sex, smoking and year of birth 362636 20833 0.93 (0.91 to 0.95) 352052 8623 0.95 (0.92 to 0.98) 322527 15172 1.05 (1.02 to 1.07)
Plus education 362636 20833 0.94 (0.92 to 0.96) 352052 8623 0.96 (0.93 to 0.99) 322527 15172 1.06 (1.03 to 1.09)
Age, sex, smoking and year of birth 357759 15892 0.93 (0.91 to 0.95) 350935 7373 0.94 (0.91 to 0.96) 343381 12445 1.03 (1.01 to 1.05)
Plus occupation/job 357759 15892 0.93 (0.91 to 0.96) 350935 7373 0.94 (0.92 to 0.97) 343381 12445 1.04 (1.02 to 1.06)
Age, sex, smoking and year of birth 500367 22003 0.92 (0.90 to 0.93) 488113 11076 0.93 (0.91 to 0.95) 468497 17353 1.03 (1.01 to 1.05)
Plus alcohol consumption 500367 22003 0.92 (0.90 to 0.93) 488113 11076 0.93 (0.91 to 0.96) 468497 17353 1.03 (1.01 to 1.05)
Age, sex, smoking and year of birth 72208 6463 0.90 (0.87 to 0.93) 69139 1872 0.97 (0.93 to 1.02) 70858 5294 1.04 (0.99 to 1.10)
Plus FEV1 72208 6463 0.98 (0.92 to 1.03) 69139 1872 1.03 (0.98 to 1.09) 70858 5294 1.13 (1.05 to 1.21)
Coronary heart disease* Stroke* Cancer mortality
 
*Includes both fatal and non-fatal events. 
†All basic models were adjusted for age, sex, year of birth, smoking status, systolic blood pressure, history of diabetes, body-mass index and total cholesterol. 
‡Total cholesterol was not included in further adjustments. 
 
Risk ratios were adjusted as shown, and stratified by decades of year of birth and, where appropriate, by sex and trial arm.  
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Table A3.5 Risk ratios for major outcomes per 1-SD (6.5cm) higher baseline height, adjusted 
for age, sex, year of birth and smoking status 
 
Description of 
supplementary analysis Outcome
No of 
events RR (95% CI) I
2
 (95% CI)
Excluding 5 years of follow-up Coronary heart disease* 31680 0.93 (0.91 to 0.95) 44 (29 to 56)
Stroke* 13590 0.93 (0.91 to 0.96) 47 (32 to 59)
Cancer mortality 39346 1.05 (1.04 to 1.07) 18 (0 to 38)
Excluding current smokers Coronary heart disease* 27290 0.92 (0.90 to 0.94) 45 (31 to 56)
Stroke* 14182 0.94 (0.92 to 0.97) 40 (24 to 53)
Cancer mortality 29029 1.04 (1.03 to 1.06) 11 (0 to 31)
Lung 3164 1.07 (1.03 to 1.10) 0 (0 to 30)
Respiratory disease 5435 0.93 (0.88 to 0.98) 54 (40 to 65)
Excluding non-European descents Coronary heart disease* 40743 0.92 (0.91 to 0.94) 44 (29 to 55)
Stroke* 16197 0.94 (0.91 to 0.96) 43 (28 to 55)
Cancer mortality 45089 1.04 (1.03 to 1.06) 19 (0 to 38)
Restricted to men only Coronary heart disease* 30958 0.93 (0.91 to 0.94) 39 (23 to 51)
Stroke* 10227 0.93 (0.90 to 0.95) 34 (16 to 48)
Cancer mortality 25875 1.04 (1.03 to 1.06) 4 (0 to 26)
All cause-mortality 79763 0.97 (0.96 to 0.98) 56 (45 to 64)
Restricted to women only Coronary heart disease* 12236 0.93 (0.90 to 0.95) 29 (5 to 46)
Stroke* 8235 0.94 (0.91 to 0.98) 43 (24 to 57)
Cancer mortality 21616 1.05 (1.02 to 1.07) 17 (0 to 39)
All cause mortality 56968 0.97 (0.95 to 0.99) 59 (48 to 68)
Coronary heart disease* 6043 0.93 (0.90 to 0.96) 14 (0 to 41)
Stroke* 4016 0.95 (0.91 to 1.00) 32 (0 to 54)
Cancer mortality 4950 1.04 (1.00 to 1.08) 28 (0 to 52)
Coronary heart disease* 5913 0.95 (0.92 to 0.98) 5 (0 to 33)
Stroke* 3908 0.97 (0.92 to 1.02) 37 (5 to 58)
Cancer mortality 4840 1.05 (1.00 to 1.09) 30 (0 to 53)
Adjustment for waist 
circumference instead of BMI†
Adjustment for waist/hip ratio instead of 
BMI†
 
 
*Includes both fatal and non-fatal events. 
†Analyses were additionally adjusted for systolic blood pressure, history of diabetes and total cholesterol.  
 
Risk ratios (RRs) were adjusted for age at baseline and smoking status and stratified by decades of year of birth and, where 
appropriate, by sex and trial arm.  
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Table A3.6 Risk ratios of cause-specific mortality without censoring for previous non-fatal 
outcomes per 1-SD (6.5 cm) higher baseline of height, adjusted for age, sex, year of birth and 
smoking status 
 
No of 
deaths RR (95%CI) I
2 (95% CI)
All cardiovascular deaths 56989 0.94 (0.93 to 0.96) 61 (52 to 68)
Coronary deaths 30552 0.93 (0.91 to 0.95) 40 (24 to 52)
Stroke 11749 0.92 (0.89 to 0.95) 55 (43 to 64)
Ischaemic stroke 1662 0.90 (0.84 to 0.96) 27 (0 to 47)
Haemorrhagic stroke 1711 0.93 (0.87 to 1.00) 31 (3 to 51)
Subarachnoid haemorrhage 1145 0.90 (0.81 to 1.01) 38 (4 to 60)
Unclassified stroke 5123 0.93 (0.89 to 0.97) 38 (18 to 54)
Other vascular deaths
Hypertensive disease 978 0.91 (0.83 to 1.00) 43 (15 to 61)
Heart failure 2970 0.94 (0.90 to 0.97) 6 (0 to 31)
Sudden death 1737 0.99 (0.93 to 1.05) 27 (0 to 55)
Cardiac dysrhythmia 1201 1.02 (0.95 to 1.09) 25 (0 to 49)
Peripheral vascular disease 361 0.99 (0.86 to 1.13) 17 (0 to 53)
Pulmonary embolism 780 1.12 (1.03 to 1.22) 16 (0 to 44)
Ruptured aortic aneurysm 1457 1.12 (1.05 to 1.19) 20 (0 to 46)
All cancer deaths 50926 1.04 (1.03 to 1.06) 18 (0 to 36)
Melanoma 693 1.25 (1.11 to 1.40) 41 (7 to 62)
Connective tissue 431 1.12 (1.01 to 1.24) 5 (0 to 37)
Pancreas 2889 1.09 (1.05 to 1.14) 9 (0 to 33)
Endocrine & nervous 1585 1.11 (1.05 to 1.16) 0 (0 to 33)
Breast (female) 4026 1.08 (1.04 to 1.11) 0 (0 to 34)
Bladder 1107 1.07 (0.98 to 1.17) 38 (11 to 57)
Liver 795 1.06 (0.96 to 1.16) 34 (3 to 55)
Ovary 1428 1.07 (1.01 to 1.13) 0 (0 to 38)
Prostate 3036 1.06 (1.02 to 1.11) 5 (0 to 31)
Colorectum 5116 1.06 (1.03 to 1.10) 16 (0 to 38)
Haematological 4481 1.05 (1.02 to 1.08) 0 (0 to 29)
Lung 10569 1.04 (1.02 to 1.07) 3 (0 to 24)
Oesophagus 1074 0.97 (0.90 to 1.04) 12 (0 to 40)
Stomach 2154 0.95 (0.91 to 1.00) 14 (0 to 38)
Oral 665 0.88 (0.81 to 0.96) 8 (0 to 40)
Other/Unspecified 9937 1.03 (1.01 to 1.05) 0 (0 to 25)
Non-vascular non-cancer deaths 37173 0.92 (0.90 to 0.94) 49 (37 to 60)
COPD & related conditions 4351 0.85 (0.81 to 0.89) 35 (13 to 52)
Mental disorders 2534 0.89 (0.83 to 0.96) 36 (8 to 56)
Liver disease 2066 0.88 (0.84 to 0.93) 16 (0 to 40)
Diabetes mellitus 1610 0.93 (0.88 to 0.99) 16 (0 to 45)
All external causes 5716 0.96 (0.93 to 1.00) 25 (0 to 43)
Infections 1517 0.96 (0.89 to 1.02) 25 (0 to 49)
Alzheimer's and related conditions 1763 0.97 (0.93 to 1.02) 0 (0 to 40)
Pneumonia 4176 0.95 (0.91 to 0.99) 24 (0 to 45)
Renal disease 1022 0.97 (0.91 to 1.03) 0 (0 to 37)
Intentional self-harm 1119 0.98 (0.89 to 1.07) 35 (0 to 57)
Digestive system disorders (except liver) 2584 0.99 (0.95 to 1.04) 15 (0 to 39)
Falls 574 1.12 (1.02 to 1.24) 12 (0 to 47)
Other/Unspecified 9182 0.96 (0.94 to 0.99) 6 (0 to 28)
11033 0.96 (0.93 to 0.99) 43 (26 to 57)
All-cause mortality 156185 0.97 (0.96 to 0.98) 73 (67 to 78)
Endpoint
Deaths of unknown or
ill-defined cause
 
 
Risk ratios (RRs) are presented per 1-SD (6.5 cm) higher baseline height values. Risk ratios were adjusted for age and 
smoking and stratified by decades of year of birth and, where appropriate, by sex and trial arm.  
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Figure A3.1 Sex-specific mean baseline height values (95% CI, +/- 1-SD), by geographical 
region  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4 lists study acronyms. 
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Figure A3.2 Mean baseline height within 5-year age bands (panel A) and differences in 
baseline height across calendar years relative to individuals born before 1910 (panel B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All analyses were adjusted for study. Also, mean baseline height values were adjusted for year of birth (panel A), and 
differences in baseline height were adjusted to age 50 years (panel B).  
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Figure A3.3 Cross-sectional associations between height and some continuous risk factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean risk factor levels were adjusted to age 50 years. The values above each figure correspond to the age, sex and birth 
year adjusted partial correlation coefficient (95% CI) between risk factor and height in males and females combined. 
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Figure A3.4 Regression dilution ratios for height plotted against time since baseline 
measurement by study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyses were adjusted for age at baseline, sex and decades of year of birth.  
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Figure A3.5 Risk ratios for coronary heart disease, stroke, cancer mortality and all-cause mortality across quantiles of baseline 
height, among males and females 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Includes fatal and non-fatal events. Regression analyses were adjusted for age at baseline and smoking status, and stratified by decades of year of birth and, where 
appropriate, by trial arm. Reference groups are the fifth deciles or third quintiles in the plots.   
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Figure A3.6 Risk ratios for vascular outcomes across quintiles of baseline height 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Includes fatal and non-fatal events. Regression analyses were adjusted for age at baseline and smoking status, and 
stratified by decades of year of birth and, where appropriate, by trial arm. Reference groups are the third quintile of the plots. 
Other vascular outcomes are not shown, because there were generally too few deaths for each sex to characterise reliably 
shape of associations. 
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Figure A3.7 Risk ratios for vascular outcomes per 1-SD (6.5cm) higher baseline height, 
adjusted for age, sex, smoking and year of birth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Includes both fatal and non-fatal events. 
†Restricted to studies contributing to both outcomes. 
 
Causes of other vascular deaths are ordered by their strength of association. Risk ratios (RRs) were adjusted for age at 
baseline and smoking status, and stratified by decades of year of birth and, where appropriate, by sex and trial arm. There 
was evidence of heterogeneity in risk ratios among vascular outcomes (P-value for heterogeneity <0.001). 
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Figure A3.8 Risk ratios for coronary heart disease, stroke and cancer mortality per 1-SD (6.5cm) higher baseline height, according to 
baseline levels of various characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk ratios were adjusted for age at baseline and smoking status, and stratified by decades of year of birth, and, where appropriate, by sex and trial arm. Abbreviations: 
Assessed = height was assessed using standardised protocol; Self-reported = height was measured by the subject itself.  
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Figure A3.9 Risk ratios for site-specific cancer mortality across quintiles of baseline height  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression analyses were adjusted for age at baseline and smoking status, and stratified by decades of year of birth and, 
where appropriate, by trial arm. Reference groups are the third quintile of the plots. Other cancer outcomes are not shown, 
because there were generally too few deaths for each sex to characterise reliably shape of associations. 
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Figure A3.10 Risk ratios for cause-specific non-vascular mortality per 1-SD (6.5cm) higher 
baseline height, adjusted for age, sex, smoking and year of birth  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With the exception of the classifications "Other/Unspecified", causes of deaths are ordered by their strength of association. 
Risk ratios (RRs) were adjusted for age at baseline and smoking status, and stratified by decades of year of birth and, where 
appropriate, by sex and trial arm. There was evidence of heterogeneity in risk ratios among cancer sites and among the non-
vascular non-cancer causes of deaths (P-value for heterogeneity <0.001 for both comparisons). Risk ratio for all-cause 
mortality per 1-SD (6.5cm) was 0.97 (0.96-0.99), I2 = 69% (63% to 75%) and for unknown or ill-defined cause was 0.96 
(0.93-1.00), I2 = 45% (27% to 58%). 
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Figure A3.11 Age-at-risk specific risk ratios for breast cancer mortality by fifth of baseline 
height, adjusted for year of birth and smoking status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk ratios (RRs) were adjusted for smoking status and stratified by decades of year of birth and, where applicable, by trial 
arm. P-value for interaction between baseline height values and age-at-risk groups was 0.53. 
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Figure A3.12 Risk ratios for non-vascular non-cancer specific mortality across quintiles of 
baseline height 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression analyses were adjusted for age at baseline and smoking status, and stratified by decades of year of birth and, 
where appropriate, by trial arm. Reference groups are the third quintile of the plots. Other outcomes are not shown, because 
there were generally too few deaths for each sex to characterise reliably shape of associations  
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Figure A3.13 Study-specific risk ratios for coronary heart disease per 1-SD (6.5cm) higher 
baseline height, adjusted for age, sex, year of birth and smoking status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I2 = 49% (95% CI 37% to 59%). 
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APPENDIX 4: List of study acronyms 
 
AFTCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT, 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; AMORIS, 
Apolipoprotein Related Mortality Risk Study; ARIC, Atherosclerosis Risk in Communities 
Study; ATENA, cohort of Progetto CUORE; ATS_SAR, cohort of Risk Factors and Life 
Expectancy Pooling Project; ATTICA, ATTICA Study; AUSDIAB, Australian Diabetes, Obesity 
and Lifestyle Study; BHS, Busselton Health Study; BRHS, British Regional Heart Study; 
BRUN, Bruneck Study; BUPA, BUPA Study; BWHHS, British Women's Heart and Health 
Study; CaPS, Caerphilly Prospective Study; CASTEL, Cardiovascular Study in the Elderly; 
CHA, Chicago Heart Association Study; CHARL, Charleston Heart Study; CHS-1, original 
cohort of the Cardiovascular Health Study; CHS-2, supplemental African-American cohort of 
the Cardiovascular Health Study; COPEN, Copenhagen City Heart Study; DISCO, cohort of 
Risk Factors and Life Expectancy Pooling Project; CUORE, Progetto CUORE; DRECE, Diet 
and Risk of Cardiovascular Disease in Spain; DUBBO, Dubbo Study of the Elderly; EAS, 
Edinburgh Artery Study; EMOFRI, part of CUORE; EPESEBOS, The Established Populations 
for the Epidemiologic Study of the Elderly Studies, Boston; EPESEIOW, The Established 
Populations for the Epidemiologic Study of the Elderly Studies, Iowa; EPESENCA, The 
Established Populations for the Epidemiologic Study of the Elderly Studies, North Carolina; 
EPESENHA, The Established Populations for the Epidemiologic Study of the Elderly Studies, 
New Haven; EPICNOR, European Prospective Investigation of Cancer Norfolk Study; 
ESTHER, Epidemiologische Studie zu Chancen der Verhutung und optimierten Therapie 
chronischer Erkrankungen in der alteren Bevolkerung; FIA, First Myocardial Infarction in 
Northern Sweden; FINE-FIN, Finland, Italy and Netherlands Elderly Study - Finland cohort; 
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